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Abstract 
1α,25-dihydroxyvitamin D3 signals via its canonical nuclear receptor: Vitamin D 
Receptor (VDR). While higher levels of serum vitamin D have been reported to be 
associated with thinner primary melanomas and better outcome, increased VDR 
expression has been associated with decreased tumour progression and improved 
prognosis in melanoma primaries. However, the genomic basis of this effect remains to 
be explored and a causal mechanism is yet to be established. To address this question, 
I have used microarray data from a cohort of 703 treatment-naïve primary melanomas 
from the Leeds Melanoma Cohort (LMC) and corresponding clinical data.  
In the LMC primary melanomas, serum vitamin D was not significantly associated 
with melanoma survival. However, tumour VDR expression was significantly (and 
independently) protective for melanoma death in both the LMC and the TCGA 
metastatic melanoma datasets. Tumour VDR expression was found to be significantly 
positively correlated with genes enriched for ECM organization, TNF signalling, IFNg 
signalling, IL12-mediated signalling and NFkB signalling, which are predominantly 
immune-related. Concordantly, VDR expression was lower in tumours graded by the 
pathologist as having no immune infiltrate, compared to tumours with brisk and non-
brisk immune infiltrate.  Additionally, VDR correlated positively with imputed immune 
cells scores. Conversely, the negatively correlated genes were enriched for Mitotic 
Prophase, Wnt signalling pathway, Mitochondrial translation, citric acid cycle and 
oxidative phosphorylation, which are predominantly proliferation-related. Of particular 
interest among the negatively correlated pathways was the Wnt/b-catenin signalling 
pathway. Functional validation using an in vivo tail-vein metastasis assay revealed that 
murine melanoma cells stably expressing VDR produced significantly fewer pulmonary 
metastases compared to control cells with null VDR expression. VDR-expressing cells 
also had significantly lower expression of Wnt/b-catenin signalling genes compared to 
control cells. These findings indicate that vitamin D-VDR signalling contributes to 
control of pro-proliferative and immunosuppressive Wnt/b-catenin signalling in 
melanoma and that this is associated with less proliferative, less metastatic disease 
and stronger host immune responses.  
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AJCC stage: Classification of melanomas according to the recommendations of the 7th 
edition of the American Joint Committee on Cancer 
Vascular invasion: vascular invasion indicates the presence (or absence) of tumour 
cells which are fixed to the walls and within the lumens of lymphatic or blood vessels 
(3). 
Melanoma survival/death: survival information for participants was obtained both 
directly (by annual re-contact) and indirectly from review of national cancer registries 
and the ONS. In the case of deceased participants, the cause of death was obtained 
from death certificates and medical records. This was reviewed by research nurses in 
the Leeds Melanoma Research group led Prof. Julia Newton-Bishop, to generate 
Melanoma Specific Survival (MSS).  
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Introduction 
Melanoma is a type of skin cancer, originating from the melanocytes, which are 
neural crest-derived cells residing in the epidermis. The transformation of melanocyte 
to a melanoma malignant phenotype involves a series of genomic and molecular 
events, which lead to aberrant signalling in pathways pertaining to cell cycle arrest, 
melanocyte development and differentiation, immune response and DNA-damage 
repair. Extensive research including studies of familial susceptibility, genome-wide 
association, mutation burden, in vitro and in vivo models have contributed to the 
understanding the hierarchy of molecular and genetic events involved in melanoma 
initiation and progression (4). These studies demonstrate that while melanoma 
initiation mandates genetic predisposition and/or somatic mutations, melanoma 
progression requires additional mutation and/or copy number variation events, which 
eventually culminate in disruption of the above mentioned cellular processes (5). 
Melanoma development and progression is also influenced by various host factors, 
which contribute to disease development and progression. 
 
Chapter Aim 
This chapter aims to provide an overview of the disease that is melanoma. This 
includes discussion of melanoma incidence and mortality, melanoma aetiology, the 
molecular pathogenesis of melanoma, role of host factors in melanoma development 
and melanoma therapy. This chapter also includes discussion of vitamin D-VDR 
signalling, focusing on the functional relevance of this signalling axis in human 
disease, in cancer and in melanoma itself.  
 
 Melanoma incidence 
Melanoma of the skin is the 15th most commonly occurring cancer worldwide but is 
more common in the UK being the 5th most common (6). Among the different skin 
cancers, malignant melanoma accounts for the majority of the skin cancer deaths, 
despite representing less than 5% of all cutaneous malignancies (7, 8). There has 
been an increase in the worldwide incidence for melanoma in the past decades (7-
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9). Incidence rates have been shown to vary with ethnicity, geographical location, 
age and sex, all of which are discussed below.  
Melanoma is a cancer attributed to uncontrolled division of melanocytes: the 
pigment-producing cells in the skin, which is the human organ most exposed to sun 
and UV radiation. Thus, it is to be expected that melanoma incidence varies as a 
function of geography, skin-type and ethnicity. The role of sun/UV exposure, 
pigmentation and skin type in melanoma aetiology is discussed in detail in the 
sections below. In the case of ethnicity, melanoma incidence varies across different 
ethnicities more than do most cancers (8). Melanoma burden is highest in regions 
where the population at risk is pale-skinned: Australasia (Australia, New Zealand), 
North America and Europe (10), but living in a hot country or with access, usually on 
holiday to hot countries (as of 2012 estimates, represented in Figure 1.1). Even 
among people of the same ethnicity, melanoma incidence has been shown to vary 
by geographical region: melanoma incidence increased with decreasing latitude in 
North America and England (11) and Australia (12). Within Europe, melanoma 
incidence is however higher in Scandinavian countries compared to southern 
countries like Spain and Italy (8). These differences have been attributed to pale-
skinned and olive-skinned populations in the north and south of Europe respectively 
(13). 
Since skin type, ethnicity and geography are strongly linked to each other, 
studies using ethnically heterogeneous populations, but in the same geographical 
region, have offered better insight into delineating the effects of these factors. For 
instance, a pooled study reported that melanoma incidence increased with higher 
ultraviolet (UV) indicesi  and lower altitude only in non-Hispanic whites: not in black 
or Hispanic populations in the United States (15). Similarly, within countries whose 
population consists of heterogeneous ethnicities, melanoma rates are highest among 
the palest skinned, while incidence is lower among people of darker-skinned 
ethnicities (8, 16). Taken together, melanoma is predominantly incident in white 
skinned populations, but geographic location is also a significant factor.  
  
                                               
i Ultraviolet (UV) index: The Global Solar UV Index is a measure of incident solar UV radiation levels 
on the earth’s surface. Known commonly as the ‘UV index’, this measure includes values of zero and 
upward, with higher indices being associated with greater potential damage to the skin and eye (14.
 WHO. 2002.) 
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Figure 1.1 Worldwide incidence of melanoma sourced from GLOBOCAN 2012 
estimates 
Disability Adjusted Life Year (DALY) is a summary measure used to give an 
indication of the burden of disease. One DALY represents the loss of the 
equivalent of one year of full health. Source: international Agency for cancer 
Research-World Health Organisation (IARC-WHO) online Glossary of Terms: 
http://www-dep.iarc.fr/WHOdb/glossary.htm 
 
Melanoma incidence also increases with age, with the trend being observed in 
high risk populations such as Australia, New Zealand and Northern Europe (8) 
(depicted in Figure 1.2). Even though melanoma incidence is lower in the younger 
population (<40 years) however, it is still the most commonly diagnosed cancer 
among young adults (17, 18).  
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Figure 1.2 Worldwide incidence of melanoma by age, as per GLOBOCAN 2012 
estimates 
Age standardized Rate (ASR) is a summary measure of the rate that a 
population would have if it had a standard age structure. Source: international 
Agency for cancer Research-World Health Organisation (IARC-WHO) online 
Glossary of Terms: http://www-dep.iarc.fr/WHOdb/glossary.htm 
 
Worldwide melanoma incidence varies between men and women (depicted in 
Figure 1.3). At age over 40 years, melanoma incidence is greater in men than in 
women, worldwide (8, 19) and in high incidence populations such as United States, 
Australia and New Zealand (8, 20). This pattern of higher incidence in men is 
consistent even across different ethnicities, for instance: in the United states, 
melanoma incidence is higher in males of non-Hispanic Caucasian, Asian/Pacific 
Islander and African American ethnicities, compared to their respective female 
populations (21). This suggests that the male-female disparity in incidence is not 
confounded by geography or ethnic background. It has been postulated that this 
differential incidence could be reflections of androgen-related effects (22, 23).  
However, the current excess of melanoma in males in the UK is a new phenomenon. 
As recently as 2006, melanoma in the UK was more common in women and this had 
been the case since the incidence started to rise at the beginning of the 20th century 
(24). The change in sex incidence over time suggests that it is more likely behavioural 
change is responsible for these sex differences than hormonal factors. 
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Figure 1.3 Worldwide incidence of melanoma by sex, as per GLOBOCAN 2012 
estimates 
Age standardized Rate (ASR) is a summary measure of the rate that a 
population would have if it had a standard age structure. Source: international 
Agency for cancer Research-World Health Organisation (IARC-WHO) online 
Glossary of Terms: http://www-dep.iarc.fr/WHOdb/glossary.htm 
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 Melanoma mortality 
Much like melanoma incidence, trends in melanoma mortality vary by geography, 
ethnicity, age and sex. The worldwide melanoma mortality is depicted in Figure 1.4, 
as per 2012 estimates. Melanoma mortality has steadily increased in the past 
decade, particularly in pale-skinned populations living in high-risk countries such as 
Australia and New Zealand (25). Similar trends have been reported in Scandinavian 
countries and the United Kingdom (25) and also in East Asian populations (26). 
Within an ethnically heterogenous population, non-white subgroups have higher 
mortality rates compared to their white counterparts, despite lower incidence reported 
in these subgroups. For instance, non-Hispanic African Americans have lower 5-year 
survival rates compared to white subgroups in the United States (27), with the 
discrepancy being attributed by some to socioeconomic inequalities (28). The type of 
melanoma suffered by non-white patients however is the histologically defined acral 
lentiginous melanoma (29), which is one of the melanoma subtypes with worse 
prognosis compared to cutaneous melanoma (30). This could also explain the higher 
melanoma mortality in non-white populations.  
Similar to melanoma incidence, mortality is higher in males compared to females, 
across all races (31).This difference is also reported to be significant at all stages of 
the disease: even advanced stage IV (32).  Annual melanoma mortality is also 
highest in individuals aged >70 worldwide (31): that is that increased age increases 
the risk of dying for every individual case. 
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Figure 1.4 Worldwide mortality from melanoma, as per GLOBOCAN 2012 
estimates 
Age standardized Rate (ASR) is a summary measure of the rate that a 
population would have if it had a standard age structure. Source: international 
Agency for cancer Research-World Health Organisation (IARC-WHO) online 
Glossary of Terms: http://www-dep.iarc.fr/WHOdb/glossary.htm 
 
 Melanoma staging system: Factors predicting melanoma 
outcome 
The melanoma staging system includes a combination of characteristics which have 
a significant effect on melanoma prognosis. The first multivariate analysis to identify 
these characteristics was based on insights from multiple institutions. It was 
published in 1981 and evaluated the effect of the following characteristics on 
melanoma prognosis: tumour thickness, Clark’s level of invasion into the skin, 
number of mitoses, growth pattern, cell type, inflammatory reaction, vascular invasion 
and microscopic ulceration. Of these characteristics, tumour thickness was found to 
be the most significant predictor of prognosis, while ulceration and number of mitoses 
remained significant predictors after adjusting for tumour thickness (33). The 
significance of formal staging in estimating patient prognosis was evident and put 
forth the necessity of a unified staging system. This led to the formation of the 
American Joint Committee on Cancer (AJCC) in 1998 comprised of experts from 
North America, Europe and Australia. The AJCC set up a melanoma staging 
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database, for the continued collection and review of melanoma outcome data (34). 
The consensus staging system developed by the committee was subject to the 
following criteria: a) it should be evidence-based and reflect prognostic factors 
identified by multivariate Cox regression analyses, b) should be based on melanoma 
outcome results from multiple institutions and countries and c) should be practical 
and readily reproducible (35) using pathology reports from thousands of different 
histopathologists. 
AJCC staging is based on the tumour-node-metastasis (TNM) categories to 
define the groupings: T (primary tumour characteristics), N (Regional Lymph node 
characteristics) and M (distant metastases characteristics). Characteristics pertaining 
to each category are described below, as per AJCC edition 7 (35-37):  
“T” classification is based on: 
• Tumour thickness (Breslow thickness): measurement (in millimetres) of 
thickness of tumour from top of epidermal granular layer to the deepest 
point of invasion 
• Ulceration: the absence of intact epidermis above primary melanoma  
• Mitotic rate: the number of mitotic cells per square millimetre of tumour.  
“N” classification is based on 
• number and type of regional lymph node metastases.  
“M” classification is based on 
• number and type of distant metastases.  
The 7th Edition of the AJCC staging system was used to classify the melanomas 
used in this thesis, as this was active during the period of recruitment to the cohort 
and therefore that used by the pathologists reporting the histopathology slides. There 
is a new system in use since January 2018 (8th Edition of the AJCC staging system), 
but analyses performed by the research group showed that using only the broad 
staging, I, II, III of IV, there were only 3 participants with differences in the staging of 
disease in the data which formed the basis of this research. 
 Melanoma aetiology 
Melanoma aetiology is multifactorial and involves a combination of genetic and 
environmental host factors. Epidemiological, in vitro, in vivo and most recently, omic 
studies have helped gain a deeper insight into this process. Melanoma risk factors 
can be broadly classified into environmental (UV/solar exposure) and host factors 
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(melanoma susceptibility genes, a phenotype characterised by increased numbers 
of melanocytic naevi, and pale skin type/pigmentation). However, the mechanisms 
underlying these factors are not mutually exclusive. The following sections will 
discuss each of these factors in detail, followed by a discussion of the molecular 
pathology of melanoma initiation.  
1.4.1 Melanoma susceptibility genes 
Melanoma susceptibility genes are those which when mutated or coded by 
polymorphisms (a mutation which is more common in the population having relatively 
minor effects biologically), confer an increased risk of developing melanoma. High-
risk mutated genes have historically been identified using genetic studies of families 
with multiple family members with melanomas. Familial melanoma is considered to 
be the familial aggregation of melanoma, as defined by occurrence of melanoma in 
at least two relatives (either first degree or irrespective of degree of relationship) or 
families with three or more melanoma cases irrespective of degree of relationship 
(38). Melanoma susceptibility genes are normally classified as high-risk or 
low/moderate risk depending on the degree of risk they confer for developing 
melanoma, as indicated by the frequency of melanoma cases within an affected 
family. The first high-risk gene to be identified as associated with melanoma 
susceptibility was Cyclin-dependent kinase inhibitor 2A (CDKN2A) (39, 40) which 
was identified as result of linkage analyses of melanoma-affected families. CDKN2A 
encodes the tumour suppressor proteins p16INK4A and p14ARF: p16INK4A 
promotes cell cycle arrest by inhibiting retinoblastoma protein (RB) (41) and p14ARF 
induces cell cycle arrest and apoptosis via the p53 pathway (42). Hussussian et al 
first reported 8 different p16 germline mutations using a genotyping-based approach 
of melanoma-affected families. This included 1 nonsense mutation, 1 splice donor 
mutation and 6 missense mutations (Hussussian, 1994 #295). Since then, p16INK4A 
mutations have been predominantly reported to be loss-of-function missense 
mutations (39, 40, 43).  For p14ARF, inactivation has been shown to be via whole 
gene deletions or splice mutations at the exon 1b (44-46). CDKN2A remains the most 
frequent high-risk melanoma gene with mutations detected in around 20-30% 
melanoma-prone families (47). However, other melanoma susceptibility genes have 
been identified since. Cyclin dependent kinase 4 (CDK4) was the second high-risk 
melanoma susceptibility gene identified in a candidate gene screening approach, an 
unsurprising finding given that CDK4 is the binding partner for p16INKA (48). The 
other high-risk melanoma susceptibility genes include the gene coding for Breast 
cancer associated protein 1 (BAP1) as well as genes involved in telomere 
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maintenance such as TERT (49), POT1 (50, 51), ACD and TERF2IP (52), indicating 
the significance of telomere maintenance in melanoma susceptibility.  
Among the intermediate-risk melanoma susceptibility genes is the 
Microphthalmia-associated transcription factor (MITF): a master regulator of 
melanocyte development and differentiation, (53, 54).  The low-risk melanoma 
susceptibility genes include genes involved in a variety of biological processes such 
as pigmentation (TYR, TYRP1, OCA2, MTAP) (55), immune response (HLA class II 
genes, IRF4) (56, 57) and metabolism (GSTM1, GSTT1, GSTP1)(58). The 
predominance of pigment related genes as low risk melanoma susceptibility genes 
is related to the geographical variation in incidence described above. The single most 
important polymorphic gene associated with melanoma risk (MC1R) is most common 
in Northern Europe or in countries populated by migrants from Northern Europe such 
as Australia and New Zealand and is thought to underlie a significant proportion of 
susceptibility in those areas of the world. 
While the genes mentioned above were discovered largely by Genome Wide 
Association Studies (GWAS), the role of other genes in melanoma susceptibility were 
identified using a ‘candidate’ approach. For instance, epidemiological studies to 
estimate the association of selected polymorphisms in the vitamin D Receptor (VDR) 
with risk of cutaneous melanoma have been reported (59).  
1.4.2 Ultraviolet radiation and sun exposure 
Ultraviolet/sun exposure is the most extensively studied environmental risk factor for 
melanoma, given the mutagenic role of ultraviolet radiation in skin cancers (60). 
Ultraviolet radiation is composed of Ultraviolet A (UVA: 315-400nm), Ultraviolet B 
(UVB: 280-315nm) and Ultraviolet C (UVC: 100-280nm), with 90-99% of radiation 
incident on earth’s surface being UVA (60). The roles of UV radiation in initiating 
melanoma development and progression are discussed in the subsequent 
paragraphs. However, it is worth noting that incident UVB on the skin initiates a series 
of reactions leading to the synthesis of the essential hormone, vitamin D, which is 
known to have prognostic significance in melanomas: this aspect is discussed in 
detail in section 1.8. briefly, evidence described below indicating that sun exposure 
causes melanoma in the susceptible is complicated at least in public health terms 
because most people are dependent on sun exposure to manufacture enough 
vitamin D. 
A combination of epidemiological and experimental evidence indicates the role 
of solar radiation in melanoma aetiology. In the case of epidemiological studies, the 
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association of melanoma incidence with various measures pertaining to sun 
exposure has been studied. For instance, mortality rates for malignant melanoma 
were shown to be inversely correlated with geographical latitude and annual 
ultraviolet radiation dose, in Canadian and American populations (61) as well as 
across 30 populations of European origin (62). It is to be noted that such studies are 
prone to population bias i.e. the effects associated with geographical gradient could 
alternatively be explained by gradient population mix and associated occupational 
sun exposure. Other studies have assessed the association of melanoma risk in 
relation to ambient solar radiation and length of residence in a specific geographical 
area. These studies collectively indicate that melanoma risk increases with 
increasing length of residence in a region of high ambient solar radiation (63). 
Because much of a person’s sun exposure is during childhood and adolescence, 
studies have interrogated the effect of childhood sunburn on melanoma risk. 
However, there are no reported differences in melanoma risk among individuals who 
sunburn in childhood, adolescence or adulthood (64-66), suggesting that exposure 
is an important factor, irrespective of when it was acquired.  In other words, the 
interpretation is that sunburn causes melanoma whenever it occurs. While the above 
studies have used incident solar radiation (in a particular geographical region) and 
sunburn history to gauge effects of radiation on melanoma risk, some others have 
used self-reported sun exposure as a measure of exposure to radiation.  
For instance, a meta-analysis of 15 studies showed that reported recreational 
sun exposure was a risk factor for melanoma on the trunk and limbs, but not head 
and neck melanomas (67). Extensive epidemiological data linking UV radiation and 
melanoma risk is complemented by in vitro studies, wherein UV radiation has been 
shown to promote melanoma progression through several mechanisms (68). For 
instance, UVA-induced DNA damage is mediated by Reactive Oxygen Species 
(ROS) leading to intracellular oxidative damage (69). A recent study by Kemenisch 
et al report effects of that UVA treatment on melanoma cell lines from initial 
melanomas (vertical and radial growth phase). They demonstrated that UVA-treated 
early melanoma cells exhibit increased glucose uptake, lactate production and 
increased invasiveness. In other words, they provide in vitro evidence for UVA-
induced Warburg effect mediated by oxidative stress in early melanomas, leading to 
an invasive phenotype (70). UV treatment (both UVA and UVB) have been shown to 
induce migration and invasion of not only melanoma cells in vitro, but also cells of 
the tumour microenvironment such as fibroblasts and untransformed melanocytes 
(71). Neonatal erythemagenic dose of UVB exposure has also been shown to 
increase melanoma progression, vascular invasion and an aggressive invasive 
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phenotype in 15 Hgf-Cdk4(R24C) mice, in which a DMBA-induced oncogenic CDK4 
germline mutation leads to invasive melanomas as seen in patients (72). In the same 
mouse model, UV-induced immune suppression and subsequent tumour initiation 
was also shown. The same study also provided in vivo evidence for UV-induced 
TLR4/MYD88-driven neutrophilic inflammatory response, in addition to the UV-
induced metastatic phenotype (73).  
The advent of omic studies also provided significant insight into the signature of 
UV exposure in human melanomas. A study of 147 melanoma exomes (Whole 
Exome Sequencing- WES) identified excess C>T transitions in melanomas in sun-
exposed body sites, which is an indicator of UV exposure and sun damage. They 
identified a motif (TTTCGT) to be enriched in genomic regions that are more likely to 
be mutated in sun-exposed melanoma. Given that this motif is a hotspot for creating 
UV-induced photoproducts, these findings argue for relevance of UV-induced DNA 
damage in melanoma initiation (74). Moreover, melanoma is known to harbour high 
mutation load compared to other cancer types (75, 76). In the TCGA melanoma 
dataset, 76% of primaries and 84% of metastatic melanomas harboured UV-driven 
C>T transitions (77). Notably, these studies have identified that the oncogenic 
RAC1P29S mutation harbours the UV-induced C>T transitions in sun-exposed 
melanomas (compared to sun-shielded melanomas) (74, 77), thus accruing further 
evidence for UV-induced onset of melanoma.  
1.4.3 Melanocytic Naevi 
Just as UV radiation is a major environmental risk factor, increased numbers of 
melanocytic naevi is one of the major host-related risk factor for melanoma (pale skin 
with tendency to sunburn being the other major risk factor, being associated with 
inherited polymorphisms in pigment genes eg MC1R). Naevi were first observed and 
reported to be prevalent among melanoma-prone families (78), with the term 
Dysplastic Naevus Syndrome (DNS) being introduced to describe the naevus 
phenotype (79) characterised by a greater than average number of naevi and naevi 
which are individually unusual (dysplastic or atypical).  Features such as increased 
size, border and pigmentation were used to define dysplastic naevi originally by Clark 
et al (78). However, there was historically a lack of consensus among dermatologists 
and dermatopathologists regarding the definition and classification of naevi: while 
‘dysplastic naevi’ have a histologically-defined connotation, ‘atypical naevi’ appear to 
be more clinically-defined (80). A clinically defined atypical naevus is usually 
considered to be >5mm in diameter, with an irregular shape and colour. Despite 
differences in classification that thwart comparative/pooled analyses, the number of 
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naevi remains a significant factor for melanoma risk and hence has been extensively 
studied.  Since the first report by Clark et al and coinage of the term ‘dysplastic naevi’, 
it has since been reported to occur frequently in Scottish (81), Dutch (82), English 
(83), Australian (84), Swedish (85), Italian (86), Spanish (87) and French (88) 
melanoma families. There is evidence for an autosomal dominant inheritance pattern 
of dysplastic naevi, as well as for a polygenic mode of inheritance (89). However, 
these naevi have been reported in sporadic cases as well, with occurrence in people 
with no family history of melanoma (90).  
Despite differing criteria for classification of dysplastic naevi across 
epidemiological studies, it remains a consistent risk factor for melanoma (91). For 
instance, a pooled analysis of 15 case-control studies (across different latitudes) 
showed that higher whole-body naevus count was associated with significantly 
increased melanoma risk in participants aged<50 years and also those aged>50 
years (92). In another meta-analysis of 47 case-control datasets, among which 27 
studies had assessed melanoma risk, dysplastic naevi were highly significantly 
predictive of melanoma risk, despite differing criteria of clinical assessment (93).  The 
phenotype is therefore a robust clinical marker of risk. 
Though the aetiology of naevus development is not fully understood, there is 
some epidemiological and experimental evidence that offers insight. The role of sun 
exposure and ultraviolet radiation in naevus development has been widely explored. 
Studies have reported increased naevus counts in younger individuals living in 
sunnier regions (Australia) compared to less-sunnier regions (England), with no 
difference among older individuals (94). In Australian children, with very high naevus 
counts, there was associated self-reported sun exposure of >4 hours per day and 
family history of sunburn (95). Increased naevus counts (both dysplastic and 
common naevi) in sun-exposed compared to sun-shielded body sights have also 
been reported (96), adding further evidence for a role of solar radiation in naevus 
aetiology.  
Genetic components associated with naevus aetiology have been identified from 
Genome Wide Association Studies (GWAS) of cutaneous naevus count (97) but not 
for dysplastic naevi. However, in a study of five melanoma families, family members 
with atypical mole syndrome were more likely to carry the CDKN2A mutation than a 
relative with no atypical mole syndrome (98). Linkage studies aiming to identify cause 
if dysplastic naevi have provided suggestive but inconclusive results for susceptibility 
loci on chromosomes 1,6, X (99) and 7 (100). The conclusion is therefore that the 
phenotype of increased numbers of naevi, which may or may not be associated with 
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clinically atypical naevi, is associated with risk and inherited melanoma susceptibility 
genes which may be highly penetrant or to have low penetrance. 
Despite dysplastic naevi being a marker of melanoma risk, it is widely observed 
that these naevi rarely directly progress to melanoma. Follow-up studies of 
melanoma-prone families show that most naevi remained stable and rarely 
‘progressed’ to a melanoma (101) (102). The study by Tsao et al estimated that the 
rate of transformation of any single naevus to a melanoma was <1 in 200,000 per 
year, in both men and women <40 years old. They also reported the lifetime risk of a 
‘naevus to melanoma transformation’ as 0.03% for men and 0.009% for women. 
Though melanocytic lesions (dysplastic naevi, common naevi and/or atypical naevi)  
are considered to be ‘growth-arrested’, they harbour oncogenic BRAF mutations 
(103-106) and mutations in genes coding for the mitogen-activated protein kinase 
(MAPK) pathway (107). One explanation of this phenomenon is Oncogene Induced 
Senescence (108): for instance, overexpression of the activated oncoprotein 
BRAFV600E  in cultured human melanocytes was shown to arrest growth and exhibit 
hallmarks of the senescent phenotype (109). In addition to the common BRAF 
mutation harboured by naevi, genetic alterations in GNAQ, ROS, ALK, NTRK1, RET, 
HRAS and BAP1 have also been reported across the heterogenous spectrum of 
naevi (110).  
Taken together, the development of benign proliferation of melanocytes which 
are naevi are most common in pale-skinned people and are associated with similar 
exposures and inherited genetic variation as melanoma. Moreover, it is not 
uncommon that melanomas arise in naevi. The initiating mutations e.g. in BRAF are 
not sufficient to cause a melanoma but proliferation occurring in a small percentage 
of melanocytes may result in a melanoma if additional changes occur which 
overcome the senescence normally associated with BRAF mutation.  
1.4.4 Pigmentation and skin type 
Pigmentation traits such as freckles, skin, hair and eye colour are known risk factors 
for skin cancers (111). In the case of melanoma, pigmentation has been identified as 
a risk factor in multiple epidemiological studies, with increased risk for pale-skinned 
individuals (91, 112). In other words, lower levels of pigmentation are associated with 
higher risk. Concordantly, melanoma burden is significantly higher in geographical 
regions with predominant pale-skinned populations (10).  
Cutaneous pigmentation is of relevance to my thesis as most people derive 
vitamin D predominantly as a result of cutaneous synthesis in the presence of sun 
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exposure.  That is that man evolved pale skin associated with an increased 
melanoma risk as the species migrated out of Africa, putatively as a result of the need 
to synthesise vitamin D (positive selection) and the loss of selection against the red 
hair gene coding for the MC1R “R” variant at the equator (Hochberg, 2010 #1096). 
The effects of vitamin D on melanoma are discussed separately in detail in section 
1.8.  
Skin pigmentation is determined by the amount and type of pigmentation 
produced by melanocytes, rather than the number of melanocytes. Eumelanin is 
black/brown pigment whereas pheomelanin is yellow/orange. The primary 
explanation for the association of reduced pigmentation and melanoma risk is that 
eumelanin produced by melanocytes scatters and absorbs 50-75% of UVR thus 
minimising DNA photo damage. In other words, eumelanin acts as a ‘natural 
sunscreen’ and thus prevent damage from UV exposure more efficiently than 
pheomelanin. Carcinogenicity of pheomelanin has also been postulated, with 
evidence for pheomelanin-dependent cellular oxidative stress (114): the presence of 
sulphur in the aromatic ring of pheomelanin makes it less stable and hence more 
efficient at producing reactive oxygen species (ROS) (115).  
The eumelanin/pheomelanin ratio in melanocytes determines pigmentation and 
is regulated by the melanocortin 1 receptor (MC1R) signalling. The MC1R agonist 
melanocyte stimulating hormone-a (aMSH), upon activation leads to transcription of 
enzymes necessary for eumelanin signalling. On the other hand, the MC1R 
antagonist agouti signalling protein (ASIP in humans) promotes expression of 
enzymes for pheomelanin production and also inhibits eumelanin synthesis (116, 
117). Thus, MC1R expression and signalling is a significant factor affecting 
pigmentation and consequently, UV-induced photodamage. MC1R is highly 
polymorphic with over 200 coding region variants described to date (118). Loss-of-
function variants affecting the receptor’s signalling ability lead to a shift away from 
eumelanin and towards pheomelanin synthesis (119, 120). This shift to pheomelanin 
is associated with the ‘red hair colour’ (RHC phenotypeii) which is characterised by 
pale skin, freckling and sun sensitivity (121). MC1R variants are classified according 
to the strength of associations with the RHC phenotype into “R” (strong association) 
(122, 123) or “r” (weaker association) alleles (122, 124).  
                                               
iiRHC phenotype: The Red Hair Colour phenotype is characterised by the following pigmentary traits: 
pale skin pigmentation, red hair, lack of tanning ability and propensity to freckle.  
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MC1R variants associated with melanoma risk have been reported by several 
studies in different human populations. These studies have demonstrated that while 
some MC1R variants are associated with both melanoma risk and the RHC 
phenotype, others are associated only with melanoma risk, suggesting that the role 
of MC1R in melanoma development involves non-pigmentary routes/components 
(124-126) as well as pigmentary routes. Melanomas from individuals carrying 
germline MC1R “R” variants have a significantly higher somatic mutational burden, 
compared to those with no MC1R “R” variants. This effect was independent of 
confounders such as age, sex, site of melanoma, Breslow thickness and ulceration 
status (127). This study complements the notion of eumelanin (produced by 
functionally intact MC1R) being a ‘natural sunscreen’: loss-of-function MC1R 
variants, lead to reduced eumelanin production with consequent increase in 
susceptibility to UV-induced DNA damage and increased somatic mutation load.  
The non-pigmentary effects of MC1R signalling have been reported to have a 
role in cutaneous immune responses and nucleotide excision repair. aMSH (the 
eumelanin producing agonist of MC1R), has been shown to modulate cutaneous 
immune response by inhibiting pro-inflammatory cytokines such as IL-1, IL-2 and 
interferon-gamma (128). It has also shown to have immunomodulatory effects via 
MC1R signalling in neutrophils and macrophages (129). However, a-MSH and MC1R 
are not necessarily dependent on each other for activity: a-MSH can signal via other 
melanocortin receptors (MC3R and MC5R) and MC1R can be stimulated by other 
agonists/antagonists. The ability of effective MC1R signalling (with the receptor being 
functionally intact) to boost UV-induced nucleotide excision repair (NER), via the 
cAMP production has been demonstrated in in vitro and in vivo models (130, 131). 
Thus, ineffective MC1R signalling can adversely affect cutaneous immune and DNA 
damage responses, thus offering additional explanations as to why MC1R variants 
(with partial/complete disrupted MC1R signalling) are associated with increased 
melanoma susceptibility (132).  
Though MC1R variants have bene extensively studied, there are several other 
genes that contribute to pigmentation in humans. While some of these genes 
contribute to melanin production, others control the function of the primary melanin 
producing cells, the melanocytes. The genes that control melanin production encode 
enzymes regulating ratio of eumelanin to pheomelanin. Polymorphisms in these 
genes have been identified using GWASs, to be associated with increased 
melanoma risk: those coding for tyrosinase (133, 134), tyrosinase-related protein-1 
(TYRP1), tyrosinase-related protein-2 (TYRP2), oculocutaneous albinism 2 (OCA2), 
solute carrier family 45, member 2 (SLC45A2), solute carrier family 24, member 4 
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(SLC24A4), and agouti signalling protein ASIP (135). These findings were confirmed 
in an independent GWAS study which agnostically identified the previously reported 
genetic loci associated with melanoma risk (136). The microphthalmia-associated 
transcription factor (MITF) is a melanocyte lineage-specific transcription factor which 
controls melanocyte migration and differentiation. The aMSH-MC1R-cAMP signalling 
axis leads to MITF-mediated transcription of target genes, which include eumelanin-
synthesizing enzymes as well as pro-survival genes anti-apoptotic genes such as 
BCL2A1, BCL2 and BIRC7 (137), thus making MITF signalling a crucial link between 
pigmentation and tumour progression (138).  
Taken together, the contribution of the ‘pigmentation machinery’ to melanoma 
risk is evident from genetic and functional studies, which have unravelled the 
mechanistic basis of the protective effect of melanisation.  
 
 Molecular pathogenesis of melanoma 
The complex and multifactorial aetiology of melanoma has been described in the 
previous section. In addition to identifying the environmental and genetic factors that 
contribute to melanomagenesis, research efforts have focussed on understanding 
the molecular basis of melanomagenesis. The collective understanding of aberrant 
signalling pathways involved in melanomagenesis have also formed the basis of 
diagnostic and therapeutic approaches, which aid the management of the disease. A 
particular pathway or gene is considered likely to contribute to melanomagenesis if 
an aberration (mutation, genetic loss/gain, change in expression) is i) observed to 
exist consistently across melanoma stages or ii) be functionally proven to initiate 
melanoma development in in vitro and/or in vivo models. Based on this ‘definition’, 
various pathways and genes have been shown to contribute variably to 
melanomagenesis. This section will discuss the contributions of the major signalling 
pathways and genes whose dysregulation has been shown to contribute to 
melanomagenesis. The intent of this section is to give an overview of the molecular 
pathways and the consequent cellular processes, without being exhaustive. 
1.5.1 The Ras-Raf-MEK-ERK pathway 
The Ras-Raf-MEK-ERK pathway is a complex signalling cascade which responds to 
various hormones, differentiation and growth factors, to regulate crucial cellular 
functions. Aberrations in this pathway are frequently observed in many cancer types, 
with consequent effects on tumour proliferation, apoptosis and differentiation (139). 
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The three Ras proteins: H-Ras, N-Ras and K-Ras are small GTPases activated by 
the conformational change induced by the exchange of GDP for GTP. The active 
forms of the Ras proteins function as adapter molecules by binding to Raf kinases 
(three isoforms: A-Raf, B-Raf and C-Raf), which in turn lead to the sequential 
phosphorylation of the kinases MEK (MEK1 and MEK2) and ERK (ERK1 and ERK2). 
These kinases in turn phosphorylate and activate transcription factors which regulate 
crucial cellular functions (140). In sporadic cutaneous melanoma, two particular 
components of this signalling pathway are known to be dysregulated: the proto-
oncogenes N-Ras and B-Raf (141). The mutually exclusivity of NRAS and BRAF 
mutations in melanoma has been reported (142). NRAS mutations are known to 
occur in approximately one-third of primary and metastatic sporadic cutaneous 
melanomas (143), the most common mutation being the Q61R (Glutamine- Arginine) 
mutation which impairs GTP hydrolysis and thus renders N-Ras constitutively active 
(144). BRAF mutations are known to occur in about 50-70% of melanomas, with the 
V600E (Valine to Glutamic acid) mutation accounting for 90% of all BRAF mutated 
melanomas. The V600E mutation affects the kinase domain leading to increased 
kinase activity of B-Raf (145). As discussed in section 1.4.3, BRAF mutations are 
observed in about 80% of benign naevi, including dysplastic naevi, suggesting that 
BRAFV600E is an early mutational event. Though, introduction of only the BRAFV600E in 
human melanoma cells has been shown to cause cell cycle arrest and senescence 
(109), expression of BRAFV600E combined with knockdown of the tumour suppressors 
TP53 or PTEN, has been shown to lead to spontaneous melanoma development 
(146, 147) in animal models. This supports the view that the BRAFV600E mutation is 
an early oncogenic event and leads to malignant transformation by acquisition of 
additional mutations (148). Taken together, these and other studies implicate 
BRAFV600E mutations as a significant and early player in melanomagenesis. 
1.5.2 PI3K, AKT and PTEN pathway 
The PI3K-Akt-PTEN pathway is one of the downstream effector pathways of the Ras 
proteins: activation of Ras leads to phosphorylation of PI3K (phosphotidyl inositol-3-
kinase) which in turn activates Akt, which is a key signalling molecule mediating 
processes such as angiogenesis, proliferation, apoptosis and cellular metabolism 
(149). This signalling axis begins with a ligand-dependent activation of tyrosine 
kinase receptors, G-protein coupled receptors or integrins (150). The tumour 
suppressor PTEN (Phosphatase and tensin homolog) inhibits the activation of PI3K, 
thus controlling the downstream effects of this signalling axis (151). In melanoma, 
loss or reduction of PTEN activity has been shown to eliminate Akt regulation, 
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resulting in melanoma progression and invasion (152-154). PTEN loss is considered 
an early event in melanoma development, as a consequence of single copy loss of 
chromosome 10, on which PTEN is located (155, 156). PTEN loss has been shown 
to bestow tumourigenic potential in melanoma cell lines by increasing Akt activity, 
thus circumventing anti-apoptotic signals (157). PTEN loss has also been shown to 
cooperate with NRASQ61K mutations to initiate melanomagenesis, in a PI3K-
independent and b-catenin dependent manner (158).  
The mammalian Akt (also named protein kinase B-PKB) family is comprised of 
three highly homologous isoforms: Akt1, Akt2 and Akt3, all of which are crucial 
components of the PI3K-Akt-MEK-ERK signalling axis. Constitutive activation of Akt 
signalling, in particular Akt3 (one of the three isoforms of Akt), has been shown to be 
prevalent in over 60% of melanomas (152, 154). This increased activity of Akt can 
be attributed to activating mutations of AKT3 (159) or due to loss of its negative 
regulator PTEN (152). Thus, the deregulation of the PI3K-AKT-PTEN signalling axis 
has been shown to affect melanoma initiation and progression.  
1.5.3 MITF 
MITF (Microphthalmia-associated transcription factor) is the master transcription 
factor for the regulation of melanocyte differentiation and pigmentation. The latter has 
been discussed in the context of the role of pigmentation in the section: Melanoma 
Aetiology: Pigmentation and skin type (section 1.4.4). MITF amplification is more 
common in metastatic compared to primary melanomas and is associated with worse 
prognosis. However, MITF is considered to play a ‘double role’ of inducing and 
supressing cellular proliferation, depending on the level of MITF expression (160). 
MITF amplifications in conjunction with BRAFV600E has been shown to transform 
human melanocytes in vitro. Moreover, this study also identified MITF as a ‘lineage 
survival oncogene’: a gene required for the development of melanocytes, but 
amplification of which is maintained as a feature in melanoma initiation and 
progression (161).  
The other genes implicated in the molecular pathogenesis of melanoma include 
KIT and TP53. Mutations or amplifications of KIT (CD117) have been reported in 
melanomas that occur in anatomic sites with little UV exposure such as oral mucosal 
melanomas, acral melanomas and anal melanomas (162, 163). The precise 
mechanism of how KIT contributes to melanomagenesis is unclear. However, studies 
show that constitute KIT activation in melanocytes leads to MITF and ERK2 
activation, suggesting a potential route for melanoma initiation. p53 is a master 
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transcription factor which is activated in response to cellular stress cues such DNA 
damage and hypoxia (164). Inactivating mutations and deletions of the TP53 gene 
have been reported in many cancer types. However, in melanoma TP53 alterations 
are reported to be of low frequency, detected in 1-5% in primary (165) and 11-25% 
in metastatic melanomas (166), though variable frequencies have been reported.  
In addition, a more recent study using whole exome sequencing (WES) of 213 
melanomas identified inactivating mutations in the NF1 gene in tumours that were 
wild-type for both BRAF and NRAS, the most common mutations in sporadic 
melanomas. Since loss of function of NF1 was accompanied by activation of the RAS 
pathway in a proportion of the samples, this study posited the role of NF1 as a tumour 
suppressor gene in a subgroup of sporadic melanomas (167). BRAF, NRAS and NF-
1 are considered to be the most frequent melanoma driver mutations. 
 
 Tumour host interaction: role tumour microenvironment 
in melanoma development and progression 
The tumour microenvironment has been accepted to be a significant contributor to 
the process of tumour progression. The ‘seed and soil’ hypothesis (168) suggests 
that tumour growth and survival is contextual: some physiological environments are 
more conducive for tumour development than others. The significance of the tumour 
microenvironment (TME) (169) in tumourigenesis and progression has since been 
extensively explored and remains an active area of cancer research in multiple 
cancer types. Components of the TME that have been implicated in tumour 
development include the extracellular matrix (ECM), fibroblasts (including cancer-
associated fibroblasts- CAFs), immune and inflammatory cells, vascular networks 
and adipose cells. The crosstalk between these components and with tumour cells 
has been shown to influence the crucial characteristics of tumour development, as 
typified by the ten Hallmarks of Cancer (170). It is now known that melanoma cells 
actively interact with various components of their microenvironment, with significant 
implications on disease progression. Selected TME components and their role in 
melanoma progression are discussed below. 
1.6.1 Immune response to melanoma 
The role of the host immune response has been extensively studied and shown to 
be an important determinant of melanoma progression. Even prior to the era of 
molecular and genomic profiling, histological evidence of lymphocytic infiltration was 
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identified as a feature of spontaneous regression in primary melanomas (171). 
Multiple studies have since shown that tumour infiltrating lymphocytes (TILs) are of 
prognostic significance in independent cutaneous melanoma patient cohorts. 
Collectively, these studies have identified the following measures of immune 
infiltration to be of prognostic significance:  intratumoural/peritumoural TIL density 
(172-175) and patterns of infiltration (brisk versus non-brisk infiltration) (176, 177). 
The vast majority of studies indicate that histological evidence of the presence of TILs 
is associated with improved prognosis and reduced chance of lymph node metastasis 
(178). A lack of prognostic significance has also been reported (179) in which the 
authors suppose that their findings suggest a role for TILs in vertical growth phase 
tumours rather than radial growth phase tumours. In the case of immune cell types, 
histological expression of markers for CD3, CD4 and CD8 cells (180, 181) and B cells 
(182, 183) have been associated with improved prognosis. On the other hand, 
markers for NK cells (184) and expression of FOXP3 (185) were associated with 
higher risk of relapse and worse progression free survival respectively. However, it 
has been shown that in the case of metastatic melanomas, tumours are not 
eliminated despite detectable immune infiltrate (186), indicating that immune evasion 
mechanisms could be involved. Taken together, this indicates that the interplay 
between melanoma cells and the host immune response is complex and extensive 
research efforts in the field are being focused on understanding this relationship 
better.  
The apparent immunogenic behaviour of melanoma has been attributed partially 
to the high mutational burden in melanomas compared to other cancer types (75). 
Despite melanoma being one of the most immunogenic cancer types and increased 
immune infiltration predicting improved melanoma prognosis, metastatic melanoma 
mortality remains high (discussed in Melanoma Mortality section). This suggests that 
melanoma progression involves mechanisms that enable evasion of anti-tumour 
immune response. The response of the host immune response to tumour cells is a 
multi-step process and defects in these steps are characteristic of immune evasion.  
In the case of melanoma, the following steps give a brief overview of how melanoma 
cells evade the host immune response:  
Defective antigen presentation: inefficient antigen presentation by melanoma cells 
is one of the causes of ineffective immune recognition. Expression of MHC Class I 
(187) and MHC Class II (188) may be downregulated in melanoma cells.  Mutations 
in components of antigen presenting machinery in melanoma cell have also been 
reported (189). Moreover, since T cell cytotoxicity requires antigen presentation by 
mature dendritic cells (DCs), tumour-produced factors that prevent DC maturation or 
22 
 
switch to a tolerogenic phenotype have been described to be part of the immune 
evasion mechanism (190). 
Defective priming and activation of T cells: cytotoxic T cell function is also 
inhibited by upregulation of immune checkpoint molecules. The role of immune 
checkpoint signals in normal physiology is to limit T cell responses in order to 
preserve self-tolerance during an immune response against a foreign antigen (191): 
to reduce tissue damage resulting from uncontrolled inflammation. However, 
upregulation of checkpoint molecules by melanoma cells dampens a cytotoxic T cell 
response against the tumour, thus becoming a mechanism of tumour immune 
evasion. Increased expression of the following checkpoint molecules has been 
shown to reduce the anti-melanoma immune response: CTLA4, PD1, LAG3, TIM3, 
VISTA and the checkpoint ligands PD-L1 and PD-L2 (192). Current immunotherapy 
approaches to treat metastatic melanoma aim to inhibit these checkpoint molecules, 
thus permitting an active T-cell mediated immune response against melanoma. This 
might be considered to be equivalent to removing the brakes on the immune 
responses. This is discussed in detail in subsequent section titled ‘Melanoma 
immunotherapy’. 
Reduced activity of anti-tumour immune populations: Inefficient antigen 
presentation impairs the ability of CD8 T cells to detect tumour-specific antigens. In 
addition to T-cell suppression, reduced NK cell responses have also been reported 
in melanoma patient-derived tumours as well as murine melanoma models. In normal 
physiology, NK cell activation and responses are mediated by activating receptors 
such as NKG2D, NKp46 and DNAM-1 (193). However, tumours from melanoma 
patients have reduced expression of these activating receptors (194) indicating NK 
cell-associated immune evasion (195). Moreover, NK cell functions are also inhibited 
by MDSC-mediated factors, as discussed below. 
Upregulation of immunosuppressive immune populations: in normal physiology, 
cells such as T-regs and MDSCs function to balance immune responses and prevent 
‘excessive’ immune response which could lead to autoimmunity. While T-regs are a 
specialised subpopulation of T cells that inhibit T-cell proliferation and cytokine 
production (196), MDSCs are a heterogenous population of myeloid origin cells which 
suppress various T-cell functions (197). In melanoma, T-regs-mediated over-
production of factors which dampen activity of CD4 and CD8 T-cells and NK-cells 
(such as IDO and IL10) have been reported (198). The recruitment and stimulation 
of MDSCs to the TME has been shown to increase production of factors (such as 
nitric oxide, ROS-Reactive Oxygen Species and arginase-1) that inhibit anti-tumour 
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activity of T-cell and NK cells (199). A study by Jordan et al also reported  increased 
MDSCs (defines as CD3- CD19- CD56- CD11b+ HLA-DRA- CD33+ CD14+ population) 
in the peripheral blood of stage IV melanomas compared to healthy donors (200), 
which indicates that MDSCs are associated with advanced melanomas. 
1.6.2 Fibroblasts in the microenvironment 
CAFs have been described as a subpopulation of functionally distinct fibroblasts that 
facilitate tumour promotion by enhancing pro-tumourigenic processes such as 
angiogenesis, inflammation and metastasis (201). CAFs are identifiable in the close 
vicinity of tumour cells and are functionally distinct from normal fibroblasts, in that 
they produce (and respond to) tumour promoting signals (202-204). CAFs have also 
been shown to selectively suppress CD8-mediated anti-tumour immune responses 
(205), thus highlighting the importance of this cellular subpopulation in tumour 
progression in general and melanoma in particular.  
Melanoma-associated CAFs have been shown to mediate melanoma 
progression in both murine and human melanoma tumours. For instance, the NK cell-
dependent cytotoxicity of fibroblasts derived from normal skin (normal fibroblasts) 
and primary melanoma tumours (CAFs) were compared: the CAFs decreased the 
susceptibility of melanoma cells to NK cytotoxicity by production of matrix 
metalloproteinases (MMPs) (206). Melanoma associated fibroblasts, in concert with 
fibronectin-rich matrices, have been shown to confer resistance to BRAF inhibitors, 
in the adjacent melanoma cells (207). This finding suggests that therapy resistance 
in melanoma patients to BRAF inhibitors is at least partially explained by the TME, 
making the TME an important factor in determining therapy resistance. 
 
 Melanoma therapy options: immunotherapy 
Treatment options for melanoma are dependent on the stage of melanoma at 
diagnosis (Macbeth, 2015 #1107). The prevalent recommendation for stage I 
melanoma is surgery with wide excision, which involves the removal of the melanoma 
as well as the normal skin surrounding it. Stage II melanomas are also treated with 
surgery, but additional lymph node biopsies are also undertaken to gauge the spread 
of the disease. In the case of stage III and stage IV melanomas, surgical excision 
and lymph node biopsies are followed by adjuvant treatment with immunotherapies 
or targeted therapies (typically BRAF and MEK inhibitors). Radiation therapy is also 
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recommended in cases where lymph nodes are excised and found to contain 
malignant lesions.  
Cancer immunotherapy is the collective term used to describe cancer therapies 
which aim to harness the ‘cancer-eliminating’ properties of the immune system. The 
concept of the immune system being capable of identifying and targeting transformed 
cancer cells stems from the Cancer Immunosurveilance model (208). This model 
describes the interaction between the host immune system and the tumour cell, 
wherein the tumour cell evades the attempts of the immune system to retard its 
progression (209). Simply put, immunotherapy aims to bolster the immune system’s 
ability to detect and destroy transformed cancer cells. Various lines of 
immunotherapy exist which target various components of the immune system in order 
to increase anti-tumour immune response. Among them is the use of immune 
checkpoint inhibitors, in particular: anti-cytotoxic T lymphocyte antigen 4 (anti-
CTLA4) and anti-programmed cell death protein 1 (anti-PD-1). CTLA4 and PD-1 are 
checkpoint molecules expressed on T-cells. PD-1, expressed on surface of T-cells, 
is the binding receptor for PD-L1/2 (expressed on tumour cells). In normal physiology, 
the binding of the receptor (PD-1) to the respective ligands (PD-L1/2) serves to 
regulate T-cell activation by competing with the co-stimulator CD28 to prevent 
persistent T-cell activation (210). The mechanism by which CTLA4 participates in 
regulation of T-cell activity is by competitive inhibition: CTLA4 competes with 
costimulatory molecule CD28 for binding to the B7 ligands B7-1 (CD80) and B7-2 
(CD86). While CD28 binding to the B7 ligands provides positive costimulatory signals 
(and T cell activation), binding of CTLA4 to B7 ligands dampens T cell response 
(Linsley, 1994 #1098). Negative costimulation by CTLA4 is thus crucial in balancing 
T cell responses (Wei, 2018 #1097). Given both PD-1 and CTLA4 function as 
regulators of T cell response, led to the term ‘checkpoint molecules’. The rationale 
behind using this mechanism for checkpoint immunotherapies is that blocking these 
checkpoint molecules would enable uninhibited cytotoxic attack by T-cells on the 
tumour. The checkpoint inhibitors that are currently used (FDA-approved) to treat 
metastatic melanoma are Ipilimumab, Nivolumab and Pembrolizumab and most 
recently adjuvant use of some has also been approved. While Ipilimumab targets 
CTLA-4, Nivolumab and Pembrolizumab target PD-1. Though CTLA4 and PD-1 are 
the active drug targets at the moment, other costimulatory and inhibitory ligands on 
cytotoxic T lymphocytes (CTLs) T-regs and other immune cells in the tumour 
microenvironment have been investigated. These include lymphocyte activation gene 
3 (LAG3), whose binding ligand is MHC class II and is expressed on T-regs and 
inhibits T cell response (211).  
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The determinants of response to checkpoint therapies have been investigated in 
patient cohorts, in order to identify the factors that best predict response. Increased 
response rates to PD-1 inhibition in patients whose tumours or TILs express PD-L1 
have been reported in some trials (212, 213). MHC Class II expression has also been 
associated with improved response to PD-1 inhibition (214). However, the following 
factors thwart the development of a reliable measure to predict response to 
checkpoint therapies: significant variation in the estimation of PD-L1 expression 
(using IHC), demonstrable response in some patients whose tumours do not express 
PD-L1 and lack of correlation between tumour PD-1 expression and CTLA4 
response. More recently, researchers have taken a retrospective, genomic view of 
assessing differences between responders and non-responders to immunotherapy, 
i.e. identifying omic-based biomarkers to predict therapy response.  
Whole Exome Sequencing (WES) has been used to identify associations 
between factors such as mutational burden and clinical benefit. This approach has 
been adopted in studies by Snyder at el (215) (64 patients treated with anti-CTLA4) 
and Van Allen et al (216) (110 patients treated with anti-CTLA4), who arrived at the 
consensus: high mutation burden is associated with clinical benefit to anti-CTLA4 
treatment. Another study by Riaz et al (217) (WES on 174 patients treated with anti-
CTLA4) reported that a subset (n=48) of patients with mutations in SERPINB3 and 
SERPINB4 had a higher likelihood of being responders. WES and RNAseq data from 
patients treated with anti-PD1 therapy were analysed by Hugo et al, who reported 
that mutation burden was not associated with therapy response. Albeit in a very small 
cohort (38 patients), whereas in a subset of patients (n=28), a gene signature of 26 
genes was able to classify responders and non-responders (218). The lack of a 
validation data set in this study and in the other studies listed reflects the paucity of 
data yet available to address this need. Non-the-less these studies suggest that 
mutation load and specific, biologically relevant gene expression patterns underlie 
variation in response to immunotherapy in metastatic melanoma.  
Other studies have explored the effect of factors such as the diversity of the T 
cell repertoire before treatment and its effect on response to immunotherapy (219-
222), this area of research is actively expanding.  
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 Vitamin D-VDR signalling  
1.8.1 Components of vitamin D-VDR signalling 
Vitamin D-VDR signalling refers to the signalling system activated in response to the 
ligand 1α,25-dihydroxyvitamin D3 (vitamin D3 henceforth), with consequent effects on 
transcription of target genes. The vitamin D3 endocrine system is composed of two 
‘arms’: a) vitamin D3-metabolising enzymes which belong to the Cytochrome P450- 
CYP family of anabolic and catabolic enzymes and b) dedicated nuclear receptors 
such as VDR (Vitamin D Receptor) and RXR (Retinoid X Receptor), which upon 
activation bind to Vitamin D Receptor Element (VDRE)- containing regions of the 
chromatin and facilitate transcription of target genes (223). While the machinery to 
synthesis biologically active form of vitamin D3 is found in yeast, plants and some 
invertebrates, the complete vitamin D3 endocrine system (both the ‘arms’) is unique 
to vertebrates, indicating that vitamin D signalling gained importance as organisms 
evolved to cope with environmental stresses (223). 
The biologically active form of vitamin D is vitamin D3 (1,25 dihydroxyvitamin D3), 
which is produced by a series of enzymatic reactions. Most humans obtain sufficient 
vitamin D primarily as a result of sun exposure, as there are few good dietary sources. 
While vitamin D3 obtained from dietary sources enters circulation after processing in 
the intestine, cutaneously synthesised vitamin D3 is metabolised in the dermis. The 
first cutaneous step involves the UVB-mediated non-enzymatic conversion of 7-DHC 
(7-dehydrocholesterol) to vitamin D3 (also known as cholecalciferol). Intensity of UVB 
as well as skin pigmentation determine this first step (224), with increased melanin 
content retarding the UVB-mediated production of vitamin D3 (225). Vitamin D levels 
in Northern Europe therefore are on average some 20 nmol/L lower in winter months 
where there is insufficient exposure to UVB for efficient synthesis (226, 227). The 
next enzymatic reactions are facilitated by the cytochrome P450 (CYP) family of 
enzymes, which specialise in catalysing various biological functions in human 
physiology. Six CYPs are involved in vitamin D metabolism via stepwise 
hydroxylation reactions of intermediate molecules.  Among these, the primary CYPs 
associated with Vitamin D anabolism (synthesis) are CYP27A1 and CYP27B1, 
processes taking place in the liver and kidney respectively. Circulating cholecalciferol 
is converted to 25(OH)vitamin D3 in the liver, which is then transported to the kidneys 
to be converted to 1α,25-dihydroxyvitamin D3: the ‘final’ hormonal form of vitamin D. 
The catabolism (break-down) of vitamin D is mediated by CYP24A1 in the kidney. 
CYP24A1 responds to high levels of circulating vitamin D3 by catalysing the break-
down of 25-hydroxy vitamin D3, to lower the level of hormonal vitamin D3. Both 
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anabolic and catabolic CYPs are transcriptionally controlled: they contain the VDRE 
and hence are tightly regulated by the concentration of active vitamin D3 at any given 
point (228). This process is summarized in Figure 1.5 (229).  
The Vitamin D Receptor (VDR) and Retinoid X Receptor (RXR) are members of 
the Nuclear Hormone Receptors (NHR) family- which includes other members such 
as the Retinoid Activated Receptor(RAR), Peroxisome Proliferator-activated 
Receptor (PPAR), Tyrosine Receptor (TR) and Liver X Receptor (LXR), to name a 
few (230). Because VDR is the canonical receptor of vitamin D signalling and 
mediates its genomic effects, it is discussed in detail below. However, the role of RXR 
and its canonical ligand Retinol (vitamin A) in cancer and metabolic disease have 
also been extensively researched (231). In my thesis, I do account for the effects of 
RXR, when interrogating the effects of VDR on the LMC melanoma transcriptome 
but I have not explored this literature in the thesis.  
 
Figure 1.5 Summary of the vitamin D-VDR signalling axis. 
Adapted from: Deeb KK, Trump DL, and Johnson CS. Vitamin D signalling 
pathways in cancer: potential for anticancer therapeutics. Nature reviews 
Cancer. 2007;7(9):684-700. 
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1.8.2 The Vitamin D Receptor (VDR) 
The Vitamin D Receptor (VDR) is the high-affinity Nuclear Hormone Receptor (NHR) 
of hormonal vitamin D3. Being a transcription factor, VDR dimerizes with RXR 
(Retinoid X Receptor) to enable transcription of genes whose promoters contain 
VDRE (Vitamin D Responsive Elements) (232). VDR belongs to the Nuclear 
Receptor superfamily whose members contain a conserved DNA-binding and ligand-
binding domains as well as variable C-terminal and N-terminal regions (233).  
1.8.2.1 VDR structure: functionally relevant features of VDR 
The cloning of the human VDR (hVDR) in 1988 (234) paved the way for numerous 
studies that unravelled the structure-function relationship of VDR (235). Human VDR 
is a 423 amino acid protein composed of multiple structural domains that have been 
ascribed specific functional relevance based on structure/function data. VDR can 
thus be split into three functional domains described below (236).  
The N-terminal DNA binding domain (DBD) is the most conserved among nuclear 
receptors and is composed of three a-helical sub-domains (P-box, D-box and T-box) 
which enable stable DNA-binding (positively charged amino acids bind strongly to 
negatively charged phosphate backbone of DNA) as well as response element 
specificity.  
The C-terminal ligand-binding domain (LBD) is composed of a-helices and b-
strands that encompass a lipophilic ligand-binding pocket. In addition to ligand-
binding, the LBD also mediates heterodimerization with RXR and ligand-activated 
recruitment of coregulatory complexes.  
The Hinge region links the DBD and LBD and offers rotational freedom for binding 
various response elements. 
1.8.2.2 VDR-mediated regulation of target genes: The Vitamin D 
Response Element (VDRE) 
The tissue and gene specificity of ligand-bound VDR-mediated transcription is 
regulated by two factors: DNA binding specificity (presence of VDRE) within 
regulatory regions of target genes and recruitment of ancillary transcription 
complexes.  These factors are crucial, given that they determine the specificity and 
intensity of VDR-mediated transcription.  
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Like other members of the nuclear receptor family, ligand activated VDR-RXR 
dimers have affinity for specific DNA binding sequences. In addition to the actual 
repeat sequence, the nature of the repeat (direct, everted, inverted or palindromic) 
and spacer length (+3 nucleotides, +4 nucleotides etc) determine binding specificity 
among HREs (Hormone Response Elements). For instance, two direct hexameric 
repeats of AGGTCA form the binding site for VDR (known as DR3-type VDRE), all-
trans retinoic acid receptor and 9-cis retinoic acid receptor.  However, these response 
elements differ in the number of spacer nucleotides between the half sites: 1nt for 
the 9-cis retinoic acid receptor, 5nt for the all-trans retinoic acid receptor and 3nt for 
the VDR (237). This highlights the potential of these unique repeat sequences to 
control transcriptional diversity. The VDREs are typically composed of the DR3-like 
elements (described above), other VDRE types exist- ER9-type (Everted Repeat with 
9nt spacer) and even a transrepressor VDRE (nVDRE- negative VDRE) (238). The 
first genes to be identified as having a proximal VDRE that facilitated their 
transcription were Osteocalcin (239) and Osteopontin (240), which were specifically 
studied owing to the known role of vitamin D-VDR signalling on bone remodelling. 
This was followed by discovery of this specific VDRE sequence in regulatory 
elements of other genes, thus putting forth a conclusive VDRE sequence. This 
eventually lead to identification of VDRE across the genome with the advent of high 
throughput technologies such as ChIP-Seq (Chromatin Immunoprecipitation). I have 
used data from these studies to support my own research, which I have discussed in 
detail in Section 3.4.5.3.  
1.8.2.3 Role of coregulatory complexes in VDR function 
Ligand binding to VDR causes a series of conformational changes, one of which is 
an alteration to the AF2 domain of the LBD, making available hydrophobic docking 
surfaces for cofactor binding. A typical example is the SRC1 (Steroid Receptor 
Coactivator-1) which has autonomous transcription activation potential, histone 
acetylase activity capable of directly altering chromatin structure (241) and is known 
to bind and facilitate VDR-mediated transcription activity (242, 243). A more 
specialized coactivator complex for VDR is the DRIP (VDR-interacting proteins) 
complex that has no homology with SRC family coactivators and yet recognizes the 
AF-2 transactivation motif of VDR. DRIP complex proteins were the first VDR-
specialised coactivators to be discovered, owing to their ability to selectively enhance 
transactivation of ligand bound VDR-RXR dimers (244). Thus, coactivator complexes 
make the chromatin environment more conducive to transcription initiation, while also 
offering selectivity for VDR-mediated transactivation.  
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1.8.2.4 Ligand-induced activation of VDR 
Ligand binding to nuclear VDR prompts a change in the co-factors bound to VDR: 
co-repressors are now released and replaced by co-activators. This leads to a more 
‘receptive’ chromatin confirmation prompting mobilization of transcription machinery 
and transcription of target genes. The negative feedback loop keeps this process in 
check by a) ‘supply’ of the ligand vitamin D is controlled by anabolic CYPs- 
transcribed by vitamin D-VDR binding and b) resultant unliganded cytoplasmic VDR 
is degraded by proteosomal and polyubiquitination events (245) 
Taken together, the above section gives an overview of the different mechanisms 
by which VDR exerts transcriptional control over target genes, highlighting the 
complexity and yet the specificity of this transcription factor.  
1.8.3 Vitamin D signalling targets 
The most well-established physiological effect of Vitamin D3 is the effect on bone 
mineral homeostasis, where vitamin D3 is known to mediate the balance of calcium 
and phosphate-associated signal transduction pathways. vitamin D3-bound VDR 
induces expression of calcium channel proteins such as TRPV6 in the small intestine, 
as well as calcium absorption-enabling enzymes such as calbindin (246). 
Additionally, vitamin D3 synthesis is stimulated in response to reduced circulating 
phosphorous, leading to vitamin D-VDR-mediated transcription of phosphorous-
absorbing enzymes and membrane proteins (247). In the case of inadequate serum 
vitamin D3 (vitamin D deficiency), this leads to decreased calcium and phosphorous 
absorption by the bone chondrocytes, i.e. bone resorption. This weakens the bone 
and cartilage architecture (248). However, VDR expression is not restricted to 
intestines and skeletal tissue, but is also expressed in the brain, skin, muscle, heart, 
stomach, pancreas, mammary glands, testes and in activated T and B lymphocytes 
(249, 250). The enzymatic machinery needed to metabolize vitamin D3 is expressed 
in colon, prostate, breast, and skin (250). In addition to the classic genomic response, 
vitamin D3 is also known to elicit certain non-genomic responses that are rapid (within 
seconds to minutes, depending on tissue type) and transcription-independent, such 
as the rapid intestinal absorption of calcium (transcaltachia), opening of voltage-
gated Ca2+ and Cl- channels in osteoblasts and rapid migration of endothelial cells 
(251). Taken together, it can be deduced that most human tissue are responsive to 
vitamin D3 (249, 252), indicating the ubiquity of this signalling axis, with potential 
tissue-specific effects.  
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1.8.4 Vitamin D signalling and the immune system 
Evidence linking vitamin D and the immune system originates back to when cod liver 
(which is a rich source of dietary vitamin D) was used to treat tuberculosis, albeit 
without attributing the effects to vitamin D itself (253). The understanding of the 
relationship between vitamin D and the immune system has since burgeoned, with 
evidence indicating both ‘pro-immune’ and ‘anti-immune’ effects of vitamin D. The 
evidence that vitamin D is associated with an increased (pro-immune) response 
stems from both epidemiological observations and functional studies. Multiple cross-
sectional studies have reported low vitamin D to be associated with increased reports 
of infections such as upper respiratory tract infection (254, 255), influenza (256) and 
HIV infection (257). An association between vitamin D deficiency and infections 
suggests therefore a role for the hormone in mounting immune responses to 
infections: or that vitamin D deficiency is associated with immune failure. 
Epidemiological evidence indicates that vitamin D deficiency is also associated with 
development of autoimmune diseases such as multiple sclerosis (258), diabetes 
mellitus (259) and rheumatoid arthritis (260) which might suggest that upregulation 
of immune responses to “self” tissues is also related to vitamin D deficiency. There 
is extensive literature indicating that lupus patients have lower vitamin D levels 
compared to healthy controls (261). Moreover, the canonical receptor for vitamin D 
activity: VDR, is expressed on lymphocytes (262), suggesting that immune cells can 
respond to vitamin D stimulus. The role of vitamin D in anti-bacterial immunity has 
been shown to be mediated by components of the innate immune system. Binding 
and activation of toll-like receptors (TLRs) by APC cells has been shown to induce 
the expression of both VDR and the anabolic enzymes for vitamin D synthesis (263). 
Microarray-based studies have revealed that gene targets of 1,25D3-VDR signalling 
include anti-bacterial proteins: cathelcidin (264) and b-defensin-2 (DEFB4)(265).  
The inhibitory role of vitamin D (‘anti-immune’) have also been reported. Two 
independent studies have demonstrated the role of vitamin D3 as an inhibitor of T-
cell proliferation that blocks transition from early G1 phase to late G1 phase (266, 
267). In addition, 1,25D3 has been shown to promote regulatory T-cells (T-regs) by 
mechanisms that involve Antigen Presenting Cells (APCs) (268). In the context of B-
cells, 1,25D3  has been shown to suppress B-cell maturation into plasma cells and 
class-switching memory cells as well as to regulate IL-10 (269) and CCR10 (270).   
In summary, the current evidence suggests that there is indeed interaction 
between hormonal vitamin D and components of the immune system. However, the 
direction of interaction could be dictated by cellular context and a complex set of 
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feedback loop mechanisms, which could explain the apparent contrast in effects on 
the immune system. There are strong data suggesting vitamin moderates and 
interacts with immune cells both epidemiological and in vitro/in vivo but the literature 
describes enormous complexities which I feel are as yet unresolved. 
1.8.5 Vitamin D signalling in cancer 
1.8.5.1 Epidemiological evidence 
The scepticism around the associations between high vitamin D levels and better 
outcomes is generally based upon the observation that people who are leaner, fitter 
and wealthier in many countries. Furthermore, that supplementation trials for a 
number of conditions were negative except for a general increased overall survival 
in a meta-analysis performed by Autier (271). The suspicion was that the association 
between lower vitamin D levels and reduced risk of a variety of conditions had 
occurred because of reverse causalityiii. In particular, the negative correlation 
between low vitamin D levels and high levels of C-reactive protein (CRP) (273) 
suggested the association between low vitamin D levels and ill health, rather than 
low vitamin D levels were acting as a biomarker of systemic inflammation. Despite 
this scepticism, epidemiological studies have reported associations of serum vitamin 
D levels with cancer risk and mortality in colorectal, breast, prostate, bladder, lung, 
melanoma and other skin cancers (274).  
Colorectal cancer: the strongest consensus evidence that low serum/plasma 
25(OH)vitamin D is associated with increased cancer risk exists in the case of 
colorectal cancer. This evidence stems from meta analyses (275-277) as well as 
nested case-control studies (278, 279).  
Breast cancer: the evidence for 25(OH)vitamin D and risk of breast cancer is not as 
consistent compared to colorectal cancer. However, a meta-analysis of 8 studies 
showed that higher circulating 25(OH)vitamin D was associated with lower risk of 
breast cancer incidence (280). However, there is lack of concordance of findings 
between retrospective and prospective studies: the inverse association of circulating 
25(OH)vitamin D3 with breast cancer risk seemed to be restricted to retrospective 
studies such as by Shao et al (280), with null association for prospective studies (275, 
                                               
iii Reverse Causality: reverse causality is when the exposure-disease process is reversed. In other 
words, instead of the exposure causing the disease (causality), the event of having the disease (e.g. 
Being diagnosed with a disease) can cause a change in the pattern of the exposure (e.g. Lifestyle 
changes in relation to the disease).(272. To SH. Statistics How To. 
https://www.statisticshowto.datasciencecentral.com/reverse-causality/. 
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281). This discordance between retrospective and prospective studies indicates the 
possibility of bias, in particular of reverse causality as mentioned above. 
Prostate cancer: among the various cancer types whose association with circulating 
vitamin D have been investigated, prostate cancer is the only malignancy with 
evidence for a positive association with cancer risk i.e. higher serum vitamin D has 
been reported to be associated with increased risk of prostate cancer. For instance, 
a meta-analysis of 21 studies reported that in 16 of the studies, men with higher 
serum levels of 25(OH)vitamin D3 had an increased risk of prostate cancer, compared 
to men with lower 25(OH)vitamin D3. On the other hand, prostate cancer incidence 
and mortality in African-American males, who have reduced cutaneous synthesis of 
vitamin D owing to skin pigmentation, is higher than their Caucasian counterparts 
(282). But this effect could be confounded by the disparity in medical care or 
socioeconomic status. Taken together, the association between prostate cancer 
incidence and circulating vitamin D levels is still unclear and the focus of ongoing 
research efforts.  
Bladder cancer: there is evidence for inverse relationship between high serum 
25(OH)vitamin D3 and reduced risk of bladder cancer, based on meta-analyses (283, 
284).  
Lung cancer: two meta-analyses assessing the association between circulating 
25(OH)vitamin D3 and risk of lung cancer indicate an inverse relationship i.e. patients 
with low circulating 25(OH)vitamin D3 had a higher risk of lung cancer (285, 286).  
Skin cancers: when considering the relationship between skin cancer and vitamin 
D, it is important to note an important factor common to both: UVB radiation. While 
UVB is an important part of skin cancer aetiology, it is also necessary for the 
cutaneous synthesis of vitamin D. This relationship has been discussed in section 
1.4.4. 
Lower incidence of non-melanoma skin cancers (NMSC) has been reported in 
subjects with highest serum vitamin D concentrations, compared to those with lowest 
serum vitamin D concentrations (287).  
Melanoma: several studies have investigated the role of serum vitamin D in 
melanoma. Our research group has particularly focussed on this aspect. In a small 
retrospective studied carried out in Leeds, designed to identify lifestyle factors 
associated with late relapse from melanoma, participants who had suffered a relapse 
were less likely to report taking vitamin D supplements than controls who were 
melanoma cases who had not relapsed after 5 years (256). The group then carried 
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out a prospective study of 872 patients in the Leeds Melanoma Cohort, in which 
higher 25(OH)vitamin D3 (henceforth referred to as vitamin D) levels at recruitment 
were found to be associated with lower Breslow thickness and better Melanoma 
Specific Survival (MSS) (288). Subsequently a similar relationship between vitamin 
D levels and stage at diagnosis was reported in studies from France (289) Germany 
(290), America (291) and Australia (292). Fang et al reported a similar study which 
also addressed the issue of the degree to which vitamin D levels might merely be a 
surrogate for higher levels is systemic inflammation. In that study Fang et al showed 
that low serum vitamin D levels were associated with higher C-Reactive Protein levels 
(CRP-a marker of systemic inflammation, frequently higher in patients with the 
metabolic syndrome/obesity), higher ulceration, increased tumour thickness and poor 
MSS. The crucial result was that the relationship between vitamin D levels and 
survival was independent of CRP level. 
In summary, there is strong evidence that low levels of vitamin D at diagnosis are 
associated with thicker melanomas and poorer prognosis in 4 continents. This effect 
seems to be independent of the CRP level. The strong negative correlation between 
CRP and vitamin D levels is however of interest and it has been suggested by Amer 
(273) and others that some of the beneficial effects of vitamin D might be a result of 
suppression of systemic inflammation.  
1.8.5.2 In vitro evidence  
The first study to indicate the anti-proliferative activity of 1,25(OH)2D3 was the study 
by Colston et al, who elegantly demonstrated that 1,25(OH)2D3  had high affinity for 
VDR protein and decreased the doubling time of melanoma cells in a dose-
dependent manner (293). This was followed by a mounting evidence for anti-tumour 
activity of vitamin D-VDR signalling from in vitro studies performed in the 1990s and 
early 2000s. These studies were designed to assess a specific aspect of the anti-
tumour effects of vitamin D treatment, such as its effect on proliferation, apoptosis, 
invasive potential and DNA repair. In the context of proliferation, a ‘targeted’ 
approach was taken, wherein the effect of 1,25(OH)2D3 (or its analogues) on a 
particular cell cycle and/or proliferation-associated pathway was assessed. For 
instance, 1,25(OH)2D3 was shown to induce cell cycle arrest in squamous cell 
carcinoma (294), breast cancer (295), leukaemia, myeloma and colon cancer (296). 
Efforts were also focused on identifying gene targets of the signalling axis. A study 
using the myelomonocytic cell line U937 demonstrated that p21 (waf1/cip1) was 
differentially expressed in response to 1,25(OH)2D3 treatment and also contained a 
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VDRE (297). The gene was later confirmed to be a primary VDR target gene using 
ChIP-Seq (298). 1,25(OH)2D3  treatment has also been shown to cause stress-
induced apoptosis by upregulation of VDUP (Vitamin D Upregulated Protein- a 
vitamin D transcription target (299)) which neutralizes thioredoxin (300, 301). It was 
recently demonstrated that VDR expression in various normal as well as cancer cells 
played a role in avoiding impaired mitochondrial function and eventual cell death 
(302). The effect of vitamin D-VDR signalling in tumour invasion and metastasis has 
been explored by Munoz et al who have used a colorectal cancer cell models to 
describe a mechanistic basis for this effect. 1,25(OH)2D3 was shown to repress DKK4 
(303) as well as Wnt/b-catenin signalling (304), both of which were shown to promote 
invasion and angiogenesis. Expression of SNAIL, which promotes invasiveness, 
progression and poor prognosis was shown to inhibit VDR expression and response 
to 1,25(OH)2D3, indicating that vitamin D-VDR signalling was inversely related to 
invasion-associated prognosis (305). Studies to assess the role of VDR in DNA-
damage response stemmed from the link between VDR and the p53 pathway, in that 
they’re known to physically interact and share ‘common’ target genes (306).  
In addition to the studies described in the previous paragraph which have 
investigated the genomic and functional impact of vitamin D-VDR signalling, there 
are many others which have investigated the epigenetic effect of this signalling axis. 
This effect on the epigenome is of significance, given its ability to affect key biological 
processes (307).  1,25(OH)2D3 treatment has been shown to decrease promoter 
methylation of E-cadherin and thus increase expression in MDA-MB-231 breast 
cancer cells (308) 
In the case of melanoma, one of the earliest in vitro experiments to demonstrate 
the anti-proliferative effect of vitamin D was done in human melanoma Hs695t cell 
line, whose doubling time was significantly increased upon vitamin D treatment (293). 
More recently Reichrath et al tested the effect of vitamin D on a panel of metastatic 
melanoma cell lines and showed that only some of the cell lines were responsive to 
the anti-proliferative effects of vitamin D, putting forth the notion that vitamin D 
signalling exerts its impact on a subtype of metastasizing cell types (309). In addition, 
the pro-differentiation roles of vitamin D analogue were demonstrated in the human 
metastatic cell line SKMEL-188 (310). Efforts to investigate the prospective role of 
VDR in melanoma include studies that look into polymorphisms in the gene that 
codes for VDR. The study conducted in Leeds reported VDR alleles that were 
associated with increased or decreased risk of MSS (311).  
36 
 
Since one of the focuses of my thesis is to assess the role of vitamin D in 
melanoma using transcriptomic and clinical data, I have elaborated more on this topic 
in a dedicated chapter: ‘Chapter 3: Vitamin D-VDR signalling in melanomas’.  
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Description of data and Methods 
This chapter includes a description of two main data sets used in this thesis: the 
Leeds Melanoma Cohort (LMC) and The Cancer Genome Atlas (TCGA) melanoma 
datasets. This chapter also details the methods and relevant materials used 
throughout the thesis while more details pertaining to Chapter-specific analyses are 
detailed in the Methods section of that chapter.  
 
2.1 The Leeds Melanoma Cohort (LMC) 
The Leeds Melanoma Cohort (LMC) is composed of 2184 population-ascertained 
participants of primary melanoma from the North of England. Invitations to participate 
in the study were extended 3 months after initial diagnosis of disease. If the invitation 
was accepted, the intent was to interview and obtain biological specimens (such as 
blood, excised tumour) within 3-6 months after diagnosis. The time to interview (from 
the initial invitation to participate) was variable, with a median of 5.2 months. The 
total recruitment period extended between 2001-2013. Participants who consented 
to participate (‘participants’ henceforth) completed detailed questionnaires, which 
queried various lifestyle factors. The parts of the questionnaire which are relevant to 
my research projects are: age, sex, dietary supplement intake and sun-exposure 
information. Variables pertaining to the melanoma tumour itself which were obtained 
from histopathology reports include Breslow thickness, ulceration status, vascular 
invasion, tumour site and tumour mitotic rate. Patient survival information was also 
recorded and periodically updated using national databases such as the ONS (Office 
for National Statistics) and the National Cancer Registry.  
Approvals for the study have been granted by the Multicentre Research Ethics 
Committee (MREC) (1/3/057) and the Patient Information Advisory Group (PIAG) (3-
09(d)/2003). 
2.1.1 Subset of 703 participants from the LMC used in this thesis  
The initial Leeds Melanoma Cohort is composed of 2184 melanoma participants (as 
described above). For a subset of these participants (n=703), the primary melanomas 
which were excised at diagnosis were processed into Formalin-fixed paraffin-
embedded (FFPE) tumour blocks. The tumour blocks were then used to generate 
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Tissue Microarray (TMA) cores, from which mRNA was extracted and used to 
generate transcriptomic profiles (described in section 2.2). For the purposes of this 
thesis: the clinical, histopathological and transcriptomic data pertaining to this subset 
of 703 participants will be referred to as the ‘LMC dataset’, despite the ‘original’ Leeds 
Melanoma Cohort being composed of 2184 participants. To this effect, any 
reference to ‘LMC dataset’ in this thesis, refers to the subset of 703 participant. 
Lifestyle, histopathological and survival variables pertaining to these 703 participants, 
which have been used for analyses in this thesis are summarised below.  
Treatment status: Only 10 of the 703 participants had been treated with BRAF 
inhibitors, 10 with Ipilimumab and 2 with Pembrolizumab.  
Age: Age at diagnosis, in years. The median age of the 703 participants was 58.37 
years and Standard Deviation (SD) was 12.88 years.  
Sex: Sex at diagnosis, indicated as Male or Female (self-reported in questionnaire) 
Breslow thickness: the measurement of Breslow thickness is described as: 
“Breslow thickness is measured from the top of the granular layer of the 
epidermis (or, if the surface is ulcerated, from the base of the ulcer) to the deepest 
invasive cell across the broad base of the tumour (dermal/subcutaneous) as 
described by Breslow.” (1, 2).  
In the LMC dataset of 703 participants, the minimum and maximum Breslow 
thickness were 0.33 mm and 20 mm respectively, with a median of 2.3 mm and SD 
of 2.30 mm. 
Ulceration: melanoma ulceration is defined as : “full thickness absence of an intact 
epidermis above any portion of the primary tumour with an associated host reaction 
(characterized by a fibrinous and acute inflammatory exudate) above the primary 
tumour based on histopathological examination.” (2).  
In the dataset of 703 participants, ulceration status was assigned ‘yes’ or ‘no’ by 
the reviewing pathologist. 
Mitotic rate: Mitotic rate is defined as the number of tumour cells which are 
mitotically active per square millimetre of tumour area, as estimated by the reviewing 
pathologist. In the dataset of 703 participants, mitotic rate data was available for 595 
tumours, in which the minimum and maximum mitotic rate were 0 and 83 respectively, 
with median value of 3 mitoses per square millimetre of tumour area and SD of 9.18 
mitoses per square millimetre of tumour area. 
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AJCC stage: All tumours were classified according to the recommendations of the 
7th edition of the AJCC (312) Melanoma staging system (313). Though a more recent 
(8th edition) of the AJCC staging system was published, the LMC cohort participants 
were diagnosed (and subsequently treated) based on the 7th edition’s 
recommendation and hence this classification was retained. However, a 
reclassification of the 703 participants by 8th edition’s recommendation revealed that 
only 3 participants were discordantly classified compared to the 7th edition-based 
classification (verified by Mrs. Joanne Gascoyne in the Leeds group). Taken 
together, the classification by 7th edition still remains relevant despite the recently 
updated recommendations and hence was used as such in all analyses in this thesis.  
Vascular invasion: vascular invasion indicates the presence (or absence) of tumour 
cells which are fixed to the walls and within the lumens of lymphatic or blood vessels 
(3). In the dataset of 703 participants, vascular invasion status was available for 626 
tumours, for which vascular invasion status was assigned ‘yes’ or ‘no’ by the 
reviewing pathologist. 
Melanoma survival/death: survival information for participants was obtained both 
directly (by annual re-contact) and indirectly from review of national cancer registries 
and the ONS. In the case of deceased participants, the cause of death was obtained 
from death certificates and medical records. This was reviewed by research nurses 
in the Leeds Melanoma Research group led Prof. Julia Newton-Bishop, to generate 
Melanoma Specific Survival (MSS).  
Distribution of 703 LMC participants based on survival data and 
clinicopathological features defined above is detailed in Table 2.1. Because of 
missing data for some variables, information is not complete for some participants, 
but overall the coverage is very good.  
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Table 2.1 Distribution of 703 LMC participants based on age, sex and 
histopathological variables 
Variable  Number of participants 
Age at diagnosis (in years, median= 58.37 years) 
    <58.37  years 
    >58.37  years 
    Total  
 
352 
351 
703 
Sex  
    Females 
    Males 
    Total  
 
385 
318 
703 
Breslow thickness (in mm, median= 2.3mm) 
    < 2.3 mm 
    > 2.3 mm 
    Total 
 
357 
346 
703 
Ulceration status 
    Yes 
    No 
    Total 
 
235 
468 
703 
Mitotic rate (number of mitoses/square mm of tumour, median= 
3 mitoses/square mm of tumour) 
    < 3 mitoses/square mm of tumour 
    > 3 mitoses/square mm of tumour 
    Total 
 
 
301 
402 
703 
AJCC Stage 
    Stage I 
    Stage II 
    Stage III 
    Stage unavailable 
    Total 
 
 
233 
355 
107 
8 
703 
 
Vascular invasion status 
    Yes 
    No 
    Unavailable 
    Total 
 
69 
558 
76 
703 
Melanoma survival  
    Alive 
    Dead 
          Death from melanoma-specific causes (MSS) 
          Death from non-melanoma causes 
 
470 
233 
196 
36 
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2.2 Generation of the LMC transcriptome 
Primary melanoma tumours excised from participants and stored as FFPE (Formalin 
Fixed Paraffin Embedded) blocks in various hospitals in the North of England were 
mailed to our lab, with participants consent, as per the standard operating procedures 
(SOP) developed by the Leeds Melanoma Research group, in compliance with the 
ethical approvals and the Human Tissue Act. The FFPE blocks were then sectioned, 
H&E stained and reviewed for sampling. Tumour cores were selected after 
examination under microscope then sampled using a TMA (Tissue Microarray) 
needle. RNA was extracted and used to generate transcriptomic data which will be 
referred to as the ‘LMC transcriptome’ henceforth. The steps involved in generating 
and pre-processing the LMC transcriptome are detailed below. These steps and were 
performed prior to the commencement of my PhD project.  
2.2.1 Tumour sampling, expression profiling and processing 
FFPE tumour blocks were sectioned to produce 5µm sections mounted on glass 
slides to be used for Haematoxylin and Eosin (H&E) staining. Protocol for H&E 
staining is described in section 3.3. The H&E stained slides were reviewed by Prof. 
Julia Newton-Bishop and Dr Jonathan Laye (Senior Histopathologist) to identify a 
region of the tumour that was suitable for sampling. The intent was to identify the 
deepest part of the tumour which had the highest tumour cell content and least 
stromal invasion. The tumour region satisfying these criteria were marked as a core 
with a marker on the H&E slides of primary tumours obtained from the 703 
participants. The sampling of the core tumour was done on the TMA apparatus. Each 
marked H&E slide was aligned over its respective tumour block and the TMA needle 
was used to guide a horizontal 0.6mm core through the block. The contents of the 
core were then stored at 4oC before subsequent RNA extraction. The tissue cores 
were dewaxed in xylene and absolute ethanol (two changes) after which RNA was 
extracted using High Pure Paraffin RNA kit (Roche Diagnostics) according to the 
manufacturer's protocol and eluted in nuclease-free water. Transcriptomic 
expression was quantified using the Illumina DASL (cDNA-mediated Annealing, 
Selection, extension and Ligation) Human HT12 v4 array (whole genome) by a 
service provider: Service XS (Leiden, Netherlands). The processing and 
normalisation of the microarray data was performed by Dr Jeremie Nsengimana 
(Senior Statistician). Briefly: the microarray image data files (quantifies gene 
expression as fluorescence intensity) was processed in the Illumina proprietary 
software GenomeStudio to obtain the raw numerical data. The R package Lumi (314) 
was used to background-correct and quantile-normalise the data. Technical 
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variabilities which could confound ‘true’ variability of gene expression such as batch, 
chip, age of the FFPE block and RNA concentration were identified using the R 
package Swamp (function used: quickadjust.zero) (315) and adjusted out. In 
addition, outliers were identified by examining raw and normalised density plots. Post 
these quality control processes, expression values pertaining to each probe was 
standardised to mean 0 and variance 1. These data have been published  (316) and 
have been deposited in the European Genome-Phenome Archieve (EGA) at the 
European Bioinformatics Institute (EBI), with accession number EGAS00001002922. 
2.2.2 Choice of probes, probe to gene mapping strategy 
The Illumina DASL Human HT12 v4 array includes multiple probes which are 
designed to span different regions of a particular gene, allowing isoform specific 
analyses. Studying isoform specific mechanisms can be of interest for certain genes 
if taken as candidates, but it is less informative in agnostic whole-genome studies, 
such as those conducted in this thesis. It was thus necessary to select one probe per 
gene. To this effect, a ‘probe-to-gene’ mapping strategy was implemented. 
Information regarding the number of isoforms ‘covered’ by each probe was 
downloaded from the Illumina product support website 
(https://support.illumina.com/downloads.html). This document matched each probe 
as: 
• A = All isoforms. The probe is designed to hit all splice isoforms of a gene. 
• I = Isoform specific. The probe is designed to hit a specific splice isoform of a 
gene, for which multiple isoforms are known to exist. 
• S = Single isoform. The gene has only one known splice isoform and our probe 
hits it. 
• M = Multiple isoforms. This gene has multiple isoforms. The probe targets more 
than one and fewer than all of them. 
The proportion of samples for which a particular probe was detected with reliable 
intensity (above the background noise) was also known for each probe, referred to 
as ‘Proportion Detected’. Among the total of 29,354 probes on the array, those which 
were isoform specific (‘I’) and detected only one splice isoform of the gene, despite 
the gene being known to have multiple isoforms were dropped (4644 probes).  
Among the remaining probes, if a gene still mapped to more than one probe, then 
the probe with lowest Proportion Detected was dropped. This resulted in 20,560 
unique probe-gene pairs. This strategy of probe filtration ensured that a gene was 
not represented by probes which i) spanned only one isoform of the gene, with no 
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information regarding the other isoforms, despite being detected reliably in a majority 
of the samples (represented by high Proportion Detected) and ii) spanned multiple 
isoforms of the gene but detected unreliably in a majority of the samples (represented 
by low Proportion Detected). 
 
2.3 Copy Number Alteration (CNA) data in the LMC 
Copy number alternation profiles were estimated from Next-Generation Sequencing 
(NGS) data generated from DNA extracted from 303 LMC tumours. However, only 
276 tumours (of these 303 tumours) are a subset of the 703 samples for which 
transcriptomic data was generated. In other words, ‘matching’ NGS and 
transcriptomic data was available for a set of 276 tumours.  
Quality control of the NGS data included normalisation to control samples from 
the 1000 Genomes Project (Phase 3, 1KGP, n=312, 
ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/phase3/data/) that matches our 
experimental set up (Illumina platform, low coverage, paired end library layout). 
These data were generated by Dr Anastasia Filia, a former PhD student in the Leeds 
Melanoma Research group and were in part pre-processed by Joey Mark Diaz, a 
colleague Marie-Curie Research Fellow in the same group. Joey used the package 
bamwindow (https://github.com/alastair-droop/bamwindow) to create bins or 
windows of size 10k across the genome, identified and excluded blacklisted regions 
(those known to generate unreliable sequences. QDNASeq package in R was used 
to identify highly variable regions in the genome which were added to the blacklist 
and to adjust the read counts on each valid window based on the interaction between 
GC content and Mappability (317). Log2 ratio of window read counts between each 
LMC sample and the median in each window of the 1KGP normal samples were 
obtain and segmented. Segmentation of copy number was performed using circular 
binary segmentation available in the R package DNAcopy (318). Gistic2.0  (319) was 
used to identify significant copy number aberrations peaks and gene level copy 
number estimate. These DNA Copy Number Alteration (CNA henceforth) data were 
used in my thesis in conjunction with transcriptomic profiles to investigate or validate 
mechanisms of gene regulation. 
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2.4 Statistical methods 
Statistical tests performed for analyses pertaining to relevant chapters are detailed 
in the Methods section of that chapter. All statistical analyses were performed in 
Stata/SE 14.2 (320) unless otherwise specified. 
 
2.5 Gene and pathway enrichment analyses 
All gene and pathway enrichment analyses were performed in Reactome FIViz (321) 
on the Cytoscape (version 3.5.1) (322) desktop feature. Reactome FIViz is an app 
designed to discover pathways and network patterns associated with gene 
expression profiles from cancer and other types of disease. The app allows access 
and use of the Reactome Functional Interaction (hence the name Reactome FI) 
network, which is a manually curated database. The unique feature of the Reactome 
Functional Interaction network is that it is constructed from two types of data sources: 
i. High-coverage, pairwise networks derived from experimental sources (such as 
yeast two-hybrid techniques, mass spectrometry pull down assays and DNA 
microarrays), databases such as BioGrid, Database of Interacting Proteins 
(DIP), the Human Protein Reference Database (HPRD), I2D, IntACT, and 
Molecular Interaction Database (MINT) and expression data sets from the 
Stanford Microarray Database and the Gene Expression Omnibus. While 
these datasets provide ample pairwise interaction data, interaction does not 
necessarily indicate a biologically-relevant relationship. As a consequence, 
these data sources tend to have high degree of false positivity. 
ii. Low-coverage, highly-curated pathway data derived form databases such as 
Reactome, IntAct, Protein Analysis Through Evolutionary Relationship 
(PANTHER), Kyoto Encyclopaedia of Genes and Genomes (KEGG) and 
BioCarta. These databases are based on manually-curated interactions 
between proteins/genes.  
The authors use a naïve Bayes classifier approach to identify high-likelihood 
functional interactions from non-functional interactions and false positives (321, 323). 
Taken together, Reactome Functional Interaction network was created by combining 
the Interaction data (in the form of interaction between two genes/proteins) from both 
data sources listed above i.e. combining high-coverage, unreliable pairwise data and 
low-coverage, curated pathway data. 
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It is for this reason that I chose to use Reactome FIViz (the web-based tool which 
works on the basis of the Reactome Functional Interaction network) for my pathway 
enrichment analyses. 
In order to identify the pathways which are enriched in any given list of genes 
(e.g. list of genes that correlate positively with tumour VDR expression), the following 
steps were performed: 
i) The Cytoscape app was launched and the Reactome FI plugin was chosen in 
the ‘Apps’ tab. From among the features of Reactome FI, the ‘Gene 
set/Mutation analysis’ option was chosen. The latest version Reactome FI 
network version (2015 update) was chosen to be used as the basis of the 
enrichment analysis.  
ii) The list of gene names which needs to be queried is entered manually or 
uploaded as a text file. Upon choosing the ‘perform Pathway Enrichment’ 
option from the dropdown options, the list of genes is compared with the 
‘background’ Reactome FI network. The output from this comparison is 
represented by a P-value (from a hypergeometric test) and FDR (Benjamini-
Hochberg) for each identified pathway. 
For instance, for an input query gene list, m genes were identified to 
belong to a certain Pathway-x, which is composed of n genes (as defined by 
the Reactome FI network) then the following values are computed (done 
automatically by by Reactome FIViz): 
- Ratio of protein in gene set: ratios of numbers of genes contained in 
pathways to total genes in the Reactome FI network (n/total genes in 
Reactome FI 2015 version) 
- Number of protein in gene set: numbers of genes in pathways (n) 
- Protein from network: numbers of hit genes from the query gene list 
(m/n) 
- Nodes: nodal genes from my input query gene list, which ‘matches’ 
with the genes in Pathway-x. in other words, these are the names of 
the n genes.  
In addition, the source database for each of the enriched pathways are indicated 
by a letter in parentheses after each pathway gene set name. The source database 
annotations are:  
• C - CellMap, 
• R – Reactome, 
• K – KEGG, 
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• N – NCI PID, 
• P - Panther, and  
• B – BioCarta. 
In the case of my analyses, I restricted the results to pathways which had 
FDR<0.05, which I used for further interpretation. Upon filtering by this threshold, I 
exported the ‘pathway table’ which was composed of the names of enriched 
pathways, the nodal genes pertaining to each pathway, Ratio of protein in gene set, 
Number of protein in gene set and Protein from network. For all the enrichment 
analyses I have performed, the exported pathway table with all of the aforementioned 
information is attached in the Appendix. In the main text of the Results section, I have 
included a concise table of the top pathways, the respective FDR values and nodal 
genes.  
 
2.6 TCGA data 
The Cancer Genome Atlas (TCGA) metastatic melanoma data such as 
transcriptomic (RNA-Seq), clinical, methylation and copy number data were 
downloaded from cBioPortal (http://www.cbioportal.org/). Of note, the TCGA 
expression profiles were generated from fresh-frozen tissue using RNAseq platform 
and they were all from highly selected and advanced tumours (as opposed to FFPE, 
array platform and unselected population design in the LMC). For all the analyses, 
the same statistical tests and software/packages were used to analyse the LMC and 
the TCGA datasets. Since the TCGA data is a composed of participants from multiple 
clinical sites, there was the issue of incomplete or unreliable data for some variables. 
In my thesis, I have used transcriptomic (RNASeq), CNA (NGS) and methylation 
(HM450K array) data pertaining to the melanomas samples from the TCGA 
melanoma cohort. The availability of each of these data in subsets of the TCGA 
cohort are described in Table 2.2.  
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Table 2.2 Table indicating availability of data pertaining to the TCGA melanoma 
cohort 
 Transcriptomic data available? 
CNA data 
available? 
Methylation data 
available? 
Primary melanomas 
(n=103) Yes No Yes 
Metastatic 
melanomas (n=365) Yes Yes Yes 
 
 Haematoxylin and eosin staining  
FFPE sections from the LMC primary melanomas (Chapter 3) and mouse lungs 
(Chapter 4) were counterstained with Haematoxylin and Eosin (H&E), after staining 
with the respective antibodies. The protocol used for H&E staining is as follows: 
1. The slides after treatment with the secondary antibody step, were washed 3x in 
wash buffer. This was followed by submerging the slides in Meyer’s 
haematoxylin for 30 seconds 
2. Slides were then rinsed in tap water till the water went clear 
3. Slides were then submerged for 2 minutes in Scott’s tap water 
4. Slides were washed in tap water for 1 minute  
5. Slides were dabbed with paper towels to remove excess water, but without 
dehydrating the slides. This was followed by sequential hydration in gradient 
ethanol solutions followed by xylene treatment.  
100% ethanol for 15 seconds à 100 % ethanol for 2 minutes à 80% ethanol 
for 3 minutes à 80% ethanol for 3 minutes à 100% xylene for 3 minutes à 
100% xylene for 3 minutes à 100% xylene for 3 minutes à slides were 
mounted with DPX slide-mountant à Slides were air dried overnight and used 
for subsequent review.  
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Vitamin D-VDR signalling in melanoma 
 Introduction 
3.1.1 Vitamin D-VDR signalling: an overview 
The hormone 1α,25-dihydroxyvitamin D3 (vitamin D3 henceforth) is the biologically 
active form of vitamin D and is the ligand for the dimeric Vitamin D Receptor (VDR) and 
Retinoid X Receptor (RXR). The ‘classic’ model of vitamin D signalling involves ligand 
binding to the receptor dimer, facilitating transcription of target genes that contain the 
Vitamin D Response Element (VDRE) (230, 324). However, both genomic and non-
genomic actions of vitamin D3 have been described, as discussed below and are also 
pictorially depicted in Figure 3.1. The VDRE consists of two hexanucleotide repeats 
with a nucleotide triplet sandwiched in between (GGTCCA-NNN-GGTCCA): this is 
referred to as the DR3 sequence, which is present in the promoter region of target 
genes. While VDR occupies the 3’ half site, RXR occupies the 5’ half site of the double 
hexanucleotide in the promoter region of target genes to facilitate transcription (325). 
Vitamin D3 has also been shown to repress gene expression in a mechanism that 
involves binding of the VDR-RXR dimer to negative-VDREs comprised of a CANNTG-
like motif (referred to as VDR-interacting repressor: VDIR) of genes such as PTH (238). 
Vitamin D3 has also been shown to induce association of VDR and VDIR, leading to 
recruitment of HDAC co-repressor to repress CYP27B1 expression (326, 327). On the 
other hand, transcriptional activation by vitamin D3 involves binding of activated VDR-
RXR dimer to the DR3 complex (as described above) to facilitate transcription of targets 
such as CYP24A1 (328), BGLAP (240) and CDKN1A (297). In addition to the classic 
genomic response, vitamin D3 is also known to elicit certain non-genomic responses 
that are transcription-independent and rapid (within seconds to minutes, depending on 
tissue type) such as the rapid intestinal absorption of calcium (transcaltachia), opening 
of voltage-gated Ca2+ and Cl- channels in osteoblasts and rapid migration of endothelial 
cells (251). This has been shown to be mediated by signalling cascades such as Protein 
Kinase C (PKC), leading to increase in intracellular Ca2+ (329). Increased intracellular 
Ca2+ can in turn lead to activation of pathways such as the Raf-MEK-MAPK-ERK 
cascade, which mediates proliferation in skeletal muscles (330) and normal colon cells 
(329). In addition, non-genomic activation of PKC has been shown to increase 
transcriptional activity of VDR by phosphorylation-dependent stabilisation (331, 332). 
This demonstrates the overlap in cell signalling components that are influenced by 
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genomic and non-genomic effects of vitamin D3 and suggests a cooperative relationship 
that impacts the overall downstream effect of vitamin D3 (summarized in Figure 3.1). 
 
Figure 3.1: The possible modes-of-action of vitamin D 
PM: Membrane level effect where vitamin D could bind and signal via non-
canonical receptors, Cytosolic effects include possible influence of vitamin D on 
cytosolic signalling factors that could affect downstream signalling pathways and 
direct genomic effect is the vitamin D-VDR signalling axis via VDRE-containing 
genes. RXR-Retinoid Receptor, R-acid-Retinoic acid. Adapted from (333). 
 
3.1.2 Physiological effects of vitamin D-VDR signalling  
The physiological effect of the vitamin D-VDR signalling axis is context specific: in the 
intestines and bones it is known to mediate calcium and phosphate homeostasis (334) 
while in the epidermis it contributes to stratum-specific keratinocyte differentiation (335, 
336), anti-microbial innate immune response (337, 338) and reduced keratinocyte 
proliferation (339). Vitamin D deficiency has historically been of interest in the context 
of several aspects of public health  (340-342) given its reported association with risk of 
tuberculosis (343), autoimmune disorders such as SLE (344), arthritis (260), type I 
diabetes (345), and the incontrovertible evidence for its role in bone and muscle health. 
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It is worth noting that in vitro studies indicate a synergistic relationship between 
vitamin D and VDR, wherein both vitamin D3 treatment and intact VDR expression are 
necessary for downstream effects, as would be expected between a ligand and its 
canonical receptor. However, this does not preclude ligand-independent effects of VDR. 
Studies to understand the ligand-independent effects of VDR have been used to 
disentangle the vitamin D- VDR functional relationship and to provide a mechanistic 
basis for ‘VDR-specific’ physiological functions (346).  For instance, unliganded VDR  
has been shown to bind to a novel corepressor Hairless (HR) (347) to affect 
keratinocyte/hair-follicle homeostasis (348). Notably, a study by Trivedi et al 
demonstrated a ligand-independent effect of VDR on the proliferation of MCF-7 breast 
cancer cells (349), suggesting that cancer cells are amenable to ligand-independent 
effects of VDR. Taken together, these data suggest that the vitamin D-VDR signalling 
axis may consist of both an independent and synergistic relationship between the ligand 
and the receptor, with distinct physiological and pathological consequences. 
3.1.3 Vitamin D signalling in cancer: summary of in vitro and in vivo 
evidence 
Studies that demonstrate the effect of vitamin D3 signalling on tumour progression have 
used in vitro cancer cell line models and in vivo VDR knockout mouse models to 
understand the mechanism of action of vitamin D signalling. Genomic profiles of in vitro 
responses to vitamin D3  treatment in cell lines of prostate cancer (350), breast cancer 
(351), leukaemia (352), colon carcinoma (353) and squamous cell carcinoma (265) 
indicate that the genes/pathways corresponding to the following cellular processes are 
perturbed in response to vitamin D treatment: DNA repair, cell cycle progression, 
apoptosis, cell adhesion, metastatic potential, differentiation, membrane transport and 
growth regulation. Vitamin D3  has been shown to exert its anti-proliferative effects by 
inhibiting cell cycle progression into S-phase (354), inhibiting pro-proliferative pathways 
such as TGF-β (355) and Wnt/β-catenin (356) and mitogenic pathways involving 
EGF/MAPK/MEK/ERK (357) and IGF (358). VDR-null mice showed colorectal cell 
hyperproliferation in the absence of vitamin D3-mediated anti-proliferative effects (359), 
thus corroborating the aforementioned in vitro observations. Vitamin D3  has also been 
shown to have a potent anti-angiogenic effect on tumour-induced angiogenesis in 
BALB/c mice (360) and in tumour-derived endothelial cells (361). In addition, vitamin D3  
has been shown to diminish invasive phenotype and lung metastasis by decreasing 
activity of cell-adhesion proteins in VDR-null mice (362) and in mammary epithelial cells 
(363).  
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3.1.4 Vitamin D signalling in melanoma: in vitro and in vivo evidence 
The relationship between vitamin D and melanoma is particularly interesting given that 
ultraviolet light is responsible not only for vitamin D production but also for melanoma 
carcinogenesis. One of the earliest in vitro experiments to demonstrate an anti-
proliferative effect of vitamin D3 was done in human melanoma Hs695t cell line, whose 
doubling time was significantly increased upon vitamin D3 treatment (293). More 
recently Reichrath et al tested the effect of vitamin D3 on a panel of metastatic 
melanoma cell lines and showed that only some of the cell lines were responsive to the 
anti-proliferative effects of vitamin D3, putting forth the notion that vitamin D3 signalling 
exerts its impact on a subtype of metastasizing cell types (309). In addition, the pro-
differentiation roles of vitamin D3 analogues were demonstrated in human metastatic 
cell line SKMEL-188 (310).  
Multiple research groups have also investigated the in vitro effects of non-calcemic 
vitamin D metabolites, as an alternative to vitamin D3. The primary rationale behind this 
being: the hypercalcemic effects (elevated calcium levels in the blood stream) of vitamin 
D3 can cause medical complications as severe as organ failure (364). Non-calcemic 
metabolites which have comparable physiological potency could potentially circumvent 
this issue and hence have been extensively explored as therapeutic options. One such 
non-calcemic metabolite is 20-hydroxyvitamin D3. In vitro studies by Slominski et al 
have demonstrated that the vitamin D metabolite 20-hydroxyvitamin D3 has an anti-
proliferative effect on melanoma cells (310, 365) by inhibition of NFκB signalling (366). 
A more recent study by the same group elegantly exhibited that 20(OH)D3 inhibits cell 
migration and cell-cell adhesion in vitro while reducing tumour load in vivo with no 
evidence of toxicity (367).  
As for the effect of VDR expression on melanoma, Brożyna et al used an 
immunostaining-based approach to show that high VDR-expressing tumours were less 
advanced (decreased ulceration, Breslow thickness and increased immune infiltrate) 
and had better prognosis compared to low VDR-expressing tumours (368). Though the 
effects of VDR expression on tumour progression have been explored extensively in 
colon cancer, the evidence for melanoma are currently limited to the study by Brożyna 
et al. Thus, one of the aims of my PhD project (and this chapter in particular) is to 
interrogate the role of VDR in melanoma progression using melanoma transcriptomic 
and clinical data.  
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3.1.5 Vitamin D signalling in melanoma: epidemiological evidence 
The current evidence for a protective role of vitamin D-VDR signalling in melanoma 
survival comes from both epidemiological studies and in vitro studies. In a prospective 
study of 872 patients in the Leeds Melanoma Cohort, higher 25-hydroxyvitamin D3 
levels were associated with lower Breslow thickness and better Melanoma Specific 
Survival (MSS) (288). This was followed by independent studies in American (291), 
Australian (292) and German (290) patient cohorts. In the American cohort (1,042 
patients diagnosed with primary melanoma), lower vitamin D was associated with 
increased tumour thickness, advanced melanoma stage and high CRP (C-Reactive 
Protein) levels. Importantly, the associations with melanoma thickness and stage 
persisted after adjusting for CRP, which is a marker of systemic inflammation and high 
CRP levels predict poor prognosis. This finding indicated that though vitamin D and 
CRP are correlated, the association of vitamin D with tumour stage and thickness is not 
simply a reflection of systemic inflammation. In the Australian cohort (100 patients 
diagnosed with primary melanoma), serum vitamin D of <50nmol/L was associated with 
four-fold increase in risk of having a thicker tumour, compared to patients with 
>50nmol/L. In the German cohort (764 patients diagnosed with metastatic melanoma), 
once again, low serum vitamin D levels were associated with increased tumour 
thickness and stage. Taken together, it is worth noting that these studies were 
performed in populations from 3 different continents. Though the levels of serum vitamin 
D were variable amongst the different populations, low serum vitamin D was associated 
with increased tumour stage and thickness, when performing ‘intra-population’ 
comparisons.  
Efforts to investigate the prospective role of VDR in melanoma include studies that 
look into polymorphisms in the gene that codes for VDR. The study conducted in Leeds 
reported VDR alleles that were associated with increased or decreased risk of MSS 
(311).  
3.1.6 Relevance of my research in understanding the role of vitamin 
D signalling in melanoma 
While previous studies have assessed the individual effects of either vitamin D or VDR, 
my research used both tumour VDR expression and corresponding serum vitamin D 
levels at diagnosis to assess their synergistic as well as individual contributions to 
melanoma survival and their genome-wide effects. The data set used was a unique set 
of 703 formalin fixed paraffin embedded (FFPE) primary melanomas, which are a 
subset of tumours from the Leeds Melanoma Cohort (LMC) (316). For these tumours, 
tumour core-derived transcriptomic data, extensive clinical data (including serum 25-
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hydroxyvitamin D at diagnosis and accurate melanoma-specific survival), single 
observer histopathological data (such as quantified TILs and tumour mitotic number) 
and whole-genome Copy Number Alteration (CNA) data were used to assess and 
validate the pan-genome effects of vitamin D-VDR signalling.  
The primary questions addressed in this chapter of my thesis are: 
1. Are serum vitamin D levels associated with increased tumour thickness and stage 
in the cohort of 703 LMC primary melanomas, as has been previously reported by 
others? 
2. Is transcriptomic tumour VDR associated with melanoma survival in the LMC 
primary melanomas?  
3. Are serum vitamin D levels associated with melanoma survival, within the context 
of tumour VDR expression? 
4. Given that tumour VDR expression is prognostically significant, what are the 
signalling genes, pathways and processes that are significantly associated with 
tumour VDR expression?  
5. Can these findings be validated in silico using independent data sets and reported 
melanoma molecular phenotypes? 
6. Is there causal evidence for the transcriptome-derived findings?  
This is addressed in a separate chapter: Chapter 4, which is composed of the 
functional validation for findings from Chapter 3.  
To address these questions, I have used a combination of statistical models and 
bioinformatic tools to interrogate the LMC transcriptome, which are detailed in the 
sections below.  
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 Chapter aims and overview 
Chapter aims Section 
To assess the association of vitamin D and VDR with clinicopathological 
features and expression of other vitamin D-VDR signalling pathway 
genes  
3.4.1 
To assess the association of vitamin D-VDR signalling with melanoma 
prognosis 3.4.2 
To assess the effect of serum vitamin D on melanoma prognosis, within 
the context of tumour VDR expression 3.4.3 
To identify the transcriptomic characteristics of melanomas pertaining to 
participants with very high serum vitamin D levels (>115nmol/L) 3.4.4 
To identify the transcriptomic correlates of tumour VDR expression 3.4.5 
To validate in silico the transcriptomic correlates of tumour VDR 
expression 3.4.6 
 
Contributions to this chapter:  
• Sathya Muralidhar performed statistical and bioinformatics analyses described in 
this chapter, under the supervision of Dr Jeremie Nsengimana (senior statistician 
in the group) and guided by Prof. Julia Newton-Bishop and Prof. Tim Bishop. 
• Imputed immune cell scores (described in 3.4.3.2) were generated by Ms. Joanna 
Pozniak (PhD student in the group). This extensive work is described in detail in 
the publication ‘Genetic and environmental determinants of immune response to 
cutaneous melanoma’ Pozniak et al, in press, Cancer Research, January 2019.   
• Histopathological measures of immune infiltrate (described in 3.4.6.2) in the LMC 
primary melanomas was derived from extensive work done by Dr Sally O’Shea 
who reviewed all the histological slides according to protocol 
• Immunohistochemical staining of the LMC primary melanoma sections (described 
in 3.4.6.2) for VDR expression was optimised and performed by Dr Jonathan Laye 
(Senior Histopathologist in the group).  
• Review and quantification of the extent and localisation of VDR expression the 
LMC primary melanoma sections (described in 3.4.6.2) was jointly performed by 
Dr Jonathan Laye, Sathya Muralidhar and Prof. Julia Newton-Bishop.  
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The work described in this chapter has been presented by me at the following 
scientific conferences/meetings: 
• Selected abstract- Melanoma discovery and medicine session, NCRI annual 
meeting, Glasgow 2018 
• Invited speaker- Ulster University, Coleraine, September 2017 
• Selected abstract- GenoMel/MELGEN annual meetings held in Leeds (2016), 
Genoa (2017) and Essen (2018)  
• Selected abstract- Vitamin D and analogs in Prevention and Therapy annual 
meeting, Homburg 2017 
 
 Methods 
3.3.1 Variables used in this chapter 
The following lifestyle, clinical and histopathological variables which have been used in 
this chapter are detailed below. 
3.3.1.1 Season-adjusted serum vitamin D 
For 549 of the 703 LMC participants, concentrations of cryopreserved serum 25-
hydroxyvitamin vitamin D2 and D3 (nmol/L) were measured in 100 µL by Liquid 
Chromatography Tandem Mass Spectrometry (LC-MS/MS) by the NHS laboratory in 
the Leeds Teaching Hospitals Trust as described previously (288). Concentration of 
serum 25-hydroxyvitamin vitamin D2 and D3 for the remaining 154 samples was not 
available because: i) the initial batch of serum samples (from participants recruited early 
in the study) were stored in -20oC. Later in the study, it came to light that storage at -
80oC was the most commonly reported storage temperature for sera from which 25-
hydroxyvitamin vitamin D2 and D3 concentrations were measured. So, the samples 
saved at -20oC were not used for analyses and only samples stored at -80oC were 
deemed suitable for analysis ii) laboratory results of 25-hydroxyvitamin vitamin D2 and 
D3 concentrations were misplaced by the NHS laboratory in the Leeds Teaching 
Hospitals Trust, thus making these concentration values unavailable.  
Of the available data, levels of D2 were in the range of <10 nmol/L, which despite 
being detectable, is not quantifiable. Therefore, D2 and D3 levels were summed. Even 
though 1,25 dihydroxy vitamin D3 is the metabolite which binds and signals via VDR-
RXR, 25-hydroxyvitamin vitamin D2 and D3 (commonly referred to as 25(OH)D in 
publications) are the immediate precursors of 1,25 dihydroxy vitamin D3 and are more 
stable in storage (369). Hence, they are widely used as proxy measures of 1,25 
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dihydroxy vitamin D3 in the serum. Thus, these measured levels of 25-hydroxy vitamin 
D2/D3 were used for subsequent seasonal adjustment.  
The blood samples (from which serum 25-hydroxy vitamin D2/D3 was measured) 
had been drawn at diagnosis, which was distributed across various seasons. Thus, the 
effect of the season had to be adjusted for, in order to make the samples comparable 
across the dataset without the confounding effect of seasonal variation in vitamin D 
synthesis. This was done using a linear regression model. Diagnoses made in January-
March were considered as winter-diagnosed, April-June as spring-diagnosed, July-
September as summer-diagnosed and October-December as autumn-diagnosed. A 
dummy variable was created for each season and Winter was set as baseline. After 
adjusting out the season effect on vitamin D, residuals were added to the intercept to 
obtain the corresponding winter vitamin D for each patient. This value of season-
adjusted levels of 25-hydroxy vitamin D2/D3 will be used for all analyses 
henceforth and will be referred to as ‘serum vitamin D’.  
3.3.1.2 Tumour VDR expression  
All references to ‘tumour VDR expression’ refers to the log-normalised expression 
value of VDR expression in the LMC transcriptome. This value pertains to the probe 
designed to detect the VDR transcript (probe ID: ilmn_2319952). The ‘Proportion 
detected’ value (described in section 2.2.2) for this probe was 0.93. This meant that this 
probe was detected in 93% of samples with reliable intensity, above the background 
noise. In addition, this probe is designed to hit all splice isoforms of the VDR gene.  
3.3.1.3 Tumour anatomical site 
The anatomical site from which the primary tumour was excised from was recorded 
as part of clinical data. This was necessary because: i) the anatomical site on which the 
melanoma occurs is a prognostic factor (370) and ii) anatomical site of melanomas is 
also associated with sun-exposure patterns. One of the hypotheses that I tested in this 
chapter is the association of tumour VDR expression and sun-exposure, which I 
performed using both anatomical site and a direct measure of sun-exposure. The 
anatomical sites were grouped into the following broader categories (Table 3.1) 
and referred to as ‘tumour site’ henceforth. 
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Table 3.1: Distribution of 703 LMC participants based on the anatomical site from 
which their tumour was extracted 
Tumour anatomical site group Anatomical site Number of tumours 
Head/neck Head/neck 81 
Limbs 
Arm unspecified 
Dorsal foot 
Elbow  
Knee 
Lower arm 
Lower leg 
Leg unspecified 
Thigh  
Upper arm 
Total on Limbs 
2 
2 
5 
11 
34 
102 
1 
74 
68 
299 
Trunk 
Abdomen 
Back 
Chest 
Shoulder 
Buttock 
Total on Trunk 
34 
157 
34 
2 
6 
233 
Rare (sun protected sites) 
ENT 
Acral 
Anal 
Cervix 
Foot 
Inside of hand 
Nodal with no known 
primary 
Penis 
Perineal 
Subungual 
Vaginal 
Vulval 
Total on Rare sites 
5 
19 
5 
1 
18 
5 
 
3 
3 
1 
14 
3 
13 
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3.3.1.4 Mitotic rate 
The number of tumour cells in which mitoses can be detected per square millimetre of 
tumour area was counted and referred to as ‘mitotic rate’. This was done by the 
histopathologist (Dr Sally O’Shea) using a light microscope. The 703 LMC melanomas 
were categorised into two categories, to enable certain analyses described in this 
chapter, for example: comparing VDR expression between tumours with ‘low’ and ‘high’ 
mitotic rate. To this effect, tumours with < 1 mitoses (0 or 1 mitoses) per square 
millimetre of tumour area (n=346) were categorised as ‘low’ mitotic rate. Tumours with 
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> 1 mitoses per square millimetre of tumour area (n=356) were categorised as ‘high’ 
mitotic rate. These grouped values will be referred to as ‘mitotic rate’ henceforth. 
3.3.1.5 Histopathological measure of tumour immune infiltrate  
A categorical variable describing 3 categories of tumour-infiltrating lymphocytes within 
the whole tumour was categorised as follows:  
• Absent (where there were either no TILs or TILs did not infiltrate the melanoma) 
(n=45) 
• Non-brisk (where there were TILs but they either focally infiltrated the melanoma 
and/or sub totally infiltrated the invasive margin/base of the melanoma) (n=493) 
• Brisk (where TILs infiltrated the entire base of the melanoma and may even 
have infiltrated the majority of the tumour) (n=64) 
These grouped values of pathologist-graded measure of tumour immune 
infiltration in the whole tumour section will be referred to as ‘histological TILs’ 
henceforth 
3.3.1.6 Self-reported supplement intake 
Data had been collected on the regular use of vitamins, minerals, fish oils, fibre or food 
supplements in the period of 1 year prior to the interview. Details pertaining to dietary 
supplement intake are in Table 3.2. 
Table 3.2: Distribution of 703 LMC participants based on self-reported dietary 
supplement data 
Variable Number of participants 
Response if participant to  
‘A year ago, did you regularly take dietary supplements?’ 
    Answered ‘yes’ 
    Answered ‘no’ 
    Total  
 
 
269 
392 
661 
If ‘yes’, what supplements were taken (self-reported)? 
    Cod liver oil 
    Fish oil 
    Multivitamins/ vitamin C, E, B complex/ vitamin D 
    Other  
 
103 
22 
66 
78 
 
3.3.1.7 Sun exposure 
For a proportion of the 703 participants, the following sun exposure measures were 
recorded via the questionnaire.  
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• Average weekday exposure in warmer months: median= 1.75 hours per day 
• Average weekday exposure in cooler months: median= 1.20 hours per day  
• Average weekend exposure in warmer months: 4.30 hours per day 
• Average weekend exposure in cooler months: 2.83 hours per day 
• Average weekday exposure overall (combining warmer and cooler months): 
median=1.5 hours per day 
• Average weekend exposure overall (combining warmer and cooler months): 3.6 
hours per day 
Details pertaining to sun exposure data are in Table 3.3 
Table 3.3: Distribution of self-reported sun exposure patterns in the LMC dataset 
Self-reported sun-exposure measure Number of participants 
Average weekday exposure in warmer months 
   < 1.75 hours per day 
   > 1.75 hours per day 
 
Average weekday exposure in cooler months 
    < 1.2 hours per day 
    > 1.2 hours per day 
 
Average weekday exposure overall 
    < 1.5 hours per day 
    > 1.5 hours per day 
    
Average weekend exposure in warmer months 
    < 4.3 hours per day 
    > 4.3 hours per day 
 
Average weekend exposure in cooler months 
    < 2.83 hours per day 
    > 2.83 hours per day 
 
Average weekend exposure overall 
    < 3.6 hours per day 
    > 3.6 hours per day 
349 
174 
175 
 
345 
173 
172 
 
344 
172 
172 
 
353 
176 
177 
 
352 
176 
176 
 
351 
175 
176 
 
The other variables used in this chapter, which have already been described in 
detail in ‘Chapter 2: Methods’ are: sex, age at diagnosis, AJCC stage, ulceration, 
Vascular invasion and Melanoma Specific Survival (MSS).  
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3.3.2 Univariable and multivariable regression analyses 
Univariable linear regression was used to assess the correlations of serum vitamin D 
or VDR expression with clinicopathological variables. The clinicopathological variables 
which were found to correlate significantly, were used in a subsequent multivariable 
linear regression model to identify clinicopathological variables which correlated 
independently with serum vitamin D or VDR expression.  
While the Regression coefficient (R) represents the strength of correlation, with R>0 
denoting increased expression compared to baseline and R<0 denoting decreased 
expression compared to baseline. B indicates the group used as the baseline for 
comparison with other groups. 
The Stata function ‘regress’ was used for univariable regression analysis.  
3.3.3 Univariable and multivariable survival analysis 
A univariable Cox Proportional Hazards model was used to estimate the effect of serum 
vitamin D or VDR expression on melanoma survival. The Stata function used for this 
analysis was ‘stcox’. The time to failure was set as the time to death i.e number of years 
from date of diagnosis to date of death (melanoma-specific death). The failure event in 
this case was melanoma-specific death.  
3.3.4 Creating 3 VDR-groups using X-tile 
VDR expression and MSS were used as input for X-tile (264), which used this 
information to categorise the 703 tumours into 3 groups with most divergent melanoma 
specific survival. To avoid overfitting, this approach was trained in randomly selected 
2/3 of the samples and validated in the remaining 1/3. In both sets, tumours with the 
lowest 17%, middle 66% and highest 17% of VDR expression were identified as low, 
intermediate and high-VDR groups respectively. These percentiles were applied to the 
TCGA melanoma dataset to identify low, intermediate and high-VDR groups. The 
statistical significance of the difference in prognosis between the 3 groups was tested 
using Cox Proportional Hazards model in the Leeds data and TCGA melanoma data. 
3.3.5 Whole-transcriptome correlations 
A linear regression analysis (STATA command ‘regress’) was used to test the 
correlation of each gene with VDR expression, as a result of which each gene was 
assigned a regression coefficient and p-value (P) to measure the strength of the 
correlation. The linear regression model is used to describe the relationship between a 
predictor variable (say ‘x’, expression value of VDR) and a response variable (say ‘y’, 
expression value of a gene). In this case, the equation to describe the relationship would 
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be: y=bx+c, where b is the regression coefficient and c is the intercept value. The null 
hypothesis (H0) in this model is that there is no association between the predictor 
variable and response variable i.e b=0. The p-value from this model is the probability 
that the null hypothesis is rejected i.e b¹0. Since a p-value was generated to test the 
correlation of the expression of each gene with VDR, it was necessary to perform 
multiple correction, in order to eliminate identification of ‘true positive’ correlates by 
chance. To this effect, multiple testing (Benjamini-Hochberg False Discovery Rate- 
FDR) was used to identify the most significant correlates, thus minimizing selection of 
genes correlated by chance. Additionally, only genes with |R|>0.2 were selected to 
exclude genes with ‘weak’ correlations. This pipeline was used for whole-genome 
correlation in both the LMC and TCGA data. Genes which passed the aforementioned 
significance threshold were plotted in a volcano plot (‘plot’ function in R) and used for 
functional enrichment analysis. In the volcano plots, the regression coefficient (x-axis) 
versus p-values (y-axis) were plotted, in order to graphically represent significantly 
correlated genes (as indicated by p-value) along with strength of correlation (as 
indicated by regression coefficient) with the predictor variable (VDR expression). 
FLG-adjusted correlations with VDR: A sensitivity analysis was conducted adjusting 
the expression of FLG2 to account for any bias in VDR expression which might have 
originated from keratinocytes. The rationale for this being: FLG2 is the gene marker of 
differentiated keratinocytes (371) and hence FLG2 expression was considered to be a 
proxy for a melanoma with ‘high epidermal content’.  
3.3.6 Gene and pathways enrichment analyses 
Functional enrichment of significant VDR-correlated genes was carried out using 
Reactome FIViz (321) in Cytoscape. The ‘Gene set/mutation analysis’ feature was used 
to produce a Functional Interaction Network and perform pathway enrichment of a given 
input gene list. Significantly enriched pathways were identified as those with a FDR 
<0.05 (hypergeometric test computed by Reactome FIViz).  
3.3.7 Replicating TCGA and Lund molecular phenotypes in the LMC 
melanoma transcriptome 
A classification of 208 LMC primary melanomas (subset of the 703 used in this thesis) 
as high immune, normal-like, proliferative or pigmentation subtypes (defined by 
Jonsson et al. 2010 and referred to as Lund molecular phenotypes) has been published 
by our group (372). The same classification approach (nearest centroid) was used to 
assign each of the 703 tumours to one of these subtypes and similarly to one of the 3 
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subtypes (Immune, Keratin and MITF.low) defined by the TCGA signature (TCGA, 
2015).  
3.3.8 Imputed immune cell scores  
As described by Pozniak et al (in press, 2019, Cancer Research). Briefly, genes that 
were expressed among the top 25% across the whole genome in a melanocyte and 
melanoma cell lines were removed from the initial list of the genes provided by Angelova 
et al (373). A particular cell type was eliminated if less than 10% of its original genes 
remained after this filtering process. For each immune cell type, the negatively 
correlating genes were removed. This produced 26 immune cell types, for which the 
immune cell scores were calculated as the mean of expression values of all genes 
attributed to specific cell types after z-score normalization.  
3.3.9 VDR genomic binding regions 
3.3.9.1 ChIP-Seq analysis 
The  genomic regions identified as having VDR-binding peaks across 6 tissue types 
(accessible data from (374))  were downloaded as a BED file and analysed in GREAT 
3.0.0 (375). ‘Basal plus extension’ approach was used with Human GRCh37 species 
assembly, whole genome as background regions and the gene regulatory domain set 
to +20 kb upstream and +400 kb distal. The genes mapped to these regions (‘region-
gene associations’) were exported and overlap with VDR-correlated genes in the LMC 
(at FDR<0.05) were assessed for each tissue-type. The process of estimating ‘region-
gene associations’ is as follows: first, every gene is assigned a regulatory domain and 
then each genomic region is associated with all genes whose regulatory domain it 
overlaps.  
3.3.9.2 VDR-binding motifs 
The database MotifMap was used, from which data pertaining to the transcription factor 
binding sites (based on hg19 build) was downloaded. From this, the following data 
specific to VDR binding motifs was extracted: start site, end site and chromosomal 
location. These regions (containing the VDR0binding motif) were mapped to genes 
using GREAT. Similar to the process described above, ‘Basal plus extension’ approach 
was used with Human GRCh37 species assembly, whole genome as background 
regions and the gene regulatory domain set to +20 kb upstream and +400 kb distal. 
The genes mapped to these regions (‘region-gene associations’) were exported and 
overlap with VDR-correlated genes in the LMC (at FDR<0.05) were assessed.  
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3.3.10 Immunohistochemistry of VDR in the LMC tumours 
3.3.10.1 Optimisation of the anti-VDR antibody 
The anti-VDR antibody (D-6 Sc-13133, Santa Cruz) was optimised on FFPE-derived 
sections of normal (no melanoma) human skin, in order to identify the optimal 
experimental conditions which would enable quantification of VDR expression in the 
melanoma tissue sections from the LMC participants. The following protocol was used 
for the optimisation process: 
1) The FFPE blocks were sectioned using a microtome to produce 5µm sections 
2) The tissue sections were deparaffinised on a hotplate at 70oC followed by antigen 
retrieval in a pressure cooker, with the slides submerged in 1x antigen retrieval 
solution (Menapath technologies). After antigen retrieval, the slides were washed 
in wash buffer (1x, Menapath technologies) followed by rinsing in running tap 
water.  
3) The slides were then marked around the tissue region of interest, with a wax 
marker. Slides were kept in a humidity chamber after this step to ensure tissue 
hydration. 
4) The tissue was then treated with 100µl peroxide blocking solution (Menapath 
technologies) for 11 minutes. The solution was then washed away with wash 
buffer (1x, Menapath technologies) 
5) The tissue was then treated with 100µl Casein blocking solution (Menapath 
technologies) for 10 minutes 
6) The tissues were then treated with the desired primary antibody concentrations, 
diluted in antibody-diluent solution (Menapath technologies). In this case, 5 
concentrations were performed on 5 consecutively sectioned human skin 
sections: 1:50, 1:100, 1:200, 1:330, 1:400 and negative control (no antibody, only 
the diluent solution). The primary antibody treatment was allowed to incubate at 
4oC overnight.  
7) This was followed by secondary antibody treatment using ImmPRESS HRP 
reagents (MP-7452, Vector Laboratories) and visualised using purple Vector VIP 
substrate (SK-4600, Vector Laboratories). 
8) The sections were left to dry overnight, after which they were reviewed.  
9) Figure 3.2 includes representative images of the human skin sections stained with 
VDR as per the above protocol. Of the 5 concentrations of antibody that were 
used, the use of 1:200 concentration appeared to have the most lucid staining as 
evaluated by the following criteria: i) positive staining for VDR in the keratinocytes, 
which is distinguishable from the remaining epidermal tissue. This is because 
64 
 
VDR is known to be expressed in epidermal keratinocytes ii) negative staining in 
the dermal tissue. While the higher concentrations (1:50 and 1:100) stained 
positive for VDR in the epidermal keratinocytes, the staining was not completely 
negative in the dermal tissue. On the other hand, the lower concentration (1:300 
and 1:400) produced staining that was too weak to be able to identify distinct 
keratinocyte positivity. However, the concentration of 1:200 satisfied both criteria 
and was thus chosen to be used for staining the melanoma sections from the 
LMC.  
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Figure 3.2: Optimisation of immunohistochemical staining of VDR using sections 
of human skin. 
The concentrations tested are indicated inset: negative control (A); 1:400 (B); 
1:300 (C); 1:200 (D); 1:100 (E); and 1:50 (F). 
1:200
1:100
1:50
D 
E 
F 
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3.3.10.2 Immunohistochemical staining and evaluation of tissue 
sections from LMC melanomas 
A subset of the LMC tumours (n=30) were sectioned and stained for VDR expression 
using the anti-VDR antibody (D-6 Sc-13133, Santa Cruz). The reason for the availability 
of a limited number of tumour sections for IHC staining was because only tumour blocks 
from deceased participants could be used. The protocol detailed above was used for 
this purpose and the chosen antibody concentration was 1:200. The stained sections 
were then reviewed by myself and Dr. Jon Laye (senior histopathologist in the Leeds 
group). We reviewed each stained tumour section as follows: 
- Positive staining of keratinocytes was evaluated, as an ‘internal control’ to ensure 
each section was adequately stained. To this effect, all 30 sections showed 
keratinocyte VDR positivity.  
- A focal region was defined to be that around the ‘tumour core’: the part of the 
tumour from which the TMA needle had been used to extract cells from which the 
transcriptomic profiles were generated. In this focal region around the tumour core 
(5-10 cell width) the following measures were evaluated:  
i) number of tumour cells which stained positive for VDR in the cytoplasm,  
ii) number of tumour cells which stained positive for VDR in the nucleus, and 
iii) presence/absence of TILs which stained positive for VDR in the nucleus. 
Representative images from this experiment are presented and discussed in 
section 3.4.5.2. 
 
 Results 
3.4.1 Serum vitamin D and VDR in the LMC 
This section will begin with a description of the distribution of serum vitamin D and 
tumour VDR expression in the LMC dataset. This is followed by the assessment of 
individual correlations of serum vitamin D level and tumour VDR expression with  
i) each other i.e. the correlation between VDR and serum vitamin D levels  
ii) clinicopathological features that characterise the progression of primary 
cutaneous melanoma  
iii) measures of self-reported sun-exposure in participants  
iv) expression of genes that code for key components of the vitamin D-VDR 
endocrine system such as the CYP metabolic enzymes and RXR and 
v) expression of genes that code for the other NR1L family of nuclear receptors.  
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The clinicopathological factors tested include AJCC stage, mitotic rate, age at 
diagnosis, sex and anatomic site of melanoma. Age at diagnosis and sex were tested 
because melanoma diagnosis has been reported to vary with sex and age at diagnosis 
(376), both of which are risk factors associated with melanoma survival. Anatomic site 
of melanoma at diagnosis has also been reported as primary prognostic factor for 
primary cutaneous melanoma (377), and hence was tested.  
Though the LMC transcriptomic data set is derived from 703 primary melanomas, 
this section (3.4.1) is based on analysis carried out on data from 700 primary 
melanoma tumours, after excluding 3 samples from participants with vitamin D 
levels greater than 115nmol/L (considered outliers). The significance of these 
participants is discussed in section 3.4.4. 
3.4.1.1 Distribution of serum vitamin D levels and VDR expression in the 
Leeds Melanoma Cohort 
In the 700 LMC primary melanomas, VDR expression was normally distributed, with a 
log-normalised mean expression value of 7.7, minimum of 2.9 and maximum of 9.5 
(Figure 3.3A).  Figure 3.3B represents the distribution of serum vitamin D levels of all 
549 participants, highlighting the 3 participants with serum vitamin D levels >115nmol/L 
and the remaining 546 participants with serum vitamin D levels <115nmol/L. In the 546 
participants, the mean serum vitamin D level was 41.95 nmol/L, the minimum value was 
-2.8 nmol/L and maximum was 105 nmol/L. The negative minimum value of serum 
vitamin D is a consequence of the ‘season-adjustment’ process, to account for the 
20nmol/L average variation of vitamin D levels between summer and winter in the UK. 
This season-adjustment is explained in detail in the methods section.  
3.4.1.2 Correlation of serum vitamin D levels with tumour VDR expression  
The vitamin D-VDR signalling axis exerts transcriptional control over target genes, 
which include genes whose protein products control the metabolism of vitamin D, thus 
maintaining equilibrium of this signalling pathway. Owing to this negative feedback loop, 
the correlation between serum vitamin D (vitamin D in circulation) and tumour VDR 
expression was assessed.  
Serum vitamin D did not correlate significantly with tumour VDR expression 
(R=0.36, P=0.74) in the subset of participants for whom serum vitamin D levels was 
available (n= 549; Figure 3.3C). The correlation between serum vitamin D and VDR 
expression was also not significant in the 546 participants after exclusion of the 3 
samples from participants with outlier serum vitamin D levels >115nmol/L (R=0.34, 
P=0.73; Figure 3.3D).  
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Figure 3.3: Distribution and correlation of serum vitamin D and VDR expression 
in the LMC 
A: Distribution of tumour VDR expression in the 703 LMC primary melanomas;  
B: Distribution of serum vitamin D levels in the 549 LMC primary melanomas, 
highlighting the 546 participants with serum vitamin D levels<115nmol/L (yellow 
box) and 3 participants with serum vitamin D>115nmol/L (green box); 
C: Correlation between serum vitamin D and tumour VDR expression in 549 LMC 
primary melanomas (including 3 participants with serum vitamin D>115nmol/L); 
D: Correlation between serum vitamin D and tumour VDR expression in 546 LMC 
primary melanomas (excluding the 3 participants with outlier serum vitamin D 
levels >115nmol/L)  
 
3.4.1.3 Clinicopathological Correlates of serum vitamin D 
In the 700 LMC primary melanomas, univariable regression analyses revealed that 
serum vitamin D did not correlate significantly with sex (P=0.77), AJCC stage (P>0.07), 
mitotic rate (P=0.26), tumour site (P>0.26) or ulceration (P=0.92) (Table 3.4). 
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C
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Table 3.4: Association of season-adjusted serum vitamin D with 
clinicopathological variables in 703 LMC participants 
B indicates the group used as the baseline for comparison with other groups. 
 Univariable 
Season-adjusted serum vitamin D 
association with Reg Coef Std. Error P-val 
Age (years)  0.14 0.07 0.04 
Sex    
    FemalesB    
    Males 0.55 1.89 0.77 
AJCC Stage    
   Stage IB    
   Stage II -3.05 2.04 0.136 
   Stage III -5.28 2.96 0.075 
Mitotic rate    
    <1 mitoses/mm2 tumourB    
    >=1mitoses/mm2 tumour 2.10 1.86 0.26 
Tumour site     
    HeadB    
    Limbs -3.44 3.05 0.26 
    Trunk -1.52 3.16 0.63 
    Rare (sun-protected sites) -3.65 3.91 0.35 
Ulceration    
    UlceratedB    
    Non-ulcerated -0.00009 0.0009 0.925 
 
Members of the Cytochrome P450 (CYP) enzyme superfamily play a role in maintaining 
vitamin D homeostasis. The primary CYPs associated with Vitamin D anabolism 
(synthesis) are CYP27A1 and CYP27B1 in the liver and kidney respectively. The 
catabolism (break-down) of vitamin D is mediated by CYP24A1 in the kidney. To 
investigate if serum vitamin D levels are associated with the expression of CYP genes 
in the LMC primary melanomas, a correlation analysis was done. To this effect, serum 
vitamin D did not correlate significantly with CYP27A1 (R=-0.72, P=0.57), CYP27B1 
(R=-0.85, P=0.28) or CYP24A1 (R=-0.53, P=0.46) (Figure 3.4). 
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Figure 3.4: Correlation of serum vitamin D with expression of Cytochrome P450 
(CYP) genes involved in vitamin D metabolism 
Correlation of serum vitamin D with CYP27A1 (A), CYP27B1 (B) and CYP24A1 
(C) expression in the 546 LMC primary melanomas. 
  
A 
B 
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3.4.1.4 Clinicopathological correlates of tumour VDR expression   
Univariable regression analyses identified the clinicopathological features that 
significantly correlated with VDR expression. The significant correlates were then used 
in a multivariable regression model to identify the independent correlates of VDR 
expression.  
The univariable regression analysis revealed the following observations 
(summarised in Table 3.5). B indicates the group used as the baseline for comparison 
with other groups. 
• VDR expression was marginally significantly correlated with age at diagnosis (R=-
0.005, P=0.04) 
• VDR expression was significantly higher in femalesB compared to males 
(P=0.003).  
• VDR expression was significantly higher in AJCC Stage IB tumours compared to 
AJCC Stage II (R=-0.17, P=0.012) and AJCC Stage III (R=-0.25, P=0.009) 
tumours.  
• VDR expression was significantly higher in tumours with <=1 mitosis/sq.mmB  than 
those with >1 mitoses/sq.mm (R=-0.23, P=0.0004).  
• VDR expression did not vary significantly between tumours on the head/neckB and 
limbs (R=-0.04, P=0.63). However, tumour VDR expression was significantly 
lower in truncal tumours (R=-0.35, P=0.001) and Rare tumours (R=-0.44, 
P=0.001) compared to head/neck tumours. Rare tumours are those on sun-
protected sites.  
Taken together, the univariable analyses identified the following clinicopathological 
features to be significantly associated with VDR: AJCC stage, mitotic rate, sex and 
tumour site. However, it is important to assess which of these characteristics were 
independently associated with VDR expression. Multivariable analysis estimates the 
significance of the association of one variable with VDR expression, after adjusting for 
all other variables.  
In the multivariable regression analysis, age at diagnosis (P=0.14) and sex 
(P=0.14) were not significantly associated with VDR expression, suggesting that age 
and sex were not independently associated with VDR expression. In other words, age 
and sex were confounded by AJCC stage and tumour site. On the other hand, AJCC 
stage, mitotic number and tumour site remained significantly associated with VDR 
expression in the multivariable analysis. VDR expression was significantly higher in 
stage I tumours compared to stage II (P=0.08) and stage III tumours (P=0.06), after 
adjusting for age, sex and tumour site. VDR expression was also independently 
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inversely correlated with mitotic number (P=0.001). Similarly, VDR expression was 
significantly higher in head tumours compared to truncal (P=0.001) and rare tumours 
(P=0.003), after adjusting for age, sex and tumour site. Taken together, these results 
indicated that AJCC stage, mitotic number and tumour site were independently 
associated with tumour VDR expression whereas age and sex were not.  
Table 3.5: Association of tumour VDR expression with clinicopathological 
variables in 703 LMC tumours 
B indicates the group used as the baseline for comparison with other groups. 
 Univariable Multivariable 
VDR association with Reg Coef 
Std. 
Error P-val 
Reg 
Coef 
Std. 
Error P-val 
Age (years)  -0.005 0.002 0.04 -0.003 0.002 0.14 
Sex       
    FemalesB       
    Males -0.18 0.06 0.003 -0.09 0.06 0.16 
AJCC Stage       
   Stage IB       
   Stage II -0.17 0.07 0.012 -0.12 0.07 0.08 
   Stage III -0.25 0.09 0.009 -0.18 0.09 0.06 
Mitotic rate       
    <1 mitoses/mm2 tumourB       
    >=1mitoses/mm2 tumour -0.23 0.06 0.0004 -0.20 0.06 0.001 
Tumour site        
    HeadB       
    Limbs -0.04 0.10 0.63 -0.11 0.10 0.28 
    Trunk -0.35 0.10 0.001 -0.36 0.10 0.001 
    Rare (sun protected sites) -0.44 0.12 0.001 -0.38 0.13 0.003 
 
Additionally, VDR has been shown to be higher in primary melanomas with 
increased immune infiltrate (368), which by itself is a predictor of improved melanoma 
prognosis (171, 172). Hence, the association of VDR expression with pathologist-
graded measure of tumour immune infiltration was assessed. VDR expression was 
significantly lower in tumours with no immune infiltrate ('absent') compared to those with 
non-brisk (P=0.02) and brisk (P=0.006) immune infiltrate (Figure 3.5).  
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Figure 3.5: Association of tumour VDR expression with pathologist-graded 
measure of tumour immune infiltration in the whole tumour section 
VDR expression was compared between tumours with ‘absent’ (n=45), ‘non-brisk’ 
(n=492) or ‘brisk’ (n=64) immune infiltrate. P-values from linear regression model.  
 
3.4.1.5 Tumour VDR expression and self-reported sun exposure  
Since tumour VDR expression varied between tumours diagnosed in different 
anatomical sites, being significantly lower in sun-protected sites compared to those on 
the head, it was hypothesised that VDR expression in the tumour would be associated 
with the participants’ sun-exposure pattern. The association of tumour VDR expression 
with each of these sun-exposure measures was estimated using a linear regression 
model.  
To this effect, tumour VDR expression was significantly associated with only one of 
the sun exposure measures: average measure of sun exposure in the weekend in both 
warmer and cooler months (measured in hours per week, P=0.04). This measure is a 
combined measure of two other measures: average measure of sun exposure in the 
weekend in warmer months and average measure of sun exposure in the weekend in 
cooler months, both of which also have borderline significant associations with VDR 
expression (P=0.06) (Table 3.6).  
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Table 3.6: Association of sun-exposure measures with tumour VDR expression 
Self-reported sun-exposure measure Regression Coefficient P-value 
Average weekday exposure in warmer months 
Average weekday exposure in cooler months   
Average weekday exposure overall 
Average weekend exposure in warmer months 
Average weekend exposure in cooler months 
Average weekend exposure overall 
0.04 
0.03 
0.04 
0.06 
0.06 
0.07 
0.17 
0.32 
0.23 
0.06 
0.06 
0.04 
 
3.4.1.6 Correlation of tumour VDR expression with expression of NR1L 
superfamily genes 
DR belongs to the NR1L superfamily of nuclear receptors which consists of other 
nuclear hormone receptors such as LXRB, FXR1, RXR, FXR2 and PXR. Of these NR1L 
superfamily members, RXR is of particular interest since vitamin D-activated VDR forms 
a dimeric complex with RXR, which together facilitate transcription of target genes. 
Thus, the correlation of VDR with the expression of three RXR isoforms as well as the 
other NR1L family members was checked. VDR correlated significantly with RXRB, 
LXRB, PXR, FXR1 and FXR2 (Table 3.7) 
Table 3.7: VDR correlation with expression of NR1L superfamily members 
Correlation of VDR with  Regression Coefficient P-value 
RXRA 0.01 0.73 
RXRB -0.4 2.9x 10-6 
RXRG 0.002 0.90 
LXRB 0.27 7x 10-14 
PXR -0.13 0.0004 
FXR1 0.13 0.0003 
FXR2 -0.12 0.001 
CAR1 0.01 0.75 
 
3.4.2 Vitamin D-VDR signalling and melanoma prognosis  
This section will focus on assessing the individual effects of serum vitamin D and tumour 
VDR expression on melanoma prognosis in the LMC primary melanomas. To validate 
the findings from the LMC, the prognostic significance of tumour VDR expression was 
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also evaluated in the metastatic melanomas from the TCGA melanoma cohort. It was 
not possible to assess the prognostic effect of serum vitamin D in the TCGA cohort, 
owing to absence of data for serum vitamin D in this cohort of patients.  
3.4.2.1 Serum vitamin D levels and melanoma prognosis in the LMC 
High serum vitamin D levels at diagnosis have been associated with improved 
prognosis in patients from 6 independent melanoma cohorts, including the larger 
‘original’ Leeds Melanoma Cohort of 2184 participants. Hence, the effect of higher 
serum vitamin D in the 546 LMC primary melanomas was assessed. There was no 
significant association of serum vitamin D with prognosis (HR=0.99, P=0.06). This was 
analysis was done using serum vitamin D on a continuous scale, indicating that for 
every 1nmol/L increase in serum vitamin D, the estimated risk of death fell by 1%. 
However, various thresholds of vitamin D levels to indicate deficiency and sufficiency 
have been proposed, with different cut-off limits in different human populations. The 
clinical definition of deficient winter vitamin D set by the UK Government Scientific 
Advisory Committee on Nutrition (378) was 25 nmol/L. So, the LMC participants were 
categorised based on their vitamin D levels into ‘low’ serum vitamin D (<25nmol/L, 
n=116) and ‘high’ serum vitamin D (>25nmol/L, n=430) groups and will be referred to 
as such henceforth. Interestingly, this threshold of 25nmol/L was very close to the 
optimum cut-off identified as best predicting survival in our data set (22nmol/L) using X-
tile (see section 3.3). In comparing the prognosis of participants with categorised levels 
of vitamin D, there was borderline significant variation in melanoma prognosis between 
the participants with high and low serum vitamin D at diagnosis (HR=0.72, P=0.07).  
3.4.2.2 Tumour VDR expression and melanoma prognosis  
VDR loss (as measured by IHC) has been reported to be associated with cutaneous 
melanoma progression (368) and VDR polymorphisms have been shown to be 
associated with melanoma survival (379). So, the prognostic significance of tumour 
VDR expression was assessed in the LMC primary melanomas. Higher VDR 
expression was significantly correlated with clinicopathological features such as lower 
AJCC stage, lower mitotic rate, increased immune infiltrate and tumours of the 
head/neck (compared to truncal and sun-protected tumours) (section 3.4.1.4), which by 
themselves are significant predictors of melanoma outcomes. In order to ensure that 
the effect of VDR expression on melanoma survival was not confounded by the 
aforementioned clinicopathological features, a multivariable analysis was performed to 
assess if tumour VDR expression was an independent predictor of melanoma survival. 
Tumour VDR expression was found to be protective for melanoma death 
(univariable model, HR=0.75, P=0.0001). A multivariable model revealed that tumour 
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VDR expression was protective for melanoma death independent of AJCC stage, 
mitotic rate, tumour site and tumour immune infiltrate (HR=0.8, P=0.008) (Table 3.8). In 
other words, the protective effect of tumour VDR (on melanoma death) persisted even 
after adjusting for clinicopathological features, which are also significantly correlated 
with VDR. 
Table 3.8: Association of VDR expression with death from melanoma in the LMC 
VDR: association with death from melanoma Hazard Ratio Std. Error P-value 
Univariable 0.75 0.05 0.0001 
Adjusted for AJCC stage, mitotic rate, tumour 
site and tumour immune infiltrate 0.80 0.06 0.008 
 
VDR correlated significantly with expression of some members of the NR1L 
superfamily of nuclear receptors (see section 3.4.1.4). This put forth the possibility that 
the prognostic significance of tumour VDR expression could be confounded by the 
expression of these genes. This was tested using a multivariable survival analysis, in 
which the prognostic significance of VDR was estimated after adjusting for each of the 
significantly correlated NR1L family genes. Tumour VDR expression was significantly 
protective for melanoma death after adjusting for RXRB, LXR, PXR, FXR1 or FXR2 
(Table 3.9). This indicated that the association of VDR with improved melanoma 
prognosis was independent of the expression of other NR1L superfamily members.  
Table 3.9: Association of VDR expression with melanoma death after adjusting 
for expression of NR1L family genes 
VDR: association with death from melanoma Hazard Ratio Std. Error P-value 
Univariable 0.75 0.05 0.0001 
Adjusted for RXRB expression 0.76 0.05 0.00006 
Adjusted for LXR expression 0.76 0.05 0.0002 
Adjusted for PXR expression 0.74 0.05 0.00003 
Adjusted for FXR1 expression 0.76 0.05 0.00003 
Adjusted for FXR2 expression 0.77 0.05 0.00009 
 
Collectively, in the 700 LMC primary melanomas, VDR expression but not serum 
vitamin D level was significantly associated with improved melanoma survival. In order 
to assess if serum vitamin D offered a prognostic benefit within the context of VDR 
expression, the 700 tumours were stratified into 3 VDR-groups. To this effect, a survival-
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based stratification using X-tile (see Methods 3.3) was performed, which identified three 
tumour groups: low-VDR (17% of tumours with lowest VDR expression, n=119), high-
VDR (17% of tumours with highest VDR expression, n=119) and intermediate-VDR 
(middle 66% of tumours, n=462) (Figure 3.6A). Compared to the low-VDR group (which 
had the worst prognosis and hence used as baseline) the intermediate-VDR group 
(HR=0.51, P=0.0003) and the high-VDR group (HR=0.25, P=5.4 x 10-8) had significantly 
improved prognosis (Figure 3.6B). These VDR-groups were used subsequently in a 
‘vitamin D-VDR subgroup analysis’, to explore the association of serum vitamin D within 
the context of tumour VDR expression: discussed in section 3.4.3.  
Having identified 3 VDR-groups in the LMC primary melanomas, it remained to be 
tested if this VDR-associated improvement in survival was also relevant in metastatic 
melanomas. To this effect, the TCGA metastatic melanoma data set was used. When 
the same VDR expression cut offs (lowest 17%, middle 66% and highest 17%) were 
applied to the TCGA metastatic melanoma data, the replication produced three VDR-
based tumour groups: low-VDR (n=71), intermediate-VDR (n=270) and high-VDR 
(n=69) (Figure 3.6C) with a progressive improvement in melanoma survival with 
increasing VDR expression (overall HR=0.774, P=0.05) (Figure 3.6D).  
Taken together, increased tumour VDR expression was associated with improved 
prognosis in both primary and metastatic melanomas, as evidenced in the LMC and 
TCGA datasets respectively.  
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Figure 3.6: Three VDR-groups in the LMC primary melanomas 
A: Stratification of the 700 LMC primary melanomas into low-VDR (n=119), 
intermediate-VDR (n=463) and high-VDR (n=119) groups using X-tile; 
B: Difference in survival of the 3 VDR-groups in the LMC dataset. Cox 
Proportional Hazards model was used to identify HR (Hazard Ratio) of 
intermediate- and high-VDR groups, relative to the low-VDR group; 
C: Stratification of the TCGA metastatic melanomas into low-VDR (n=71), 
intermediate-VDR (n=270) and high-VDR (n=69) upon applying the proportions 
derived from the LMC analyses (lowest 17%, middle 66% and highest17% of VDR 
expression); 
D: Difference in survival of the 3 VDR-groups in the TCGA dataset. Cox 
Proportional Hazards model was used to identify HR (Hazard Ratio) and P-value.  
  
A B 
C D 
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3.4.3 Context-specific protective effect of serum vitamin D on 
melanoma survival  
This section will focus on the vitamin D- VDR subgroup analysis, wherein each of the 
three VDR -groups (described in 3.4.2.2) were further subdivided based on the serum 
vitamin D level (low or high serum vitamin D) at diagnosis of the participants. This 
produced 6 subgroups: high-VDR tumours with low (n=20) or high (n=73) vitamin D, 
intermediate-VDR tumours with low (n=73) or high (n=288) vitamin D and low-VDR 
tumours with low (n=20) or high (n=73) vitamin D. The melanoma prognosis of 
participants with low or high serum vitamin D within each of the three VDR groups was 
compared. In other words, the prognostic significance of serum vitamin D within the 
context of tumour VDR expression was assessed. Serum vitamin D was not significantly 
associated with melanoma prognosis in the low-VDR (P=0.66) and high-VDR (P=0.57) 
groups. However, in the intermediate-VDR group, participant with low serum vitamin D 
levels had a significantly worse prognosis compared to those with high serum vitamin 
D (HR=1.73, P=0.02) (Figure 3.7). Based on this observation, it was postulated that the 
intermediate-VDR group would be an optimal subset of primary melanomas to identify 
factors associated with the protective of vitamin D on melanoma survival. To this effect, 
the two intermediate-VDR subgroups (with low/high serum vitamin D) were used for 
subsequent comparative analyses. Differences in clinicopathological features as well 
as transcriptomic differences were assessed between participants with low or high 
serum vitamin D in the intermediate-VDR group. 
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Figure 3.7: Context-specific protect effect of serum vitamin D on melanoma death 
Vitamin D-VDR subgroup analysis splitting each of the three VDR-groups into two 
based on their serum vitamin D level (low or high serum vitamin D) to produce 6 
groups. The Kaplan-Meier plot depicts the difference in survival of these 6 groups. 
Participants in the intermediate-VDR group who had higher serum vitamin D level 
at diagnosis having significantly improved prognosis compared to those with low 
vitamin D.  
 
3.4.3.1 Clinicopathological features associated with serum vitamin D level 
in the intermediate-VDR group 
There was no significant variation in age at diagnosis, sex, tumour mitotic rate, site of 
melanoma and ulceration status between participants with low (n=73) or high (n=288) 
serum vitamin D levels in the intermediate-VDR group (Table 3.10). However, 
participants with low serum vitamin D in the intermediate-VDR group had significantly 
higher Breslow thickness (linear regression test, P=0.02, Figure 3.8A, Table 3.10) and 
higher frequency of AJCC stage II tumours (Pearson’s Chi-squared test, compared to 
AJCC stage I tumours: P=0.01, Figure 3.8B, Table 3.10), when compared to 
participants with high serum vitamin D. Additionally, histopathological measure of 
vascular invasion was available for a subset of patients (n=326) for whom a measure 
of serum vitamin D levels at diagnosis was available. The frequency of tumours with 
vascular invasion was significantly (Pearson’s Chi-squared test, P=0.01) higher in 
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participants with low serum vitamin D (20% had vascular invasion) compared to those 
with high serum vitamin D (10% had vascular invasion) Figure 3.8C, Table 3.10).  
 
Table 3.10: Association of serum vitamin D with clinicopathological features in 
melanomas from the intermediate-VDR group 
B indicates the group used as the baseline for comparison with other groups. 
Association of serum vitamin D 
(in the intermediate-VDR group) with Reg Coef Std. Error P-val 
Age (years)  -0.002 0.001 0.20 
Sex    
    FemalesB    
    Males 0.03 0.03 0.31 
AJCC Stage    
    Stage IB    
    Stage II -0.10 0.04 0.01 
    Stage III -0.03 0.06 0.60 
Mitotic rate    
    <1 mitoses/mm2 tumourB    
    >=1mitoses/mm2 tumour 0.01 0.03 0.79 
Breslow thickness (mm) -0.68 0.29 0.02 
Ulceration status     
    NoB    
    Yes -0.05 0.06 0.43 
Site of melanoma    
    HeadB    
    Limbs -0.09 0.06 0.11 
    Trunk -0.04 0.06 0.46 
    Rare (sun protected sites) -0.06 0.11 0.58 
Vascular invasion    
    NoB    
    Yes -0.16 0.06 0.01 
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Figure 3.8: Clinicopathological features which varied significantly between 
tumours from participants with low (n=73) and high (n=288) serum vitamin 
D in the intermediate-VDR group 
A: Comparison of Breslow thickness (mm) between participants with low/high 
serum vitamin D in the intermediate-VDR group. P-value from linear regression 
model; 
B: Comparison of AJCC stage between participants with low/high serum vitamin 
D in the intermediate-VDR group. P-value from Pearson’s Chi-squared test; 
C: Comparison of vascular invasion between participants with low/high serum 
vitamin D in the intermediate-VDR group. P-value from Pearson’s Chi-squared 
test 
 
In an effort to identify the potential reason behind the low or high levels of serum vitamin 
D in the intermediate-VDR participants, self-reported supplementation data were used. 
Among the intermediate-VDR group, those with high serum vitamin D were more likely 
to have taken dietary supplements (46%) compared to those with low serum vitamin D 
(20%) (P=0.0004, Figure 3.9). However, in the low-VDR groups, the proportion of 
patients who had reported to have taken dietary supplements was borderline 
significantly associated with their serum vitamin D levels (P=0.062) (Table 3.11). In the 
A B 
C 
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high-VDR groups, the proportion of patients who had reported to have taken/not taken 
dietary supplements was not significantly associated with their serum vitamin D levels 
(P=0.23) (Table 3.12). This observation could be reflective of the fact that vitamin D 
intake is proportional to the serum vitamin D levels, but this effect is apparent in the 
intermediate-VDR group because this group has the highest number of participants.  
 
Figure 3.9: Association of self-reported dietary supplement intake with serum 
vitamin D in participants of the intermediate-VDR group 
Comparison of supplement intake (‘Yes’ or ‘No’ in the year preceding 
questionnaire) between participants with low/high serum vitamin D in the 
intermediate-VDR group. P-value from Pearson’s Chi-squared test 
 
Table 3.11: Association of supplement intake in participants with low and high 
serum vitamin D in the low-VDR group 
Supplement intake in the past 1 year Low vitamin D High vitamin D 
Yes  4 (25%) 38 (51%) 
No 12 (75%) 37 (49%) 
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Table 3.12: Association of supplement intake in participants with low and high 
serum vitamin D in the high-VDR group 
Supplement intake in the past 1 year Low vitamin D High vitamin D 
Yes  3 (20%) 27 (36%) 
No 12 (80%) 48 (64%) 
 
3.4.3.2 Imputed immune cell scores, cytokine and chemokine gene 
expression associated with serum vitamin D level in the 
intermediate-VDR group 
Since vitamin D has been shown to affect components of the immune system (as 
discussed in 3.1), the immune landscape of tumours in participants with high 
(>25nmol/L) or low (<25nmol/L) serum vitamin D levels in the intermediate-VDR group 
was compared. This was done using imputed immune cell scores and the expression 
of cytokine and chemokine genes. The imputed immune cell scores (see 3.3), 
henceforth referred to as Angelova immune cell scores were used. Briefly, each tumour 
sample was assigned 26 Angelova immune cell scores (pertaining to 26 immune cell 
types) based on expression of genes deemed to be uniquely expressed by the particular 
cell type. Angelova immune cell scores represent a quantitative, in silico measure of 
the tumour’s immune landscape. In comparing the 26 Angelova immune cell scores 
between the two groups, 2 of the 26 imputed immune cell scores were significantly 
lower in tumours of participants with high serum vitamin D: scores for neutrophils 
(P=0.02) and monocytes (P=0.04) (Table 3.13).  
The differential expression of 154 cytokine and chemokine genes was compared 
between the high and low vitamin D participants in the intermediate-VDR group 
(Appendix Table T3-1). After adjusting for multiple correction, only the expression of 
CXCL2 was significantly lower in the high vitamin D participants compared to low 
vitamin D participants (adjusted P=0.03). 
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Table 3.13: Differences in imputed immune cell scores between participants with 
low (<25nmol/L) or high (>25nmol/L) serum vitamin D in the intermediate-
VDR group 
Imputed immune  
cell score 
P-val 
(from T-test) 
Mean expression 
in low vitamin D 
group 
Mean expression 
in high vitamin D 
group 
Neutrophils 0.02 0.16 -0.01 
Monocytes 0.04 0.16 -0.01 
T Gamma Delta cells 0.07 0.18 0.02 
Macrophages 0.07 0.13 -0.01 
Natural Killer cels 0.08 0.20 0.04 
Cytotoxic cells 0.09 0.24 0.05 
Natural Killer T cells 0.11 0.21 0.05 
Central memory CD8 cells 0.14 0.15 0.02 
Mast cells 0.17 0.11 0.02 
Immature B cells 0.17 0.16 0.02 
T cells 0.18 0.16 0.05 
Myeloid Derived Suppressor 
Cells 0.18 0.16 0.04 
Th17 0.19 -0.09 -0.02 
Dendritic cells 0.19 0.12 0.04 
NK56 dim 0.19 0.14 0.03 
Th1 0.24 0.16 0.06 
Activated B cells 0.25 0.17 0.06 
Effector_memory_CD8 0.26 0.13 0.04 
Central memory CD4 0.26 0.13 0.05 
T-regulatory cells  0.32 0.11 0.03 
T Follicular Helper cells 0.36 0.17 0.07 
NK56 bright 0.67 0.13 0.08 
Plasmacytoid Dendritic Cells 0.74 -0.03 0.01 
Immature Dendritic Cells 0.79 0.06 0.04 
Th2  0.85 0.08 0.06 
Eosinophils 0.90 0.00 -0.01 
Activated CD4 cells 0.91 0.01 0.00 
Memory B cells 0.98 -0.03 -0.03 
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3.4.3.3 Whole-transcriptome correlations with serum vitamin D level in the 
intermediate-VDR group 
Given that serum vitamin D levels >25nmol/L were protective for melanoma death only 
in the intermediate-VDR group of tumours, a whole-transcriptome correlation analysis 
was performed to identify the genes that were significantly differentially expressed 
between participants with low serum vitamin D (n=58) and high serum vitamin D 
(n=303) in the intermediate-VDR subgroup. To this effect, a linear regression model 
was used to estimate the correlation between each gene and serum vitamin D. The 
strength of correlation was gauged by the P-value (produced by the linear regression 
model), which was subsequently adjusted for multiple correction to produce the FDR 
(False Discovery Rate). Of the 20,560 genes tested, none of the genes reached the 
significance threshold of FDR<0.05. This is depicted in a histogram of FDR values 
corresponding to each gene, with the majority of the genes having FDR>0.05 (Figure 
3.10).  
 
 
Figure 3.10: Frequency of genes that are significantly associated with serum 
vitamin D in the intermediate-VDR group, excluding participants with serum 
vitamin D >115 nmol/L 
FDR values generated from P-values (Benjamini-Hochberg FDR) produced from 
a linear regression model, regressing each gene (of the 20,560 genes) with serum 
vitamin D in the intermediate-VDR group are plotted in a histogram. Most of the 
genes have FDR close to 1 as indicated by the histogram. 
  
88 
 
In summary: in the 700 LMC participants, high serum vitamin D levels (>25nmol/L) 
offer a survival benefit only in a subgroup of patients belonging to the 
intermediate-VDR group. An agnostic whole-transcriptome correlation analysis 
of the intermediate-VDR tumours revealed that there were no genes that were 
significantly differentially expressed between participants with low or high serum 
vitamin. However, imputed immune cell scores for neutrophils and monocytes 
were inversely associated with serum vitamin D levels, as was the expression of 
CXCL2. 
As mentioned earlier in this section, there were 3 participants with serum vitamin D 
levels >115 nmol/L, who were not included for analyses thus far. Though there are only 
3 participants, their levels of serum vitamin D are still within the physiological range. 
Thus, it was of interest to assess the transcriptomic characteristics of melanomas 
>115nmol/L, which is described in the following section 3.4.3.4. 
3.4.3.4 Transcriptomic characteristics of melanomas from participants 
with serum vitamin D levels >115nmol/L  
Among the 703 LMC primary melanomas, season-adjusted serum vitamin D levels 
were available for 549 participants. However, 3 of the 549 patients had serum vitamin 
D levels greater than 115nmol/L. The analyses described in section 3.4.3 were done 
excluding these three patients. However, this section (3.4.4) focuses on analyses done 
including these three patients i.e. using all 549 participants for whom serum vitamin D 
levels were available. The three participants with serum vitamin D greater than 
115nmol/L belonged to intermediate-VDR group with high serum vitamin D. When a 
whole-transcriptome correlation was performed with serum vitamin D in the 
intermediate-VDR group, 441 genes were found to correlate significantly with serum 
vitamin D after adjusting for multiple correction (FDR<0.05, Figure 3.11B).  
At the same multiple correction threshold, there were no genes that correlated 
significantly with serum vitamin D in the low-VDR (Figure 3.11A) and high-VDR (Figure 
3.11C) groups. These findings are depicted using volcano plots.   
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Figure 3.11: Volcano plots of genes that are significantly associated with serum 
vitamin D in the low-, high- and intermediate-VDR groups (including 
participants with serum vitamin D >115 nmol/L) 
A: Volcano plot of genes which correlate with serum vitamin D in the low-VDR 
group (n=119); 
B: Volcano plot of genes which correlate with serum vitamin D in the intermediate-
VDR group (n=465). Red dots denote significantly negatively correlated genes 
and green dots denote significantly positively correlated genes; 
C: Volcano plot of genes which correlate with serum vitamin D in the high-VDR 
group (n=119). 
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Thus, the inclusion of participants with serum vitamin D greater than 115nmol/L 
significantly affects the whole-transcriptome correlates of serum vitamin D in the 
intermediate-VDR subgroup of tumours. This highlights that serum vitamin D levels 
greater than 115nmol/L are associated with variation in gene expression in the 
intermediate-VDR group. This prompted further investigation to identify the biological 
function of these genes associated with ‘very high’ serum vitamin D. Among the 441 
genes that correlated with serum vitamin D in the intermediate-VDR group, 283 
correlated negatively whereas 158 correlated positively with serum vitamin D. The 
negatively correlated genes were enriched for pathways such as T cell activation, 
mitochondrial translation, MHC class II antigen presentation, HIF-1 pathway and Renal 
cell carcinoma (Table 3.14). The nodal genes pertaining to these pathways were 
PPP3CB, PPP3CC, HLADOA, HLADQA1, BRAF, MRPS5, MRPS33, MRPS30, ARNT, 
PLCG1, HMOX1, EGLN1 and PFKL.  
The positively correlated genes were enriched for pathways such as retinol 
metabolism, Cytochrome P450-drug metabolism, fatty acid degradation and 
glycolysis/gluconeogenesis, to name a few (Table 3.15). The nodal genes pertaining to 
these pathways were ADH1A, TUBA3C, UGT1A10, DYNC1LI1 and MIP.  
Because the inclusion of only 3 participants has a radical effect on the 
transcriptomic correlates of serum vitamin D, these participants were deemed to 
be outliers and excluded for subsequent analyses.  
Table 3.14: List of pathways enriched for genes negatively correlated with serum 
vitamin D in the intermediate-VDR group without exclusion of the 3 samples 
from participants with levels >115nmol/L. 
Pathways P-value FDR Nodes 
T cell activation(P) 1.15E-05 3.95E-03 PPP3CB, PPP3CC, HLA-DOA, PLCG1, HLA-DQA1, BRAF 
Mitochondrial translation(R) 1.94E-05 3.95E-03 MRPL4, MRPL40, MRPL9, MRPS5, MRPS33, MRPS30 
MHC class II antigen 
presentation(R) 2.32E-04 0.0313 
CLTA, HLA-DOA, KIFAP3, 
DCTN2, HLA-DQA1 
HIF-1 signalling pathway(K) 4.51E-04 0.0445 ARNT, HMOX1, PLCG1, EGLN1, PFKL 
Regulation of Hypoxia-inducible 
Factor (HIF) by oxygen(R) 5.84E-04 0.0445 ARNT, EPAS1, EGLN1 
HIF-1-alpha transcription factor 
network(N) 7.67E-04 0.0445 ARNT, HMOX1, EGLN1, PFKL 
Renal cell carcinoma(K) 7.67E-04 0.0445 ARNT, EPAS1, EGLN1, BRAF 
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Table 3.15: List of pathways enriched for genes positively correlated with serum 
vitamin D in the intermediate-VDR group 
Pathway P-value FDR Nodes  
Retinol metabolism(K) 4.00E-04 3.71E-03 UGT1A10, ADH1C 
Drug metabolism - cytochrome P450(K) 4.37E-04 3.71E-03 UGT1A10, ADH1C 
Metabolism of xenobiotics by 
cytochrome P450(K) 5.17E-04 3.71E-03 UGT1A10, ADH1C 
Chemical carcinogenesis(K) 6.19E-04 3.71E-03 UGT1A10, ADH1C 
Phagosome(K) 2.18E-03 0.0109 DYNC1LI1, TUBA3C 
Passive transport by Aquaporins(R) 3.91E-03 0.0156 MIP 
downregulated of mta-3 in er-negative 
breast tumours(B) 8.78E-03 0.0204 TUBA3C 
stathmin and breast cancer resistance 
to antimicrotubule agents(B) 0.0107 0.0204 TUBA3C 
Ascorbate and aldarate metabolism(K) 0.0131 0.0204 UGT1A10 
Signalling by Retinoic Acid(R) 0.0165 0.0204 ADH1C 
Tyrosine metabolism(K) 0.017 0.0204 ADH1C 
Pentose and glucuronate 
interconversions(K) 0.0175 0.0204 UGT1A10 
Protein folding(R) 0.0185 0.0204 TUBA3C 
Porphyrin and chlorophyll 
metabolism(K) 0.0204 0.0204 UGT1A10 
Vasopressin-regulated water 
reabsorption(K) 0.0214 0.0214 DYNC1LI1 
Fatty acid degradation(K) 0.0214 0.0214 ADH1C 
Drug metabolism - other enzymes(K) 0.0223 0.0223 UGT1A10 
Pathogenic Escherichia coli infection(K) 0.0266 0.0266 TUBA3C 
Starch and sucrose metabolism(K) 0.0271 0.0271 UGT1A10 
Steroid hormone biosynthesis(K) 0.0281 0.0281 UGT1A10 
Glycolysis / Gluconeogenesis(K) 0.0324 0.0324 ADH1C 
Phase 1 - Functionalization of 
compounds(R) 0.0338 0.0338 ADH1C 
Salmonella infection(K) 0.0414 0.0414 DYNC1LI1 
Gap junction(K) 0.0423 0.0423 TUBA3C 
 
Since these pathways were identified in the whole-transcriptome correlation 
including the 3 participants with >115nmol/L serum vitamin D (549 participants), it was 
of interest to test if these genes/pathways also correlated with serum vitamin D in the 
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intermediate-VDR group, excluding the 3 participants (546 participants). To this effect, 
none of the negatively correlated nodal genes (from analysis including 3 outliers) were 
differentially expressed between participants with low serum vitamin D and high serum 
vitamin D (in cohort excluding 3 outliers): PPP3CB (P=0.67), PPP3CC (P=0.11), 
HLADOA (P=0.06), HLADQA1 (P=0.10), BRAF (P=0.70), MRPS5 (P=0.23), MRPS33 
(P=0.23), MRPS30 (P=0.40), ARNT (P=0.29), PLCG1 (P=0.86), HMOX1 (P=0.27), 
EGLN1 (P=0.13) and PFKL (P=0.33). Among the positively correlated genes, there was 
no significant variation for ADH1A (P=0.16), TUBA3C (P=0.89) and UGT1A10 (P=0.13) 
between participant with low or high serum vitamin D (in cohort excluding 3 outliers). 
However, DYNC1LI1 (P=0.02) and MIP (P=0.001) were expressed significantly higher 
in participants with high serum vitamin D compared to those with low serum vitamin D. 
DYNC1LI1 is a coding gene which codes for the Dynein Cytoplasmic 1 Light 
Intermediate Chain 1 protein, whose Gene Ontology (GO) terms include RNA binding 
and microtubule motor activity. MIP codes for the Major Intrinsic Protein: a water-
transporting aquaporin, whose Gene Ontology (GO) terms include calmodulin binding 
and water channel activity.  
In summary: Among the genes identified in the whole-transcriptome correlation with 
serum vitamin D in cohort of patients with serum vitamin D >115nmol/L, only MIP and 
DYNC1LI1 are of relevance in the dataset of patients excluding these outliers.   
3.4.4 Tumour VDR expression:  transcriptomic characteristics 
The prognostic significance of tumour VDR expression in both the LMC primary and 
TCGA metastatic melanomas has been discussed in section 3.4.2.2. The significant 
association of tumour VDR expression with improved melanoma survival necessitated 
the identification of genes that correlate significantly with tumour VDR expression. The 
rationale was that the significantly correlated genes and the correspondingly enriched 
biological pathways would offer insights into the mechanistic basis of the protective 
effect of VDR on melanoma death. To this effect, an agnostic correlation analysis was 
used to identify genes and signalling pathways that most significantly correlated with 
VDR expression in the LMC primary melanomas. This agnostic correlation with VDR 
was also performed on TCGA transcriptomes from metastatic melanomas, for 
comparison. The concordance between genes agnostically identified to be correlated 
with VDR in the LMC and genomic regions reported to have a VDR binding site (based 
on ChIP-Seq experiments) was also assessed. Factors contributing to reduced VDR 
expression were also explored in the LMC as well as TCGA melanoma data sets.  
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3.4.4.1 Whole-transcriptome correlation with tumour VDR expression in 
the LMC primary melanomas 
The correlation of tumour VDR expression with 20,560 genes (each represented by a 
unique probe) was computed using a linear regression model. The direction of 
correlation (positive or negative) was denoted by the regression coefficient (‘R’) while 
the significance of correlation with a particular gene was denoted by the P-value. Given 
that 20,560 tests were performed (one per gene), it was necessary to account for 
multiple testing. This was done using the Benjamini-Hochberg FDR method which 
produced an adjusted P-value (‘adj-P-value’). 12,158 genes with adj-P-value<0.05 were 
identified to be significantly correlated with VDR. Additionally, a regression coefficient 
threshold of 0.2 was used to identify the strongest correlates of VDR expression. In 
doing so, 1383 genes with R<-0.2 were identified to be significant negative correlates, 
whereas 2025 genes with R>0.2 were identified to be significant positive correlates with 
VDR. The aforementioned significant transcriptomic correlates of VDR are depicted in 
a volcano plot (Figure 3.12). Each of these gene lists was used in a subsequent 
enrichment analysis. Reactome FIViz enrichment of the 1383 negatively correlated 
identified pathways known to be involved in Mitotic Metaphase/Anaphase, Wnt 
signalling pathway, Mitochondrial translation, cadherin signalling, TCA cycle and 
oxidative phosphorylation, to name a few (Table 3.16), see Appendix Table T3-2 for full 
list). Similar Reactome FiViz analysis of the 2025 positive correlates resulted in 
pathways known to be involved in Extracellular Matrix organization, cytokine-cytokine 
receptor interaction, TNF signalling pathway, Interferon gamma signalling, Osteoclast 
differentiation, IL-12 mediated signalling events and NF-kappa B signalling pathway, to 
name a few (Table 3.17, see Appendix Table T3-3 for full list). A clear distinction 
between the two lists of pathways was observed: while the negatively correlating 
pathways seem to be predominantly cell cycle and proliferation related, the positively 
correlating pathways include those involved in immune response.  
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Figure 3.12: Volcano plot of genes that are significantly associated with tumour 
VDR expression 
Genes with FDR<0.05 were considered to be significant correlates. Among these, 
1383 genes with R<-0.2 were identified to be significant negative correlates (red 
dots), whereas 2025 genes with R>0.2 were identified to be significant positive 
(green dots) correlates with VDR.  
 
Table 3.16: List of top pathways enriched for genes negatively correlated with 
tumour VDR expression 
Pathways P-val 
Mitotic Prometaphase(R) 1.38x10-9 
Wnt signalling pathway(P) 3.58x10-8 
Mitotic Metaphase and Anaphase(R) 7.50x10-8 
Mitochondrial translation(R) 5.24x10-7 
Cadherin signalling pathway(P) 2.47x10-6 
SUMOylation(R) 2.47x10-6 
RNA Polymerase I, RNA Polymerase III,  
and Mitochondrial Transcription(R) 3.83x10
-6 
The citric acid (TCA) cycle and respiratory electron transport(R) 1.06x10-5 
Cell cycle(K) 1.81x10-5 
Mitotic G2-G2/M phases(R) 2.16x10-5 
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Table 3.17: List of top pathways enriched for genes positively correlated with 
tumour VDR expression 
Pathways P-val 
Extracellular matrix organization(R) 1.11x10-16 
Cytokine-cytokine receptor interaction(K) 1.11x10-16 
Pathways in cancer(K) 1.11x10-16 
Cell adhesion molecules (CAMs)(K) 3x10-15 
TNF signalling pathway(K) 3.28x10-13 
Interferon gamma signalling(R) 1.64x10-12 
Osteoclast differentiation(K) 8.05x10-12 
Chemokine signalling pathway(K) 1.09x10-11 
IL12-mediated signalling events(N) 2.16x10-11 
NF-kappa B signalling pathway(K) 2.38x10-11 
 
Since VDR is known to be expressed by keratinocytes (371), I examined the 
possibility that putative epidermal contamination (during tumour core sampling) could 
confound the findings from the whole-transcriptome correlation analysis. To exclude 
this possibility, the analysis was adjusted for expression of the gene coding for filagrin 
(FLG2-adjusted) in a whole-transcriptome correlation with VDR, filagrin being a marker 
of keratinocyte differentiation (380). This analysis identified 11,471 genes to be 
significantly correlated (adj-P-value<0.05) with VDR, independent of the expression of 
FLG2. Of these 11,471 genes, 95.15% (10,951 genes) were also identified in the whole-
transcriptome correlation analysis (unadjusted for FLG2) as significant correlates of 
VDR. Thus, the transcriptomic correlates of VDR remained largely unchanged after 
adjusting for FLG2 expression. Next, the biological pathways enriched for these 11,471 
genes which correlated with VDR after adjusting for FLG2 were assessed. The genes 
negatively correlated with VDR (FLG2-adjused) were enriched for pathways such as 
Mitotic Metaphase/Anaphase, Wnt signalling pathway, Mitochondrial translation, 
cadherin signalling, TCA cycle and oxidative phosphorylation, to name a few (see 
Appendix Table T3-4 for full list). Similar Reactome FiViz analysis of the positive 
correlates (FLG2-adjusted) identified pathways known to be involved in Extracellular 
Matrix organization, cytokine-cytokine receptor interaction, TNF signalling pathway, 
Interferon gamma signalling, Osteoclast differentiation, IL-12 mediated signalling 
events and the NF-kappa B signalling pathway, to name a few (see Appendix Table T3-
5 for full list). Taken together, the biological pathways enriched for genes correlating 
with VDR remained largely unchanged, suggesting that the original pathways 
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associated with VDR expression were not significantly confounded by keratinocyte 
signals.  
Though the presence of keratinocyte-derived genes and pathways have been dealt 
with as ‘contamination’ when assessing the transcriptomic correlates of VDR, in reality 
presence of keratinocytes within melanoma tumour mass is not uncommon. Sampling 
of keratinocytes while sampling for melanomas is a common issue encountered by 
other groups studying primary melanomas and by our own group. However, the 
resolution of this issue is not trivial. In that, a subpopulation of tumours cannot be 
denounced as epidermal contamination, since an epidermal-like phenotype of 
undifferentiated melanomas have been previously described (381). However, the 
justification for my ‘FLG2-adjusted’ whole transcriptome correlation with VDR, is to 
ensure that the correlated pathways are not simply a reflection of high epidermal 
content.  
3.4.4.1.1 Do the pathways that correlate significantly with VDR also correlate 
with serum vitamin D in the intermediate-VDR participants? 
No genes were found to correlate agnostically with serum vitamin D in the intermediate-
VDR group (546 participants, excluding the outliers), based on an agnostic analysis 
(section 3.4.3.3). So, I adopted an alternative ‘candidate approach’, wherein I tested if 
the most significantly correlated pathways with VDR, also correlate with serum vitamin 
D in the intermediate-VDR group. To this effect, pathway scores were computed for the 
negatively (Wnt signalling, mitochondrial translation, cell cycle, mitotic metaphase and 
anaphase) and positively (extracellular matrix organisation, Interferon gamma 
signalling, IL12 signalling, TCR signalling on naïve CD4 and CD8 cells, TNF signalling 
and NK-mediated cell killing) correlated pathways. The pathway scores were computed 
as the average expression of all nodal genes pertaining to that pathway (see Appendix 
table T3-2 and T3-3 for list of nodal genes pertaining to each pathway). The following 
pathways which correlate positively with VDR, also correlate inversely with serum 
vitamin D in the intermediate-VDR group: IL12 signalling, TCR signalling on naïve CD4 
and CD8 cells and NK-mediated cell killing (Table 3.18).  
In summary: In addition to the findings in section 3.4.3.2 (where serum vitamin D 
was found to correlate inversely with neutrophil and monocyte imputed immune cell 
scores), the current ‘candidate approach’ revealed that serum vitamin D is inversely 
associated with specific immune signalling pathways in the intermediate-VDR group. 
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Table 3.18: Correlation of VDR-correlated pathways with serum vitamin D in the 
intermediate-VDR group 
The regression coefficient and P-value indicate the strength of association of 
pathway scores with serum vitamin D in the intermediate-VDR group of tumours. 
Pathway scores for pathways correlated with VDR 
expression  
Regression 
coefficient P-value 
Pathways negatively-correlated with VDR   
      Wnt signalling 0.0009 0.39 
      Mitochondrial translation -0.00015 0.88 
      Cell cycle -0.0002 0.78 
      Mitotic metaphase and anaphase -0.0004 0.72 
Pathways positively-correlated with VDR   
      Extracellular matrix organisation  0.00003 0.97 
      Interferon gamma signalling -0.002 0.11 
      IL12 signalling -0.005 0.03 
      TCR signalling on naïve CD4 and CD8 cells -0.003 0.05 
      TNF signalling -0.001 0.25 
      NK-mediated cell killing -0.004 0.02 
 
3.4.4.2 Whole-transcriptome correlation with tumour VDR expression in 
the TCGA metastatic melanomas 
High VDR expression was protective for melanoma death in the TCGA metastatic 
melanoma cohort (3.4.2.2). So, a whole-transcriptome correlation with VDR was carried 
out to identify the most significantly correlated genes and pathways in the TCGA 
metastatic melanoma cohort. Similar to the whole-transcriptome analysis of the LMC 
melanomas, a linear regression model was used. The direction of correlation (positive 
or negative) was denoted by the regression coefficient (‘R’) while the significance of 
correlation with a particular gene was denoted by the P-value. Upon applying the same 
multiple testing and regression coefficient thresholds as the LMC whole-transcriptome 
analysis, 8756 genes correlated significantly with VDR expression in TCGA data after 
correcting for multiple testing using Benjamini-Hochberg FDR (adj-P-value<0.05). Of 
these, 1500 genes correlated positively with VDR expression (R>0.2) and were 
enriched for pathways such as NFkB, TNF, IFNa/b, IFNg, IL12-mediated, TCR and 
chemokine signalling in naïve CD4 T cells (see Appendix Table T3-6 for full list). 912 
genes correlated negatively with VDR expression (R<-0.2) and were enriched for 
pathways such as Wnt signalling, extracellular matrix organization, cadherin signalling, 
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eukaryotic translation initiation, TGFb and VEGFR1 signalling (see Appendix Table T3-
7 for full list).  
3.4.4.3 VDR- transcription factor binding 
Upon vitamin D binding and RXR dimerization, VDR acts as a transcription factor that 
binds to specific VDRE-containing genomic regions, which are under direct 
transcriptional control of VDR. Based on my analyses, the whole-transcriptome 
correlation with VDR in the LMC and TCGA datasets identified the significant 
transcriptomic correlates of VDR expression. This put forth the question: what 
proportion of genes that are under the direct transcriptional control of VDR also 
correlate with VDR expression in the LMC melanomas? This was addressed using two 
approaches:  
i) Using previously reported ChIP-Seq datasets which identify VDR-binding genomic 
sites 
ii) By identifying genomic regions that contain the VDR-binding motif  
Both analyses identified genomic regions which are likely to be under direct 
transcriptional control of VDR: either VDR binding targets identified by ChIP-Seq or 
genomic regions which contain the motif for VDR-binding. Once these genomic regions 
were identified by either approach, they were mapped to the coding genes which are 
likely to fall within the regions. The correlation of the genes thus identified, with tumour 
VDR expression in the LMC was assessed. Thus, the ‘overlapping’ set of genes which 
correlate with VDR in the LMC and are also likely to be transcriptionally controlled by 
VDR, were identified.  
The description of each approach is detailed below. 
3.4.4.3.1 Comparison with VDR ChIP-Seq data 
Currently there are 6 tissue types for which VDR ChIP-Seq data was generated and 
jointly analysed in a meta-analysis by Tuoresmaki et al (374). The tissue types analysed 
in this study and the original studies in which the VDR ChIP-Seq was first described are 
were: THP-1(human monocytic cell line)- LPS stimulated and unstimulated (382), 
GM10855 (immortalised lymphoblastoid cell line) (383), GM10861 (immortalised 
lymphoblastoid cell line) (383), LX2 (hepatic stellate cells) (384) and LS180 (colorectal 
cancer cells) (385). The findings from the meta-analysis by Tuoresmaki et al are crucial 
because they used a harmonised analysis pipeline (MACS, version 2) to re-analyse 
results from the individual ChIP-Seq datasets, which were derived using different peak-
calling software and alternative threshold settings. In total, the meta-analysis identified 
21,776 non-overlapping genomic sites across all 6 datasets. Interestingly, they reported 
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that 67% of these sites are unique to a single cell type, while only 54 non-overlapping 
genomic VDR-binding regions were common to all 6 tissue types. I obtained data 
pertaining to these 54 regions: chromosomal location and genomic start and end sites, 
which were downloaded from the Tuoresmaki et al supplementary data. In mapping the 
54 genomic binding sites to genes, 73 genes were identified (using GREAT, see 
Methods).  Of the 73 genes, 43 genes (58%) correlated significantly (at FDR<0.05) with 
tumour VDR expression in the Leeds data, indicating that a proportion of genes which 
are transcriptionally controlled by VDR are also correlated with VDR expression in our 
data set.  
In addition, I also extracted the tissue-specific VDR-binding regions i.e. the number 
of VDR-binding regions in each of the 6 tissues analysed by Tuoresmaki et al. The 
number of VDR-binding regions in each cell line are: THP-1 LPS stimulated (1318 
regions) and unstimulated (1146 regions), GM10855 (7887 regions), GM10861 (13924 
regions), LX2 (2291 regions) and LS180 (3770 regions). These regions were mapped 
to genes (using GREAT, see methods). The number of genes mapped to genomic 
regions in each cell line is detailed in Table 3.19. Of these identified genes. the 
proportion of genes which also correlated with VDR in the LMC dataset was estimated. 
This percentage was found to be consistent across all 6 cell lines (approx. 57%, Table 
3.19).  This analysis is therefore indicative that for a significant proportion of genes that 
correlate with VDR in the LMC primary melanomas are also likely to be under the direct 
transcriptional control by the VDR transcription factor.  
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Table 3.19: Comparison of the LMC VDR correlates and VDR ChIP-Seq data from 
6 cell lines 
First two columns denote number of VDR-binding peaks identified in 6 cell lines 
(derived from Tuoresmaki et al). Genes mapped to these peaks (using GREAT) 
and the overlap (percentage) of genes which correlated with VDR expression in 
the LMC, are on columns 3 and 4 respectively. 
Tissue 
type 
 
 
Source tissue Number of VDR-
binding regions 
Number of 
genes mapped 
to the VDR-
binding regions 
(Identified by 
GREAT) 
% genes in 
peak regions 
that also 
correlate with 
VDR in the 
LMC 
THP-1: 
LPS  
stimulated 
Human 
monocytic cell 
line 
1318 1728 57.29 
THP-1 
Human 
monocytic cell 
line 
1146 1385 57.68 
GM10855 Lymphoblastoid cell line 7887 6029 57.58 
GM10861 Lymphoblastoid cell line 13924 8784 57.38 
LX2 Hepatic stellate cells 2291 2803 57.11 
LS180 Colorectal cancer cells 3770 3799 56.62 
 
3.4.4.3.2 Comparison using VDR-binding motifs  
Being a transcription factor, the protein VDR has a high affinity to bind to DNA 
sequences composed of a specific motif. Similarly, the VDR-RXR dimer has a high 
affinity to bind to DNA sequences composed of a specific motif. Since these motifs are 
transcription factor-specific, it can be inferred that DNA sequences (genomic regions) 
containing the VDR-specific motif, are likely to bind with high affinity to VDR and hence 
under its transcriptional control. To identify such VDR-specific motifs and the genomic 
regions containing the motif, I used the resource Motifmap (386, 387), which identified 
the binding motifs for VDR (3 regions), VDR:RXR (dimer-binding motif, 12 regions), 
RXR:VDR (dimer-binding motif, 23 rgions) and the motif common to other nuclear 
hormone receptors such as PXR and CAR (1 regions). The binding motif, the 
corresponding sequence logo and the number of genomic regions containing the motif 
(as catalogued by Motifmap) are described in Figure 3.13. This identified a total of 39 
genomic regions which contain the motif for either VDR or VDR as a dimer with RXR. I 
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mapped these 39 regions to genes (using GREAT, see methods) and identified 49 
genes which were associated with these 39 genomic regions. Among the 49 genes, 29 
genes (60%) also correlated significantly with VDR in the LMC (at FDR<0.05). These 
genes are listed in Table 3.20.  
In order to estimate if the probability of overlap between genes correlating with VDR in 
LMC and mapping to VDR motif containing regions is greater than that expected by 
chance, a hypergeometric test was performed, wherein:  
The number of genes represented in the LMC transcriptome (N) = 20,560 genes 
The number of genes that correlate significantly with VDR expression in the LMC (k) 
= 3408 genes 
The number of genes associated with the 39 VDR motif-containing regions (obtained 
from Motifmap) (n) = 49 genes 
Overlapping genes which correlate with VDR in LMC and map to VDR motif-containing 
regions (k) = 29 genes 
Based on these parameters, the hypergeometric probability: P(x=49) = 0.043 
In other words, the probability of a VDR motif-containing gene to be correlated with VDR 
in the LMC by random chance is 4.3%.  
Much like the results from the analysis of ChIP-Seq data described in the previous 
section, this analysis indicates that a significant proportion of genes which are 
associated with genomic regions containing the VDR binding-motif are also correlated 
with VDR in the LMC primary melanomas.  
 
Figure 3.13: VDR-binding motifs: identified by MotifMap. 
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Table 3. 1: List of genes that correlate with VDR in the LMC primary melanomas 
and are also mapped to genomic regions containing the VDR-binding motif.  
Regression coefficient and p-value from linear regression model. 
Gene Regression Coefficient p-value 
GSDMC 0.70 1E-15 
ASTN2 -0.32 1E-15 
CHD6 -0.16 1E-12 
WDR41 -0.18 1E-11 
EFNB2 0.29 1E-11 
FGFR1 0.21 5E-10 
MSX2 -0.17 8E-10 
KCTD3 -0.12 4E-09 
KLHL13 -0.34 9E-09 
OLFML2B 0.19 5E-08 
ADAT2 -0.16 2E-07 
RUNX1T1 0.29 2E-07 
LMOD3 -0.09 1E-06 
ZNF688 -0.14 2E-06 
GPC5 -0.15 2E-05 
ATF6 -0.11 4E-05 
CTLA4 0.23 5E-05 
GPR116 0.16 1E-04 
LETM2 -0.10 3E-04 
SNTB1 -0.14 8E-04 
TAF2 -0.09 4E-03 
ERCC4 0.09 5E-03 
CD28 0.13 6E-03 
RNF5 -0.09 1E-02 
ENPP2 0.10 1E-02 
HOXC11 -0.06 2E-02 
HAS2 -0.12 2E-02 
SIX3 0.13 3E-02 
TRIM32 -0.08 5E-02 
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3.4.4.4 Factors controlling VDR expression in primary and metastatic 
melanomas 
In order to identify factors which could explain the gradient VDR expression, it was 
hypothesised that Copy Number Alterations (CNAs) and methylation could control 
expression of VDR. These hypotheses were tested using both the LMC primary and 
TCGA metastatic melanoma datasets.  
3.4.4.4.1 VDR expression and Copy Number Alterations in the LMC primaries 
Copy Number Alteration (CNA) data were available for 276 primary melanoma samples 
in LMC dataset. These samples are a subset of the 703 LMC samples used thus far. 
The generation and normalisation of these data is described in the Methods section. 
Briefly, DNA samples (from the 276 LMC tumour cores) were used to generate log2-
normalised ratios of window read counts, from which gene level median copy number 
estimates were generated using Gistic 2.0. The availability of these CNA data enabled 
the comparison of VDR expression and VDR copy number in the 276 samples. The 
log2-normalised VDR copy number values were found to be centred around 0 i.e. most 
of the tumour samples had a log2-normalised VDR copy number value of 0, suggesting 
that the VDR gene remains diploid. Concordant with this observation, the GISTIC-
derived q-value (a confidence measure of copy number alterations across a genomic 
regions) for the VDR-containing region 12q13.11 was >0.25, indicating that VDR copy 
number remains unaltered in most of the 276 samples.  The correlation between VDR 
expression and VDR CNA (log2-normalised) was assessed using both variables on a 
continuous as well as categorical scale. When VDR expression and VDR CNA were 
represented on a continuous scale, a linear regression model revealed the lack of 
significant correlation between the two variables (R=0.005, P=0.62, Figure 3.14A). 
Given that a majority of the samples had log2-normalised VDR copy number value of 
0, the scale of the VDR CNA values was revised (changed to exponential scale) and 
the correlation with VDR expression was assessed. The correlation between VDR CNA 
and expression remained statistically insignificant (R=0.46, P=0.19), suggesting that 
the lack of correlation is irrespective of the distribution of the CNAs.  
Alternatively, VDR CNA was compared across the 3 VDR-groups (pairwise T-
tests, Figure 3.14B) which have been described in section 3.4.1.4.  Median VDR CNA 
did not vary significantly between the Low-VDR group compared to the Intermediate-
VDR group (P=0.5) and High-VDR group (P=0.35). There was also no significant 
difference in VDR CNA between the Intermediate-VDR group and High-VDR group 
(P=0.33). Even though VDR CNA on a continuous scale reliably represents the 
distribution of VDR CNAs in the 276 samples, the extremities of the distribution 
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(samples with very high or low VDR copy number) were also compared with VDR 
expression. This categorised analysis affects the sample size of the compared groups, 
since stringent cut-off values will result in reduced sample size per group. However, 
comparison of categorised VDR CNA data can validate observations derived from VDR 
CNA data on a continuous scale. To this effect, VDR expression did not vary 
significantly between the samples belonging to the following VDR CNA categories: VDR 
CNA <-0.3 or >0.3 (P=0.34, Figure 3.14C), VDR CNA <-0.2 or >0.2 (P=0.39, Figure 
3.14D), VDR CNA <-0.1 or >0.1 (P=0.17, Figure 3.14E). This is consistent with the lack 
of significant correlation between VDR expression and VDR CAN, when represented 
on a continuous scale. Thus, there is no evidence for significant correlation between 
VDR expression and VDR CNA in the 276 LMC primary melanomas.   
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Figure 3.14: Association of VDR expression with VDR CNAs in LMC primary 
melanomas 
A: Correlation between VDR expression and VDR CNAs: both being represented 
on a continuous scale, R: Regression Coefficient, P: P-value from linear 
regression model; 
B: Comparison of VDR CNAs across the 3 VDR-groups. P-values from pairwise 
T-tests; 
C: Comparison of VDR expression between tumours with VDR CNA <-0.3 or >0.3. 
P-values from pairwise T-tests; 
D: Comparison of VDR expression between tumours with VDR CNA <-0.2 or >0.2. 
P-values from pairwise T-tests; 
E: Comparison of VDR expression between tumours with VDR CNA <-0.1 or >0.1. 
P-values from pairwise T-tests 
  
A B 
C D E 
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3.4.4.4.2 VDR expression and Copy Number Alterations in the TCGA metastatic 
melanomas   
The TCGA melanoma dataset includes matching copy number data and gene 
expression data for the metastatic melanoma samples. Matching VDR CNA and VDR 
expression data were available for distant metastases (n=68) and regional lymph node 
metastases (n=222), but not for primary tumours. The lack of CNA data in the TCGA 
data and the relative lack in the LMC data reflect the difficulties in sampling very small 
melanoma samples. In the TCGA data, this permitted the comparison of VDR 
expression with VDR CNA, as well as the variation of VDR CNA across metastatic 
melanomas, but not primary melanomas. To this effect, VDR expression correlated 
significantly and positively with VDR CNA in the TCGA metastatic melanomas (R=0.76, 
P=3.1x10-6, Figure 3.15A). Lower VDR copy number were more common in distant 
metastases than in regional lymph node metastases (P=0.015, Figure 3.15B). It is to 
be noted that distant metastases are considered to be indicators of more aggressive 
disease with worse prognosis (compared to regional metastasis). Thus, the association 
of VDR expression with VDR CNA in the TCGA, with increase in copy number with 
advanced disease, suggests that expression is controlled at least in part by CNA in a 
progression-dependent manner.  
 
Figure 3.15: Association of VDR expression with VDR CNAs in TCGA melanomas 
A: Correlation between VDR expression and VDR CNAs: both being represented 
on a continuous scale. R: Regression Coefficient, P: P-value from linear 
regression model; 
B: Comparison of VDR CNAs between distant metastases and regional lymph 
nodes in the TCGA data. P-value from T-test 
  
A B 
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3.4.4.4.3 VDR expression and methylation in TCGA data 
Matching VDR expression and methylation data were available for 469 samples in the 
TCGA melanoma dataset. The VDR methylation status was represented by Beta 
values, which were downloaded from cBioportal. These data were generated on the 
HM450 methylation array in which the probe corresponding to a gene covers sites in 
the promoter region, 5’ UTR, first exon, gene body and 3’ UTR. VDR expression was 
significantly and inversely correlated (R=-0.06, P= 5.06 x 10-11, Figure 3.16) with 
methylation Beta values pertaining to the VDR genomic region. This observation, 
combined with the analysis using VDR CNAs suggest that both methylation and copy 
number control VDR expression. 
 
Figure 3.16: Association of VDR expression with methylation in TCGA 
melanomas 
Correlation between VDR expression and VDR methylation (beta values): both 
being represented on a continuous scale. P-value from linear regression model 
 
3.4.5 Validation of transcriptomic correlates of tumour VDR 
expression  
3.4.5.1 In silico validation 
3.4.5.1.1 Reported molecular phenotypes 
The whole-transcriptome correlation analysis of the LMC and TCGA melanoma 
datasets indicated that tumour VDR was strongly correlated with immune and 
proliferation-associated signalling pathways. In an effort to validate this observation, 
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VDR expression was compared across molecular melanoma phenotypes. These 
molecular phenotypes were derived from classification approaches applied to 
independent melanoma data sets, to identify melanoma subtypes which are both 
biologically and prognostically significant. The rationale behind this analysis is that: if 
VDR is indeed strongly associated with immune and proliferative pathways, VDR 
expression should vary significantly between the independently-derived molecular 
phenotypes, which are defined by these characteristics. The melanoma molecular 
phenotypes used for this analysis are those described in the TCGA melanoma data set 
(388) and in a Swedish melanoma data set (389). Both studies identified pro-
proliferative and immune phenotypes as key melanoma subtypes predicting survival. In 
2015, Nsengimana et al described a centroid-based approach to replicate the Swedish 
subtypes in 300 LMC samples (372), which are a subset of the 703 LMC melanomas 
analyzed in the current report. In brief, a tumour was assigned to the particular 
melanoma subtype with which its expression profile has the highest correlation (see 
Methods 3.3). Using this approach, each of the 700 LMC tumours were classified using 
the TCGA and Swedish classifications. Tumours which didn’t pass the correlation 
threshold of 0.10 were deemed ‘unclassifiable’.  
Classification by TCGA subtypes split the 700 LMC tumours into the following 
groups: Immune (n=192), Keratin (n=247) and MITF-low (n=150) with 111 samples 
unclassifiable. The Leeds melanoma tumours which were classified according to TCGA 
classification will henceforth be referred to as 'TCGA-subtypes'. Among the TCGA-
subtypes in the LMC melanomas, the MITF-low subtype had the worst prognosis, being 
significantly worse compared to the Immune subtype (HR=1.98, P=0.0004) (Figure 
3.17A). On the other hand, prognosis of the Keratin subtype did not vary significantly 
compared to the Immune subtype (P=0.86) (Figure 3.17A). In comparing VDR 
expression among the three TCGA-subtypes, VDR expression was significantly higher 
in the Immune subtype compared to the MITF-low subtype (P=1.07x 10-6) but was not 
significantly different from the Keratin subtype (P=0.07) (Figure 3.17B).  
Classification of the LMC dataset using the Lund classification produced the 
following subtypes: High-immune (n=173), Normal-like (n=198), Pigmentation (n=222) 
and Proliferative (n=83) groups, with 24 samples unclassifiable. The Leeds melanoma 
tumours which were classified according to the Lund classification will henceforth be 
referred to as 'Lund-subtypes'. Among the Lund-subtypes, the Pigmentation (HR=2.5, 
P=3.1 x 10-6) and Proliferative (HR=2.62, P=0.0001) subtypes had significantly worse 
prognosis compared to the High-immune subtype. On the other hand, prognosis of the 
Normal-like subtype did not vary significantly compared to the High-immune group 
(P=0.98) (Figure 3.17C). In comparing VDR expression across the 4 Lund-subtypes 
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(Figure 3.17D), VDR was significantly higher in the High-immune compared to the 
Proliferative (P= 7.4x10-8) and Pigmentation (P=6x10-13) subtypes. However, VDR 
expression was also significantly higher in the Normal-like subtype (P=0.0004) 
compared to the High-Immune subtype. Overall, these data support the view that VDR 
expression is higher in primary melanoma subtypes identified by analysis of TCGA and 
Lund molecular signatures, which have a better prognosis and have less proliferative, 
more immune active phenotypes. Notably, these observations are consistent with 
findings from the whole-transcriptome correlation with VDR expression. 
 
 
 
Figure 3.17: Comparison of VDR expression across reported melanoma 
signatures 
A: Melanoma specific survival of participants classified according to the three 
TCGA-subtypes: Immune (n=192), Keratin (n=247) and MITF-low (n=150); 
B: Comparison of VDR expression across the three TCGA-subtypes. P-values 
from T-test; 
  
A B 
C D 
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Figure 3.17 description cont. 
C: Melanoma specific survival of participants classified according to the three 
Lund-subtypes: High-immune (n=173), normal-like (n=198) pigmentation (n=222) 
and proliferative (n=83); 
D: Comparison of VDR expression across the three Lund-subtypes. P-values from 
T-test 
 
3.4.5.1.2 Imputed immune cells scores  
The whole-transcriptome correlation (section 3.4.4.1) and the validation using reported 
melanoma molecular phenotypes (section 3.4.6.1.1) indicated that VDR expression is 
positively associated with immune-associated pathways and immune-active subtypes 
respectively. These findings prompted the assessment of the correlation of VDR with 
imputed immune cells scores, with the view of estimating the immune cell types with 
which VDR is most significantly associated. To this effect, the correlation of each of the 
26 Angelova imputed immune cells scores (described in section 3.4.3.2) with VDR 
expression was assessed. A linear regression model was used to estimate the 
significance (denoted by P-value) and direction (denoted by regression coefficient R) of 
correlation. VDR expression correlated positively with 25 of the 26 immune cell scores 
(at P<0.05, Table 3.20) of which the strongest correlation (R>0.20, P<0.05) was with 
NK, cytotoxic, dendritic, Th1, activated B, Th2, central memory CD4, T, effector memory 
CD8 cell and neutrophil scores. Memory B cell scores were the only cell type which had 
a negative correlation, although the correlation was not strong (R=-0.06).  
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Table 3.20: Correlation of tumour VDR expression with imputed immune cell 
scores 
Immune cell score Regression Coefficient (R) P-value 
Natural Killer cells 0.27 4.63E-21 
Cytotoxic T cells 0.27 5.28E-16 
Dendritic Cells 0.25 4.65E-33 
Th1 0.24 1.99E-20 
Myeloid Derived Suppressor Cells 0.23 8.86E-18 
T Follicular Helper cells 0.23 9.15E-13 
Activated B cells 0.23 7.56E-15 
Th2 0.22 3.71E-17 
Central memory CD4 0.22 6.40E-23 
T cells 0.22 1.82E-18 
Neutrophils 0.20 7.78E-18 
Effector memory CD8 0.20 1.48E-14 
T Gamma Delta cells  0.19 8.97E-13 
T regulatory cells 0.19 1.76E-13 
Macrophages 0.18 5.96E-15 
Immature Dendritic Cells 0.17 3.22E-12 
Central memory CD8 0.17 2.38E-12 
NK56 dim 0.17 1.39E-10 
NK56 bright 0.16 1.12E-06 
Immature B cells 0.15 1.55E-07 
Monocytes 0.15 4.29E-08 
Mast cells 0.14 1.01E-11 
Plasmacytoid Dendritic Cells 0.13 0.0028 
Natural Killer T cells 0.12 0.00007323 
Activated CD4 cells 0.10 0.0006 
Memory B cells -0.06 0.01170618 
 
3.4.5.2 Histopathological and immunohistochemical validation  
The transcriptomic analyses described in the above sections indicate that VDR is 
significantly and positively associated with immune pathways, signatures and imputed 
immune cell scores. However, it remained to be assessed if this positive association 
could be validated by independent histopathological measures of immune infiltrate. To 
this effect, VDR expression was compared across pathologist-graded measure of 
tumour immune infiltration. Of the 703 tumours whose cores were used to generate the 
transcriptome, 665 tumours were subjected to detailed histological assessment by the 
pathologist working with our group (Dr. Sally O'Shea) who was blinded to VDR status. 
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Among the histopathological characteristics that were measured, the ones pertaining to 
immune infiltrate were: whole section immune infiltrate (absent, brisk or non-brisk 
immune infiltrate) and core immune infiltrate (none, some, moderate or lots of immune 
infiltrate). Direct comparison of VDR expression and immune/lymphocytic infiltrate was 
thus done for the 665 tumours.  
As described in section 3.4.1.3 (Figure 3.5) VDR expression was significantly lower 
in tumours whose whole-section immune infiltrate estimate was 'absent' compared to 
those with non-brisk (P=0.021) and brisk (P=0.005) immune infiltrate. While the whole-
section immune infiltrate indicated the immune infiltration status of the tumour as a 
whole, it did not necessarily represent the tumour core that was used to generate the 
transcriptome. Which is why VDR expression was compared across measures of 
immune infiltrate within the tumour core. To this effect, VDR expression was 
significantly lower in tumours with none/barely perceptible immune infiltrate compared 
to those with 'lots' of immune infiltrate (P=0.035, Figure 3.18, T-test). However, VDR 
expression did not vary significantly in tumours with 'some' or 'moderate' immune 
infiltrate compared to those with no immune infiltrate (Figure 3.18). Thus, VDR 
expression was significantly associated with histopathological measures of tumour 
immune infiltrate, which is concordant with the transcriptome-derived findings described 
in previous sections.  
 
 
Figure 3.18: Comparison of VDR expression across histopathological measures 
of immune infiltrate in the tumour core 
VDR expression was compared between tumours with ‘non/barely perceptible’ 
(n=247), ‘some’ (n=217) or ‘moderate’ (n=87) or ‘lots’ (n=42) immune infiltrate in 
the tumour core. P-values from linear regression model.  
113 
 
VDR is known to be expressed by immune cells. In the LMC analyses described 
thus far, VDR expression was strongly associated with transcriptomic and 
histopathological indicators of immune-activity. Increased tumour immune infiltrate is 
associated with improved melanoma prognosis, as is VDR expression in the current 
LMC dataset. This posed the possibility that the prognostic significance of VDR could 
simply be an attribute of increased immune infiltrate, rather than being a feature of VDR 
expression itself. This issue was addressed using two approaches. First, in the 
multivariable survival analysis described in section 3.4.2.2, tumour immune infiltrate 
was one of the variables that was adjusted for. In other words, the prognostic 
significance of VDR expression was persistent even after adjusting for the degree of 
histopathologically measured tumour immune infiltration. Secondly, I asked if the 
expression of VDR protein in the LMC primary melanoma tumour sections was localised 
to the tumour cells or the infiltrating immune cells. To this effect, a subset of the LMC 
tumours (n=30) were sectioned and stained for VDR expression using 
Immunohistochemistry (IHC). The stained sections were then evaluated for nuclear and 
cytoplasmic expression of VDR in both the tumour and the infiltrating immune cells. The 
evaluation was restricted to the region surrounding the site from which the tumour core 
was taken, since this was indicative of the tumour from which the transcriptome was 
generated. Of the 30 tumour sections that were evaluated, 2 had ‘lots’ (>5 cells), 
whereas 4 had ‘some’ (1-5 cells) TILs that were positive for VDR expression. The other 
24 sections had no TILs that stained positive for VDR expression, though the tumour 
cells themselves stained positive for cytoplasmic and/or nuclear VDR expression 
(Appendix Table T3-8). Figure 3.19 is comprised of representative images of tumour 
sections which show nuclear and cytoplasmic positivity for VDR expression in the 
tumour cells (with corresponding VDR negative sections for reference), with no VDR 
positivity on TILs in any of the sections. These data suggest therefore that the 
correlation between immune signals and VDR is not simply a reflection of numbers of 
TILs infiltrating the tumour. 
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Figure 3.19: Representative images of tumour sections showing nuclear and 
cytoplasmic positivity for VDR expression in the tumour cells (with 
corresponding VDR negative sections for reference) 
 
3.4.6 VDR expression and Wnt/b-catenin signalling in the LMC 
primary melanomas 
The agnostic whole-transcriptome correlation with VDR expression identified the Wnt/b-
catenin signalling pathway as one of the most significant negatively correlated 
pathways in both the LMC primary (section 3.4.4.1) and the TCGA metastatic 
melanomas (section 3.4.4.2). This finding is of particular interest because VDR has 
been shown to inhibit Wnt/b-catenin signalling in colon carcinoma cells, with 
consequent increase in anti-tumour immune infiltrate (356). It is to be noted that colon 
cancer is the other cancer type (in addition to melanoma) for which most evidence exists 
for a protective role of vitamin D-VDR signalling on survival. However, the inhibitory 
effect of VDR on Wnt/b-catenin in melanomas has not previously been demonstrated. 
This highlighted the significance of Wnt/b-catenin being agnostically identified to 
correlate inversely with VDR, thus prompting further investigation to gain evidence for 
this mechanism.  
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A previous study from our group by Nsengimana et al reported a classification of 
the 703 LMC primary melanomas into 6 melanoma subtypes. This classification was 
based on the transcriptomic immune profile of the melanomas, characterised by 
immune cell scores. These melanoma subtypes were hence referred to as Consensus 
Immunome Clusters (CICs). One of the CICs: CIC4 was characterised by high Wnt/b-
catenin signalling, reduced immune infiltrate and worse prognosis, compared to 5 other 
subgroups (316). On comparing VDR expression across these 6 previously reported 
CICs, VDR expression was lowest in CIC4: a high-Wnt/b-catenin tumour group 
compared to the other CICs (Figure 3.20A) which complemented the results from the 
agnostic correlations with VDR. This is also represented in a heatmap of the 6 CICs, 
depicting the expression of key Wnt//b-catenin signalling along with distribution of the 3 
VDR-groups (Low-, Intermediate- and High-VDR) (Figure 3.20B). The majority of the 
low-VDR tumours belonged to CIC4, which also had high expression of genes in the b-
catenin signalling pathway CTNNB1, CMYC, SOX11, SOX2, VEGFA, TCF12, TCF1, 
APC2 and EFNB3.  
The observation that low VDR-expressing tumours have high expression of Wnt/b-
catenin signalling genes in the LMC dataset put forth the possibility that these tumours 
could have high CTNNB1 copy number. Since CTNNB1 codes for one of the key 
transcription factors controlling the Wnt//b-catenin pathway, increased copies of 
CTNNB1 could lead to increased expression of genes in this pathway. So, it was 
necessary to ascertain that high Wnt//b-catenin signalling in low VDR-expressing 
tumours was attributable to VDR-inhibitory effects, rather than a consequence of 
increased CTNNB1 copy number. To this effect, it was assessed if CTNNB1 copy 
number varied significantly across the three VDR-groups. CTNNB1 copy number (on a 
continuous scale) did not vary significantly across 3 VDR-groups (Figure 3.20C). On 
categorising CTNNB1 copy number, the frequency of tumours with CTNNB1 deletions 
(median copy number<-0.3) and amplifications (median copy number>0.3) did not vary 
significantly across the 3 VDR groups (Fisher’s exact P=0.83, Table 3.21). Similarly, 
the frequency of tumours with CTNNB1 deletions (median copy number<-0.2) and 
amplifications (median copy number>0.2) did not vary significantly across the 3 VDR 
groups (Fisher’s exact P=0.44, Table 3.22). 
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Figure 3.20: VDR expression and Wnt/b-catenin signalling in the LMC primary 
melanomas 
A: Comparison of VDR expression across the 6 Consensus Immunome Clusters 
(CICs) described by Nsengimana et al; 
B: Heatmap depicting distribution of the 3 VDR groups along with other key Wnt/b-
catenin signalling genes in the 700 LMC primary melanomas; 
C: comparison of CTNNB1 CAN across the 3 VDR-groups 
A 
B 
C 
117 
 
Table 3.21: Frequency of tumours with CTNNB1 copy number <-0.3 and >0.3 
across the 3 VDR-groups 
 Low VDR Intermediate VDR High VDR 
CTNNB1 Del (<-0.3) 6 13 1 
CTNNB1 Amp (>0.3) 2 5 1 
 
Table 3.22: Frequency of tumours with CTNNB1 copy number <-0.2 and >0.2 
across the 3 VDR-groups 
 Low VDR Intermediate VDR High VDR 
CTNNB1 Del (<-0.2) 9 22 2 
CTNNB1 Amp (>0.2) 5 9 3 
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 Graphical summary 
A graphical summary of the key questions and relevant findings addressed in this 
chapter is presented below 
 
 
Is tumour VDR
expression associated 
with MSS in the 703 
LMC melanomas?
Participants split based 
on VDR expression:
low-VDR, intermediate-
VDR and high-VDR 
groups
Are serum vitamin D levels 
protective for melanoma 
death within the context of 
the 3 VDR groups?
Are serum 
vitamin D levels 
normally 
distributed in the 
LMC?
Participants 
Including
those with 
serum 
vitamin D 
level 
>115nmol/L
(n=549)
Participants
excluding
Participants 
with serum 
vitamin D 
level 
>115nmol/L
(n=546)
Based on agnostic analysis, are 
there genes/pathways that 
correlate significantly with 
serum vitamin D?
Based on agnostic 
analysis, what are the 
genes/pathways that 
correlate significantly 
with tumour VDR
expression?
Can these 
observations be  
validated in silico?
Can these 
observations be  
validated in vivo?
Do the VDR-correlated 
pathways also correlate 
with serum vitamin D in 
the intermediate-VDR
group?
No
(There are three outliers 
whose values 
>115nmol/L)
Yes
65 genes 
correlate at 
FDR<0.10
No
Since inclusion of 3 participants 
has a dramatic effect on gene 
expression profiles, they were 
considered ‘outliers’ henceforth
Yes
high VDR expression is 
independently
associated with improved 
MSS
Yes
serum vitamin D is protective for 
melanoma death in the
intermediate-VDR group
Yes, 
when 3 ‘outliers’ 
are included: 
441 genes 
correlate with 
serum vitamin D 
in the 
intermediate-
VDR group
No, 
when 3 ‘outliers’ 
are excluded: 0 
genes correlate 
with serum 
vitamin D in the 
intermediate-
VDR group 
Yes
Tumour VDR expression 
correlates positively with 
immune-relate pathways and 
negatively with proliferation-
related pathways 
Yes
This was done using 
reported melanoma 
signatures and imputed 
immune cell scores
Yes
VDR-expressing murine 
melanoma cells produce 
lower pulmonary 
metastatic load and have 
reduced expression of 
Wnt/B-catenin signaling. 
See chapter 4
Yes
Serum vitamin D is inversely 
correlated with neutrophils 
and monocyte scores
Yes
Serum vitamin D is inversely 
correlated with IL12, TCR and NK-
cell mediated signaling
Based on agnostic analysis, are 
there genes/pathways that 
correlate significantly with serum 
vitamin D in the 
intermediate-VDR group ?
Dataset/participants/genes 
used for analysis
Question posed
Answers/findings 
Workflow
Indicator of dataset 
used for analysis
Does serum vitamin D 
correlate with imputed 
immune cell scores in 
the intermediate-VDR 
group?
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 Discussion   
Vitamin D3 is an essential nutrient important for human health. It is derived from dietary 
sources and also synthesised in the skin in the presence of sunlight. The role of vitamin 
D3 in human health has been the focus of multiple research efforts aiming to understand 
the effect of this steroidal hormone on various diseases. Since the synthesis of vitamin 
D3 is strongly linked to incident UV radiation and the melanin content of the skin, these 
factors contribute partially to the heterogeneity in global trends of vitamin D levels. 
Additionally, even though there is agreement on the levels that indicate deficiency (for 
instance levels that cause rickets), there is lack of consensus about vitamin D 
insufficiency i.e. as to what levels are causally associated with any number of diseases. 
This issue is further complicated by factors such as variability in assay differences, 
seasonal variations, use of single measure vitamin D levels and association of vitamin 
D with ‘active’ lifestyle patterns (going out more, leaner, fitter individuals free from 
illnesses causing systemic inflammation).  
The issue of causality is important for melanoma. As melanoma is caused by 
sunburn in the pale skinned, the usual advice given to patients treated for primary 
melanoma is to avoid the sun after diagnosis: advice that potentially could worsen 
outcomes if the result was vitamin D deficiency and vitamin D deficiency is causally 
related to tumour progression.  
While previous studies have assessed the individual effects of either vitamin D 
treatment or VDR expression, this research study used both tumour VDR expression 
and corresponding serum vitamin D levels at recruitment (on average some 5 months 
after diagnosis of primary melanoma) to assess their synergistic as well as individual 
contributions to melanoma survival and their genome-wide effects. This study aimed to 
systematically identify the clinical and histopathological factors that are significantly 
associated with both serum vitamin D and tumour VDR expression. This was followed 
by identification of transcriptomic correlates of serum vitamin D and tumour VDR 
expression. An agnostic approach was chosen for these analyses with the view of 
identifying signalling pathways which are most significantly associated with low serum 
vitamin D levels or evidence for VDR signalling. The pathways/processes which were 
identified to be the most strongly associated with either, were subject to validation. This 
included both in-silico and in vivo validation approaches. While the former reinforced 
transcriptome-derived correlative evidence, the latter added causal evidence to the 
findings. Taken together, the aforementioned ‘pipeline’ enabled a better understanding 
of the effect of vitamin D-VDR signalling in primary melanomas.  
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In the LMC primary melanomas, serum Vitamin D itself was not significantly 
associated with variables such as sex, AJCC stage, mitotic rate and tumour site. 
Though low serum vitamin D was shown to be associated with poor prognosis tumours 
in the larger cohort of 2184 melanomas (of which the 703 tumours are a subset) (288), 
this effect was not significant in the current cohort of 703 tumours. The observation that 
serum vitamin D tended to be lower in Stage II and III tumours compared to Stage I 
tumours, albeit not significantly, could be attributed to reduced sample size compared 
to the original cohort. Serum vitamin D levels did not correlate significantly with anabolic 
and catabolic enzymes of the Cytochrome P450 superfamily. This could be owing to 
the fact that the serum vitamin D pertains to a single measure at diagnosis does not 
necessarily reflect the expression of vitamin D-regulating enzymes in the tumour. The 
issues surrounding the use of single measure of serum vitamin D are: i) possibility of 
the participant making lifestyle changes after diagnosis and excision of the melanoma. 
Examples of lifestyle changes which could lead to variable serum vitamin D levels 
before and after diagnosis include staying indoors and commence/increase dietary 
supplement intake and ii) concerns around the reproducibility of the LC-MS-MS-based 
assay for measuring vitamin D. Taken together, it is to be noted that while the single 
measure of serum vitamin D has provided useful insights, it remains a relatively ‘blunt 
tool’ and requires further optimisation.  
Vitamin D signals via its canonical receptor VDR which has been shown to be 
associated with tumour progression in colon cancer and in melanoma. It was therefore 
hypothesised that exploration of tumour VDR expression would provide insight into 
vitamin D-VDR signalling in the LMC melanomas. The LMC tumours were thus stratified 
based on their VDR expression, to produce 3 VDR-groups. This was a survival-based 
stratification i.e. the cut-off points to establish low-, intermediate- and high-VDR groups 
were based on the most divergent melanoma survival in these groups. This identified 
groups that not only varied in VDR expression but also had significantly different 
melanoma survival. The high-VDR group had the best survival (and highest VDR 
expression) while the intermediate- and low-VDR groups had progressively worse 
survival. These subgroups proved to be a useful categorisation of VDR expression in 
the LMC and were used throughout the study. When these proportions were applied to 
the TCGA metastatic melanoma dataset, the resultant VDR-groups also had similar 
survival patterns: high-VDR being best, low and intermediate-VDR significantly worse 
survival. This suggests that these VDR categories are relevant not only in primary but 
also in metastatic melanomas. The rationale behind applying LMC-derived VDR 
proportions (lowest 17%, middle 66% and highest 17%) to stratify the TCGA metastatic 
tumours was: since mean VDR expression is lower in metastatic tumours compared to 
primary melanomas, the expression level-based cut-offs derived from primary 
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melanomas would not be directly applicable to metastatic melanomas. Moreover, the 
LMC and TCGA transcriptomic datasets were generated on different platforms, adding 
a further justification to apply the proportions rather than the expression level-based 
cut-offs.  
To address the hypothesis of a possible context-specific effect of vitamin D, a 
vitamin D-VDR subgroup analysis was done. This analysis (which categorised the 700 
LMC tumours into 6 subgroups) revealed that serum vitamin D indeed was protective 
for melanoma survival, but only in the intermediate-VDR group of tumours. In patients 
with low-VDR expression, the lack of a protective effect of higher vitamin was not 
unexpected, since low receptor expression could preclude effective signalling despite 
ligand sufficiency. On the other hand, a lack of benefit in the high-VDR tumours could 
be a reflection of receptor saturation as reported in other NHR family receptors (390) or 
potentially a ligand-independent effect of VDR, which has been described in other 
cancers (348, 349).  The context-specific effect observed in the intermediate-VDR 
group naturally prompted the identification of factors which could contribute to this 
effect. Intermediate-VDR tumours from patients with low serum were more likely to have 
higher frequency of AJCC stage II tumours (compared to AJCC stage I), increased 
frequency of vascular invasion and higher Breslow thickness, all of which could explain 
why these patients had a worse prognosis. Patients with high serum vitamin D in this 
group had reduced imputed immune cell scores for neutrophils and monocytes, as well 
as reduced pathways scores for IL12, TCR and NK cell-mediated signalling (identified 
by ‘candidate approach’ of checking VDR-correlated pathways). The role of vitamin D 
in modulating innate immune responses has been previously reported, with particular 
focus on the vitamin D3-mediated anti-bacterial innate immune response (391). There 
is also extensive literature which indicate a protective role for vitamin D on respiratory 
tract infections such as tuberculosis (392), which are characterised by innate immune 
responses. While a vast portion of the literature indicate that vitamin D is associated 
with a pro-innate immune response, the consensus remains equivocal. There are 
studies which indicate that vitamin D can modulate both pro and anti-innate immune 
responses, depending on the assaulting antigen and responding immune cell (393). 
Individual studies have shown Vitamin D deficiency to be inversely associated with 
Neutrophil-to-Lymphocyte ratio (NLR) (394) and eosinophil counts (395). These studies 
used NLR and eosinophil counts as indicators of systemic inflammation, suggesting 
that vitamin D has an anti-systemic inflammation role. Collectively, the observation in 
the intermediate-VDR group in the LMC of serum vitamin D being inversely correlated 
with imputed neutrophils and monocytes cell scores could be a reflection of systemic 
inflammatory differences in this group of tumours. But this hypothesis cannot be tested 
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owing to lack of data pertaining to indicators of systemic inflammation. Overall, the 
relationship between vitamin D and immune cell function remains unclear.  
However, it was of interest to assess if transcriptomic variations could also explain 
the difference in prognosis in this group. An agnostic whole-transcriptome correlation 
analysis did not identify genes that correlate with serum vitamin D in the intermediate-
VDR group, after applying multiple correction thresholds. While the self-reported 
supplement intake data indicated that the patients with high serum vitamin D were more 
likely to have taken vitamin supplements, this still did not explain the difference in 
survival. One possible explanation for this context-specific protective effect is systemic 
factors i.e. the effects of serum vitamin D in this group could be via systemic effects. 
This cannot be tested in the present study but present a possible question for future 
studies. The other possible reason which could explain the improved survival in 
participants with high serum vitamin D in the intermediate-VDR group (compared to low 
serum vitamin D) could be owing to more effective signalling via VDR in this subset of 
tumours. Though there is no statistically significant difference in VDR expression 
between these subgroups, it is worth positing that the transcriptomic data are insensitive 
to subtle changes in expression. Moreover, it is to be noted that the ‘season-adjusted’ 
level of serum vitamin D, while accounting for the drop in circulating vitamin D in winter, 
could perhaps have masked and could explain the lack of correlation between one 
measure of vitamin D and VDR in the intermediate group.  
The intermediate-VDR group is also of interest as the 3 patients with serum vitamin 
D> 115nmol/L all belonged to this group. The whole-transcriptome correlation analysis 
(discussed above) was performed excluding these 3 samples. The reason being: these 
levels are beyond the normal distribution of serum vitamin D in this cohort of patients 
and hence were considered statistical outliers rendering the data set difficult to interpret 
with confidence. The levels were not in themselves very high when considering world-
wide data. However, when the whole-transcriptome correlation analysis (in the 
intermediate-VDR group) was repeated after including these 3 patients, a significant set 
of genes crossed the multiple-testing threshold. In analysing these genes, serum 
vitamin D was positively associated with retinol metabolism, Cytochrome P450-drug 
metabolism, fatty acid degradation and glycolysis/gluconeogenesis, to name a few. The 
pathways are composed of the recurrent nodal genes such as ADH1AC, TUBA3, 
UGT1A10, DYNC1L1: genes involved in cellular metabolism. This could imply a 
reflection of a subset of tumours that have increased metabolic activity. On the other 
hand, the pathways negatively correlated with serum vitamin D in the intermediate-VDR 
group include T cell activation, mitochondrial translation, MHC class II antigen 
presentation, HIF-1 pathway and Renal cell carcinoma. This could indicate that tumours 
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from high serum vitamin D patients have overall reduced T cell activity and 
transcriptional activity. However, it is to be noted that these pathways were identified 
after including 3 patients with >115nmol/L, making these finding inconclusive but worthy 
of further exploring the effects of ‘very high’ vitamin D levels on melanoma primaries.  
Since high tumour VDR expression by itself was strongly associated with improved 
melanoma survival, the effects of the receptor were explored in further detail. Though 
serum vitamin D did not correlate significantly with tumour VDR expression, this could 
be a reflection of the dynamic interactions between circulating vitamin D and tumour 
expression, being regulated by feedback loops. Moreover, the measures of vitamin D 
and VDR are from a single time point (at diagnosis), which could explain the lack of 
correlation in the 703 LMC primary melanomas. However, tumour VDR expression 
correlated significantly with clinicopathological features (age at diagnosis, sex, AJCC 
stage, mitotic rate and tumour site) that by themselves are predictors of melanoma 
prognosis. So, to ensure that the protective effect of VDR is not confounded by these 
features, a multivariable analysis was done. This revealed that the association of VDR 
with melanoma prognosis was independent of these factors, indicating that the 
protective effect of VDR expression was not simply a reflection of staging and degree 
of immune infiltrate. Additionally, this protective effect of VDR was independent of the 
expression of other NR1L family genes, despite reports of integrated activity among 
other nuclear receptors (396).  
The finding that VDR expression is lower in tumours from habitually covered skin is 
novel. It is of interest in terms of understanding progression as tumour origin on the 
back, thorax, upper arm, neck, and scalp has long been recognized as a marker of poor 
prognosis (377) in melanoma. The underlying biology is however unknown. VDR 
expression has been reported to increase as a result of experimental exposure to 
ultraviolet light (UVB) in man (397), and the in vitro data reported here showed 
upregulation of VDR after melanoma cell lines were treated with vitamin D. These data 
suggest the possibility that regular sun exposure resulting in increased VDR signalling 
in early melanoma cells may moderate cancer progression. This is consistent with 
previous epidemiological data reported by the Leeds group in which the only 
behavioural measure associated with melanoma risk was actually a protective effect of 
increased regular sun exposure at home in the north of England during summer months 
(398). That is, that it is possible that there is a very complex relationship between sun 
exposure and melanoma risk: that intense intermittent sun exposure associated with 
sunburn (67) is causal for melanoma but that regular non-burning sun exposure may 
be protective and that effect may be mediated by VDR signalling. This has considerable 
implication for public health advice given. 
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Given the prognostic significance of VDR expression in the LMC primaries and 
TCGA metastases, I sought to explore its mechanistic basis by adopting an agnostic 
approach using whole genome correlations and stringent false-discovery filters to 
identify the most significant genomic correlates of VDR expression. Broadly speaking, 
VDR expression was strongly positively correlated with immune-related pathways 
whereas it was negatively correlated with proliferative pathways. Since VDR is also 
expressed in keratinocytes, it was ensured that the VDR-correlated genes were not an 
artefact of keratinocyte contamination and to this effect observed no significant change 
in the correlated pathways after adjusting for FLG2 expression.  
Being the primary transcription factor for vitamin D-VDR signalling, VDR has been 
the focus of ChIP-seq-based approaches to identify transcriptional targets. Tuoresmaki 
et al performed a combined analysis of VDR ChIP-seq data from 6 cellular models and 
identified VDR-binding regions, a large proportion of which are tissue type specific.  In 
an effort to gauge the overlap between genes that are transcriptionally controlled by 
VDR in other tissue types and those that correlate with VDR in melanoma primaries. 
Irrespective of tissue type, about 57% of genes with VDR-binding sites also correlated 
significantly with VDR in our analysis, indicating that a significant proportion of the VDR-
correlating genes are under direct transcriptional control of the VDR transcription factor.  
Given the strength of correlation of VDR expression with immune pathways, this 
was validated by pathologist-graded TILs and indeed found that VDR expression was 
higher in tumours with a brisk immune infiltrate. Melanoma molecular phenotypes have 
been described which identify biologically relevant tumour subtypes based on their 
gene expression profiles. By applying these signatures to the LMC tumour 
transcriptomes, it was observed that VDR expression was significantly higher in high-
immune compared to proliferative subtypes, even using independently-derived 
molecular subtypes. The high VDR expression in TCGA Keratin subtype and Lund 
Normal-like subtype could be a reflection of high VDR expression in epidermis and 
keratinocytes. Alternatively, given that these two subtypes have the best prognosis 
among their counterparts, it could represent high VDR expression in thinner, early stage 
tumours, which have remnants of the skin/keratinocyte molecular signature. 
In assessing the correlation of VDR with individual immune cell scores, the aim was 
to identify specific immune cell scores associated with VDR expression. However, 
almost all immune cell scores correlated significantly, with no indication of any trend 
towards innate or adaptive immune cells. This observation could be a reflection of the 
methods of imputed immune cell scoring. In that, all the imputed immune cell scores 
are highly correlated with each other (Pozniak et al, in press). This could be a possible 
explanation for the strong positive correlation of VDR with all the immune scores. 
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Alternatively, it could indicate that VDR is part of a broader immune response, but this 
would require detailed IHC experiments staining for various immune cell types. The 
collective transcriptome-based evidence for a pro-immune effect of VDR is supported 
by a previous IHC-based study for the association of immune cell infiltration with VDR 
expression, albeit for a smaller number of tumours (368). This study has furthered the 
understanding of this pro-immune effect by identifying specific immune pathways and 
genes associated with VDR in melanoma primaries. The reported strong positive 
correlation of VDR with genes involved in pathways such as extracellular matrix 
organization, TNFa signalling, NFkB activation, IFNg and IL-12 mediated signalling are 
novel findings in primary melanoma. 
Among the proliferation-related pathways that correlated inversely with VDR in both 
the LMC and TCGA, Wnt/b-catenin signalling was of particular interest since it has 
previously been reported to be inhibited by vitamin D-VDR signalling in colon cancer 
cells with consequent increase in anti-tumour immune infiltrate (356). On comparing 
VDR expression across the 6 previously reported CICs (Nsengimana et al), it was 
observed that VDR expression was lowest in the ‘high-Wnt/b-catenin’ tumours which 
complements the results from the agnostic correlations with VDR. This suggests that 
some of the effects of VDR signalling in melanoma cells are mediated by inhibition of 
Wnt/b-catenin signalling as reported for colon cancer cells. It was also demonstrated 
that low expression of Wnt/b-catenin signalling genes in high-VDR tumours was not 
simply a consequence of decreased copies of CTNNB1 which codes for the key 
transcription factor for Wnt/b-catenin signalling. VDR has been shown to inhibit Wnt/b-
catenin signalling by directly binding to the transcription factor b-catenin and by 
increasing expression of E-cadherin: an inhibitor of Wnt/b-catenin signalling (304). This 
could also be the case in melanoma, which requires further functional validation.  
In an effort to identify factors that could affect VDR expression, it was observed that 
metastatic tumours with high VDR expression were more likely to be hypomethylated, 
suggesting that epigenetic control of VDR expression is active in melanoma as 
previously reported (399) (400). Though VDR copy number was not associated with 
expression in LMC primaries, distant metastases (which have worse prognosis) had 
lower median copy number compared to regional lymph node metastases in the TCGA, 
suggesting a progression-associated genomic loss of VDR.  
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From among the findings reported in this chapter, I performed functional validation 
to add causal evidence to two particular findings: 
i) The strong independent protective effect of VDR expression which is also strongly 
inversely correlated with proliferation-associated pathways.  
ii) The inverse association of VDR with Wnt/b-catenin signalling 
These functional validation studies are detailed in Chapter 4 
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In-vitro and in-vivo validation of transcriptomic 
evidence 
 Introduction  
The transcriptomic and histopathological findings described in chapter 3 indicated that 
VDR expression was positively associated with an immune-active environment, while 
being negatively associated with factors indicative of melanoma progression. These 
significant correlative evidences provided the basis for functional validation 
experiments. The hypothesis which was functionally tested was that VDR-expressing 
melanoma cells would have reduced proliferative potential and lower expression of 
Wnt/b-catenin signalling genes, compared to cells which don’t express VDR. To this 
effect, an in vivo murine metastatic assay was used to assess the effect of VDR-
expressing murine melanoma cells on pulmonary metastasis formation. The murine 
melanoma B16-BL6 cell line was chosen for this experiment owing to its endogenously 
very low expression of VDR, compared to other B16 strains such as B16-F0 and B16-
F10 (unpublished data, personal correspondence with and courtesy of Dr. Martin del 
Castillo and Dr. David Adams, Wellcome Trust Sanger Institute). Briefly, early passage 
B16-BL6 cells were subjected to transposon-mediated transfection with a vector 
carrying the murine VDR cDNA (referred to as the ‘VDR construct’), to generate a cell 
line with increased VDR expression. These cells will be referred to henceforth as ‘VDR: 
B16-BL6 cells’. As a control, B16-BL6 cells were stably-transfected with only the 
backbone vector to generate cells expressing only the endogenously low levels of VDR: 
referred henceforth as ‘control: B16-BL6’ cells. The resultant clones, from both VDR 
cDNA and control transfections were screened for VDR expression using Western Blot 
and qRT-PCR. Two clones per cell-type, V1 and V2 (VDR: B16-BL6 cells), C1 and C2 
(control: B16BL6 cells) were used in the in the in vivo tail-vein metastasis assay. The 
details of this experiment and the relevant results are discussed below. 
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 Chapter aims and overview 
Chapter aims Section 
To describe the procedure and outcome of steps involved in cloning the 
VDR construct 4.2.1 
To describe the steps involved and outcome of transposon-mediated 
transfection of B16-BL6 cells 4.2.2 
To describe the steps and outcome of the In-vivo tail-vein metastasis 
assay 4.2.3 
To validate the transcriptome-derived observation that VDR is inversely 
correlated with Wnt/B-catenin signalling 4.2.4 
 
Contributions to this chapter 
Sathya Muralidhar performed the following work under supervision of Dr David J. 
Adams (Wellcome Trust Sanger Institute) Dr Louise van der Weyden (Wellcome Trust 
Sanger Institute) and Prof. Julia Newton-Bishop.  
- In vitro propagation and maintenance of B16-BL6 cells  
- Cloning of VDR construct, with help from Dr James Hewinson (WTSI) 
- Transposon transfection of B16-BL6 cells to generate VDR: B16-BL6 and B16-
BL6: control cells 
- Western blot screening of transfection clones 
- qRT-PCR screening of transfection clones, with help from Dr Mark Harland (UL*) 
- Immunohistochemistry of the FFPE blocks of murine lungs generated from the in-
vivo metastatic tail-vein assay for CD3 
- Digital estimation of metastatic area and CD3 positive immune infiltration 
- Statistical analysis of raw data from metastatic assay (metastatic load and CD3 
positive immune infiltrate) and graphical representation  
- Array-based comparison of expression of Wnt/B-catenin genes between VDR: 
B16-BL6 and control: B16-BL6: cells, with help from Dr. Mark Harland (UL) 
Dr Jon Laye performed: 
- Sectioning of FFPE blocks of murine lungs lung blocks generated from the in-vivo 
metastatic tail-vein assay 
- H&E staining of lung sections.  
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Dr Louise van der Weyden performed: 
- The in-vivo metastatic tail-vein assay which included tail-vein injection of early 
passage transfected cells, sacrifice of mice upon reaching experimental end point 
and macroscopic counting of pulmonary metastases. 
 
 Methods 
4.3.1 Cloning the murine pB-VDR construct 
The visualisation of plasmids, primer alignment and analysis of results from Sanger 
sequencing were done using SnapGene viewer® (401). 
The Insert: A pMS-VDRiresPuroKATGx construct (4986bp) with flanking PmeI and NotI 
restriction sites construct was synthesized by GeneArtTM. The construct consisted of 
1266bp mouse VDR sequence, an IRES (Internal Ribosomal Entry Site), the Puromycin 
Resistence gene (Puro) and a Kozak sequence (gccAccatgg). The synthesized vector 
was digested using PmeI, NotI and EcorV (in NEB buf 2.1 and BSA, 2 hours at 37oC) 
to produce three fragments of which the 2.4kb fragment (containing the VDR-IRES-
Puro) was gel-purified (Wizard SV Gel and PCR cleanup system, Promega) and used 
as the Insert for subsequent ligation step.  
The Backbone: The backbone vector used was: PB-BirA_P2A_rtTA_P2A_PURO-TRE-
cherry (11,849bp) which includes the inverted terminal repeat sequences that are 
flanked once again by PmeI and NotI digestion sites. A PmeI and NotI double digest (in 
NEB buf 2.1 and BSA, 2h at 37C) and the resulting 6.7kb fragment was gel purified and 
used as the backbone for subsequent ligation. This backbone vector was also used to 
generate the control cells which do not express VDR (for comparison with the VDR-
expressing cells).  
The Ligation: the Insert and the Backbone were ligated at 5:1 and 3:1 using T4 DNA 
Ligase (70) for 2h at room temperature and transformed into OneShot Top10 chemically 
competent bacteria (Life Technologies) as per manufacturers’ protocol. The 
Transformed bacteria were cultured in SOC (Super Optimal Broth with Catabolite 
repression, ThermoFisher) medium and were plated on Ampicillin-Agar plates and 
incubated at 37C overnight. Two colonies were spotted, both of which were inoculated 
in LB broth+ Ampicillin (1ul/ml). Both colonies (Colony 1 and Colony 2) were used for 
plasmid isolation using miniprep (PureYield Plasmid Miniprep system, Promega) per 
manufacturers’ protocol. Resulting plasmids were digestion-checked with SpeI and 
PmlI (CutSmart buf 10x, BSA, 2hrs at 37C) to produce 3.2kb and 5.9kb fragments. Both 
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Colony 1 and Colony 2 were positive for digestion checks, but Colony 1 had low 
concentration so Colony 2 was used for sequencing check. Primers were designed at 
approximately 700bp intervals, to span the entire 9186bp Cloned plasmid. Colony 2 
was sent for sequencing using the 13 primers (‘Round 1’ primers) and the sequencing 
results were verified. In addition, 6 primers were designed to span only the VDR-IRES-
Puro region (‘Round 2’ primers) to be absolutely sure about the sequence similarities. 
Sanger sequencing was done using the Eurofins service at the Wellcome Trust Sanger 
Institute. See Appendix Table T4-1 for primer sequences and related information. The 
ligated PB-BirA_P2A_rtTA_P2A_VDR_IRES_Puro construct will be referred to as ‘pB-
VDR’ henceforth.  
4.3.2 Transfection of B16-BL6 cells 
B16-BL6 stock vials were revived in complete DMEM (DMEM, 10% FBS, 1% 
PenStrepGlutamine) and early passage cells were plated in 6-well plates to reach 90% 
confluence at which time they were used for transfection. LipofectamineTM 2000 
transfection reagent (11668027, Thermo Fisher) was used as per manufacturer’s 
protocol (10µl LipofectamineTM 2000 + 240µl OptiMem per 6-well). Briefly, the 
‘transposon construct’ (either pB-VDR or the backbone vector) and Transposase 
plasmid (which codes for expression of the enzyme transposase) were mixed in 1:2 
ratio and made up to 1500µl using Opti-MEM (Thermo Fisher). This was combined with 
Lipofectamine 2000 mixture (10µl Lipo2000 + 240µl Opti-MEM per 6-well), incubated 
for 20 minutes at room temperature and added to the 90% confluent cells. 24 hours 
post-transfection, the cells were treated with 5µg/ml puromycin. 48hours post-
transfection, medium was replaced with 5µg/ml puromycin in high serum DMEM (20% 
FBS). 13 days post-antibiotic treatment, all wells were observed to have cell death but 
with surviving colonies which were sizeable and conducive for colony-picking. Individual 
colonies were picked (after trypsinisation) using pipette, seeded into 12-well plates and 
supplemented with puromycin-DMEM. Transfected colonies were always maintained in 
5µg/ml Puromycin-DMEM medium (with 10% FBS and 1% Pen-Strep-Glutamine). Each 
colony was expanded onto 6-well plates and then 10cm dishes. Upon reaching 
confluence in 10cm dish, 1/3 of cells were frozen down whereas 2/3 of cells were used 
for western blot screening.  
4.3.3 Western blot screening 
Cells were trypsinised, PBS-washed, lysed (RIPA buffer for 20 mins in cold room, with 
agitation) and sonicated (30 second cycles at max and centrifuged at 13000 rpm for 30 
minutes to spin down the debris. The clear lysate was collected, combined with loading 
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dye (1X NuPAGE LDS Sample buffer NP0007) and denatured at 95C for 5 minutes. 
Denatured samples were loaded into protein gel (NuPAGE 4-12% Bis-Tris Protein gels 
NP0321) which were used for electrophoresis using the X-cell SureLock Mini-Cell 
system with 1X NuPAGE MOPS SDS Running buffer (ThermoFisher), 0.05% NuPAGE 
antioxidant (ThermoFisher) and run at 50V 1hr and then 100V 15mins. Protein transfer 
was done using the X-cell SureLock system using 1X NuPAGE transfer buffer 
(ThermoFisher), 0.05% antioxidant (ThermoFisher), 10% MeOH onto to a nylon 
membrane (Amersham Hybond XL) for 2hrs at 30V (room temperature). The membrane 
was then washed with Tris-buffered saline, 0.1% Tween 20 (TBST) followed by blocking 
with 5% skim milk solution (in TBST) for 1hour at room temperature. This was followed 
by washing (3x wash in TBST on rocker) and incubation with primary antibody (antibody 
info in table below) in 5% milk solution (in TBST) at 4oC on a rocker overnight. This was 
followed by washing (3x wash in TBST on rocker) and then secondary antibody 
incubation for 1 hour at room temperature. Proteins on blot were visualised using the 
Western Bright ECL HRP-conjugate Spray (Advansta, K-12049-D50) on the Image 
Quant LAS4000 (exposure time: 10sec).  
4.3.4 Quantification of VDR expression using qRT-PCR 
Of the transfected clones screened by Western blot for VDR expression, only 4 
transfected clones were assessed for murine VDR expression and used for subsequent 
assays. These were: the VDR-expressing clones V1 and V2, and the control clones C1 
and C2.  
Murine VDR expression was measured using the TaqMan Assay for murine VDR: 
Mm00437297_m1 (ThermoFisher, catalogue number 4331182). The assay spans the 
boundaries of exon 3 and 4, with an amplicon length of 95bp. As a housekeeping 
control, murine GAPDH: Mm99999915_g1 (ThermoFisher, catalogue number 
4453320) was used. The TaqMan™ Gene Expression Master Mix (Thermo fisher) was 
used for both reactions. The qRT-PCR cycles were programmed and executed in the 
QS5 system (Thermo Fisher, University of Leeds core facility) with the following 
parameters: 
Block type: 96 -well.0.2ml block 
Passive reference dye: ROX 
Experiment type: comparative Ct  (D-DCt) method 
Amplification cycle: Step 1: 50oC, 2 minutes 
          Step 2: 95oC, 10 minutes 
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          Step 3: 50oC, 1 minute à Record Ct 
               Step 4: 95oC, 15 seconds 
               Step 5: 95oC, 15 seconds 
               Step 6: 60oC, 1 minute 
The results at the end of the PCR run were exported as a Microsoft excel (.xls) file 
which listed the Ct values from each well (one sample per well). Relative expression 
was calculated using the D-DCt method, normalized to average Ct of the housekeeping 
gene (GAPDH). Fold change (FC) of the VDR: B16-BL6 clones (V1 and V2) and the 
control: B16-BL6 clone C2 were calculated relative to the clone C1, which was chosen 
as the ‘baseline’. The Fold Change was calculated as follows: FC = 2^(-DDCt) where 
DDCt= DCt-DCtC1.  
4.3.5 In-vivo tail-vein metastasis assay 
The care and use of all mice in this study were in accordance with the UK Animals in 
Science Regulation Unit’s Code of Practice for the Housing and Care of Animals Bred, 
Supplied or Used for Scientific Purposes, the Animals (Scientific Procedures) Act 1986 
Amendment Regulations 2012, and all procedures were performed under a UK Home 
Office Project license, which was reviewed and approved by the Sanger Institute’s 
Animal Welfare and Ethical Review Body. Housing and husbandry conditions were as 
described previously [van der Weyden et al., 2017] and mice were maintained on Mouse 
Breeders Diet (Laboratory Diets, 5021-3) throughout the study. V1, V2, C1 and C2 cells 
(detailed above) were tail vein administered to 6-10 weeks old sex-matched wildtype 
(C57BL/6NTac) mice (104 cells in 0.1mL PBS). After 21 days, mice were humanely 
sacrificed and their lungs macroscopically examined to determine the number of 
metastatic deposits in all 5 lobes (‘met count’). Lungs were formalin fixed, processed 
and embedded in paraffin wax blocks, from which consecutive 5µm sections were cut 
and used for H&E and CD3 staining.  
4.3.5.1 Estimation of metastatic area 
H&E (Chapter 2: methods for H&E protocol) sections were digitally scanned (Leica 
Aperio AT2) and metastatic area (in µm2) was digitally estimated using Aperio 
Imagescope (Leica Biosystems) software. Total area (‘met area’) was calculated as the 
sum of area of all metastatic deposits, across all 5 lung lobes. Statistical significance in 
metastatic load from mice injected with VDR: B16-BL6 cells (V1 and V2 combined into 
a group) and control: B16-BL6 cells (C1 and C2 combined into a group) was determined 
using a Mann-Whitney U-test (Stata command: ‘ranksum’).  
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4.1.1.1 CD3 Staining and counting strategy 
5µm sections were stained for mouse CD3 (see below for protocol). The CD3-stained 
sections were digitally scanned as described above. The number of peri-tumoural 
(within two-cell distance form tumour margin) and intra-tumoural (within the tumour 
margin) CD3 positive infiltrating lymphocytes were digitally estimated (at 20x 
magnification) in all 5 pulmonary lobes using the Aperio Imagescope (Leica 
Biosystems) software. The total number of CD3 positive cells thus estimated was 
divided by the total tumour area (described above) per lung, to calculate the number of 
CD3 positive cells per 100 mm2 tumour.  Statistical significance in tumour-infiltrating 
CD3 positive lymphocytes from mice injected with VDR: B16-BL6 cells (V1 and V2 
combined into a group) and control: B16-BL6 cells (C1 and C2 combined into a group) 
was determined using a Mann-Whitney U-test (Stata command: ‘ranksum’). 
4.3.5.1.1 Protocol for immunohistochemistry of FFPE lung sections for CD3 
expression: 
1) The FFPE blocks were sectioned using a microtome to produce 5µm sections 
2) The tissue sections were deparaffinised on a hotplate at 70oC followed by antigen 
retrieval in a pressure cooker, with the slides submerged in 1x antigen retrieval 
solution (Menapath technologies). After antigen retrieval, the slides were washed 
in wash buffer (1x, Menapath technologies) followed by rinsing in running tap 
water.  
3) The slides were then marked around the tissue region of interest, with a wax 
marker. Slides were kept in a humidity chamber after this step to ensure tissue 
hydration. 
4) The tissue was then treated with 100µl peroxide blocking solution (Menapath 
technologies) for 11 minutes. The solution was then washed away with wash 
buffer (1x, Menapath technologies) 
5) The tissue was then treated with 100µl Casein blocking solution (Menapath 
technologies) for 10 minutes 
6) The tissues were then treated with the primary antibody: anti CD3 (ab5690, 
Abcam) diluted in antibody-diluent solution at 1:100 dilution, as per the antibody 
manufacturer’s recommendation (Menapath technologies). The primary antibody 
treatment was allowed to incubate at room temperature for 10 minutes.  
7) This was followed by secondary antibody treatment using ImmPRESS HRP 
reagents (MP-7452, Vector Laboratories) and visualised using purple Vector VIP 
substrate (SK-4600, Vector Laboratories).  Slides were counterstained using H&E 
(Chapter 2: methods for H&E protocol). 
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8) The sections were left to air dry overnight, after which they were digitally scanned.  
4.3.6 Difference in b-catenin signalling genes between VDR: B16-
BL6 and control:B16BL6 cells 
RNA was extracted from V1, V2, C1 and C2 cells (RNeasy Mini kit, Qiagen). 2.5µg was 
used for cDNA synthesis (SuperScript™ VILO™ cDNA Synthesis Kit, Thermo Fisher). 
The 4 clones were analysed in triplicate on a pathway-specific RT-PCR array of 84 
mouse Wnt/b-catenin pathway genes (RT² Profiler™ PCR Array #330231 and RT² 
SYBR Green ROX qPCR Mastermix, Qiagen) as per manufacturer’s protocol. The qRT-
PCR cycles were programmed and executed in the QS5 system (Thermo Fisher, 
University of Leeds core facility) with the following parameters:  
Block type: 96 -well.0.2ml block 
Passive reference dye: ROX 
Experiment type: comparative Ct  (D-DCt) method 
Amplification cycle: Step 1: 50oC, 2 minutes 
          Step 2: 95oC, 10 minutes 
          Step 3: 50oC, 1 minute à Record Ct 
               Step 4: 95oC, 15 seconds 
               Step 5: 95oC, 15 seconds 
               Step 6: 60oC, 1 minute 
Relative expression was calculated using the Delta-Delta CT method, normalized 
to average Ct of the 5 housekeeping genes provided in the array. Fold change (FC) of 
the VDR: B16-BL6 clones relative to control:B16BL6 clones was calculated as follows: 
FCV1(or)V2= 2^(-DDCt)V1(or)V2 where DDCtV1(or)V2= DCtV1(or)V2-DCtavg(C1 & C2). 
 
 Results 
4.4.1 Cloning of the VDR construct 
A transposon-mediated transfection approach was used for to generate the VDR: B16-
BL6 and Control: B16-BL6 cells. This approach is based on the concept of transposable 
repeat elements (also known as Inverted Terminal Repeat sequences- ITRs), which 
enable genes of interest (situated between two ITRs) to be stably integrated into target 
genomes. This ‘cut and paste’ mechanism requires transposase: an enzyme which 
targets and excises the transposon elements (the ITRs) along with the genes of interest 
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in-between the repeats. This system allows for insertion of multiple copies of the 
gene(s) of interest into random TTAA sites within the target genome (402). The 
transposon-transposase system used in this study is the piggyBac (PB) transposon and 
corresponding PB-transposase. The steps involved in this process are depicted in 
Figure 4.1. A vector containing the transposon element (PB-BirA-P2A-rtTA-P2A-Puro-
Tre-Cherry) was used as the backbone vector, within which the gene of interest had to 
be inserted. The gene of interest in this case was the murine VDR sequence, which 
was synthesised commercially (GeneArt, see methods) in an ‘insert’ plasmid (pMS-
VDR-Ires-PuroRKATGx). Both the backbone vector and insert plasmids were double 
digested at the same restriction digestion sites (PmeI and NotI) to excise the requisite 
sequences: the transposon repeats (6.7kb) from the backbone vector and the VDR-
IRES-PuroR (2.9kb) sequences from the insert plasmid. The excised sequences were 
ligated to produce the ‘VDR-construct’ (9.2kb) (2.9+6.7=9.2kb). This construct was 
Sanger sequenced using 13 primers that were designed to span the length of the 
construct. Sanger sequencing produced short reads which upon alignment revealed 
that no mismatches were present in any of the important regions i.e VDR, PuroR, 
CAAGS promoter and IRES. The sequence reads from the 13 primers aligned to the 
Cloned construct is represented in Figure 4.2. This meant that the VDR-construct was 
suitable for subsequent co-transfection into the B16-BL6 cells. In addition, the 
transposase-expressing plasmid was revived from glycerol stock and plasmid isolation 
was done to be used for subsequent co-transfection.   
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Figure 4.1: Schematic of cloning and transfection strategy used to generate VDR: 
B16-BL6 and control: B16-BL6 cells 
The backbone vector and the insert or only the backbone vector was used to 
generate the VDR-construct and the control plasmid respectively. While the 
former includes the VDR cDNA insert, the latter does not contain this, hence 
making it a null VDR-expressing control. The plasmids were then checked for 
mutations/aberrations using Sanger sequencing. The VDR-construct and the 
control plasmid were then co-transfected with the vector which expresses the 
transposase enzyme (‘transposase’ plasmid) into B16-BL6 cells. The former 
transfection produced VDR: B16-BL6 cells while the latter produced control: B16-
BL6 cells after puromycin selection. Of the clones that survived puromycin 
selection and screened for VDR expression using Western blot, only two clones 
per group (V1 and V2, C1 and C2) were used for subsequent assay. 
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Figure 4.2: The thirteen primers used for Sanger sequencing of the VDR-
construct 
The VDR-construct was verified by Sanger sequencing using 13 primers which 
were designed to periodically span the entire length of the VDR-construct. 
Graphical representation was generated using SnapGene viewer® 
 
4.4.2 Co-transfection of B16-BL6 cells with VDR construct and 
transposase plasmid 
B16-BL6 cells were grown to 60% confluency in a 24-well plate and were co-transfected 
with the transposase construct along with either the VDR-construct or the backbone 
vector (the steps involved in this process are depicted in Figure 4.1. Two separate 
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transfection experiments were done. All transfections in an experiment were set up at 
the same instance (day and time).  
Experiment 1: The aim was to identify the ‘transposon to transposase’ ratio which 
would result in optimum integration. Two ratios were tested: i) 0.5ug pB-VDR or 
backbone vector + 0.2ug transposase vector and ii) 1ug pB-VDR or backbone vector + 
0.5ug transposase vector. B16-BL6 cells were seeded at density of 106 cells per well 
and grown to confluency, prior to transfection. This was performed in two 6-well plates, 
the plating schema is described in Figure 4.3. 
 
 
 
 
 
 
 
 
Figure 4.3: Plating schema of Experiment 1: to identify the optimal ratio of 
‘transposon to transposase’ plasmids 
Plate 1 and plate 2 are the plating schemas for two separate 6-well plates which 
were plated on the same instance. Labels in red indicate the state of the cells, 10 
days after puromycin selection. Duplicates were included for every transfection, 
i.e. two wells per transfection. 
 
After 10 days of puromycin selection, the following observations were made. The 
observations are representative of duplicate wells. 
- The untransfected cells were B16-BL6 cells taken from the pool of B16-BL6 cells 
plated, to ensure they were a ‘healthy’ pool. The cells looked viable and attained 
confluence in 2-3 days, as was expected. However, after puromycin treatment, 
the cells underwent cell death.  
- The cells transfected with only the pB-VDR cells were over-confluent and 
underwent eventual cell death after 10 days of puromycin treatment. The reason 
being: without the transposase vector (which is required for successful integration 
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of the VDR cDNA into the host genome), the B16-BL6 cells can only uptake the 
pB-VDR plasmid and thus express ‘baseline’ levels of VDR. Since this level is not 
sufficient to inhibit cell growth, the cells became over confluent and underwent cell 
death eventually 
- Of the two ratios used, the 2:1 ratio (1ug pB-VDR or backbone vector + 0.5ug 
transposase vector) was the one that produced a viable number of colonies in the 
case of both pB-VDR and the backbone vector transfections. Hence, this ratio was 
used for the subsequent Experiment 2.  
 
Experiment 2: The aim was to produce viable colonies of clones which survive the 
puromycin selection and hence should have successfully integrated the pB-VDR or 
backbone vector. The transfection schema for this experiment is described in the Figure 
4.4. 
 
 
 
 
 
 
 
Figure 4.4: Plating schema of Experiment 2: to produce viable colonies of clones 
which survive puromycin selection and hence should have successfully 
integrated the pB-VDR or backbone vector 
 
After 10 days of puromycin selection, the following observations were made. The 
observations are representative of duplicate wells. 
- The untransfected cells were B16-BL6 cells taken from the pool of B16-BL6 cells 
plated, to ensure they were a ‘healthy’ pool. The cells looked viable and attained 
confluence in 2-3 days, as was expected. However, after puromycin treatment, 
the cells underwent cell death.  
- B16-BL6 cells which had assimilated plasmids containing the puromycin 
resistance gene survived and formed colonies. In other words, the cells which 
survived and formed colonies were the ones which had been transfected with 
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either the pB-VDR plasmid (in wells A2, B2) or the backbone vector (in wells A3, 
B3).  
Thus, the cell colonies which survived puromycin treatment were picked and each 
colony was individually seeded into single wells in a 24-well plate. Total of 10 colonies 
were picked from the wells which were transfected with the VDR-construct plasmid, 
while 8 colonies were picked from the wells which were transfected with the backbone 
vector. Upon reaching confluence, the cells were expanded successively in 12-well, 6-
well, 10cm plates and finally in 15cm plates. When the cells reached 90% confluency 
in 15cm plates, the cells were screened for VDR expression using Western blot. All 10 
colonies transfected with the VDR-construct plasmid produced a 48.5 kDa band when 
exposed to anti-VDR antibody, whereas none of the 8 colonies transfected with the 
backbone vector produced a band (Figure 4.5A). Of these screened colonies, 2 per 
group were selected for subsequent in vivo experiments. Of the colonies transfected 
with the VDR-construct plasmid, V1 and V2 (VDR: B16-BL6 henceforth) were chosen 
for subsequent in vivo experiments. Of the colonies transfected with the backbone 
vector, C1 and C2 (control: B16-BL6 henceforth) were chosen for subsequent in vivo 
experiments. Western Blot was repeated for these 4 clones (to replicate observations 
from the first Western Blot screen) and confirmed that the V1 and V2 clones expressed 
VDR, whereas C1 and C2 had no detectable VDR expression (Figure 4.5B). 
Additionally, qRT-PCR to assess differential expression of VDR revealed that V1 and 
V2 cells expressed significantly higher levels of VDR, relative to C1 and C2 cells (Figure 
4.5C), with V1 expressing more VDR compared to V2. Thus, both Western blot and 
qRT-PCR screening indicated that the V1 and V2 cells expressed VDR whereas the C1 
and C2 cells had little to no VDR expression.  
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Figure 4.5: Screening of transfected clones using Western blot and qRT-PCR 
A: Western Blot of 10 VDR: B16-BL6 clones and 8 control: B16-BL6 clones for 
VDR (48.5 kDa) relative to housekeeping protein Vinculin (137 kDa); 
B: Western Blot of the 4 selected clones: V1 and V2 (VDR: B16-BL6) and C1 and 
C2 (control: B16-BL6) for VDR (48.5 kDa) relative to housekeeping protein 
Vinculin (137 kDa); 
C: qRT-PCR of the 4 selected clones: V1 and V2 (VDR: B16-BL6) and C1 and C2 
(control: B16-BL6) relative to the housekeeping gene GAPDH. Relative 
expression of VDR among the 4 clones was estimated using the D-DCt method to 
calculate Fold Change.  
 
A 
B C 
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4.4.3 In vivo tail-vein metastasis assay 
4.4.3.1 Estimation of metastatic load 
4.4.3.1.1 Choice of optimal dosage and duration of tail-vein assay 
The VDR: B16-BL6 (V1 and V2) and control: B16-BL6 (C1 and C2) cells were used in 
an in vivo experimental metastasis assay (403, 404). The optimal choice of cell dosage 
for tail-vein injection and experimental duration (number of days between tail-vein 
injection and culling of the mouse) was made based on an experiment where multiple 
cell dosages and time points were evaluated in order to assess the ideal choice. Both 
VDR: B16-BL6 (clone V1) and control: B16-BL6 (clone C1) were used for this 
experiment, whose outcome is described in Table 4.1 and Table 4.2 respectively. The 
mice injected with a specific cell dosage (104, 2.5x104, 5x104 or 7.5x104 cells) were 
periodically assessed for signs of ill-health and humanely sacrificed if found to be so. In 
cases where the mice reached the specified end-point without any signs of ill-health, 
the macroscopic count of pulmonary metastases was performed by Dr Louise van der 
Weyden.  
In the following cases, the cell dosage and duration were considered to be a non-
viable option: 
- If the mouse (during regular inspection), was found to suffer from ill health, the cell 
dosage was not considered as a viable experimental option. Such cases are 
indicated by ‘x’ in Table 4.1 and Table 4.2. This was the case in mice injected with 
VDR: B16-BL6 cells at 25 days after injection of 104, 2.5x104 or 5x104 cells. This 
was also the case in mice injected with control:  B16-BL6 cells at 25 days after 
injection of 104, 2.5x104, 5x104 or 7.5x104cells. 
- If a mouse reached the specified end-point without any signs of ill-health, then the 
mouse was humanely sacrificed and the estimate of macroscopic count of 
pulmonary metastases was too ‘diffuse’ (too many metastases to count 
accurately), then that particular dosage/duration was also considered a non-viable 
viable experimental option, since it does not permit accurate estimation of 
macroscopic metastatic load. Such cases are indicated by ‘too many to count’ in 
Table 4.1 and Table 4.2. This was the case in mice injected with the VDR: B16-
BL6 cells at 25 days after injection 7.5x104 cells and in mice injected with the 
control: B16-BL6 cells at 21 days after injection with 5x104 or 7.5x104 cells 
The mice which reached their respective end points with no signs of ill-health were 
humanely sacrificed and contain pulmonary metastases that could be counted by 
macroscopic evaluation (upon estimation of macroscopic metastases) were considered 
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viable options. In such cases, the number of macroscopic metastases (counted by Dr 
Louise van der Weyden) are indicated in Table 4.1 and Table 4.2. 
The main aim of this experiment was to identify the ideal dosage and duration, 
which would be a viable option in both groups of mice: those injected with VDR: B16-
BL6 and those injected with control: B16-BL6. To this effect, the following dosage and 
duration were considered viable options:  
i. 14 days after injection with 104, 2.5x104, 5x104 or 7.5x104cells 
ii. 21 days after injection with 104, 2.5x104, 5x104 or 7.5x104cells 
Since a single dosage and a single duration had to be chose, I (after discussion 
with Dr Louise van der Weyden, Dr David Adams and Prof. Julia Newton-Bishop) 
decided to use the dosage of 104 cells and an experimental duration of 21 days for 
subsequent experiments.  
Even though this experiment was done as an ‘initial pilot’ (with one mouse per 
dosage/duration group) to estimate ideal conditions for the subsequent ‘main’ 
experiments, it is worth noting that a mouse in a particular dosage/duration group had 
lower metastatic counts when injected with VDR: B16-BL6, compared to control: B16-
BL6. This was one of the initial suggestions of the possible effect of VDR expression 
on metastatic potential, which was explored formally in a larger cohort of mice. 
Table 4.1: Experiment to assess the optimal cell dosage of VDR: B16-BL6 cells 
and duration for the tail vein metastasis assay 
Number of cell injected refers to the total number of cells used in tail-vein injection. 
D14, D21, D25 and D26 refer to the time elapsed (number of days) between tail-
vein injection and culling of the mouse. 
Number of cells injected (dosage) D14 D21 D25 D26 
104 cells 5 20 x x 
2.5 x 104 cells 34 52 x x 
5 x 104 cells 12 110 x x 
7.5 x 104 cells 274 220 Too many to count x 
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Table 4.2: Experiment to assess the optimal cell dosage of control: B16-BL6 cells 
and duration for the tail vein metastasis assay 
Number of cell injected refers to the total number of cells used in tail-vein injection. 
D14, D21, D25 and D26 refer to the time elapsed (number of days) between tail-
vein injection and culling of the mouse. 
Number of cells injected (dosage) D14 D21 D25 D26 
104 cells 31 50 x x 
2.5 x 104 cells 85 115 x x 
5 x 104 cells 191 Too many to count x x 
7.5 x 104 cells 490 Too many to count x x 
 
4.4.3.1.2 Performing the tail vein metastasis assay using the optimal dosage 
and experimental duration 
Having identified the optimal dosage for injection and experimental duration, two 
independent experiments were performed using separate two mouse cohorts, wherein 
wild type mice were injected with 104 V1, V2, C1 or C2 cells and pulmonary metastatic 
load was estimated after 21 days. Pulmonary metastatic load was estimated both as 
macroscopic counts of surface lesions (referred to as met-counts henceforth) and as 
metastatic area estimated using digitally scanned FFPE sections (met-area henceforth, 
measured in µm2).  
In the first experiment (Experiment 1) consisting of a cohort of 34 mice (Table 4.3), 
mice injected with either the VDR: B16-BL6 clones: V1 and V2, produced significantly 
fewer pulmonary metastases compared to the control: B16-BL6 clones C1 and C2 
(Figure 4.6A). This was the case when using both microscopic met-area (P=0.04) or 
macroscopic met-count (P=0.0006). Since Experiment 1 revealed a significant 
difference in metastatic load between the VDR-expressing and control cells, the 
experiment was repeated in order to replicate the observations. To this effect, in 
Experiment 2 consisting of a cohort of 39 mice (Table 4.3), mice injected with the VDR: 
B16-BL6 clones V1 and V2, produced significantly fewer pulmonary metastases 
compared to the control: B16-BL6 clones C1 and C2 (Figure 4.6B). This was the case 
when using both microscopic met-area (P=0.0002) or macroscopic met-count 
(P=0.00002). Thus, observations from both experiments indicated that VDR: B16-BL6 
produced significantly lower metastatic load compared to the control cells, as measured 
by both macroscopic and microscopic measures of metastases. 
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Table 4.3: In-vivo tail-vein metastasis assay: experimental layout 
Experiment Number of cells injected Duration Number of mice per group 
Experiment 1 104 cells per mouse 21 days C1 (n=12),  
C2 (n=7),  
V1 (n=10),  
V2 (n=5) 
Experiment 2 104 cells per mouse 21 days C1 (n=6),  
C2 (n=11), 
V1 (n=11),  
V2 (n=11) 
 
 
 
 
 
 
Figure 4.6 (following page): In vivo tail-vein metastasis assay: estimation of 
metastatic load 
A: Comparison of metastatic load from Experiment 1, estimated by microscopic 
metastatic area (in µm2, determined digitally) and macroscopic metastatic count 
(number of pulmonary metastases) between VDR: B16-BL6 (V1 and V2) and 
control: B16-BL6 cells (C1 and C2). The data points from each clone is denoted 
in a different colour to visualise the effects of individual clones. P value from Mann-
Whitney U-test 
B: Comparison of metastatic load from Experiment 2, estimated by microscopic 
metastatic area (in µm2, determined digitally) and macroscopic metastatic count 
(number of pulmonary metastases) between VDR: B16-BL6 (V1 and V2) and 
control: B16-BL6 cells (C1 and C2). The data points from each clone is denoted 
in a different colour to visualise the effects of individual clones. P value from Mann-
Whitney U-test 
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4.4.3.2 Estimation of tumour-infiltrating CD3 positive lymphocytes 
To assess if the reduced metastatic load in mice injected with VDR: B16-BL6 cells was 
accompanied by increased tumour immune infiltrate, the number of CD3 positive 
tumour infiltrating lymphocytes was computed. For this, lung sections were used, which 
were sectioned consecutive to the sections used for Met-area estimation. The sections 
were stained with anti-CD3 antibody, after which the sections were scanned and the 
number of CD3 positive cells were digitally counted. Only the lymphocytes which 
stained positive for CD3 (membranous) in the intra-tumour region or peri-tumour region 
(2 cell distance) were counted. An illustrative example of the counting strategy used is 
depicted in Figure 4.7A. Since the estimation of CD3 positive lymphocytes was relative 
to the area of the tumour, using absolute count of CD3 positive lymphocytes could be 
potentially biased: greater the area, higher the likelihood of counting a CD3 positive 
lymphocyte. To circumvent this issue, the number of CD3 positive lymphocytes per 105 
µm2 of pulmonary met-area was estimated. In other words, estimation of the CD3 
positive tumour immune infiltrate was done relative to the total tumour area (see 
methods). In some mice, especially in some of the mice injected with B16BL6-VDR 
cells, the pulmonary metastases were too few or in some cases absent (when 
sectioned) despite having a valid met-area and met-count. Owing to this reason, CD3 
positive lymphocyte counting was not possible in all the samples, thus impacting the 
sample size of this comparison. Nevertheless, in Experiment 1 (Figure 4.7B), the 
number of tumour-infiltrating CD3 positive lymphocytes (per 105 µm2) was significantly 
higher in metastases produced by clone V1 compared to control clone C1 (P=0.02). 
However, this difference was not apparent between the other VDR-expressing clone 
V2 and the control clones C1 or C2. In Experiment 2 (Figure 4.7C), the number of 
tumour-infiltrating CD3 positive lymphocytes (per 105 µm2) was not significantly higher 
in metastases produced by clones V1 compared to control clone C1 and C2, with 
borderline significant increase in clone V2 compared to C1 (P=0.06).  
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Figure 4.7: In-vivo tail-vein metastasis assay: estimation of tumour infiltrating 
CD3 positive lymphocytes 
A: Illustrative examples of the counting strategy used to determine tumour 
infiltrating CD3 positive lymphocytes. Consecutive sections from FFPE lung 
blocks were stained for H&E and murine anti-CD3. This enabled estimation of 
CD3 positive tumour lymphocytes, within the context of the defined metastatic 
area. The top panels indicate metastatic area from H&E sections drawn digitally 
(as described in section 4.4.3.1) around a pulmonary metastasis. The bottom 
panels indicate: i) Intra-tumour CD3 positive lymphocytes are those which fall 
within the defined metastatic area ii) peri-tumour CD3 positive lymphocytes are 
those which fall just on the border of the defined metastatic area, within a 2 cell 
distance and iii) the lower corner right panel is an example of a pulmonary 
metastasis with no intra- or peri-tumour CD3 positive lymphocytes. All images 
were captured at 20x magnification.  
A 
B C 
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Figure 4.7 description cont… 
B: Comparison of number of CD3 positive tumour infiltrating lymphocytes from 
Experiment 1, between VDR: B16-BL6 (V1 and V2) and control: B16-BL6 cells 
(C1 and C2). P value from Mann-Whitney U-test. N denotes the number of lung 
sections which were used in each group.  
C: Comparison of number of CD3 positive tumour infiltrating lymphocytes from 
Experiment 2, between VDR: B16-BL6 (V1 and V2) and control: B16-BL6 cells 
(C1 and C2). P value from Mann-Whitney U-test. N denotes the number of lung 
sections which were used in each group.  
 
4.4.4 In vitro validation of the transcriptome-derived inverse 
correlation between VDR and Wnt/B-catenin signalling  
Transcriptome-based evidence in the LMC indicates that VDR expression was inversely 
associate with proliferation associated pathways including the Wnt//b-catenin signalling 
pathway, which was explored further using previously-reported melanoma subtypes. In 
addition, the in-vivo experiment described in section Error! Reference source not f
ound. revealed that VDR-expressing cells produced fewer pulmonary metastasis, 
indicating causal evidence for the anti-proliferative effect of VDR. Thus, it remained to 
be tested if the VDR-expressing murine melanoma cells (VDR: B16BL6) expressed 
significantly lower Wnt/b-catenin signalling genes compared to the control: B16BL6 
cells. Two clones per cell-type, V1 and V2 (VDR: B16-BL6 cells), C1 and C2 (control: 
B16BL6 cells), were compared for expression of Wnt/b-catenin genes using a qRT-
PCR-based array. Of the 84 Wnt/b-catenin genes tested (pre-formatted qRT-PCR-
based array), 62 genes had lower expression (Fold Change <1) with 25 genes having 
Fold Change <0.5 in both VDR clones compared to control clones. Twelve genes had 
increased expression (Fold Change>1) with none having Fold Change>2 expression in 
both VDR clones. Concomitantly, VDR-expressing cells had significantly reduced 
expression of Wnt/b-catenin genes, including Fgf4, Dkk1, Fzd8, Nkd1, and multiple Wnt 
genes. (Figure 4.8).  
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Figure 4.8: In-vitro validation of the transcriptome-derived inverse correlation 
between VDR and Wnt//b-catenin pathway genes 
qRT-PCR-based comparing expression of 84 Wnt/ β-catenin genes in the two 
VDR-transfected clones (V1 and V2) compared to control clones. Relative 
expression of each gene was estimated using the D-DCt method to calculate Fold 
Change. Genes with Fold Change <0.5 (n=25) in both VDR clones compared to 
control clones are listed in red (solid red box in graph). The genes with Fold 
Change <1 (n=62) in both VDR clones compared to control clones are listed in 
red (red region in graph). 
 
 Discussion  
Even though VDR has been shown to have reduced expression in advanced 
melanomas and in vitro evidence for its anti-proliferative effect exists for other cancers, 
causal evidence in melanoma in vivo models is lacking. To address this, we used 
B16BL6 murine melanoma cells to create stably-transfected B16BL6-VDR cells which 
were used in an experimental metastasis assay. In line with the results from the primary 
melanoma transcriptomes, the VDR-transfected cells produced a significantly lower 
pulmonary metastatic load after tail vein administration, indicating that VDR expression 
had an anti-tumourigenic effect, which has not been previously proven in melanomas. 
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The estimation of metastatic area from FFPE-sections offered us the potential to 
estimate tumour infiltrating lymphocytes, which we did by counting the intra-tumoural 
and peri-tumoural CD3 positive cells as proxy for TILs. Since lungs from B16BL6-VDR-
injected mice had no/low metastasis counts they could not be used for intra-tumoural 
and peri-tumoural CD3 positive TILs estimation, thus reducing sample size for this 
analysis. This caveat combined with the possibility that CD3 positivity might not 
necessarily represent the immune milieu amenable to VDR-specific effects, could 
contribute to non-significant results from this analysis. Moreover, I have only estimated 
the intra- and peri-tumoural CD3 positive TILs, this does not preclude the possibility of 
a ‘pan-pulmonary’ immune response. This can be quantified if by use of flow-cytometry. 
Taken together, the trend to greater numbers of CD3 positive cells in VDR-transfected 
metastases warrants further experimental validation in the form of additional assays 
(e.g. flow cytometry) for multiple immune cell lineages.  
Causal evidence for VDR-mediated inhibition of Wnt/b-catenin signalling was 
sought, owing to the strong inverse correlation between VDR and Wnt/b-catenin 
signalling in both the LMC and TCGA data. The expression of Wnt/b-catenin signalling 
genes was significantly reduced in VDR-expressing murine melanoma cells. VDR-
expressing cells had significantly reduced expression of the vast majority of the genes 
on the array i.e. 65 of the 84 genes were had fold change <1 in the VDR-expressing 
cells. Among these, 25 genes had fold change <0.5 in both VDR-expressing clones, 
including Fgf4, Dkk1, Fzd8, Nkd1, and multiple Wnt genes. The Wnt/b-catenin 
signalling pathway plays a significant role in the control of skeletal development and 
homeostasis (405), as does vitamin D-VDR signalling. This could explain why 
expression of Wnt/b-catenin signalling genes could also be controlled by VDR, as has 
been shown to be the case in colon cancer cells by Larriba et al (304). Similarly, in my 
analysis of the LMC transcriptome, FGFR1 and EFNB2, which are targets of Wnt/b-
catenin signalling axis, were among the genes that correlate with VDR and also have a 
VDR-binding site (section 3.4.4.3.2). This indicates a ‘cross-talk’ between the two 
signalling axis, which could have perhaps evolved as a means to maintain bone 
homeostasis. In the case of the 25 Wnt/b-catenin signalling genes downregulated in the 
VDR-expressing cells, some have been previously shown to be inhibited by VDR. For 
instance, Dkk1 and Sfrp2 have previously been shown to be inhibited by VDR during 
adipogenic differentiation (406), but not in melanomas. Interestingly, the ‘classic’ non-
canonical Wnt ligands Wnt5a, Wnt5b, Wnt10a, Wnt7 and Wnt11 were among those 
downregulated in the VDR-expressing cells, which has not previously been reported in 
melanomas. This finding is of significance because Wnt5a (and some other non-
canonical Wnt ligands) affect cell motility and invasion and is implicated in worse 
152 
 
melanoma prognosis (407, 408). Thus, the qRT-PCR findings are complementary and 
provide functional validation of the transcriptome-based findings for the inverse 
association between VDR and Wnt/b-catenin signalling.  
Since the above qRT-PCR based results are derived from murine melanoma cells 
which are only ‘controlled for’ VDR expression, I was curious to assess the effect of 
vitamin D treatment on Wnt/b-catenin signalling. An ideal case would have been to treat 
the VDR: B16-BL6 and control: B16-BL6 cells with 1,25-hydroxy vitamin D3 and 
compare the expression of Wnt/b-catenin signalling genes among treatment groups. 
However, this was not possible owing to logistical and time limitations. Alternatively, I 
performed an analysis of microarray data from human melanoma cells (MeWo and 
SkMel28) treated with (and without) 1,25-hydroxy vitamin D3, which was generated by 
a past PhD student in the group- Dr. Anastasia Filia (unpublished data). I queried the 
microarray data4, which were generated from two treatment time points: 24 and 48 
hours after treatment with 1,25 hydroxy vitamin D3. My analyses revealed the following:  
i. VDR expression was upregulated at 24 and 48 hours after treatment with 1,25 
hydroxy vitamin D3 
ii. Among the most significantly downregulated genes (in both cell lines), were those 
enriched for Wnt/b-catenin signalling. This was identified using an agnostic 
analysis i.e. an enrichment analysis (using Reactome FIViz) of the downregulated 
genes in response to 1,25 hydroxy vitamin D3 treatment (after 24 and 48 hours) 
identified Wnt/b-catenin signalling as one of the top downregulated pathways 
These findings, despite being from a different in vitro model (human rather than 
murine melanoma cells) agnostically identified Wnt/b-catenin signalling to be 
downregulated in response to 1,25 hydroxy vitamin D3 treatment, along with the 
upregulation of VDR expression. These findings are complementary to those derived 
from the VDR-expressing murine melanoma cells.  
Taken together, findings from both in vitro models, along with the transcriptomic 
findings suggest a significant role for the vitamin D-VDR signalling in inhibiting Wnt/b-
catenin signalling in melanomas. 
                                               
4 I have not presented data pertaining to this analysis, since it is based on data-derived by Dr. 
Anastasia Filia’s work.  
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Transcriptomic interrogation of microscopic ulceration 
of primary melanomas 
 Chapter aims and overview 
Chapter aims Section 
To assess the frequency of ulcerated and non-ulcerated tumours in the 
LMC dataset 5.4.1 
To assess the clinicopathological features associated with melanoma 
ulceration 5.4.2 
To assess the differentially expressed genes and signalling pathways that 
vary between ulcerated and non-ulcerated melanomas  5.4.3 
 
Contributions to this chapter:  
• Sathya Muralidhar performed statistical and bioinformatics analyses described in 
this chapter, under the supervision of Dr Jeremie Nsengimana (senior statistician 
in the group) and guided by Prof. Julia Newton-Bishop and Prof. Tim Bishop. 
• Histopathological measures of immune infiltrate (described in 3.4.6.2) in the LMC 
primary melanomas was derived from extensive work done by Dr Sally O’Shea 
who reviewed all the histological slides according to protocol 
 
 Introduction 
5.2.1 Melanoma ulceration 
Ulceration status of primary melanomas is an independent predictor of adverse 
prognosis (312, 409) and has been an integral part of the AJCC melanoma classification 
system (410). The most recent AJCC melanoma staging (8th edition) defines ulceration 
as ‘full thickness absence of an intact epidermis above any portion of the primary 
tumour with an associated host reaction (characterized by a fibrinous and acute 
inflammatory exudate) above the primary tumour based on histopathological 
examination’ (Figure 5.1). The AJCC staging system is widely clinically implemented, 
however there are studies that demonstrate the complexity of the ulceration 
phenomenon. For instance, ulceration has been reported to be associated with 
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alterations to the surrounding epidermis (411) and with histopathological features such 
as Consumption of Epidermis (COE) (412) and Sub-epidermal Cleft Formation (SCF) 
(413). Interestingly, the extent of ulceration (as a percentage of tumour) and type of 
ulceration (attenuative vs infiltrative) have also been shown to be independent 
predictors of adverse melanoma prognosis (414, 415). Given the prognostic 
significance of ulceration in predicting adverse melanoma prognosis, efforts to gain a 
better understanding of the ulceration ‘phenomenon’ have revealed valuable insights.  
 
 
 
Figure 5.1: Representative images of melanomas with evidence for microscopic 
ulceration 
Top image depicts loss of epidermal integrity at 0.6x magnification and the bottom 
image at 10x magnification of a selected section of the tumour. 
 
Ulceration of primary cutaneous melanomas has been associated with 
histopathological features, indicators of systemic inflammation and therapy response 
factors. Histopathological evidence indicates that ulcerated primary melanomas are 
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associated with increased macrophages and lymphatic vessel invasion. This was 
shown by a previous study by our group, where 202 cutaneous primary melanoma 
sections were assessed for IHC-based expression of CD34 (endothelial marker) and 
CD68 (macrophage marker) to estimate blood vessel density and macrophage counts 
respectively. This study showed that vessel invasion density (both blood and lymphatic 
vessels) and macrophage counts were significantly higher in ulcerated tumours 
compared to non-ulcerated tumours (416), suggesting ulceration to be a marker of 
tumour-associated inflammatory microenvironment. The association of ulceration with 
an inflammatory microenvironment has also been shown in a study by Jewell et al (from 
our own group) and was based on a subset of the 702 LMC primary melanomas (417). 
These findings combined with the view that obesity, diabetes, hypertension and 
cardiovascular disease are known to cause pro-inflammatory tumour states, a 
subsequent study by von Schuckmann et al aimed to address the association of 
melanoma ulceration with diabetes and statin usage. This study demonstrated in a 
cohort of 787 melanomas (194 ulcerated, 593 non-ulcerated) that regular statin users 
had a lower likelihood of being diagnosed with ulcerated melanomas. In the same 
cohort of patients, those with tumours <2 mm thick and diagnosed with diabetes had a 
higher likelihood of having an ulcerated melanoma.  The findings from this study 
collectively supported the hypothesis that statin use is inversely and diabetes is 
positively associated with ulcerated melanomas (418). Taken together, there is 
evidence for the association of ulcerated melanomas with indicators of both systemic 
and tumour-associated inflammation.  
Ulceration status has also been shown to be associated with response to 
melanoma therapy. Patients with ulcerated tumours benefit significantly from IFN/PEG-
IFN adjuvant therapy i.e. ulcerated tumours treated with IFN/PEG-IFN adjuvant therapy 
had improved Relapse Free Survival (RFS), Overall Survival (OS) and Distant 
Metastases Free Survival (DMFS). This observation suggested that ulceration might be 
a marker of melanoma response to IFN/PEG-IFN therapy (419). In a recent study by 
Koelblinger et al, ulcerated melanomas had a significantly higher proportion of PDL1-
expressing tumour cells compared to non-ulcerated tumours, suggesting that the 
ulceration phenomenon could be involved in immune evasion with a consequent effect 
on response to immune therapy (420).  
Efforts to understand the genomic basis of ulceration have been addressed by two 
studies to date: by Rakosy et al and Jewell et al. Rakosy et al used a dataset of 32 
samples, comparing 16 ulcerated to 16 non-ulcerated primary melanomas. This study 
identified genes/pathways, CNAs and methylation patterns associated with ulceration 
status in these tumours (421). The study by Jewell et al (417) was from our own group 
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and was based on a subset of the 702 LMC primary melanomas: comparing 50 
ulcerated to 145 non-ulcerated primary melanomas. This study interrogated the 
differential expression of a cancer gene panel of 502 genes between ulcerated and non-
ulcerated tumours. Both studies offer valuable insight into the factors that underpin 
ulceration. They indicate that ulcerated tumours are associated with reduced 
expression of genes pertaining to cell-cell-adhesion pathways and increased 
expression of proliferation-associated pathways. Moreover, the study by Rakosy et al 
indicated that ulceration is associated with changes in both transcriptomic and copy 
number level. To this effect, they identified the following pathways to be significantly 
downregulated in ulcerated melanomas: p53, NFkB and Wnt/b-catenin signalling. In 
addition, they also reported loss of regions in 6q and one region in 10q, which had 
significant loss of copy number in the ulcerated compared to non-ulcerated tumours.  
The current study uses 671 tumours (a subset of the 702 primary melanomas 
described in previous sections of this thesis) and their corresponding clinical, 
histopathological, copy number and transcriptomic data to gain a deeper insight into the 
phenomenon of melanoma ulceration. 
 
 Methods 
5.3.1 Correlations with clinicopathological variables 
In the case of the clinicopathological variables in a continuous scale: age at diagnosis 
(in years) and Breslow thickness, a univariable linear regression model was used to 
assess significant differences between ulcerated and non-ulcerated tumours. In the 
case of clinicopathological variables which were categorical: sex, tumour site, vascular 
invasion and histopathological tumour immune infiltration, a Pearson chi-squared test 
was performed to assess if the proportion of ulcerated and non-ulcerated tumours was 
significantly different between respective categories.  
5.3.2 Whole-transcriptome differences between ulcerated and non-
ulcerated tumours 
The classification of ulceration status by the clinical pathologist’s report (‘Reported’ 
ulceration) was used for this analysis, since this information was available for most 
tumours. Each gene (from a total of 20,560 genes) was checked for differential 
expression between the ulcerated (n=234) and non-ulcerated (n=468) tumours, using 
a Mann-Whitney U-test (Stata command: ‘ranksum’). Since a total of 20,560 tests were 
performed (one per gene), multiple correction had to be applied in order to adjust for 
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false discovery. The Benjamini-Hochberg method of multiple correction was used to 
compute a False Discovery Rate (FDR). The Mann-Whitney U-test also produced a z-
score, which indicated the ‘direction’ of differential expression i.e. if a gene was 
significantly higher or lower in the ulcerated tumours compared to non-ulcerated 
tumours. At z-score>0, genes were identified as having significantly lower expression 
in ulcerated tumours compared to non-ulcerated tumours. At z-score<0, genes were 
identified as having significantly higher expression in ulcerated tumours compared to 
non-ulcerated tumours. 
5.3.3 Enrichment analysis  
Reactome FIviz was used to perform enrichment analysis to identify the pathways 
enriched for a set of genes that were differentially expressed in ulcerated tumours 
(genes identified by the whole-transcriptome Mann-Whitney U-test described above).  
 
 Results 
5.4.1 Distribution of ulcerated and non-ulcerated tumours in the 
LMC dataset 
The histopathological classification of a melanoma tumour as ‘ulcerated’ or ‘non-
ulcerated’ has been shown to be variable depending on the reviewing pathologist. Thus, 
it was necessary to assess the degree of concordance between two independent 
histopathological classifications of ulceration status. The 702 primary melanomas were 
classified as either ulcerated (n=234) or non-ulcerated (n=468) upon review by the 
clinical pathologists. A subset of the 702 tumours (n=675) were also reviewed 
independently by Dr Sally O’Shea, in our group. The concordance between the 
classification of ulceration status (‘Yes’ or ‘No’) by the clinical pathologists’ (‘Reported’ 
henceforth) and Dr Sally O’Shea (‘SOS’ henceforth) was assessed in the 675 tumours 
whose ulceration status was reported by both (Figure 5.1Table 5.1). Of the 675 
tumours, the ulceration status of 84% of the tumours (n=567) was in agreement 
between the two reports. However, the other 16% of tumours (n=108) were in 
disagreement: 94 tumours were classified as ‘No’ ulceration by SOS but as ‘Yes’ 
ulceration by Reported; 14 tumours were classified as ‘Yes’ ulceration by SOS but as 
‘No’ ulceration by Reported.  
Since the clinical pathologist’s classification of ulceration (‘Reported’) was used to 
classify the tumours based on the AJCC staging system, this measure of ulceration was 
used for analyses henceforth.  
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Table 5.1: Concordance between ulceration status reported by clinical 
pathologist (‘Reported’ ulceration) and ulceration status reported by 
pathologist in our group: Dr Sally O’ Shea (‘SOS’ ulceration) 
** indicates number of overlapping samples 
 Reported No Reported Yes Total SOS ulceration 
SOS No 435 94 529 
SOS Yes 14 128 142 
Total Reported ulceration 451 224 675** 
 
5.1.1 Clinicopathological features associated with ulcerated 
tumours in the LMC  
Clinicopathological features were compared between ulcerated and non-ulcerated 
tumours. The age at diagnosis was significantly higher in participants whose tumours 
were ulcerated compared to non-ulcerated tumours (Table 5.2). There was no 
significant difference in the proportion of ulcerated and non-ulcerated tumours between 
participants who were male or female (Table 5.2). Ulcerated tumours also had a 
significantly higher Breslow thickness compared to non-ulcerated tumours (Table 5.2, 
P=6.2x10-23). Tumours in the rare sites (sun protected sites) were more likely to be 
ulcerated compared to tumours arising on the head (P=0.0003, Table 5.2). However, 
there was no significant difference in the proportion of ulcerated and non-ulcerated 
tumours, in comparing tumours from the head with those from the limbs (P=0.47) or the 
truncal tumours (P=0.62). A significantly higher proportion of ulcerated tumours (54%) 
had reported vascular invasion compared to non-ulcerated tumours (46%) (P=0.0003, 
Table 5.2). The proportion of tumours with absent and non-brisk tumour immune 
infiltration did not vary significantly between ulcerated and non-ulcerated tumours 
(P=0.26). However, the proportion of tumours with brisk immune infiltrate was 
significantly higher among ulcerated tumours (75%) compared to non-ulcerated 
tumours (48%) (P=0.005) (Table 5.2).  
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Table 5.2: Association of clinicopathological features with ulceration status in 
the LMC primary melanomas 
B indicates baseline 
Ulceration association with Regression Coefficient (R) or Pearson’s chi2 (c2) P-val 
Age at diagnosis (years)  R=3.36 0.001 
Sex 
    FemalesB 
    Males  
 
 
c2=1.65 
 
 
0.19 
Breslow thickness (mm) R=1.77 6.2e-23 
Tumour site    
    HeadB 
    Limbs 
    Trunk 
    Rare (sun-protected sites) 
 
c2=0.50 
c2=0.23 
c2=12.85 
 
0.47 
0.62 
0.0003 
Vascular invasion 
   NoB 
   Yes 
 
 
c2=12.54 
 
 
0.0003 
Tumour Immune Infiltrate 
    AbsentB 
    Non-brisk 
    Brisk 
 
 
c2=1.22 
c2=7.73 
 
 
0.26 
0.005 
 
As expected, ulcerated tumours also had a significantly worse prognosis compared 
to non-ulcerate tumours (Figure 5.2). This effect was significant even in a multivariate 
survival analysis i.e. the worse prognosis of ulcerated tumours was independent of age, 
Breslow thickness, tumour site and mitotic number (HR=1.66, P=0.001).   
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Figure 5.2: Difference in survival of participants whose melanomas were 
classified as ulcerated or non-ulcerated at diagnosis 
Hazard Ratio (HR) and P-value (P) are from univariable Cox Proportional Hazards 
model 
 
5.4.2 Transcriptomic correlates of ulcerated and non-ulcerated 
tumours 
5.4.2.1 Genes differentially expressed between ulcerated and non-
ulcerated tumours 
In order to agnostically identify the genes which are significantly differentially expressed 
between the ulcerated and non-ulcerated tumours, a whole-transcriptome Mann-
Whitney U-test was performed. The classification of ulceration status by the clinical 
pathologist (‘Reported’ ulceration) was used for this analysis. Each gene (from a total 
of 20,560 genes) was checked for differential expression between the ulcerated (n=234) 
and non-ulcerated (n=468) tumours, using a Mann-Whitney U-test. Since a total of 
20,560 tests were performed (one per gene), multiple correction had to be applied in 
order to adjust for false discovery. Using the Benjamini-Hochberg method of multiple 
correction, 4660 genes were identified (at FDR<0.05) whose expression was 
significantly different between ulcerated and non-ulcerated tumours. The Mann-
Whitney U-test also produced a z-score, which indicated the ‘direction’ of differential 
expression i.e. if a gene was significantly higher or lower in the ulcerated tumours 
compared to non-ulcerated tumours. At z-score>0, 1979 genes were identified as 
having significantly lower expression in ulcerated tumours compared to non-ulcerated 
tumours. At z-score<0, 2681 genes were identified as having significantly higher 
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expression in ulcerated tumours compared to non-ulcerated tumours. To identify the 
biological pathways enriched for the aforementioned genes differentially expressed in 
ulcerated versus non-ulcerated tumours, pathway enrichment analyses were done, 
described in the following section.  
5.4.2.2 Pathway enrichment for genes differentially expressed in ulcerated 
versus non-ulcerated tumours  
The 2681 genes whose expression was significantly higher in ulcerated tumours 
(compared to non-ulcerated tumours) were enriched for pathways such as mitotic 
prometaphase, signalling by Rho-GTPases, cell cycle checkpoint, mitochondrial 
translation, PLK-signalling and FOXM1 transcription network (top 20 pathways listed in 
Table 5.3, see Appendix T5-1 for full list of pathways). Conversely, the 1979 genes 
which had significantly lower expression in ulcerated tumours were enriched for 
Extracellular matrix organisation, Interferon gamma signalling, cytokine-cytokine 
receptor interaction, IL-12 mediated signalling, PI3K-Akt signalling, TCR signalling in 
naïve CD8 T cells and Focal adhesion (top 20 pathways are listed in Table 5.4, see 
Appendix T5-2 for full list of pathways).  
Table 5.3: List of pathways enriched for genes which are expressed significantly 
higher in ulcerated tumours compared to non-ulcerated tumours 
Pathways P-value 
Mitotic Prometaphase(R) 1.11E-16 
Mitotic Metaphase and Anaphase(R) 1.11E-16 
Signalling by Rho GTPases(R) 2.22E-16 
Mitotic G1-G1/S phases(R) 1.97E-13 
Cell Cycle Checkpoints(R) 2.35E-13 
Synthesis of DNA(R) 2.51E-11 
S Phase(R) 4.18E-11 
Mitochondrial translation(R) 2.80E-10 
Cell cycle(K) 3.76E-10 
HDR through Homologous Recombination (HR) or Single Strand 
Annealing (SSA)(R) 4.00E-10 
PLK1 signalling events(N) 1.04E-09 
RNA Polymerase I, RNA Polymerase III, and Mitochondrial 
Transcription(R) 1.14E-09 
DNA replication(K) 1.29E-09 
Nucleosome assembly(R) 2.06E-09 
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Pathways P-value 
Mitotic G2-G2/M phases(R) 3.63E-09 
Nucleotide Excision Repair(R) 6.54E-09 
Aurora B signalling(N) 6.89E-09 
Validated targets of C-MYC transcriptional activation(N) 8.28E-09 
M/G1 Transition(R) 1.23E-08 
Fanconi anemia pathway(N) 4.29E-08 
ATR signalling pathway(N) 6.74E-08 
 
Table 5.4: List of pathways enriched for genes which are expressed significantly 
lower in ulcerated tumours compared to non-ulcerated tumours 
Pathways P-value 
Extracellular matrix organization(R) 1.45E-11 
Pathways in cancer(K) 9.67E-10 
ECM-receptor interaction(K) 1.38E-09 
Cytokine-cytokine receptor interaction(K) 9.87E-09 
Interferon gamma signalling(R) 3.48E-08 
Beta1 integrin cell surface interactions(N) 1.25E-07 
HTLV-I infection(K) 2.54E-07 
Cell adhesion molecules (CAMs)(K) 3.73E-07 
PI3K-Akt signalling pathway(K) 4.57E-07 
Inflammatory bowel disease (IBD)(K) 4.61E-07 
Axon guidance(K) 1.60E-06 
Chemical carcinogenesis(K) 2.50E-06 
Metabolism of xenobiotics by cytochrome P450(K) 2.79E-06 
Drug metabolism - cytochrome P450(K) 3.67E-06 
IL12-mediated signalling events(N) 3.90E-06 
T cell activation(P) 9.37E-06 
Amoebiasis(K) 1.28E-05 
Toxoplasmosis(K) 1.52E-05 
TCR signalling in naïve CD8+ T cells(N) 1.75E-05 
Staphylococcus aureus infection(K) 2.13E-05 
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 Discussion 
The ulceration status of melanomas tumours is the second most powerful independent 
predictor of survival in melanoma patients, Breslow thickness being the first (312, 313). 
It is not just the presence but also the extent of melanomas which is associated with 
melanoma survival (415). More importantly, ulceration could be a marker of response 
to interferon treatment (419). Though ulceration is an important part of the AJCC staging 
system which has a defined ‘guideline’ for classifying a melanoma as ulcerated or non-
ulcerated, there remains discordance among pathologists with regards to classification. 
One of the reasons for this is the loss of epidermis (which is a defining characteristic of 
ulcerated melanomas) arising from sample handling (the epidermis being prone to 
lacerations during sectioning) rather than ulceration itself. This means that though there 
is overall concordance between pathologists’ classification of ulceration status, there 
still remains a portion of melanomas that are ‘misclassified’. I have described one such 
instance in the LMC primary melanomas, where ulceration status from the clinical 
pathologist (‘Reported ulceration’) and Dr. Sally O’Shea in our group (‘SOS ulceration’) 
were largely concordant, with 84% of tumours being in agreement. However, the 
remaining 16% of tumour were discordant. This observation, in addition to ulceration 
being a potential marker of therapy response, necessitate the identification of genomic 
features that characterise the phenomenon of ulceration. This also served as motivation 
for this project: to identify the clinical, histopathological and transcriptomic correlates 
associated with ulcerated melanomas in the LMC dataset. Though this has previously 
been queried in other datasets using different approaches (Rakosy et al and Jewell et 
al, discussed below), the advantage of using the LMC primaries to interrogate ulceration 
are: 
i. The relatively large sample size of the LMC primary melanomas, enabling 
comparison of ulcerated (n=234) and non-ulcerated (n=468) tumours 
ii. Availability of in silico measures of immune compartments i.e. imputed immune 
cell scores, which would enable identification of specific immune components 
associated with ulceration status.  
iii. The availability of CNA data for a subset of the LMC data enables comparison of 
these features between ulcerated and non-ulcerated tumours.  
As a first step, I identified the clinicopathological correlates of ulcerated tumours 
and report that ulcerated tumours were more likely to be thicker, have more vascular 
invasion and more likely to be from rare (sun-protected) melanomas rather than sun-
exposed melanomas arising in the head. Older participants were also more likely to be 
diagnosed with ulcerated melanomas. These findings indicate that ulceration status is 
associated with clinicopathological features that are associated with poor melanoma 
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prognosis (increased age, thicker tumours, tumours in rare sun-protected sites) and 
hence is a poor predictor of prognosis by itself.  
With the view of interrogating the transcriptomic basis of melanoma ulceration, I 
identified the differentially expressed genes in ulcerated versus non-ulcerated 
melanomas in the LMC, followed by identification of signalling pathways enriched for 
these genes. In doing so, I have compared my findings with those from other reported 
studies. Previous attempts to understand the molecular basis of ulceration have 
revealed that ulcerated melanomas have reduced expression of genes involved in cell 
adhesion such as Desmoplakin, Integrins, Cadherin 1 and fibroblast growth factors 2 
and 3 (417) and proliferation associated pathways such as p53 and Wnt/b-catenin 
signalling (421). In addition, the study by Jewell et al, which is from the Leeds group 
and was based on subset (n=195) of the 703 LMC primary melanomas, identified 
increased histopathological evidence of macrophages in ulcerated tumours. My 
analyses of ulceration in the LMC was concordant with these findings. In that, ulcerated 
tumours (n=235) had significantly higher expression of genes enriched for cell cycle, 
mitotic prometaphase and anaphase, mitochondrial translation and Aurora B signalling. 
PLK1 signalling was also identified, which is concordant with Jewell et al. Interestingly, 
DNA damage repair pathways such as ATR signalling and nucleotide excision repair 
were also identified to have higher expression in ulcerated tumours, which has not been 
previously reported. The pathways identified by Rakosy et al (Wnt signalling and p53 
signalling) though were not part of the top most significant pathways, were still 
expressed higher in ulcerated melanomas in the LMC. Among the pathways that were 
expressed significantly lower in the ulcerated LMC melanomas were integrin-beta 
signalling, extracellular matrix organisation, cell adhesion molecules, IL12 signalling, 
PI3K signalling, IFNG signalling and TCR signalling by naïve CD8 T-cells. Once again, 
these pathways were concordant with the findings from Rakosy et al and Jewell et al, 
who identified cell adhesion processes to be reduced in ulcerated tumours. However, 
the reduced expression of TCR signalling, IL12 and PI3K signalling in ulcerated tumours 
have not been previously reported. Taken together, my analyses suggest a 
concordance with previously studies, with regards to the signalling pathways/processes 
that are associated with the microscopic ulceration of primary melanomas.  
The analyses I have done thus far have provided useful insights with regards to 
identifying the transcriptomic correlates of ulceration in the LMC primary melanomas. 
However, these are preliminary analyses and are meant to complement findings from 
additional approaches, which include: 
i. Comparison of imputed immune cell scores between ulcerated and non-ulcerated 
tumours 
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ii. Using a machine learning-based approach to perform a combined analysis of 
transcriptomic gene expression and CNAs, with the view of identifying the nodal 
genes/CNAs which most significantly characterise melanoma ulceration. This 
approach will use an Artificial Neural Network (ANN) to identify the nodal genes 
and/or CNAs that are best able to distinguish between the profiles of ulcerated 
and non-ulcerated tumours. This would be followed by a Network Inference (NI) 
algorithm, which would identify the relationship (interactions) between the 
aforementioned nodal genes. This is currently work in progress and is being 
performed in collaboration between Prof. Graham Ball (Nottingham Trent 
University) and myself, under the supervision of Prof. Julia Newton-Bishop and 
Prof. Tim Bishop.  
The rationale for electing to use a machine learning-based approach is to account 
for the non-linearity of the transcriptomic and CNA data, which I have previously not 
accounted for in using linear regression models. In my analyses of vitamin D-VDR 
signalling, the linear regression model was used to identify correlates which I 
subsequently was able to validate in vitro and in vivo. However, in the case of case of 
ulceration, there are no known murine/cellular models of ulcerated melanomas. This 
necessitates the use of an approach which would reduce error and increase the 
likelihood of identifying the nodal genes/pathways. Nevertheless, as a validation of the 
findings from the machine learning-based approach, I plan to perform IHC-based 
validation. The findings from this approach, in addition to providing biological insight, 
could serve to identify a biomarker to enable classification of ulcerated melanomas with 
increased reliability.  
Taken together, the aim of this chapter was to describe the rationale and preliminary 
analyses pertaining to identifying the transcriptomic basis of melanoma ulceration in the 
LMC. However, the additional analyses using a machine learning-based approach and 
IHC validation are work in progress and will be pursued by me imminently.  
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Collaborative initiatives 
Being the largest treatment-naïve cohort of primary melanomas for which transcriptomic 
and clinical data are available, the LMC dataset is a useful source to validate in-vitro or 
in vivo-derived hypotheses. To this effect, I have worked with other melanoma research 
groups to interrogate specific questions using the LMC dataset. Though these projects 
were largely related to my own PhD projects, they have been useful learning 
experiences. In that, these projects presented me the opportunity to design and 
optimise a workflow in the LMC dataset, which were best suited to address in vitro or in 
vivo derived hypotheses.  
In this chapter I describe three such projects which I had undertaken on a 
collaborative basis, during the course of my PhD.  
 
 Association of IFNG/IL6 signatures with sun exposure in 
the LMC 
This project was undertaken in collaboration with Dr Amaya Viros (PI) and Ms. 
Katharina Roeck (PhD student) from the CRUK Manchester Institute. Based on the in 
vitro and in vivo findings from Dr Viros’s group, I tested the following hypothesis using 
the LMC dataset: IL6 and Interferon gamma signalling is significantly higher in chronic 
sun-exposed tumours from patients >60 years of age, compared to tumours with 
relatively lower sun exposure. I tested this hypothesis in the LMC using two variables 
which indicate sun exposure: the direct measure of sun exposure (described in Chapter 
3: section 3.3.1.7) and the anatomical tumour site (described in Chapter 3: section 
3.3.1.3). I also tested two different approaches to assess if IL6 and Interferon gamma 
signalling was associated with sun-exposure: a candidate approach and an agnostic 
approach. 
Candidate approach: 200 genes involved in IL6 and Interferon Gamma signalling were 
chosen (from MSigDB: HALLMARK_INTERFERON_GAMMA_RESPONSE) and their 
differential expression between head and trunk tumours in patients >60 years was 
checked. Of the 200 genes, only 11 genes were differentially expressed between head 
and trunk tumours in patients >60 years, none of which were identified in their in vitro 
screens. So alternatively, I created pathway scores for IL6 and Interferon gamma: each 
pathway score was the average expression of the composite genes, across the 703 
167 
 
LMC tumours. However, the ‘IL6 signalling score’ and ‘Interferon gamma signalling 
score’ did not vary significantly between head and trunk tumours in patients >60 years. 
Similarly, neither the IL6 signalling score nor the Interferon gamma signalling score 
correlated significantly with the measure of self-reported sun exposure.  
Agnostic approach: Whole genome differences between tumours on the head and 
those on the trunk was assessed (Mann Whitney U-test). The head and truncal tumours 
were chosen as comparison groups because these were considered to be the most 
sun-exposed and least sun-exposed respectively. Upon using a linear regression model 
and a multiple correction threshold of FDR<0.05, 802 genes were found to be 
differentially expressed between head and trunk tumours. The signalling pathways 
enriched for these genes were assessed using Reactome FIViz and are summarized 
as follows: i) pathways enriched for genes whose expression is higher in tumours on 
the head (compared to truncal tumours) include mitotic prophase and metaphase, cell 
cycle checkpoint, Wnt signalling pathways and ATM pathway. ii) pathways enriched for 
genes whose expression is higher in tumours on the trunk (compared to those on the 
head) include PI3K-Akt signalling pathway, focal adhesion, Eukaryotic translation 
initiation and Natural killer cell-mediated cytotoxicity. Though this particular analysis 
provides significant insight into the transcriptomic differences between tumours on the 
head (‘sun-exposed’) and trunk (‘non sun-exposed’), the IL6/Interferon gamma pathway 
was not amongst those identified.  
Based in the analyses described above, it was concluded that there was no 
substantial evidence for the hypothesis that IL6 or Interferon gamma signalling vary with 
respect to sun exposure in the LMC primary melanomas.  
 
 Midkine signatures in the LMC 
This project was undertaken in collaboration with Dr Marisol Soengas (PI) and Dr David 
Olmeda (Post-doctoral fellow) from CNIO, Spain. The work done by Dr Soengas’s group 
was focussed on the secretory protein Midkine (coded for by the gene MDK), which 
they had shown to be a systemic inducer of neo-lymphangiogenesis that defines patient 
prognosis (422). More recently, the group had generated Gain of function (GoF) and 
Loss of function (LoF) MDK “signatures” from melanoma cell lines which were 
genetically altered to be either MDK-null or overexpress MDK. The signatures were 
composed of genes which were significantly upregulated or downregulated in response 
to MDK loss. 
The MDK signature derived by the Soengas group was applied to the 703 Leeds 
primary tumours transcriptome. This classified each tumour into either ‘High-MDK’ or 
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‘Low-MDK’ cluster. This classification was performed by Dr. Jeremie Nsengimana in 
the Leeds group. All subsequent analyses of transcriptomic and clinical features in 
MDK-high versus MDK-low tumours were performed by me.  
The High-MDK tumours had significantly better prognosis than Low-MDK tumours. 
To better understand why this protective effect exists, I used two approaches: 
6.2.1 Check if the immune contexture is different in the Low vs High 
MDK tumours 
I used two immune signatures to assess this:  
a) Angelova/Pozniak immune scores- derived by our group (Joanna Pozniak) and is 
based on unique gene expression of 27 immune cell types. The High-MDK cluster 
appears to have a higher proportion of ‘high-immune’ tumours compared to Low-
MDK cluster. Because of this significant difference, I checked which of the 27 
immune cell scores best define the MDK clusters. 26 immune cell scores were 
significantly higher in High-MDK cluster (compared to Low-MDK cluster). 
b) The TCGA classification-  These are published molecular phenotypes which have 
been applied to the 703 primaries, thus classifying each tumour into either 
Immune, Keratin or MITF-low subtypes. The High-MDK cluster has a higher 
proportion of Immune subtype tumours compared to Low-MDK cluster. 
6.2.2 Check for whole-genome differences to agnostically identify 
genes/pathways that vary between Low and High MDK 
tumours 
The genes that vary significantly between Low and High MDK clusters were identified 
using a whole genome Mann-Whitney test. The pathways corresponding to these genes 
were identified using Reactome FIViz enrichment. The High-MDK cluster appears to 
have significantly higher expression of genes corresponding to pathways such as 
NFKB, TLR, IL12-mediated, TRAIL, MAPK and TNF signalling. The nodal genes 
involved in these pathways were STAT3, HLA-DRA, REL, JUNB, MAPK134 (slide8).  
Conversely, pathways such as Mitotic Metaphase and Anaphase, mitochondrial 
translation and mitochondrial translation were higher in low-MDK tumours. The nodal 
genes involved in these pathways were PSMD8, NDUFA7, UBA52, MRPL14 and 
RPS27A 
Similarly, The MDK signature was applied to the TCGA metastatic tumours. This 
classified each tumour into either ‘High-MDK’ or ‘Low-MDK’ cluster. Converse to the 
findings from the LMC primary melanomas, the High-MDK tumours had significantly 
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worse prognosis than Low-MDK tumours. To better understand why this effect exists, 
I used the exact same approaches as described for the Leeds primaries 
- Angelova/Pozniak immune scores: contrary to the Leeds data, the proportion of 
high/low/intermediate immune tumours does not vary between High-MDK and 
Low-MDK clusters. However, High-MDK cluster has significantly higher NK56dim, 
pDC and Th17 cells scores. Also, High-MDK cluster has significantly lower central 
memory and effector memory CD8 T-cells. 
- The High-MDK cluster appears to have significantly higher expression of genes 
corresponding to pathways such as mitochondrial translation, oxidative 
phosphorylation, TNF and VEGF signalling. The nodal genes involved in these 
pathways are RELA, AKT1, UBA52. Conversely, pathways such as Mitotic 
Metaphase/Anaphase and TLR signalling were higher in low-MDK tumours. The 
nodal genes involved in these pathways are RPS27A and HDAC2.  
In summary, High-MDK metastatic tumours have worse prognosis in the LMC, 
which is contrary to the TCGA metastatic melanomas. The LMC primary melanomas 
with high-MDK also had increased immune cell scores for NK56dim, pDC and Th17 
cells, while having lower central and effector memory CD8 cell scores. Pathways such 
as TNF, VEGF signalling and oxidative phosphorylation are upregulated in these 
tumours.  
 
 G9A in the LMC 
This project was undertaken in collaboration with Dr David Fisher (PI) and Dr. Shinichiro 
Kato (Post-doctoral fellow) from Massachusetts General Hospital, Harvard Medical 
School, USA. The design and execution of analyses related to this project were 
performed jointly by myself and Ms. Joanna Pozniak (PhD student in the group). The 
focus of the research done in Dr Fisher’s group was the methyltransferase G9A (also 
known as EHMT2), which was shown to play a role in silencing tumour suppressor 
genes and increasing the expression of genes involved in tumour survival. However, 
the role of G9A as a direct oncogenic driver has not previously been described, which 
was the primary hypothesis tested in this project. In vitro data from Dr Fisher’s group 
indicated that loss of G9A expression in melanoma cells resulted in reduced expression 
of Wnt/b-catenin target genes (such as Myc and Lef1) and increased expression of Wnt 
antagonists (such as Dkk1, Sfrp1 and Wnt5a). These in vitro observations prompted 
the assessment of the potential role of G9A in the LMC primary melanomas. To this 
effect, I assessed if G9A CNAs varied significantly across the 6 CICs (consensus 
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immunome clusters), which have been previously described by our group to identify an 
immunologically “cold” tumour subtype in the LMC (Consensus Immunome Cluster 4- 
CIC4) of which 73% was associated with increased Wnt/b-catenin signalling (316). My 
analysis revealed that G9A copy number was significantly higher in CIC4 i.e. G9A copy 
number was positively associated with increased Wnt/b-catenin signalling in the LMC 
primary melanomas. This observation was concordant with the in vitro findings by the 
Fisher group. G9A was also prognostically significant: participants whose tumours had 
low G9A copy number had a significantly improved survival compared to those with 
higher G9A copy number. Moreover, an agnostic analysis revealed that Wnt/b-catenin 
signalling was the most significantly upregulated pathway in tumours with high G9A 
copy number compared to tumours with low G9A copy number. Taken together, my 
analyses indicated a concordance with the in vitro findings for a positive relationship 
between G9A and Wnt/b-catenin signalling.  
These findings were written-up, to be part of a manuscript, which is currently under 
review.  
 
 Discussion   
The approach I have used to address questions pertaining to my own PhD projects 
(described in Chapter 3, 4 and 5) involves the interrogation of primary melanoma-
derived transcriptomic data, which was followed by in vitro and in vivo functional 
validation studies. On the contrary, the approach which I adopted to address the 
collaborative projects involved the testing of in vitro-derived hypotheses using the 
primary melanoma transcriptome. The outcome of adopting this approach was variable, 
depending on the question which was addressed. While some findings were concordant 
with the in vitro findings, some others showed lack of evidence to support the in vitro 
evidence.  
For instance, in the case of the project assessing the effect of Midkine in the LMC 
primary melanomas, the association of MDK with prognosis was found to be reversed 
in primary melanomas (my analyses) compared to metastatic melanomas (findings from 
Dr Soengas’s group). Similarly, my analyses identified specific signalling pathways and 
imputed immune cell scores associated with MDK expression, which were different from 
those identified in metastatic melanomas. The potential explanation for these 
differences could be that MDK could have context-specific effects on the tumour 
microenvironment, which is amenable to the state of progression of the tumour: the 
metastatic melanoma TME is different from primary melanoma TME. However, this 
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hypothesis of context-specific role for MDK in primary versus metastatic melanomas, 
needs further testing.  
In the case of the project testing the association of IL6/Interferon gamma signalling 
with sun exposure and age, the lack of evidence for an association could be owing to 
differences in experimental settings. However, an interesting observation which arose 
from this analysis was the list of genes and pathways which are differentially expressed 
in sun-exposed versus non sun-exposed tumours. Though this list did not include IL6/ 
Interferon gamma signalling (which was the expectation), among the identified 
pathways was the ATM pathway, which plays a role in DNA damage response and was 
found to be highly expressed in tumours on the head (sun exposed tumours). Thus, the 
identification and validation of anatomical site-specific differences in tumour gene 
expression could lead to potentially novel findings and hence requires further 
interrogation.  
The G9A project revealed perhaps the strongest evidence for an in vitro-derived 
hypothesis being validated using the LMC transcriptome. This suggests the role for G9A 
as an oncogenic driver, whose expression is associated with melanoma prognosis as 
well as with the Wnt/b-catenin signalling pathway. 
Taken together, the opportunity to adopt, optimise and derive conclusions from both 
these approaches has been a valuable learning experience in the analysis of omic data, 
with the view of interpretation biological questions.  
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Discussion 
Biological systems are complex. At a cellular level, the complexity of biological systems 
is characterised in part by dynamic changes in the ‘coding components’ of any given 
cell, i.e. changes in the structure, level and function of DNA and mRNA. The dynamics 
of these changes are spatiotemporally controlled. In that, the localisation and temporal 
sequence of events are crucial in dictating cellular function and homeostasis.  In other 
words, changes in the genetic code (‘genotype’) have a consequent effect on structure 
and function (‘phenotype’). Understanding this genotype-phenotype relationship is one 
of the key concepts underlying the use of gene expression technologies and pipelines 
to understand cellular function.  
This is particularly the case in cancer, which is typically characterised by 
aberrations in the DNA. Perturbations in homeostatic cellular function is one of the 
defining characteristics of cancer. Thus, efforts to identify the genomic basis of various 
types of cancer is being actively explored with the aim of understanding the cause, the 
progression of the cancer and eventually being able to improve the treatment of the 
disease. One of the high throughput technologies used in cancer research, is 
transcriptomics. Among the earliest transcriptomic technologies developed to quantify 
the transcriptional programme of a cell was the microarray technology. To explain very 
briefly, the expression of a gene (composed of a specific target sequence) is quantified 
by the measure of fluorescence emitted from the hybridisation of the target sequence 
to a ‘probe’, which is a sequence of nucleic acids complementary to the target gene’s 
sequence. Each probe is ‘spotted’ on a surface, producing a chip which contains 
multiple probes and is hence capable of quantifying an array of genes. The workflow of 
a typical microarray experiment is depicted in Figure 7.1. In reality, this process involves 
multiple steps, each of which is subject to various sources of variability and error. Thus, 
the use of microarrays to generate gene expression profiles from a population of cells 
involves multiple considerations which need to be identified and addressed in order to 
produce a reliable readout of the gene expression profile.  
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Figure 7.1: Overview of the workflow of a typical microarray experiment. 
Adapted from Science behind Non-Specific Science; For Molecular Biologist & 
Bio-technologist, (423). 
The use of microarrays in cancer research has been prevalent since the technique 
was first described in 1995 (424, 425). Oligonucleotide and cDNA microarrays are 
amongst the commonly used microarrays used to generate ‘gene expression profiles’ 
of tumour samples. The range of information gleaned from the gene expression profiles 
is dependent on the range of the probes spotted on the microarray. For instance, a 
‘cancer gene panel’ could include a set of genes which are known to be significant 
contributors to the cancer phenotype. Alternatively, a ‘whole-genome’ array would 
include probes pertaining to all genes known to be expressed in the genome of a 
specified organism. This type of array is subject to updates, depending on the 
improvements made to the reference genome. Some of the common applications of 
these microarrays in cancer research can be broadly classified into the following 
categories (adopted from (426-428)), where ‘classes’ refer to groups of samples that 
are being interrogated.  
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- Class comparison: the comparison of gene expression profiles between 
classes, to identify the genes which are differentially expressed between the 
predefined classes. For instance, comparison of gene expression profiles from 
tumours that carry a particular mutation with those that don’t. In the case of my 
thesis, identifying genes that vary significantly between tumours with a) high 
VDR compared to low VDR expression and b) ulceration compared to those with 
no ulceration  
- Class prediction: the prediction of sample sub-groups based on their gene 
expression profiles, into biologically or clinically relevant groups i.e. predicting if 
a sample belongs to a particular group depending on its gene expression profile. 
For instance, using a gene expression signature which best predicts response 
to therapy in phase II studies (gene signature varies between responders and 
non-responders) to predict response in phase III studies.  
- Class discovery: identification of discrete subsets (within a set of samples) 
based on the gene expression profiles. This is often used to estimate disease 
heterogeneity on the genomic level. For instance, identification of subgroups of 
patients whose tumours share a similar gene expression profile.  
These approaches have been proven to be powerful tools in both basic and 
translational research. However, like every experimental technique it comes with its 
own set of drawbacks, which need to be taken into consideration when using microarray 
data to address biologically-relevant questions. The LMC transcriptome was generated 
using the Illumina WG-DASL-HTv12.4, from FFPE-derived RNA samples. The following 
table (Table 7.1) outlines the general issues associated with microarray analysis, along 
with the steps implemented to circumvent the different potential issues while processing 
and analysing the LMC transcriptome.  
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Table 7.1: Common issues associated with microarray experiments and the 
actions implemented to resolve issues 
Common issues associated with 
microarray experiments 
Action implemented to resolve this 
issue during the generation of the 
LMC transcriptome 
“Noise” in the data generated 
requiring normalisation whilst retaining 
biological differences. “Noise” might 
occur due to variation between 
samples: 
• As a result of variation in age 
of the block (RNA degradation) 
• Differences between different 
laboratory personnel’s techniques 
in extracting RNA 
• Experimental variability due to 
batch effect 
• Other tissue-specific technical 
issues, as discussed below 
• The associations between top 
principal components and technical 
variables such as batch, age of FFPE 
block and RNA concentration were 
assessed. 
 
• The technical variables found to 
be associated with the top 
components were ‘adjusted-out’. 
 
• Outliers were detected using 
normalised full intensity plots 
Mapping probes to genes accurately, 
while accounting for probes which 
hybridise with low specificity among 
samples.  
I have implemented a ‘probe to gene’ 
mapping strategy which ensures that 
probes which do not detect multiple 
splice forms (if they exist for a given 
gene) and are not reliably detected 
across the majority of the LMC samples, 
are not used for analysis. 
Identifying biologically significant 
differences between classes rather 
than ‘background’ differences 
• Use of stringent multiple 
correction thresholds to reduce the 
probability of the finding being by 
chance. 
• In silico validation strategies as 
well as in IHC and/or in vitro 
validation of findings 
• Validation in different data sets 
to reduce overfitting or bias of 
selection of tumours  
 
In the case of the LMC transcriptome, the primary reason for electing to use the 
Illumina WG-DASL-HTv12.4 microarray was because the LMC tissue samples were 
formalin fixed. The main advantage of using FFPE melanoma samples is the possibility 
of sampling melanoma samples which would otherwise be too small to be sampled from 
cryopreservation. The disadvantage of FFPE-based sampling is that the formalin-fixing 
process is known to degrade and produce low yields of RNA from source tissue (429). 
The Illumina DASL array is designed to interrogate partially degraded RNA as well as 
intact RNA (430) and hence was the chosen to generate the LMC transcriptome. 
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In addition to the above tabulated ‘common considerations’ which were addressed 
during the generation of the LMC transcriptome, there were specific sources of error, 
as summarized below: 
- Participants were recruited at different time periods, so the corresponding FFPE 
tumour samples were of varying age. The age of the FFPE tumour block could 
dictate the degree of RNA degradation 
- Melanin, which is abundant in melanomas, is known to inhibit the polymerase 
activity, thus affecting the assay readout. 
- Differences in technique between technicians extracting RNA, although standard 
operating procedure was used. 
The LMC transcriptome was generated from tumour cores (TMA-derived), meaning 
that the transcriptomic data represented a ‘core’ region of the tumours. Though this 
approach was performed to reduce bias, by selecting to core the least inflamed part of 
the tumour, it involves the following issues: 
- Bias towards sampling thicker tumours: if the tumours were not thick enough to 
‘punch a hole’ using the TMA needle, then these tumours were not selected. 
- In the ‘thick’ tumours which permitted sampling, it was not always possibly to 
sample from the thickest part of the tumour, since the tissue was not 
homogenously stable throughout the block 
- Necrotic tumours were not sampled and hence are not represented in the LMC 
transcriptome 
Having taken into account the potential issues associated with microarray data 
analysis, I have primarily used microarray-based gene expression profiles from the 
LMC primary melanomas along with clinical data, with the view of addressing specific 
aspects of melanoma biology. The general ‘pipeline’ I have used throughout my thesis 
is pictorially depicted in Figure 7.2. Depending on the research question to be 
addressed, I modified this workflow to ‘customise’ it.  
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Figure 7.2: Overview of analysis pipeline which I have used in my PhD projects 
 
  
Formulate hypothesis to be queried using the LMC data
Is tumour VDR expression associated with melanoma survival?
What are the genes whose expression correlates significantly with VDR expression?
Is vitamin D protective for melanoma death within the context of VDR expression?
What are the genes that are significantly differentially expressed between ulcerated and non-ulcerated tumours?
Implement statistical model that would best address the question
Eg. Linear regression, univariable/multivariable regression analysis, univariable/multivariable survival analysis
Identify data set on which analysis will be performed
Identify number of samples for which relevant clinical data is available and hence can be used for statistical analysis
If checking candidate gene (such as VDR) check distribution and identify outliers
If checking clinical variables on a continuous scale (eg. Serum vitamin D), check distribution and identify outliers
Check for missing data 
Interpret results from the output of statistical model
Implement multiple correction threshold for whole-genome correlation analyses
Use Reactome FIViz to identify the pathways/biological processes associated with the identified genes 
Validate observations in-silico
Use imputed immune cell scores, expression of cytokine/chemokine panel and reported melanoma 
signatures derived from other studies to check if observations from LMC agree with these independent 
measures 
Validate observations in vitro and in silico
The specific observations from LMC which are replicated in the TCGA melanoma dataset and are also 
concordant as per in-silico validation, are then validated in vitro and in vivo
Repeat the exact same statistical analyses using TCGA melanoma data set
In cases where data is available, use the TCGA data to replicate the LMC observations by 
implementing the exact same pipeline and thresholds used on the LMC
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 Bioinformatics-based approaches used in this thesis 
The primary approach I have taken with regards to biological interpretation of a given 
set of genes was to perform pathway enrichment analysis using Reactome FIViz. This 
step was of importance because the pathways identified by enrichment analysis 
informed the subsequent steps of my analysis. For instance, the enrichment analyses 
performed on genes correlated with tumour VDR expression, the identified pathways 
instructed the hypothesis to be tested in vitroand in vivo. Thus, it was necessary to 
choose an enrichment tool/database which enabled the implementation of stringent 
thresholds, thus minimising the change of false discovery. Upon comparing multiple 
pathway/ gene set enrichment tools such as STRING, Metacore and KEGG, I elected 
to use Reactome FIViz owing to the fact that it was based on the Functional Interaction 
network. The FI network is composed of pairwise gene-gene/protein-protein interaction 
annotations from both high-coverage, low-reliability and low-coverage, highly-curated 
databases. Performing enrichment analysis on the ‘background’ of this FI network 
enabled me to reliably identify the pathways enriched for in my genes of interest. 
However, it is to be noted that I have used lists of genes to perform pathway enrichment. 
This does not account for the variation in expression of these genes. For instance, if a 
set n genes are identified by Reactome FIViz to be enriched for a Pathway x, this does 
not account for the variable contribution of each of the n genes. One of the solutions for 
this issue is the use of another feature of Reactome FIViz: the ‘Gene Expression 
analysis’. This feature allows the user to submit a particular set of genes and their 
corresponding gene expression, which are used to identify sub-networks (‘Modules’) of 
genes that are known not only to be functionally related (as per current literature) but 
also are highly correlated with each other in the input data set. This is done using 
Markov Clustering. Furthermore, every sample in the data set can be assigned a 
Module Score (mean gene expression value for all genes in a given module) enabling 
estimation of a module-specific impact on melanoma survival i.e. if a Module is 
protective for melanoma death. Though I have explored this approach in detail, I have 
not used it for the analyses described in this thesis.  
I have also used reported melanoma signatures to classify the LMC primary 
melanoma transcriptomes. These signatures are composed of biologically-relevant sets 
of genes and were derived from datasets independent from the LMC. This approach 
enabled the ‘replication’ of the described molecular phenotypes. While this approach 
provides valuable insight with regards to the broadly classifying the LMC 
transcriptomes, it did not offer much insight in terms of the composite pathways. For 
instance, the overlap between ‘pigmentation’ and ‘proliferation’ subgroup derived from 
the Lund melanoma subtypes was not evident. It was owing to this reason that I used 
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these signature-derived molecular subtypes to validate my findings, rather than as my 
primary mode of hypothesis generation.  
I have used imputed immune cell scores in my thesis, with the view of identifying 
the specific immune cell components associated with a particular feature. For instance, 
if immune-related pathways were identified agnostically to be correlated with a 
particular feature (say VDR expression, ulceration status etc), then I used the imputed 
immune cells scores to identify which particular immune cells could be associated. This 
has been a useful approach, but comes with a caveat, which is the process of 
generating the immune cells scores themselves. While the approach described in 
Pozniak et al is largely robust, issues such as lack of inverse correlation between cell 
types with known inhibitory function (such as T-regs and MDSCs) and T-cells was 
present. Nevertheless, the immune cell scores were a valuable measure for hypothesis 
validation.  
In Chapter 5, which focuses on understanding the transcriptomic basis of 
ulceration, I have presented the findings produced by adopting the ‘workflow’ described 
in Figure 7-B. However, in addition to this approach, I also elected to use a machine 
learning-based approach, which I have not described in this thesis, owing to paucity of 
time in performing and interpreting the results. However, the rationale for choosing to 
use the machine learning-based approach are: 
1. The necessity to use a statistically robust approach which takes into account the 
non-linearity of biological data (in this case: the tumour transcriptomic data) by 
implementing a non-reductionist approach.  
2. In terms of validation, the largest primary melanoma data set besides the LMC, is 
the TCGA data. However, ulceration status is not well documented for these 
tumours. So, validating findings from the LMC in an independent cohort can prove 
to be difficult. Hence, an approach which would identify the genes/CNAs which 
best predict ulceration status could circumvent this issue. Combined with 
validation of the identified nodal genes using IHC, this approach could identify 
important genomic features associated with melanoma ulceration.  
3. The use of the machine learning-approach enables the assessment of the 
ulceration phenomenon on the level of both gene expression and CNAs i.e, the 
combined data of gene expression and CNAs were used to interrogate and assess 
the most significant features contributing to ulceration.  
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 Vitamin D signalling in the LMC 
The association of serum vitamin D levels with stage at diagnosis of melanoma and 
survival has been reported in epidemiological studies where higher serum vitamin D 
was associated with thinner tumours and better survival (169, 288, 292).  In-vitro studies 
also indicated an anti-proliferative response in melanoma cell lines to vitamin D 
treatment. More recently, a study by Weinstein et al assessed the effect of serum 
25(OH)D years prior to cancer diagnosis on survival after cancer diagnosis of multiple 
cancer types. The findings from this study were concordant with previous observations, 
in that: melanoma patients with higher 25(OH)D prior to diagnosis experienced 
significantly longer survival after cancer diagnosis (431). Though there are multiple 
studies that have looked at the association of serum vitamin D with cancer incidence 
and/or mortality, there are relatively fewer studies which have assessed the effect of 
vitamin D supplementation on cancer risk. To this effect, a recent study reported 
findings from a randomised clinical trial of vitamin D supplementation in adults in New 
Zealand. Participants received 100,000 IU of vitamin D3 monthly for a median of 3.3 
years. The aim of this study was to assess if vitamin D supplementation contributes to 
cancer prevention. This study reported that the frequency of cancer diagnoses was not 
statistically significant between participants who received the vitamin D bolus (163 
cancer diagnoses out of 2550 participants: 6.4%) and placebo (165 cancer diagnoses 
out of 2558 participants: 6.5%). The authors conclude that based on their findings, high-
dose vitamin D supplementation does not contribute to cancer prevention. However, 
they acknowledge that different dosages and duration of intake could have an effect i.e. 
the administered vitamin D bolus and 3 years of follow may not be suitable to influence 
physiologically relevant levels. The study also does not allude to number of participants 
who were deficient for serum vitamin D at the start of the study.  
Nevertheless, the necessity to understand the role of vitamin D signalling in 
melanomas is owing to the following reasons: 
- Sun avoidance in melanoma patients is a serious issue and clarifying the role of 
vitamin D can help drive lifestyle changes that could benefit the patient. 
- The concerns around the precise definitions of physiologically relevant levels of 
‘low’ and ‘high’ serum vitamin D are not fully understood and need to be clarified. 
- If proven to be efficient, vitamin D could satisfy the necessity for low-toxicity 
adjuvants in melanoma therapy 
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In the case of my PhD project, the LMC dataset was an ideal data set to explore 
the complex relationship between vitamin D and melanoma owing to the following 
reasons:  
i) The availability of serum vitamin D and tumour-derived VDR expression at 
diagnosis enabled me to study the effects of both the ligand and the receptor, 
being able to explore both the individual and synergistic effects. 
ii) The serum vitamin D levels, though available only at a single time point: at 
diagnosis, was adjusted for seasonal effects which reduced the effect of seasonal 
variations on comparisons between individuals and because of the hypothesis that 
the trough level might be more important. 
iii) Well curated clinical data pertaining the tumours such as Breslow thickness, 
mitotic rate and TILs enabled me to estimate of any of the observed effects on the 
transcriptomic level could be confounded by any of these variables.  
iv) Data pertaining to patient survival, in particular the Melanoma Specific Survival 
information, enabled me to assess the prognostic significance of variables such 
as VDR expression and serum vitamin D levels on death from the cancer rather 
than overall death rates. The clinical data mentioned above, also enabled me to 
estimate if the effects on survival were independent of these factors (using 
multivariate analyses). Low vitamin D levels are reported to be associated with a 
number of different health problems so that distinguishing melanoma deaths from 
any cause of death was very important. 
v) Finally, the sample size of the data set is the largest melanoma transcriptomic 
data set to date. This enabled performance of stratified analyses (for example, the 
vitamin D-VDR subgroup analysis) without a significant adverse effect on sample 
size.  
 
To conclude my findings on this project: this project integrates clinical, transcriptomic, 
histopathological and functional validation data to provide a novel insight into vitamin 
D-VDR signalling in melanoma. I report evidence that, in addition to vitamin D-mediated 
protective effect which is apparent in a subset of participants, ligand-independent VDR-
expression bestows a prognostic benefit for melanoma patients with evidence to 
support a causal relationship involving inhibition of Wnt/b-catenin signalling and 
increasing immune cell infiltration.  
The primary reasons for studying ulceration in the LMC primary melanomas, as part 
of my thesis was to gain a deeper understanding of the biological basis of ulceration. 
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This approach has been relatively (relative to the vitamin D-VDR project) exploratory 
and is work in progress.  
The collaborative initiatives which I have undertaken during my PhD have been, in 
a manner of speaking, the opposite approach to the ‘pipeline’ I’ve used in my projects. 
In that, I have sought evidence for hypotheses generated from in-vitro and in-vivo 
experiments, in the LMC primary transcriptomes.  
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Appendix A 
A.1 Tables of output from enrichment analyses performed in 
Chapter 3 
In the case of tables containing output from enrichment analyses, pathways are 
presented based on variable FDR thresholds. The reason for this being, repetitive 
pathways appear at lower thresholds and hence the necessity to drop the display of 
these pathways.  
Table T3-2: Differential expression of 154 cytokine and chemokine genes 
compared between the high and low vitamin D participants in the 
intermediate-VDR group. 
P-value derived from T-test and FDR (False Discovery Rate) derived from 
Benjamini-Hochberg method for multiple correction. 
Cytokine/ 
chemokine 
genes 
P-value Mean expression in high vitamin D group 
Mean expression in 
low vitamin D group FDR 
CXCL2 0.0002 7.801 8.363 0.032 
CCL3L3 0.0035 7.763 8.377 0.231 
IL24 0.0078 7.796 8.431 0.346 
IL2RA 0.0197 7.697 8.137 0.656 
IL16 0.0324 7.872 7.669 0.862 
CCL5 0.0357 7.914 8.282 0.792 
IL10RA 0.0382 7.824 8.164 0.727 
CCL8 0.0467 7.804 8.222 0.776 
IL1F10 0.0758 8.421 8.998 1.000 
CXCL1 0.0774 7.888 8.147 1.000 
CCL7 0.0849 7.980 7.778 1.000 
CXCR4 0.0868 7.812 8.080 0.962 
IL12RB2 0.0871 7.806 7.457 0.891 
CXCR6 0.0888 7.668 8.119 0.843 
IL6 0.0934 7.641 8.052 0.828 
IL21R 0.1035 7.999 8.343 0.860 
IL2RG 0.1093 7.921 8.237 0.855 
IL7R 0.1165 7.888 8.258 0.861 
IL32 0.1217 7.799 8.049 0.852 
IL22 0.1234 7.883 7.756 0.820 
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Cytokine/ 
chemokine 
genes 
P-value Mean expression in high vitamin D group 
Mean expression in 
low vitamin D group FDR 
CCL3L1 0.1271 7.984 8.174 0.805 
CCR3 0.1274 7.856 7.749 0.770 
XCR1 0.1305 7.883 8.061 0.754 
IL18RAP 0.1313 8.034 8.355 0.728 
CCR7 0.1465 7.992 8.390 0.780 
CCL4L1 0.1477 7.815 8.127 0.756 
CCL2 0.1518 7.819 7.972 0.748 
IL13RA2 0.1612 7.820 7.976 0.766 
IL21 0.1631 7.956 7.823 0.748 
IL23A 0.1656 7.864 7.686 0.734 
IL1R1 0.1670 7.842 7.995 0.716 
IL31RA 0.1699 7.884 7.778 0.706 
CCR4 0.1726 7.964 8.262 0.695 
IL1RAPL2 0.1819 7.955 7.796 0.712 
IL17A 0.1851 7.814 7.905 0.703 
IL1RAP 0.1963 7.768 7.594 0.725 
IL1A 0.2010 7.933 8.108 0.723 
IL17RD 0.2014 7.804 7.875 0.705 
CXCL9 0.2041 8.208 8.594 0.696 
IL12RB1 0.2066 7.823 8.127 0.687 
IL15RA 0.2068 7.968 8.148 0.671 
CXCR3 0.2089 8.014 8.242 0.661 
CX3CR1 0.2182 7.904 8.102 0.675 
CXCL5 0.2488 7.880 7.986 0.752 
CCR1 0.2548 7.841 7.967 0.753 
IL15 0.2675 7.857 8.032 0.773 
IL34 0.2703 7.856 8.052 0.765 
IL22RA1 0.2796 7.905 7.823 0.775 
IL19 0.2838 7.858 7.754 0.770 
CCL3 0.2938 7.830 8.050 0.782 
IL2 0.2941 7.891 7.806 0.767 
IL3 0.2978 7.809 7.892 0.762 
CXCL3 0.3075 7.776 7.889 0.772 
IL13RA1 0.3148 7.759 7.846 0.775 
CCL1 0.3189 7.834 7.908 0.771 
IL27 0.3209 7.811 7.919 0.762 
CCR6 0.3246 7.832 7.839 0.757 
IL5RA 0.3248 7.878 7.802 0.745 
IL2RB 0.3462 7.924 8.104 0.780 
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Cytokine/ 
chemokine 
genes 
P-value Mean expression in high vitamin D group 
Mean expression in 
low vitamin D group FDR 
IL9 0.3503 7.841 7.771 0.777 
IL17RE 0.3586 7.706 7.540 0.782 
CXCL16 0.3663 7.889 7.956 0.786 
CCL21 0.3704 7.633 7.428 0.782 
IL11 0.3762 7.980 7.875 0.782 
IL17B 0.3777 7.959 7.794 0.773 
IL31 0.4015 7.771 7.838 0.809 
CCL23 0.4087 8.039 8.215 0.811 
IL22RA2 0.4295 7.876 7.818 0.840 
IL1RN 0.4297 7.948 8.141 0.828 
CXCL10 0.4380 7.803 8.032 0.832 
CXCL11 0.4445 8.385 8.583 0.833 
IL33 0.5049 7.783 7.903 0.933 
IL17RA 0.5178 7.741 7.810 0.943 
XCL1 0.5224 7.797 7.751 0.939 
CCR2 0.5280 7.931 7.843 0.936 
CCL14 0.5399 7.959 8.095 0.945 
CCRL2 0.5525 7.842 7.887 0.954 
IL1R2 0.5819 7.915 7.868 0.992 
CCL18 0.5943 7.883 7.994 1.000 
CCL28 0.5973 7.827 7.867 0.993 
PITPNM3 0.6013 7.900 7.975 0.987 
IL5 0.6091 7.810 7.849 0.988 
CCR8 0.6202 7.960 8.016 0.994 
IL25 0.6294 7.832 7.868 0.997 
CCL26 0.6305 7.950 8.001 0.987 
IL4 0.6348 7.782 7.749 0.982 
IL17D 0.6354 7.590 7.692 0.971 
CCL16 0.6383 7.965 7.912 0.965 
CCL25 0.6447 7.898 7.963 0.963 
CCR5 0.6496 7.838 7.796 0.960 
IL12B 0.6547 7.959 8.001 0.957 
CCR10 0.6664 7.797 7.862 0.963 
IL20RA 0.6687 8.069 8.010 0.956 
CCL22 0.6731 8.051 7.957 0.952 
IL27RA 0.6751 7.907 7.839 0.945 
CCL24 0.6791 7.912 7.986 0.941 
IL18R1 0.6793 7.915 7.840 0.931 
IL6R 0.6907 7.797 7.837 0.937 
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Cytokine/ 
chemokine 
genes 
P-value Mean expression in high vitamin D group 
Mean expression in 
low vitamin D group FDR 
IL10 0.7099 7.832 7.810 0.954 
CCL13 0.7101 7.879 7.961 0.944 
IL20RB 0.7218 8.104 8.029 0.950 
CCL19 0.7349 7.825 7.920 0.958 
IL3RA 0.7390 7.858 7.826 0.954 
IL12A 0.7419 7.826 7.856 0.949 
CCL17 0.7424 7.965 7.916 0.940 
IL18 0.7493 7.918 7.891 0.940 
IL7 0.7581 7.850 7.872 0.942 
IL17RC 0.7602 7.786 7.757 0.936 
IL13 0.7602 7.804 7.774 0.928 
IL11RA 0.7821 7.724 7.764 0.946 
CX3CL1 0.7830 7.789 7.755 0.938 
IL1B 0.7935 7.726 7.778 0.942 
CXCL14 0.7941 7.748 7.694 0.935 
CXCL17 0.8037 8.132 8.092 0.938 
IL6ST 0.8080 7.772 7.796 0.934 
CCL20 0.8113 8.030 7.993 0.930 
IL17F 0.8160 7.900 7.927 0.928 
CXCL12 0.8241 7.843 7.873 0.929 
IL1RL1 0.8377 7.846 7.802 0.936 
IL17C 0.8429 7.965 7.944 0.934 
IL26 0.8694 7.814 7.827 0.956 
CCL11 0.8755 7.968 7.989 0.954 
CXCL13 0.8986 8.132 8.161 0.972 
IL1RAPL1 0.9049 8.031 8.059 0.971 
IL10RB 0.9173 7.739 7.728 0.976 
CXCR5 0.9190 8.328 8.350 0.970 
CXCR1 0.9415 7.843 7.850 0.986 
CCR9 0.9469 7.860 7.855 0.984 
IL1RL2 0.9570 7.954 7.946 0.987 
IL20 0.9805 7.885 7.887 1.000 
IL17RB 0.9812 7.839 7.836 0.996 
CCL27 0.9844 8.504 8.509 0.992 
CXCL6 0.9989 7.922 7.922 0.999 
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Table T3-3: Full list of pathways enriched for 1383 genes negatively correlated (at 
FDR<0.00001) with tumour VDR expression. Output from Reactome FIViz 
The source database for each of the enriched pathways are indicated by a letter 
in parentheses after each pathway gene set name. The source database 
annotations are: C - CellMap, R – Reactome, K – KEGG, N – NCI PID, P - 
Panther, and B – BioCarta.  
The description of column headers are: Ratio of protein in gene set: ratios of 
numbers of genes contained in pathways to total genes in the Reactome FI 
network ; Number of protein in gene set: numbers of genes in pathways; Protein 
from network: numbers of hit genes from the query gene list; Nodes: nodal genes 
from my input query gene list, which ‘matches’ with the genes in a particular 
pathway; P-value was estimated by Reactome FIViz using hypergeometric test 
and the corresponding FDR was estimated by Benjamini Hochberg multiple 
correction. 
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GeneSet Ratio Of Protein In GeneSet 
No. Of Protein 
In GeneSet 
Protein From 
Network P-value FDR Nodes 
Cadherin signalling 
pathway(P) 
0.0098 100 16 2.81E-07 1.82E-04 PCDHA3, PCDHA9, PCDHA6, PCDHGA11, PCDHB2, PCDHB5, 
PCDH7, CTNNA2, PCDHB12, PCDHB11, PCDHB10, PCDHB16, 
PCDHGB7, PCDHGB3, PCDHGA8, PCDHGA3 
Wnt signalling 
pathway(P) 
2.62E-02 2.68E+02 25 3.37E-06 1.09E-03 PRKCA, CTBP2, PCDHA3, PCDHA9, PCDHA6, PCDHGA11, 
PCDHB2, PCDHB5, EN2, TLE1, BCL9, SMARCE1, PCDH7, APC, 
NLK, CTNNA2, PCDHB12, PCDHB11, PCDHB10, PCDHB16, 
PCDHGB7, PCDHGB3, PCDHGA8, PCDHGA3, TGFBR1 
Meiotic 
recombination(R) 
3.10E-03 3.20E+01 8 1.27E-05 2.75E-03 NBN, MSH4, BLM, CDK4, BRCA1, RAD51C, RPA1, MLH3 
Fanconi anemia 
pathway(N) 
4.40E-03 4.50E+01 9 2.12E-05 3.43E-03 RMI1, USP1, NBN, BLM, FANCC, CHEK1, BRCA1, RPA1, RAD1 
Mitochondrial 
translation(R) 
8.70E-03 8.90E+01 12 4.53E-05 5.62E-03 MRPL10, MRPL11, MRPL47, MRPL50, MRPL2, MRPL1, 
GADD45GIP1, MRPS18B, MRPS11, MRPS23, MRPS35, MRPS31 
SRP-dependent 
cotranslational protein 
targeting to 
membrane(R) 
1.03E-02 1.05E+02 13 5.21E-05 5.62E-03 RPL34, RPL29, RPL28, RPS4Y1, SSR1, SRP9, RPL13, RPL7A, 
RPL36A, SEC11A, SEC11C, RPL35A, SRPRB 
Assembly of the 
primary cilium(R) 
1.68E-02 1.72E+02 17 6.35E-05 5.81E-03 CEP72, PLK1, WDR60, CEP57, TCTN3, TCTN1, NINL, EXOC8, 
IFT140, CC2D2A, KIF24, SSNA1, RPGRIP1L, KIF3A, AHI1, 
TMEM216, ASAP1 
Cell cycle(K) 1.21E-02 1.24E+02 14 7.17E-05 5.81E-03 PRKDC, PLK1, CDC7, CDK4, TFDP2, MCM2, TTK, E2F3, CDC23, 
CHEK1, CCNB3, SMAD2, BUB1, WEE1 
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Table T3-4: Full list of pathways enriched for 2025 genes positively correlated 
with tumour VDR expression (FDR<0.00001). Output from Reactome FIViz 
The source database for each of the enriched pathways are indicated by a letter 
in parentheses after each pathway gene set name. The source database 
annotations are: C - CellMap, R – Reactome, K – KEGG, N – NCI PID, P - 
Panther, and B – BioCarta.  
The description of column headers are: Ratio of protein in gene set: ratios of 
numbers of genes contained in pathways to total genes in the Reactome FI 
network; Number of protein in gene set: numbers of genes in pathways; Protein 
from network: numbers of hit genes from the query gene list; Nodes: nodal genes 
from my input query gene list, which ‘matches’ with the genes in a particular 
pathway; P-value was estimated by Reactome FIViz using hypergeometric test 
and the corresponding FDR was estimated by Benjamini Hochberg multiple 
correction 
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GeneSet Ratio Of Protein In GeneSet 
No. Of Protein 
In GeneSet 
Protein From 
Network P-value FDR Nodes 
Extracellular matrix 
organization(R) 
0.0243 248 67 1.11E-16 2.28E-14 HSPG2, COL13A1, ADAMTS14, FN1, COL1A2, TPSAB1, MMP10, 
MMP11, MMP13, MMP19, COL3A1, EFEMP1, COL17A1, ITGB4, 
ITGB2, ITGAL, ITGAX, ITGB8, ITGB6, ITGA1, ITGA8, ITGA5, 
COL15A1, FURIN, ICAM2, CTSS, CTSG, LOXL1, PCOLCE, 
COL5A1, COL5A3, FBN1, LAMC2, MMP7, MMP1, MMP2, MMP3, 
MMP8, MMP9, LAMA2, LAMA3, LAMB3, COL7A1, SERPINE1, 
COL12A1, ELANE, ELN, FMOD, TNC, COL27A1, ADAM8, 
ADAMTS2, PECAM1, MFAP2, KLK7, CEACAM6, COMP, 
COL4A2, COL4A4, FBLN1, FBLN5, TGFB1, DCN, COL6A2, 
COL6A1, COL6A3, LUM 
Staphylococcus aureus 
infection(K) 
5.40E-03 5.50E+01 32 1.11E-16 2.28E-14 FPR3, C2, C3, HLA-DRB5, HLA-DRB4, HLA-DRB3, HLA-DRB1, 
HLA-DPA1, PTAFR, HLA-DMA, HLA-DMB, HLA-DPB1, HLA-DOA, 
HLA-DOB, HLA-DRA, ITGB2, ITGAL, FCGR3A, DSG1, C1S, C1R, 
FCGR2B, SELPLG, MASP1, CFB, CFD, CFH, HLA-DQA2, HLA-
DQA1, C1QB, C1QA, SELP 
Cytokine-cytokine 
receptor interaction(K) 
2.59E-02 2.65E+02 74 1.11E-16 2.28E-14 IL20RB, NGFR, EGFR, IL12RB1, CXCL13, CXCL14, TNFRSF4, 
TNFRSF11B, TNFRSF9, TNFRSF10D, CXCL10, CXCL11, 
CXCL12, FLT3, FLT4, FASLG, TNFSF13B, TNFRSF1B, IL2RG, 
CCL5, CCL3, CCL2, IL2RA, IL2RB, TNFRSF6B, TNFSF10, 
TNFSF14, TNFSF13, CD27, CD40, TNFRSF13B, IL24, CCR7, 
CCR4, CCR2, TNFRSF12A, IL18, OSMR, IL1A, IL1B, IL18R1, 
PDGFRA, INHBA, IL7R, CCL14, CCL13, CCL19, CCL18, CCL24, 
CCL22, CCL21, IL10RA, CCL27, CSF3R, CSF1, TNF, CSF1R, 
CX3CR1, IL21R, IL15RA, IL1R1, FLT3LG, LIF, CXCR6, CXCR3, 
IL18RAP, CSF2RB, TGFB1, BMPR1B, CXCL9, CXCL2, IFNE, 
LTA, LTB 
Hematopoietic cell 
lineage(K) 
8.50E-03 8.70E+01 38 1.11E-16 2.28E-14 HLA-DRB5, HLA-DRB4, HLA-DRB3, HLA-DRB1, HLA-DRA, FLT3, 
ITGA1, ITGA5, IL2RA, ANPEP, CD1C, CD1B, CD1A, CD19, 
CD24, CD3G, CD3E, CD3D, CD38, CD37, CD36, CD33, IL1A, 
IL1B, CD8B, CD8A, IL7R, MS4A1, CD2, CD5, CD7, CD9, CSF3R, 
CSF1, TNF, CSF1R, IL1R1, FLT3LG 
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GeneSet Ratio Of Protein In GeneSet 
No. Of Protein 
In GeneSet 
Protein From 
Network P-value FDR Nodes 
Cell adhesion 
molecules (CAMs)(K) 
1.39E-02 1.42E+02 46 1.67E-15 2.73E-13 CLDN1, CLDN5, HLA-DRB5, HLA-DRB4, HLA-DRB3, HLA-DRB1, 
CTLA4, HLA-DPA1, HLA-DMA, HLA-DMB, HLA-DPB1, SIGLEC1, 
HLA-DOA, HLA-DOB, CD274, PTPRC, HLA-DRA, ITGB2, ITGAL, 
SPN, ITGB8, ITGA8, PVRL2, PVRL1, ICAM2, CD226, CD40, 
SELPLG, CD80, CD8B, CD8A, CD2, CD6, ICOS, HLA-DQA2, 
HLA-DQA1, CDH5, PECAM1, TIGIT, ICOSLG, HLA-B, HLA-F, 
PDCD1LG2, SELE, SELP, SELL 
Osteoclast 
differentiation(K) 
1.28E-02 1.31E+02 42 4.00E-14 5.44E-12 SPI1, STAT1, NCF2, NCF4, TNFRSF11B, SOCS3, SOCS1, 
NFKB2, PIK3CG, FCGR3A, LCP2, FCGR2B, BTK, PIK3R5, 
PPP3CC, IL1A, IL1B, RELB, CYBA, OSCAR, TYROBP, MAPK13, 
MAPK11, JUNB, PLCG2, NFATC2, FOSL2, FOSL1, FOSB, CSF1, 
TNF, CSF1R, MAP3K14, LCK, IL1R1, LILRA1, LILRB2, LILRB4, 
CAMK4, SIRPG, TGFB1, BLNK 
Graft-versus-host 
disease(K) 
4.00E-03 4.10E+01 24 7.07E-14 7.35E-12 HLA-DRB5, HLA-DRB4, HLA-DRB3, HLA-DRB1, HLA-DPA1, HLA-
DMA, HLA-DMB, KIR3DL2, HLA-DPB1, HLA-DOA, HLA-DOB, 
HLA-DRA, FASLG, GZMB, PRF1, IL1A, IL1B, CD80, HLA-DQA2, 
HLA-DQA1, TNF, HLA-B, HLA-F, KLRD1 
Costimulation by the 
CD28 family(R) 
6.20E-03 6.30E+01 29 7.21E-14 7.35E-12 LYN, HLA-DRB5, HLA-DRB4, HLA-DRB3, HLA-DRB1, CTLA4, 
HLA-DPA1, HLA-DPB1, CD274, HLA-DRA, CDC42, PTPN6, 
CD247, CD3G, CD3E, CD3D, PAK1, CD80, ICOS, HLA-DQA2, 
HLA-DQA1, HLA-DQB2, GRAP2, BTLA, MAP3K14, LCK, ICOSLG, 
PDCD1LG2, VAV1 
Interferon gamma 
signalling(R) 
7.20E-03 7.40E+01 31 1.14E-13 1.04E-11 HLA-DRB5, HLA-DRB4, HLA-DRB3, HLA-DRB1, HLA-DPA1, 
PTAFR, STAT1, HLA-DPB1, SOCS3, SOCS1, HLA-DRA, CIITA, 
PTPN6, IFI30, TRIM22, IRF8, IRF5, IRF6, HLA-DQA2, HLA-DQA1, 
HLA-DQB2, PML, HLA-B, HLA-F, OASL, OAS1, OAS2, OAS3, 
CAMK2D, GBP2, GBP1 
Inflammatory bowel 
disease (IBD)(K) 
6.40E-03 6.50E+01 29 1.54E-13 1.26E-11 GATA3, HLA-DRB5, HLA-DRB4, HLA-DRB3, HLA-DRB1, HLA-
DPA1, HLA-DMA, HLA-DMB, STAT4, IL12RB1, STAT1, HLA-
DPB1, RORC, RORA, HLA-DOA, HLA-DOB, HLA-DRA, IL2RG, 
IL18, IL1A, IL1B, IL18R1, HLA-DQA2, HLA-DQA1, TNF, NOD2, 
IL21R, IL18RAP, TGFB1 
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GeneSet Ratio Of Protein In GeneSet 
No. Of Protein 
In GeneSet 
Protein From 
Network P-value FDR Nodes 
IL12-mediated 
signalling events(N) 
6.00E-03 6.10E+01 28 2.07E-13 1.53E-11 HLA-DRB1, STAT4, IL12RB1, STAT1, SOCS1, NFKB2, HLA-DRA, 
FASLG, IL2RG, CCL3, GZMA, GZMB, IL2RA, IL2RB, CD247, 
CD3G, CD3E, CD3D, IL18, IL1B, RELB, IL18R1, CD8B, CD8A, 
LCK, IL1R1, GADD45G, IL18RAP 
Tuberculosis(K) 1.73E-02 1.77E+02 48 2.52E-13 1.71E-11 C3, HLA-DRB5, HLA-DRB4, HLA-DRB3, HLA-DRB1, CASP10, 
HLA-DPA1, HLA-DMA, HLA-DMB, STAT1, HLA-DPB1, HLA-DOA, 
HLA-DOB, PLA2R1, CORO1A, HLA-DRA, CIITA, ITGB2, 
FCGR3A, ITGAX, FCGR2B, CD209, CTSS, PPP3CC, FCER1G, 
IL18, IL1A, IL1B, CD74, IRAK2, MAPK13, MAPK11, BCL10, HLA-
DQA2, HLA-DQA1, MRC2, IL10RA, CARD9, TNF, CLEC7A, 
TRADD, LSP1, NOD2, CALML5, CALML3, TGFB1, CASP8, 
CAMK2D 
Intestinal immune 
network for IgA 
production(K) 
4.60E-03 4.70E+01 24 1.22E-12 7.66E-11 HLA-DRB5, HLA-DRB4, HLA-DRB3, HLA-DRB1, HLA-DPA1, HLA-
DMA, HLA-DMB, HLA-DPB1, HLA-DOA, HLA-DOB, CXCL12, 
HLA-DRA, TNFSF13B, TNFSF13, CD40, TNFRSF13B, CD80, 
ICOS, HLA-DQA2, HLA-DQA1, MAP3K14, ICOSLG, IL15RA, 
TGFB1 
Type I diabetes 
mellitus(K) 
4.20E-03 4.30E+01 23 1.42E-12 8.25E-11 HLA-DRB5, HLA-DRB4, HLA-DRB3, HLA-DRB1, HLA-DPA1, HLA-
DMA, HLA-DMB, HLA-DPB1, HLA-DOA, HLA-DOB, HLA-DRA, 
FASLG, GZMB, PRF1, IL1A, IL1B, CD80, HLA-DQA2, HLA-DQA1, 
TNF, HLA-B, HLA-F, LTA 
Rheumatoid arthritis(K) 8.70E-03 8.90E+01 32 2.44E-12 1.32E-10 HLA-DRB5, HLA-DRB4, HLA-DRB3, HLA-DRB1, CTLA4, HLA-
DPA1, HLA-DMA, HLA-DMB, HLA-DPB1, HLA-DOA, HLA-DOB, 
CXCL12, HLA-DRA, ITGB2, ITGAL, TNFSF13B, CCL5, CCL3, 
CCL2, TNFSF13, IL18, IL1A, IL1B, CD80, MMP1, MMP3, HLA-
DQA2, HLA-DQA1, CSF1, TNF, TGFB1, LTB 
Allograft rejection(K) 3.60E-03 3.70E+01 21 4.49E-12 2.29E-10 HLA-DRB5, HLA-DRB4, HLA-DRB3, HLA-DRB1, HLA-DPA1, HLA-
DMA, HLA-DMB, HLA-DPB1, HLA-DOA, HLA-DOB, HLA-DRA, 
FASLG, GZMB, PRF1, CD40, CD80, HLA-DQA2, HLA-DQA1, 
TNF, HLA-B, HLA-F 
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GeneSet Ratio Of Protein In GeneSet 
No. Of Protein 
In GeneSet 
Protein From 
Network P-value FDR Nodes 
TCR signalling in naïve 
CD4+ T cells(N) 
6.60E-03 6.70E+01 27 1.03E-11 4.96E-10 HLA-DRB1, SHC1, PTPRC, HLA-DRA, LCP2, FYB, CDC42, 
PTPN6, CD247, RASSF5, CD3G, CD3E, CD3D, CD80, CARD11, 
RASGRP1, PRKCQ, BCL10, ITK, GRAP2, MAP3K14, LAT, LCK, 
INPP5D, VAV1, WAS, TRPV6 
TNF signalling 
pathway(K) 
1.08E-02 1.10E+02 34 2.82E-11 1.27E-09 JAG1, CASP10, RIPK3, SOCS3, CXCL10, PIK3CG, TNFRSF1B, 
BIRC3, CCL5, CCL2, PIK3R5, IL1B, IL18R1, MMP3, MMP9, 
MAPK13, MAPK11, CREB3L1, JUNB, CSF1, TNF, BCL3, 
MAP3K14, TRADD, TRAF1, NOD2, LIF, EDN1, MLKL, SELE, 
CXCL2, CASP7, CASP8, LTA 
Antigen processing 
and presentation(K) 
7.50E-03 7.70E+01 28 4.42E-11 1.90E-09 HLA-DRB5, HLA-DRB4, HLA-DRB3, HLA-DRB1, HLA-DPA1, HLA-
DMA, HLA-DMB, KIR3DL2, HLA-DPB1, HLA-DOA, HLA-DOB, 
HLA-DRA, CIITA, IFI30, CTSS, CD74, CD8B, CD8A, TAPBP, 
HLA-DQA2, HLA-DQA1, TNF, TAP2, TAP1, HLA-B, HLA-F, 
KLRC3, KLRD1 
Leishmaniasis(K) 7.00E-03 7.20E+01 27 5.03E-11 2.06E-09 C3, HLA-DRB5, HLA-DRB4, HLA-DRB3, HLA-DRB1, HLA-DPA1, 
HLA-DMA, HLA-DMB, STAT1, HLA-DPB1, NCF2, NCF4, HLA-
DOA, HLA-DOB, HLA-DRA, ITGB2, FCGR3A, PTPN6, IL1A, IL1B, 
CYBA, MAPK13, MAPK11, HLA-DQA2, HLA-DQA1, TNF, TGFB1 
Pathways in cancer(K) 3.89E-02 3.97E+02 72 6.30E-11 2.46E-09 SPI1, JUP, FN1, PPARD, EGFR, STAT1, WNT7B, WNT7A, 
ZBTB16, NFKB2, CXCL12, FLT3, FASLG, PIK3CG, BIRC3, 
CDC42, RASSF5, LPAR1, TGFA, LPAR4, PIK3R5, IGF1, RAC2, 
PDGFRA, TCF7, RASGRP1, RASGRP4, RASGRP3, WNT3, 
FGF22, WNT4, FGF11, LAMC2, MMP1, MMP2, MMP9, LAMA2, 
LAMA3, LAMB3, LAMB4, DAPK2, CTBP1, PLCG2, WNT10A, 
GLI2, PLCB3, ADCY4, RUNX1T1, CDKN2B, CSF3R, FGF1, PGF, 
CSF1R, PLEKHG5, TRAF1, CEBPA, PML, CBLC, EDNRA, 
FLT3LG, PTGER4, PTGER2, PTGER3, WNT5A, COL4A2, 
COL4A4, TGFB1, WNT3A, FGFR3, FGFR2, FGFR1, CASP8 
Phagosome(K) 1.50E-02 1.53E+02 40 7.36E-11 2.72E-09 C3, HLA-DRB5, HLA-DRB4, HLA-DRB3, HLA-DRB1, HLA-DPA1, 
HLA-DMA, HLA-DMB, HLA-DPB1, NCF2, NCF4, HLA-DOA, HLA-
DOB, TUBA4A, PLA2R1, CORO1A, HLA-DRA, ITGB2, FCGR3A, 
ITGA5, C1R, FCGR2B, CD209, CTSS, CD36, SFTPD, CYBA, 
 
 
194 
GeneSet Ratio Of Protein In GeneSet 
No. Of Protein 
In GeneSet 
Protein From 
Network P-value FDR Nodes 
HLA-DQA2, HLA-DQA1, MRC2, TAP2, TAP1, CLEC7A, HLA-B, 
HLA-F, MARCO, RAB7B, COMP, NOS1, THBS2 
Viral myocarditis(K) 5.70E-03 5.80E+01 24 8.55E-11 2.99E-09 CXADR, HLA-DRB5, HLA-DRB4, HLA-DRB3, HLA-DRB1, HLA-
DPA1, HLA-DMA, HLA-DMB, HLA-DPB1, HLA-DOA, HLA-DOB, 
HLA-DRA, ITGB2, ITGAL, PRF1, CD40, RAC2, CD80, LAMA2, 
HLA-DQA2, HLA-DQA1, HLA-B, HLA-F, CASP8 
NF-kappa B signalling 
pathway(K) 
8.90E-03 9.10E+01 30 9.22E-11 3.13E-09 LYN, TICAM1, NFKB2, CXCL12, TNFSF13B, BIRC3, BTK, 
TNFSF14, CD40, IL1B, RELB, PLAU, CARD11, PRKCQ, BCL10, 
PLCG2, CCL13, CCL19, CCL21, TNF, MAP3K14, LAT, TRADD, 
TRAF1, LCK, IL1R1, CXCL2, BLNK, LTA, LTB 
T cell receptor 
signalling pathway(K) 
1.02E-02 1.04E+02 32 1.20E-10 3.76E-09 CTLA4, PTPRC, PIK3CG, LCP2, CDC42, PTPN6, CD247, 
PIK3R5, CD3G, CD3E, CD3D, PPP3CC, PAK1, PAK6, CD8B, 
CD8A, CARD11, RASGRP1, MAPK13, MAPK11, PRKCQ, BCL10, 
ICOS, NFATC2, ITK, TNF, GRAP2, MAP3K14, LAT, LCK, CBLC, 
VAV1 
TCR signalling in naïve 
CD8+ T cells(N) 
5.30E-03 5.40E+01 23 1.21E-10 3.76E-09 SHC1, PTPRC, LCP2, PTPN6, CD247, PRF1, RASSF5, CD3G, 
CD3E, CD3D, CD80, CD8B, CD8A, CARD11, RASGRP1, PRKCQ, 
BCL10, GRAP2, MAP3K14, LAT, LCK, VAV1, TRPV6 
HTLV-I infection(K) 2.53E-02 2.58E+02 54 1.32E-10 3.96E-09 SPI1, HLA-DRB5, HLA-DRB4, HLA-DRB3, HLA-DRB1, JAK3, 
HLA-DPA1, HLA-DMA, HLA-DMB, WNT7B, WNT7A, HLA-DPB1, 
HLA-DOA, HLA-DOB, NFKB2, HLA-DRA, ITGB2, ITGAL, PIK3CG, 
IL2RG, IL2RA, IL2RB, PIK3R5, NRP1, CD40, CD3G, CD3E, 
CD3D, PPP3CC, RELB, ETS2, CCND2, PDGFRA, WNT3, WNT4, 
HLA-DQA2, HLA-DQA1, WNT10A, NFATC2, FOSL1, MRAS, 
ADCY4, CDKN2B, TNF, MAP3K14, LCK, IL15RA, IL1R1, HLA-B, 
HLA-F, WNT5A, TGFB1, WNT3A, LTA 
ECM-receptor 
interaction(K) 
8.50E-03 8.70E+01 29 1.47E-10 4.27E-09 HSPG2, FN1, COL1A2, COL3A1, ITGB4, ITGB8, ITGB6, ITGA1, 
ITGA8, ITGA5, CD36, COL5A1, COL5A3, LAMC2, LAMA2, 
LAMA3, LAMB3, LAMB4, TNC, COL27A1, TNXB, COMP, 
COL4A2, COL4A4, COL6A2, COL6A1, COL6A3, COL6A6, THBS2 
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GeneSet Ratio Of Protein In GeneSet 
No. Of Protein 
In GeneSet 
Protein From 
Network P-value FDR Nodes 
Primary 
immunodeficiency(K) 
3.50E-03 3.60E+01 19 1.54E-10 4.32E-09 JAK3, PTPRC, CIITA, IL2RG, BTK, CD19, CD40, TNFRSF13B, 
CD3E, CD3D, CD8B, CD8A, IL7R, ICOS, TAP2, TAP1, LCK, 
CD79A, BLNK 
Asthma(K) 2.90E-03 3.00E+01 17 4.92E-10 1.32E-08 HLA-DRB5, HLA-DRB4, HLA-DRB3, HLA-DRB1, HLA-DPA1, HLA-
DMA, HLA-DMB, HLA-DPB1, HLA-DOA, HLA-DOB, HLA-DRA, 
CD40, FCER1A, FCER1G, HLA-DQA2, HLA-DQA1, TNF 
Focal adhesion(K) 2.03E-02 2.07E+02 46 5.09E-10 1.32E-08 MYLK, FN1, COL1A2, EGFR, FLNB, FLNC, COL3A1, SHC1, 
ITGB4, FLT4, PIK3CG, ITGB8, ITGB6, ITGA1, ITGA8, ITGA5, 
BIRC3, CDC42, PIK3R5, IGF1, RAC2, PAK1, PAK6, CCND2, 
PDGFRA, COL5A1, COL5A3, LAMC2, LAMA2, LAMA3, LAMB3, 
LAMB4, TNC, COL27A1, PGF, PARVG, VAV1, TNXB, COMP, 
COL4A2, COL4A4, COL6A2, COL6A1, COL6A3, COL6A6, THBS2 
T cell activation(P) 7.90E-03 8.10E+01 27 6.31E-10 1.58E-08 HLA-DPA1, HLA-DMA, HLA-DMB, HLA-DOA, NFKB2, PTPRC, 
HLA-DRA, PIK3CG, LCP2, CDC42, CD247, CD3G, CD3E, CD3D, 
PPP3CC, RAC2, PAK1, CD74, PRKCQ, HLA-DQA2, HLA-DQA1, 
NFATC2, GRAP2, LAT, LCK, VAV1, WAS 
Toxoplasmosis(K) 1.16E-02 1.18E+02 33 6.64E-10 1.59E-08 HLA-DRB5, HLA-DRB4, HLA-DRB3, HLA-DRB1, HLA-DPA1, HLA-
DMA, HLA-DMB, STAT1, HLA-DPB1, HLA-DOA, HLA-DOB, 
SOCS1, HLA-DRA, CIITA, PIK3CG, BIRC3, PIK3R5, CD40, 
LAMC2, LAMA2, LAMA3, LAMB3, LAMB4, MAPK13, MAPK11, 
HLA-DQA2, HLA-DQA1, ALOX5, LDLR, IL10RA, TNF, TGFB1, 
CASP8 
Cell surface 
interactions at the 
vascular wall(R) 
9.80E-03 1.00E+02 30 8.14E-10 1.95E-08 CXADR, LYN, FN1, SHC1, ITGB2, ITGAL, SPN, ITGAX, ITGA5, 
PTPN6, CD244, GRB7, FCER1G, CD48, SELPLG, CD74, PROC, 
MMP1, CD2, GAS6, THBD, LCK, PECAM1, INPP5D, CEACAM6, 
SIRPG, SELE, SELP, SELL, AMICA1 
Beta1 integrin cell 
surface interactions(N) 
6.50E-03 6.60E+01 24 1.07E-09 2.45E-08 FN1, COL1A2, COL3A1, F13A1, ITGA1, ITGA8, ITGA5, PLAU, 
TGM2, COL5A1, FBN1, LAMC2, LAMA2, LAMA3, LAMB3, 
COL7A1, TNC, COL4A4, TGFBI, PLAUR, COL6A2, COL6A1, 
COL6A3, THBS2 
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Natural killer cell 
mediated 
cytotoxicity(K) 
1.31E-02 1.34E+02 35 1.16E-09 2.56E-08 HCST, KIR3DL2, SHC1, TNFRSF10D, ITGB2, FASLG, ITGAL, 
PIK3CG, FCGR3A, LCP2, GZMB, PTPN6, CD247, CD244, PRF1, 
ICAM2, TNFSF10, PIK3R5, PPP3CC, RAC2, FCER1G, CD48, 
PAK1, MICA, TYROBP, PLCG2, NFATC2, TNF, LAT, LCK, HLA-B, 
SH2D1A, VAV1, KLRC3, KLRD1 
Validated 
transcriptional targets 
of AP1 family members 
Fra1 and Fra2(N) 
3.60E-03 3.70E+01 18 1.64E-09 3.61E-08 COL1A2, ITGB4, CCL2, PLAU, MMP1, MMP2, MMP9, LAMA3, 
GJA1, JUNB, NFATC2, FOSL2, FOSL1, IVL, THBD, LIF, PLAUR, 
DCN 
Autoimmune thyroid 
disease(K) 
5.10E-03 5.20E+01 21 1.94E-09 4.07E-08 HLA-DRB5, HLA-DRB4, HLA-DRB3, HLA-DRB1, CTLA4, HLA-
DPA1, HLA-DMA, HLA-DMB, HLA-DPB1, HLA-DOA, HLA-DOB, 
HLA-DRA, FASLG, GZMB, PRF1, CD40, CD80, HLA-DQA2, HLA-
DQA1, HLA-B, HLA-F 
Chemokine signalling 
pathway(K) 
1.83E-02 1.87E+02 42 2.15E-09 4.51E-08 LYN, JAK3, STAT1, CXCL13, CXCL14, SHC1, CXCL10, CXCL11, 
CXCL12, ARRB2, PIK3CG, CDC42, CCL5, CCL3, CCL2, PIK3R5, 
RAC2, CCR7, CCR4, CCR2, PAK1, ITK, PLCB3, CCL14, CCL13, 
ADCY4, CCL19, CCL18, CCL24, CCL22, CCL21, CCL27, 
CX3CR1, TIAM1, VAV1, HCK, WAS, CXCR6, CXCR3, CXCL9, 
CXCL2, FGR 
Rap1 signalling 
pathway(K) 
2.07E-02 2.11E+02 45 2.71E-09 5.41E-08 SKAP1, NGFR, EGFR, FLT4, ITGB2, ITGAL, PIK3CG, LCP2, 
PARD6G, FYB, CDC42, RASSF5, EPHA2, LPAR1, LPAR4, 
PIK3R5, IGF1, ID1, RAC2, GRIN1, PDGFRA, RASGRP3, FGF22, 
FGF11, MAPK13, MAPK11, PLCB3, MRAS, ADCY4, CSF1, FGF1, 
MAGI1, PGF, CSF1R, LAT, P2RY1, CALML5, CALML3, TIAM1, 
EFNA5, EFNA3, FGFR3, FGFR2, FGFR1, RGS14 
Influenza A(K) 1.71E-02 1.75E+02 40 3.23E-09 6.45E-08 HLA-DRB5, HLA-DRB4, HLA-DRB3, HLA-DRB1, HLA-DPA1, HLA-
DMA, HLA-DMB, STAT1, HLA-DPB1, HLA-DOA, HLA-DOB, 
TICAM1, SOCS3, TNFRSF10D, CXCL10, HLA-DRA, CIITA, 
FASLG, PIK3CG, FURIN, CCL5, CCL2, TNFSF10, RSAD2, 
PIK3R5, IL18, IL1A, IL1B, MAPK13, MAPK11, PRSS3, HLA-
DQA2, HLA-DQA1, TNF, PYCARD, PML, TLR3, OAS1, OAS2, 
OAS3 
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PI3K-Akt signalling 
pathway(K) 
3.38E-02 3.45E+02 60 1.19E-08 2.26E-07 NGFR, FN1, COL1A2, JAK3, EGFR, COL3A1, ITGB4, FLT4, 
FASLG, PIK3CG, ITGB8, ITGB6, ITGA1, ITGA8, ITGA5, IL2RG, 
IL2RA, IL2RB, EPHA2, LPAR1, LPAR4, PIK3R5, CD19, IGF1, 
OSMR, CCND2, PDGFRA, FGF22, COL5A1, COL5A3, IL7R, 
FGF11, LAMC2, LAMA2, LAMA3, LAMB3, LAMB4, CREB3L1, 
CSF3R, CSF1, TNC, FGF1, COL27A1, PGF, CSF1R, TNXB, 
COMP, COL4A2, COL4A4, EFNA5, EFNA3, FGFR3, FGFR2, 
FGFR1, COL6A2, COL6A1, COL6A3, COL6A6, THBS2, PPP2R2C 
Herpes simplex 
infection(K) 
1.80E-02 1.84E+02 40 1.25E-08 2.37E-07 C3, HLA-DRB5, HLA-DRB4, HLA-DRB3, HLA-DRB1, HLA-DPA1, 
HLA-DMA, HLA-DMB, STAT1, HLA-DPB1, HLA-DOA, HLA-DOB, 
TICAM1, SOCS3, HLA-DRA, FASLG, CCL5, CCL2, PVRL2, 
PVRL1, TNFSF14, IL1B, CD74, CFP, HLA-DQA2, HLA-DQA1, 
TNF, TAP2, TAP1, TRAF1, PML, HLA-B, HLA-F, TLR3, ARNTL, 
CASP8, OAS1, OAS2, OAS3, LTA 
Axon guidance(K) 1.24E-02 1.27E+02 31 4.59E-08 8.27E-07 UNC5B, NGEF, CXCL12, NTN1, CDC42, EPHB6, EPHB2, 
EPHA4, EPHA1, EPHA2, NRP1, PPP3CC, RAC2, PAK1, PAK6, 
SLIT3, NFATC2, SEMA6B, SEMA3A, SEMA3F, ABLIM1, ABLIM2, 
SEMA4A, SEMA4D, RHOD, EFNA5, EFNB2, EFNB1, EFNA3, 
LIMK2, LIMK1 
Proteoglycans in 
cancer(K) 
1.99E-02 2.03E+02 41 5.91E-08 1.04E-06 HSPG2, FN1, EGFR, FLNB, FLNC, WNT7B, WNT7A, FASLG, 
PIK3CG, ITGA5, CDC42, PTPN6, ANK3, ANK1, PIK3R5, IGF1, 
PAK1, GPC1, PLAU, WNT3, WNT4, MMP2, MMP9, MAPK13, 
MAPK11, PLCG2, WNT10A, MRAS, HCLS1, TNF, ITPR2, CBLC, 
TIAM1, WNT5A, TGFB1, WNT3A, FGFR1, PLAUR, DCN, 
CAMK2D, LUM 
Ras signalling 
pathway(K) 
2.22E-02 2.27E+02 44 6.09E-08 1.04E-06 NGFR, EGFR, SHC1, FLT4, FASLG, PIK3CG, CDC42, RASSF5, 
EPHA2, PIK3R5, IGF1, RAC2, PAK1, PAK6, GRIN1, ETS2, 
PDGFRA, RASGRP1, RASGRP4, RASGRP3, FGF22, FGF11, 
PLA2G4F, PLA2G4D, PLA2G4E, PLA2G2A, PLCG2, MRAS, 
CSF1, FGF1, PGF, CSF1R, RASAL1, RASAL3, LAT, CALML5, 
CALML3, TIAM1, EFNA5, EFNA3, FGFR3, FGFR2, FGFR1, 
RASA2 
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Amoebiasis(K) 1.06E-02 1.08E+02 28 6.12E-08 1.04E-06 FN1, COL1A2, SERPINB13, COL3A1, ITGB2, PIK3CG, PIK3R5, 
CTSG, IL1B, COL5A1, COL5A3, LAMC2, LAMA2, LAMA3, 
LAMB3, LAMB4, SERPINB3, SERPINB4, SERPINB2, PLCB3, 
TNF, COL27A1, IL1R1, RAB7B, COL4A2, COL4A4, TGFB1, 
GNA15 
Downstream signalling 
in naïve CD8+ T 
cells(N) 
6.30E-03 6.40E+01 21 6.41E-08 1.09E-06 STAT4, TNFRSF4, TNFRSF9, FASLG, IL2RG, GZMB, IL2RA, 
IL2RB, PTPN7, CD247, PRF1, CD3G, CD3E, CD3D, CD8B, 
CD8A, JUNB, PRKCQ, NFATC2, FOSL1, TNF 
MAPK signalling 
pathway(K) 
2.50E-02 2.55E+02 47 9.27E-08 1.48E-06 CACNA2D1, CACNA2D3, DUSP1, EGFR, FLNB, FLNC, MAP3K6, 
MAPKAPK2, NFKB2, FASLG, ARRB2, CDC42, NTRK2, PTPN7, 
PPP3CC, RAC2, IL1A, IL1B, RELB, PAK1, PDGFRA, CACNA1C, 
RASGRP1, RASGRP4, RASGRP3, CACNA1I, FGF22, FGF11, 
PLA2G4F, PLA2G4D, PLA2G4E, MKNK1, MAPK13, MAPK11, 
MRAS, FGF1, TNF, CACNB1, MAP3K14, DUSP10, IL1R1, 
GADD45G, TGFB1, FGFR3, FGFR2, FGFR1, RASA2 
GPVI-mediated 
activation cascade(R) 
4.80E-03 4.90E+01 18 1.09E-07 1.75E-06 LYN, JAK3, SHC1, PIK3CG, LCP2, IL2RG, IL2RA, IL2RB, PTPN6, 
PIK3R5, RAC2, FCER1G, PLCG2, LAT, LCK, VAV1, PDPN, 
CSF2RB 
CXCR4-mediated 
signalling events(N) 
7.80E-03 8.00E+01 23 1.57E-07 2.51E-06 LYN, HLA-DRB1, STAT1, PTPRC, CXCL12, HLA-DRA, ARRB2, 
CDC42, PTPN6, CD247, CD3G, CD3E, CD3D, PAK1, RGS1, 
MMP9, PLCB3, LCK, INPP5D, VAV1, HCK, FGR, LIMK1 
NOD-like receptor 
signalling pathway(K) 
5.60E-03 5.70E+01 19 2.12E-07 3.18E-06 PYDC1, BIRC3, CCL5, CCL2, NAIP, IL18, IL1B, CARD18, 
MAPK13, MAPK11, MEFV, CARD9, TNF, PYCARD, NOD1, 
NOD2, NLRP1, CXCL2, CASP8 
IL12 signalling 
mediated by STAT4(N) 
3.00E-03 3.10E+01 14 2.52E-07 3.79E-06 HLA-DRB1, STAT4, HLA-DRA, IL2RA, CD247, PRF1, CD3G, 
CD3E, CD3D, IL18, IL18R1, CD80, IL18RAP, TGFB1 
Interferon alpha/beta 
signalling(R) 
6.50E-03 6.60E+01 20 4.48E-07 6.72E-06 STAT1, SOCS3, SOCS1, PTPN6, RSAD2, IFI27, ISG15, ISG20, 
IRF8, IRF5, IRF6, IFITM1, IFIT3, HLA-B, HLA-F, OASL, OAS1, 
OAS2, OAS3, GBP2 
Integrin signalling 
pathway(P) 
1.55E-02 1.58E+02 33 5.60E-07 7.84E-06 COL13A1, FN1, COL1A2, MICALL1, FLNB, COL3A1, COL17A1, 
SHC1, ITGB4, ITGB2, ITGAL, PIK3CG, ITGAX, ITGB8, ITGB6, 
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ITGA1, ITGA8, ITGA5, COL15A1, CDC42, GRAP, RAC2, 
COL5A1, COL5A3, MAPK13, COL7A1, COL12A1, PIK3C2B, 
COL4A2, COL4A4, COL6A2, COL6A1, COL6A3 
GPCR ligand 
binding(R) 
3.81E-02 3.89E+02 60 6.61E-07 9.25E-06 FPR3, C3, PTH1R, PTAFR, P2RY13, P2RY10, GPR68, GPR65, 
CXCL13, CXCL10, CXCL11, CXCL12, CCL5, CCL3, CCL2, 
LPAR1, LPAR4, CCR7, CCR4, CCR2, GCGR, WNT3, LTB4R, 
PTHLH, GPR132, GRP, CCL19, CCL22, CCL21, GPR4, CCL27, 
CYSLTR1, LTB4R2, ADRA2A, CX3CR1, P2RY2, P2RY1, EDNRA, 
NTSR1, NMU, FFAR2, EDN1, PTGER4, PTGER2, PTGER3, 
CXCR6, CXCR3, F2RL1, F2RL2, WNT5A, ADRB2, HRH2, 
WNT3A, CXCL9, CXCL2, PTGIR, S1PR1, S1PR3, S1PR2, S1PR4 
200 
 
Table T3-5: Full list of pathways enriched for genes negatively correlated (at 
FDR<0.01) with tumour VDR expression, after adjusting for FLG2. Output 
from Reactome FIViz 
The source database for each of the enriched pathways are indicated by a letter 
in parentheses after each pathway gene set name. The source database 
annotations are: C - CellMap, R – Reactome, K – KEGG, N – NCI PID, P - 
Panther, and B – BioCarta.  
The description of column headers are:  Ratio of protein in gene set: ratios of 
numbers of genes contained in pathways to total genes in the Reactome FI 
network; Number of protein in gene set: numbers of genes in pathways; Protein 
from network: numbers of hit genes from the query gene list; Nodes: nodal genes 
from my input query gene list, which ‘matches’ with the genes in a particular 
pathway; P-value was estimated by Reactome FIViz using hypergeometric test 
and the corresponding FDR was estimated by Benjamini Hochberg multiple 
correction 
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Mitochondrial 
translation(R) 
0.0087 89 33 6.13E-08 3.46E-05 GADD45GIP1, MRPS17, MRPS14, MRPS11, MRPS28, MRPS26, 
MRPS27, MRPS24, MRPS23, MRPS35, MRPS33, MRPS31, 
GFM1, DAP3, MRPL18, MRPL16, MRPL14, MRPL15, MRPL13, 
MRPL10, MRPL11, MRPL24, MRPL22, MRPL42, MRPL47, 
MRPL50, MRPL3, MRPL2, MRPL1, MRPS7, MRPS18B, MRRF, 
PTCD3 
Mitotic 
Prometaphase(R) 
0.0097 99 35 7.63E-08 3.46E-05 NUP107, CDCA5, CENPF, CENPH, CENPI, CENPM, CENPN, 
CENPQ, NDC80, SMC2, PLK1, PPP1CC, NSL1, XPO1, ZWILCH, 
BUB1, KIF2A, KIF2C, MIS12, SPC25, ERCC6L, PDS5B, CCNB2, 
NUP43, NUP37, SKA1, RAD21, NDE1, CLIP1, RANBP2, KNTC1, 
KIF18A, ITGB3BP, CLASP1, CLASP2 
Fanconi anemia 
pathway(K) 
0.0052 53 23 4.44E-07 1.34E-04 STRA13, ATRIP, RMI1, BLM, REV1, WDR48, USP1, FANCL, 
FANCC, FANCE, FANCG, FANCF, MLH1, EME1, MUS81, PMS2, 
BRCA1, RPA1, RPA3, RAD51C, POLK, POLH, POLN 
Mitotic Metaphase and 
Anaphase(R) 
0.016 163 45 1.15E-06 2.59E-04 NUP107, CDCA5, CENPF, CENPH, CENPI, CENPM, CENPN, 
CENPQ, NDC80, CDC23, CDC16, PLK1, PPP1CC, NSL1, XPO1, 
ZWILCH, BUB1, PSMD9, PSMD5, PSME3, PSMF1, PSMA6, 
RPS27A, PSMC5, ANAPC5, KIF2A, KIF2C, MIS12, SPC25, 
ERCC6L, PDS5B, NUP43, NUP37, SKA1, RAD21, EMD, NDE1, 
CLIP1, RANBP2, PTTG1, KNTC1, KIF18A, ITGB3BP, CLASP1, 
CLASP2 
RNA Polymerase I, 
RNA Polymerase III, 
and Mitochondrial 
Transcription(R) 
0.0087 89 30 1.63E-06 2.95E-04 POLRMT, RRN3, MTA1, MTA3, ERCC2, KAT2B, NFIA, GTF3A, 
POLR3GL, POLR1B, POLR1C, POLR1D, POLR1E, POLR2F, 
POLR3C, POLR3E, POLR3F, POLR3G, POU2F1, CBX3, 
SNAPC3, GTF3C6, CHD3, TAF1D, CD3EAP, BRF2, GTF2H4, 
RBBP4, RBBP7, TFAM 
The citric acid (TCA) 
cycle and respiratory 
electron transport(R) 
0.0156 159 42 7.36E-06 1.11E-03 SCO1, ATP5A1, UQCRB, UQCRQ, ETFA, NDUFAF2, NDUFAF1, 
COX7B, COX5A, NDUFAB1, TACO1, SDHC, SDHD, NDUFB10, 
COX11, PDHA1, LDHC, IDH3B, PDK2, PDHX, SUCLG2, PDPR, 
NDUFA13, NDUFA11, ATP5G3, ATP5G1, UQCRC2, DLD, 
NDUFC2, NDUFB8, NDUFB4, NDUFB2, NDUFA8, NDUFA7, 
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NDUFA4, ATP5E, NDUFV2, CYCS, UQCRFS1, NDUFS4, 
NDUFS2, LRPPRC 
Cell cycle(K) 0.0121 124 35 1.09E-05 1.40E-03 E2F3, CDC23, CDC16, PCNA, ANAPC13, PRKDC, PLK1, 
CDKN1C, CDKN1B, CDKN2C, CDKN2A, MCM7, SMC1B, TFDP2, 
MCM3, MCM2, TTK, BUB1, WEE1, WEE2, ANAPC5, CCNB3, 
CCNB2, RAD21, CDC7, CUL1, ABL1, CDK6, CDK4, CDK2, 
CHEK1, SKP2, SKP1, PTTG1, SMAD2 
Wnt signalling 
pathway(P) 
0.0262 268 60 1.49E-05 1.58E-03 PCDH7, SMARCAL1, CER1, SMARCA1, SMARCA4, PCDHB14, 
PCDHB13, PCDHB12, PCDHB11, PCDHB10, PCDHB16, GNG3, 
GNG2, GNG4, GNG7, PRKCI, PRKCE, PRKCA, CTBP2, 
PCDHA5, PCDHA4, PCDHA3, PCDHA2, PCDHA9, PCDHA8, 
PCDHA6, PCDHB2, PCDHB6, PCDHB5, PCDHB3, PCDHB7, 
TLE1, PYGO1, BCL9, NKD1, PCDHA12, PCDHA11, LRP5L, 
PPP2R5A, MYH3, CDH10, PCDHGA11, DCHS1, LRP6, FZD9, 
EN2, CDH4, SMARCD1, SMARCE1, APC, NLK, SIAH1, TBL1Y, 
CTNNA2, TBL1XR1, PCDHGB7, PCDHGB3, PCDHGA8, 
PCDHGA3, TGFBR1 
Ribosome(K) 0.0134 137 37 1.58E-05 1.58E-03 MRPS17, MRPS14, MRPS11, RPS4Y1, RPS15A, RSL24D1, 
RPS13, RPS23, RPS3A, MRPL18, MRPL16, MRPL14, MRPL15, 
MRPL13, MRPL10, MRPL11, MRPL24, MRPL22, RPS27A, 
MRPL3, MRPL2, MRPL1, MRPS7, RPL34, RPL7, RPL22, RPL26, 
RPL29, RPL28, RPL10, RPL13, RPL15, RPS7, RPS5, RPL7A, 
RPL36A, RPL35A 
Oxidative 
phosphorylation(K) 
0.013 133 36 1.96E-05 1.65E-03 ATP5A1, UQCRB, UQCRQ, ATP6V1E1, ATP6V1E2, ATP6V1G1, 
ATP6V1C1, COX7B, COX5A, NDUFAB1, SDHC, SDHD, 
NDUFB10, COX15, COX11, ATP6V0D2, ATP6V0A1, NDUFA13, 
NDUFA11, ATP5G3, ATP5G1, UQCRC2, NDUFC2, NDUFB8, 
NDUFB4, NDUFB2, NDUFA8, NDUFA7, NDUFA4, ATP5E, 
NDUFV2, UQCRFS1, NDUFS4, NDUFS2, ATP6V1A, ATP6V1F 
Assembly of the 
primary cilium(R) 
0.0168 172 43 2.09E-05 1.65E-03 NINL, IFT140, NEK2, BBS1, PCM1, SSNA1, AHI1, TMEM216, 
ASAP1, CDK5RAP2, CEP70, CEP72, PLK1, WDR60, CEP57, 
TCTN3, TCTN1, EXOC8, EXOC2, WDR19, CEP135, CEP164, 
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CEP152, DYNC2H1, TUBB, RAB11A, LZTFL1, ARL6, FGFR1OP, 
CCT3, KIF24, CCT5, RPGRIP1L, KIF3A, NPHP1, DCTN2, NDE1, 
INPP5E, CC2D2A, BBS12, TRIP11, PDE6D, CLASP1 
Fanconi anemia 
pathway(N) 
0.0044 45 18 2.21E-05 1.65E-03 ATRIP, RMI1, BLM, RAD1, WDR48, USP1, FANCL, FANCC, 
FANCE, FANCG, FANCF, RFC3, TOPBP1, XRCC3, BRCA1, 
RPA1, NBN, CHEK1 
BARD1 signalling 
events(N) 
0.0028 29 14 2.44E-05 1.69E-03 PCNA, PRKDC, BARD1, FANCL, FANCC, FANCE, FANCG, 
FANCF, CSTF1, TOPBP1, XRCC5, BRCA1, NBN, CDK2 
S Phase(R) 0.0117 120 33 3.15E-05 2.02E-03 CDCA5, APEX1, POLA1, PCNA, POLE2, CDKN1B, MCM7, RFC3, 
RFC1, MCM3, MCM2, ESCO1, ESCO2, DNA2, GINS2, WEE1, 
PSMD9, PSMD5, PSME3, PSMF1, PSMA6, RPS27A, PSMC5, 
RPA1, RPA3, PDS5B, RAD21, CUL1, CDK4, CDK2, SKP2, SKP1, 
CKS1B 
Cadherin signalling 
pathway(P) 
0.0098 100 29 3.73E-05 2.09E-03 PCDH7, PCDHB14, PCDHB13, PCDHB12, PCDHB11, PCDHB10, 
PCDHB16, PCDHA5, PCDHA4, PCDHA3, PCDHA2, PCDHA9, 
PCDHA8, PCDHA6, PCDHB2, PCDHB6, PCDHB5, PCDHB3, 
PCDHB7, PCDHA12, PCDHA11, PCDHGA11, DCHS1, FZD9, 
CTNNA2, PCDHGB7, PCDHGB3, PCDHGA8, PCDHGA3 
SUMOylation(R) 0.0098 100 29 3.73E-05 2.09E-03 NUP107, RING1, BLM, NOP58, PCNA, RAE1, UBE2I, NUP155, 
UBA2, MTA1, SMC6, POM121C, CDKN2A, PCGF2, PARP1, 
CBX4, SAE1, SCMH1, NSMCE2, BRCA1, RPA1, AURKA, NUP43, 
NUP35, NUP37, RAD21, MITF, RANBP2, SENP2 
Mitotic G2-G2/M 
phases(R) 
0.0109 111 31 4.09E-05 2.17E-03 LIN54, NINL, CENPF, NEK2, E2F3, PCM1, SSNA1, CDK5RAP2, 
CEP70, CEP72, PLK1, CEP57, CEP135, CEP164, CEP152, 
XPO1, TUBB, WEE1, RPS27A, TUBGCP5, FGFR1OP, 
PPP1R12A, CCNB2, DCTN2, AURKA, NDE1, CUL1, CDK2, 
RBBP4, SKP1, CLASP1 
RNA transport(K) 0.0168 172 42 4.36E-05 2.18E-03 NUP107, POP1, POP4, EIF1AY, EIF5B, EIF1B, PABPC5, RAE1, 
RPP30, RPP21, UBE2I, NUP155, TGS1, POM121C, PAIP1, 
EIF2B5, EIF2B4, MAGOH, SRRM1, XPO1, RGPD5, EIF2S2, 
EIF2S1, EIF2S3, NXF3, CLNS1A, NXT1, SAP18, EIF4A2, EIF4A3, 
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GEMIN4, GEMIN6, NCBP2, NUP43, NUP35, NUP37, UPF3B, 
FMR1, NMD3, PRMT5, RANBP2, SENP2 
Resolution of Abasic 
Sites (AP sites)(R) 
0.003 31 14 4.96E-05 2.33E-03 APEX1, PCNA, SMUG1, NTHL1, RFC3, RFC1, PARP1, LIG3, 
UNG, XRCC1, RPA1, RPA3, POLB, MUTYH 
Processing of Capped 
Intron-Containing Pre-
mRNA(R) 
0.0165 169 41 6.14E-05 2.77E-03 NUP107, NUDT21, ZCRB1, FUS, BCAS2, SNRPD1, RAE1, 
HNRNPA2B1, NUP155, PABPN1, HNRNPU, RNPC3, POM121C, 
HNRNPF, PAPOLA, SNRPG, SNRPE, SNRNP25, POLR2C, 
POLR2F, MAGOH, SRRM1, CSTF1, PRPF3, CPSF2, CWC15, 
CD2BP2, PCBP1, NCBP2, NUP43, NUP35, NUP37, UPF3B, 
GTF2F2, LSM5, LSM3, SNRPA1, SNRPB2, PRPF19, PCF11, 
RANBP2 
Huntington's 
disease(K) 
0.0189 193 45 6.83E-05 2.94E-03 BBC3, ATP5A1, UQCRB, NRF1, UQCRQ, SP1, COX7B, COX5A, 
NDUFAB1, SDHC, SDHD, NDUFB10, DNAL4, GRM5, POLR2C, 
POLR2F, NDUFA13, NDUFA11, ATP5G3, ATP5G1, TBPL1, 
UQCRC2, PPARGC1A, BDNF, NDUFC2, SLC25A5, SLC25A4, 
NDUFB8, NDUFB4, NDUFB2, NDUFA8, NDUFA7, NDUFA4, 
ATP5E, NDUFV2, CYCS, UQCRFS1, CREB3, NDUFS4, NDUFS2, 
DCTN2, DCTN4, TAF4, TFAM, VDAC2 
Mitotic G1-G1/S 
phases(R) 
0.0123 126 33 7.85E-05 3.22E-03 LIN54, E2F3, POLA1, PCNA, POLE2, CDKN1B, CDKN2C, 
CDKN2A, MCM7, TFDP2, MCM3, MCM2, TYMS, WEE1, PSMD9, 
PSMD5, PSME3, PSMF1, PSMA6, RPS27A, PSMC5, MCM10, 
RPA1, RPA3, CDC7, CUL1, CDK6, CDK4, CDK2, RBBP4, SKP2, 
SKP1, CKS1B 
HDR through 
Homologous 
Recombination (HR) or 
Single Strand 
Annealing (SSA)(R) 
0.0083 85 25 1.00E-04 3.90E-03 ATRIP, RMI1, BLM, UIMC1, RAD1, UBE2I, UBE2N, BARD1, 
RFC3, DNA2, EME1, MUS81, TOPBP1, SIRT6, RPS27A, XRCC2, 
XRCC3, BRCA1, RPA1, RPA3, NBN, ABL1, CDK2, CHEK1, 
RAD51C 
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Table T3-6: Full list of pathways enriched for genes positively correlated (at 
FDR<0.00001) with tumour VDR expression, after adjusting for FLG2. 
Output from Reactome FIViz 
The source database for each of the enriched pathways are indicated by a letter 
in parentheses after each pathway gene set name. The source database 
annotations are: C - CellMap, R – Reactome, K – KEGG, N – NCI PID, P - 
Panther, and B – BioCarta.  
The description of column headers are:  Ratio of protein in gene set: ratios of 
numbers of genes contained in pathways to total genes in the Reactome FI 
network; Number of protein in gene set: numbers of genes in pathways; Protein 
from network: numbers of hit genes from the query gene list; Nodes: nodal genes 
from my input query gene list, which ‘matches’ with the genes in a particular 
pathway; P-value was estimated by Reactome FIViz using hypergeometric test 
and the corresponding FDR was estimated by Benjamini Hochberg multiple 
correction 
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Extracellular matrix 
organization(R) 
0.0243 248 103 1.11E-16 5.51E-14 COL13A1, PDGFB, ADAMTS14, FN1, TPSAB1, BGN, MMP10, 
MMP11, MMP13, MMP16, MMP15, MMP19, COL3A1, EFEMP1, 
COL17A1, ITGB4, ITGB2, ITGAL, ITGAX, ITGB8, ITGB6, ITGA2, 
ITGA1, ITGA8, ITGA5, ICAM2, ICAM3, ICAM4, KDR, ACTN1, 
SDC3, LOXL1, VCAM1, FBN1, COL7A1, COL10A1, TNC, 
COL27A1, ADAMTS5, ADAMTS2, PECAM1, MFAP4, MFAP2, 
COL18A1, COMP, LOX, FBLN1, FBLN2, FBLN5, DCN, COL6A2, 
COL6A1, COL6A3, THBS1, LUM, HSPG2, COL1A1, COL1A2, 
COL11A1, COL15A1, FURIN, COL9A3, CTSS, CTSG, CTSD, 
CTSB, PCOLCE, PSEN1, BMP2, BMP1, COL5A1, COL5A3, 
COL5A2, LAMC2, MMP7, MMP1, MMP2, MMP3, MMP8, MMP9, 
VCAN, LAMA2, LAMA3, LAMB3, SERPINE1, COL12A1, 
SERPINH1, ELANE, ELN, FMOD, ADAM9, ADAM8, SPARC, 
COL8A2, COL8A1, CEACAM6, COL4A2, COL4A1, COL4A4, 
COL4A3, LTBP4, NID2, TGFB1 
Cytokine-cytokine 
receptor interaction(K) 
0.0259 265 109 1.11E-16 5.51E-14 PDGFB, PDGFC, EGFR, IL12RB1, TNFRSF4, TNFRSF17, 
TNFRSF9, TNFSF13B, TNFRSF1B, IL2RG, IL2RA, IL2RB, 
TNFRSF6B, TNFSF10, KDR, TNFSF14, TNFSF13, IL24, IL11, 
IL15, IL18, IL1A, IL1B, VEGFC, VEGFA, KITLG, IL18R1, IL7R, 
CNTF, IL10RB, IL10RA, CLCF1, CSF2, CSF1, TNF, IFNAR2, 
BMPR2, IL21R, IL15RA, IL1R1, FLT3LG, LIF, CCL4L1, BMPR1B, 
LTA, LTB, IL20RB, NGFR, CXCL13, CXCL14, CXCL16, 
TNFRSF11B, TNFRSF10B, TNFRSF10D, CXCL10, CXCL11, 
CXCL12, FLT3, FLT4, FASLG, CCL8, CCL7, CCL5, CCL3, CCL2, 
ACVR1, CD27, CD40, TNFRSF13B, CCR7, CCR4, CCR2, 
TNFRSF12A, OSMR, CD70, PDGFRB, PDGFRA, CCL3L1, 
INHBB, INHBA, IL6, BMP2, TNFSF4, CCL14, CCL13, CCL19, 
CCL18, CCL17, CCL24, CCL22, CCL21, CSF3R, CSF1R, IL3RA, 
CX3CR1, CXCR5, CXCR4, CXCR6, CXCR3, FAS, IL18RAP, 
CSF2RB, CSF2RA, TGFB1, CXCL9, CXCL1, CXCL2, TGFBR2, 
IFNE 
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Hematopoietic cell 
lineage(K) 
0.0085 87 50 2.22E-16 7.33E-14 HLA-DRB4, HLA-DRB3, HLA-DRB1, ITGA2, ITGA1, ITGA5, 
IL2RA, ANPEP, IL11, IL1A, IL1B, KITLG, IL7R, MS4A1, CD2, 
CD4, CD5, CD7, CD9, CSF2, CSF1, TNF, CR1, IL1R1, FLT3LG, 
HLA-DRA, FLT3, FCGR1A, CD1D, CD1C, CD1B, CD1A, CD19, 
CD22, CD3G, CD3E, CD3D, CD38, CD37, CD36, CD33, MME, 
CD8B, CD8A, IL6, FCER2, CSF3R, CSF1R, IL3RA, CSF2RA 
Staphylococcus aureus 
infection(K) 
0.0054 55 38 3.55E-15 8.81E-13 HLA-DRB4, HLA-DRB3, HLA-DRB1, PTAFR, ITGB2, ITGAL, C1S, 
C1R, SELPLG, CFB, CFD, CFH, CFI, HLA-DQA2, HLA-DQA1, 
HLA-DQB1, C1QB, C1QA, C1QC, SELP, FPR1, FPR3, C2, C3, 
HLA-DPA1, HLA-DMA, HLA-DMB, HLA-DPB1, HLA-DOA, HLA-
DOB, HLA-DRA, FCGR3A, DSG1, FCGR1A, FCGR2B, FCGR2C, 
MASP1, C5AR1 
Pathways in cancer(K) 0.0389 397 120 9.33E-15 1.85E-12 SPI1, BCR, PDGFB, FN1, JAK1, PPARD, EGFR, EGLN1, EGLN3, 
WNT7B, WNT7A, ITGA2, ROCK1, CDC42, E2F2, EPAS1, LPAR1, 
TGFA, LPAR4, STAT5B, IGF1, RAC2, ARHGEF1, RELA, GNAI2, 
VEGFC, VEGFA, KITLG, TCF7, FGF11, CTBP1, ADCY4, ADCY7, 
RUNX1T1, CDKN2B, FGF1, PGF, PLEKHG5, CEBPA, HDAC2, 
PML, CBLC, FLT3LG, PTGER4, PTGER2, PTGER3, F2RL3, 
WNT5B, WNT5A, WNT3A, FGFR3, FGFR2, FGFR1, WNT2B, 
CASP8, MAPK8, GNA12, AR, STAT1, MAX, NFKB2, CXCL12, 
FLT3, PIK3CD, FASLG, PIK3CG, BIRC3, RASSF5, PIK3R5, 
BRCA2, PDGFRB, PDGFRA, RASGRP1, RASGRP4, RASGRP3, 
WNT4, IL6, BMP2, LAMC2, MMP1, MMP2, MMP9, LAMA2, 
LAMA3, LAMB3, DAPK2, HIF1A, PLCG2, FZD1, WNT10B, 
WNT10A, FZD7, RET, GLI2, PLCB3, PAX8, CSF3R, CSF1R, 
TRAF2, TRAF1, TRAF3, SOS1, SOS2, EDNRA, RUNX1, GNG10, 
GNG11, CXCR4, FAS, COL4A2, COL4A1, COL4A4, COL4A3, 
CSF2RA, TGFB1, PTCH2, NFKBIA, BDKRB2, TGFBR2, BAD 
Osteoclast 
differentiation(K) 
0.0128 131 59 2.00E-14 3.01E-12 SPI1, JAK1, LCP2, BTK, PPP3CC, SYK, IL1A, IL1B, RELA, RELB, 
TYROBP, NFATC2, FOSL2, FOSL1, FOSB, CSF1, TNF, IFNAR2, 
MAP3K14, LCK, IL1R1, BLNK, MAPK8, STAT1, NCF1, NCF2, 
NCF4, TNFRSF11B, SOCS3, SOCS1, NFKB2, FHL2, PIK3CD, 
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PIK3CG, FCGR3A, FCGR1A, FCGR2B, FCGR2C, PIK3R5, CYBA, 
OSCAR, SIRPB1, MAPK13, MAPK11, JUNB, PLCG2, CSF1R, 
TRAF2, LILRA1, LILRA5, LILRB1, LILRB2, LILRB4, LILRB5, 
CAMK4, SIRPG, TGFB1, NFKBIA, TGFBR2 
Graft-versus-host 
disease(K) 
0.004 41 32 2.13E-14 3.01E-12 HLA-DRB4, HLA-DRB3, HLA-DRB1, KIR3DL2, KIR2DL5A, GZMB, 
IL1A, IL1B, HLA-DQA2, HLA-DQA1, HLA-DQB1, TNF, HLA-B, 
HLA-F, HLA-E, HLA-DPA1, HLA-DMA, HLA-DMB, HLA-DPB1, 
HLA-DOA, HLA-DOB, HLA-DRA, FASLG, PRF1, CD28, CD86, 
CD80, KIR2DL1, IL6, FAS, KLRC1, KLRD1 
TNF signalling 
pathway(K) 
0.0108 110 53 3.28E-14 4.06E-12 JAG1, CASP10, MAP3K8, MAP3K5, TNFRSF1B, IL15, IL1B, 
RELA, VEGFC, IL18R1, VCAM1, TNFAIP3, CSF2, CSF1, TNF, 
MAP2K3, BCL3, MAP3K14, NOD2, LIF, EDN1, MLKL, SELE, 
CASP7, CASP8, LTA, MAPK8, RIPK3, PGAM5, SOCS3, CXCL10, 
PIK3CD, PIK3CG, BIRC3, CCL5, CCL2, PIK3R5, IL6, MMP3, 
MMP9, MAPK13, MAPK11, CREB3L1, JUNB, TRADD, TRAF2, 
TRAF1, TRAF3, CFLAR, FAS, NFKBIA, CXCL1, CXCL2 
Tuberculosis(K) 0.0173 177 68 3.21E-13 3.53E-11 HLA-DRB4, HLA-DRB3, HLA-DRB1, CASP10, JAK2, JAK1, 
PLA2R1, CORO1A, CIITA, ITGB2, ITGAX, CD209, PPP3CC, 
CAMP, FCER1G, SYK, IL18, IL1A, IL1B, RELA, IRAK1, IRAK2, 
BCL10, HLA-DQA2, HLA-DQA1, HLA-DQB1, IL10RB, IL10RA, 
TNF, TCIRG1, CR1, NOD2, CALML5, CALML3, TLR9, TLR4, 
TLR2, CASP8, MAPK8, C3, HLA-DPA1, HLA-DMA, HLA-DMB, 
STAT1, HLA-DPB1, HLA-DOA, HLA-DOB, HLA-DRA, MYD88, 
FCGR3A, KSR1, FCGR1A, FCGR2B, FCGR2C, CTSS, CTSD, 
CD74, IL6, MAPK13, MAPK11, MRC2, CARD9, CLEC7A, TRADD, 
LSP1, TGFB1, CAMK2D, BAD 
Rheumatoid arthritis(K) 0.0087 89 45 5.70E-13 5.65E-11 HLA-DRB4, HLA-DRB3, HLA-DRB1, ITGB2, ITGAL, TNFSF13B, 
ATP6V1C2, TNFSF13, IL11, IL15, IL18, IL1A, IL1B, VEGFA, HLA-
DQA2, HLA-DQA1, HLA-DQB1, CSF2, CSF1, TNF, TCIRG1, 
TLR4, TLR2, LTB, CTLA4, HLA-DPA1, HLA-DMA, HLA-DMB, 
HLA-DPB1, HLA-DOA, HLA-DOB, CXCL12, HLA-DRA, CCL5, 
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CCL3, CCL2, CD28, CD86, CD80, CCL3L1, IL6, MMP1, MMP3, 
TGFB1, CXCL1 
Cell adhesion 
molecules (CAMs)(K) 
0.0139 142 58 1.67E-12 1.50E-10 HLA-DRB4, HLA-DRB3, HLA-DRB1, SIGLEC1, CD274, ITGB2, 
ITGAL, SPN, ITGB8, ITGA8, ICAM2, ICAM3, CD226, SDC3, 
SELPLG, VCAM1, CD2, CD4, CD6, ALCAM, ICOS, HLA-DQA2, 
HLA-DQA1, HLA-DQB1, PECAM1, ICOSLG, HLA-B, HLA-F, HLA-
E, PDCD1LG2, SELE, SELP, SELL, CLDN5, CTLA4, HLA-DPA1, 
HLA-DMA, HLA-DMB, HLA-DPB1, HLA-DOA, HLA-DOB, PTPRC, 
HLA-DRA, PVRL2, PVRL1, CD28, CD22, CD40, CD58, CD86, 
CD80, CD8B, CD8A, VCAN, CDH5, ESAM, TIGIT, NFASC 
Leishmaniasis(K) 0.007 72 39 2.64E-12 2.16E-10 HLA-DRB4, HLA-DRB3, HLA-DRB1, JAK2, JAK1, ITGB2, IL1A, 
IL1B, RELA, IRAK1, HLA-DQA2, HLA-DQA1, HLA-DQB1, TNF, 
CR1, TLR4, TLR2, C3, HLA-DPA1, HLA-DMA, HLA-DMB, STAT1, 
HLA-DPB1, NCF1, NCF2, NCF4, HLA-DOA, HLA-DOB, HLA-DRA, 
MYD88, FCGR3A, FCGR1A, PTPN6, FCGR2C, CYBA, MAPK13, 
MAPK11, TGFB1, NFKBIA 
Chemokine signalling 
pathway(K) 
0.0183 187 68 3.59E-12 2.73E-10 JAK2, JAK3, SHC1, ROCK1, CDC42, STAT5B, RAC2, RELA, 
GNAI2, GRK5, GRK6, PTK2B, ADCY4, ADCY7, TIAM1, VAV1, 
HCK, CCL4L1, LYN, STAT1, NCF1, CXCL13, CXCL14, CXCL16, 
CXCL10, CXCL11, CXCL12, PIK3CD, ARRB2, PIK3CG, CCL8, 
CCL7, CCL5, CCL3, CCL2, PIK3R5, CCR7, CCR4, CCR2, PAK1, 
CCL3L1, ITK, PLCB3, CCL14, CCL13, CCL19, CCL18, CCL17, 
CCL24, CCL22, CCL21, SOS1, SOS2, CX3CR1, GNG10, GNG11, 
WAS, CXCR5, CXCR4, CXCR6, CXCR3, ELMO1, NFKBIA, 
CXCL9, CXCL1, CXCL2, FGR, DOCK2 
NF-kappa B signalling 
pathway(K) 
0.0089 91 44 4.34E-12 3.04E-10 TNFSF13B, BTK, TNFSF14, SYK, IL1B, RELA, RELB, PLAU, 
CARD11, IRAK1, VCAM1, TNFAIP3, PRKCQ, BCL10, TNF, 
MAP3K14, LAT, LCK, IL1R1, TLR4, CCL4L1, BLNK, ZAP70, LTA, 
LTB, LYN, TICAM1, NFKB2, CXCL12, MYD88, BIRC3, CD40, 
PLCG2, CCL13, CCL19, CCL21, TRADD, TRAF2, TRAF1, TRAF3, 
CFLAR, GADD45B, NFKBIA, CXCL2 
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TCR signalling in naïve 
CD4+ T cells(N) 
0.0066 67 37 5.52E-12 3.57E-10 HLA-DRB1, MAP3K8, SHC1, LCP2, FYB, CDC42, CD247, 
CARD11, PDPK1, CD4, PRKCQ, BCL10, MAP3K14, LAT, LCK, 
VAV1, TRPV6, ZAP70, PTPRC, HLA-DRA, SH3BP2, PTPN6, 
RASSF5, CD28, CD3G, CD3E, CD3D, CD86, CD80, RASGRP1, 
ITK, GRAP2, STIM1, SOS1, INPP5D, MAP4K1, WAS 
Interferon gamma 
signalling(R) 
0.0072 74 39 5.89E-12 3.57E-10 HLA-DRB4, HLA-DRB3, HLA-DRB1, JAK2, JAK1, PTAFR, CIITA, 
MT2A, TRIM22, VCAM1, HLA-DQA2, HLA-DQA1, HLA-DQB2, 
HLA-DQB1, PML, HLA-B, HLA-F, HLA-E, OASL, OAS1, OAS2, 
OAS3, GBP2, GBP1, HLA-DPA1, STAT1, HLA-DPB1, SOCS3, 
SOCS1, HLA-DRA, FCGR1A, PTPN6, IFI30, IRF2, IRF7, IRF8, 
IRF5, IRF6, CAMK2D 
Focal adhesion(K) 0.0203 207 72 6.16E-12 3.57E-10 PDGFB, PDGFC, FN1, EGFR, COL3A1, SHC1, ITGB4, ITGB8, 
ITGB6, ITGA2, ITGA1, ITGA8, ITGA5, ROCK1, CDC42, KDR, 
ACTN1, IGF1, RAC2, VEGFC, VEGFA, PDPK1, TNC, COL27A1, 
PGF, PARVG, VAV1, COMP, DIAPH1, COL6A2, COL6A1, 
COL6A3, COL6A6, THBS2, THBS1, MAPK8, MYLK, MYL9, 
COL1A1, COL1A2, COL11A1, FLNB, FLNC, FLT4, PIK3CD, 
PIK3CG, PPP1R12C, BIRC3, PIK3R5, PAK1, PAK6, PPP1CA, 
CCND2, PDGFRB, PDGFRA, COL5A1, COL5A3, COL5A2, 
LAMC2, LAMA2, LAMA3, LAMB3, ZYX, VWF, SOS1, SOS2, 
TNXB, COL4A2, COL4A1, COL4A4, COL4A3, BAD 
HTLV-I infection(K) 0.0253 258 83 7.33E-12 4.03E-10 SPI1, PDGFB, HLA-DRB4, HLA-DRB3, HLA-DRB1, JAK3, JAK1, 
WNT7B, WNT7A, ITGB2, ITGAL, IL2RG, E2F2, IL2RA, IL2RB, 
CDC20, STAT5B, XBP1, NRP1, PPP3CC, IL15, RELA, RELB, 
ETS2, VCAM1, POLD3, POLD4, HLA-DQA2, HLA-DQA1, 
NFATC2, NFATC4, FOSL1, HLA-DQB1, ADCY4, ADCY7, 
CDKN2B, CSF2, TNF, MAP3K14, LCK, IL15RA, IL1R1, HLA-B, 
HLA-F, HLA-E, WNT5B, WNT5A, WNT3A, WNT2B, LTA, VAC14, 
MAPK8, HLA-DPA1, HLA-DMA, HLA-DMB, HLA-DPB1, HLA-DOA, 
HLA-DOB, ANAPC2, NFKB2, HLA-DRA, PIK3CD, PIK3CG, 
PIK3R5, CD40, CD3G, CD3E, CD3D, CCND2, PDGFRB, 
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PDGFRA, WNT4, IL6, FZD1, WNT10B, WNT10A, FZD7, MRAS, 
ZFP36, PTTG2, TGFB1, NFKBIA, TGFBR2 
Intestinal immune 
network for IgA 
production(K) 
0.0046 47 30 1.85E-11 9.60E-10 HLA-DRB4, HLA-DRB3, HLA-DRB1, TNFRSF17, TNFSF13B, 
TNFSF13, IL15, ICOS, HLA-DQA2, HLA-DQA1, HLA-DQB1, 
MAP3K14, ICOSLG, IL15RA, HLA-DPA1, HLA-DMA, HLA-DMB, 
HLA-DPB1, HLA-DOA, HLA-DOB, CXCL12, HLA-DRA, CD28, 
CD40, TNFRSF13B, CD86, CD80, IL6, CXCR4, TGFB1 
Integrin signalling 
pathway(P) 
0.0155 158 59 3.54E-11 1.73E-09 COL13A1, FN1, COL3A1, LIMS1, MAP3K5, COL17A1, SHC1, 
ARPC3, ITGB4, ITGB2, ITGAL, ITGAX, ITGB8, ITGB6, ITGA2, 
ITGA1, ARFGAP1, ITGA8, ITGA5, CDC42, ACTN1, GRAP, RAC2, 
MAP3K2, PTK2B, COL7A1, ARPC1B, COL10A1, MAP2K3, 
PIK3C2B, COL6A2, COL6A1, COL6A3, MAPK8, COL1A1, 
COL1A2, COL11A1, MICALL1, FLNB, PIK3CD, PIK3CG, 
COL15A1, COL9A3, COL5A1, COL5A3, COL5A2, MAPK13, 
COL12A1, SOS1, SOS2, COL8A2, COL8A1, COL4A2, COL4A1, 
COL4A4, COL4A3, ELMO1, ELMO2, ARHGAP26 
Natural killer cell 
mediated 
cytotoxicity(K) 
0.0131 134 53 4.75E-11 2.23E-09 HCST, KIR3DL2, SHC1, KIR2DL5A, ITGB2, ITGAL, LCP2, GZMB, 
CD247, CD244, ICAM2, TNFSF10, PPP3CC, RAC2, FCER1G, 
SYK, TYROBP, PTK2B, NFATC2, CSF2, TNF, IFNAR2, LAT, LCK, 
HLA-B, HLA-E, SH2D1A, VAV1, ZAP70, TNFRSF10B, 
TNFRSF10D, PIK3CD, FASLG, PIK3CG, FCGR3A, SH3BP2, 
PTPN6, PRF1, PIK3R5, NCR1, CD48, PAK1, MICA, MICB, 
KIR2DL1, KIR2DL4, PLCG2, SOS1, SOS2, FAS, KLRC1, KLRC3, 
KLRD1 
Costimulation by the 
CD28 family(R) 
0.0062 63 34 7.13E-11 3.21E-09 HLA-DRB4, HLA-DRB3, HLA-DRB1, MAP3K8, CD274, CDC42, 
CD247, PDPK1, CD4, ICOS, HLA-DQA2, HLA-DQA1, HLA-DQB2, 
HLA-DQB1, BTLA, MAP3K14, LCK, ICOSLG, PDCD1LG2, VAV1, 
LYN, CTLA4, HLA-DPA1, HLA-DPB1, HLA-DRA, PTPN6, CD28, 
CD3G, CD3E, CD3D, PAK1, CD86, CD80, GRAP2 
IL12-mediated 
signalling events(N) 
0.006 61 33 1.27E-10 5.46E-09 HLA-DRB1, JAK2, IL12RB1, IL2RG, GZMA, GZMB, IL2RA, IL2RB, 
CD247, IL18, IL1B, RELA, RELB, IL18R1, CD4, MAP2K3, LCK, 
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IL1R1, HLX, STAT4, STAT1, SOCS1, NFKB2, HLA-DRA, FASLG, 
CCL3, CD3G, CD3E, CD3D, CD8B, CD8A, GADD45B, IL18RAP 
Inflammatory bowel 
disease (IBD)(K) 
0.0064 65 34 1.58E-10 6.50E-09 GATA3, HLA-DRB4, HLA-DRB3, HLA-DRB1, IL12RB1, IL2RG, 
IL18, IL1A, IL1B, RELA, IL18R1, HLA-DQA2, HLA-DQA1, HLA-
DQB1, TNF, NOD2, IL21R, TLR4, TLR2, HLA-DPA1, HLA-DMA, 
HLA-DMB, STAT4, STAT1, HLA-DPB1, RORC, RORA, HLA-DOA, 
HLA-DOB, MAF, HLA-DRA, IL6, IL18RAP, TGFB1 
Beta1 integrin cell 
surface interactions(N) 
0.0065 66 34 2.33E-10 9.10E-09 FN1, COL3A1, ITGA2, ITGA1, ITGA8, ITGA5, VEGFA, PLAU, 
TGM2, VCAM1, FBN1, COL7A1, TNC, COL18A1, PLAUR, 
COL6A2, COL6A1, COL6A3, THBS2, THBS1, COL1A1, COL1A2, 
COL11A1, F13A1, COL5A1, COL5A2, LAMC2, LAMA2, LAMA3, 
LAMB3, COL4A1, COL4A4, COL4A3, TGFBI 
Antigen processing 
and presentation(K) 
0.0075 77 37 2.53E-10 9.43E-09 HLA-DRB4, HLA-DRB3, HLA-DRB1, LGMN, KIR3DL2, KIR2DL5A, 
CIITA, TAPBP, CD4, HLA-DQA2, HLA-DQA1, HLA-DQB1, TNF, 
HLA-B, HLA-F, HLA-E, PSME2, HLA-DPA1, HLA-DMA, HLA-DMB, 
HLA-DPB1, HLA-DOA, HLA-DOB, HLA-DRA, IFI30, CTSS, CTSB, 
CD74, CD8B, CD8A, KIR2DL1, KIR2DL4, TAP2, TAP1, KLRC1, 
KLRC3, KLRD1 
Type I diabetes 
mellitus(K) 
0.0042 43 27 2.62E-10 9.43E-09 HLA-DRB4, HLA-DRB3, HLA-DRB1, GZMB, IL1A, IL1B, HLA-
DQA2, HLA-DQA1, HLA-DQB1, TNF, HLA-B, HLA-F, HLA-E, LTA, 
HLA-DPA1, HLA-DMA, HLA-DMB, HLA-DPB1, HLA-DOA, HLA-
DOB, HLA-DRA, FASLG, PRF1, CD28, CD86, CD80, FAS 
Allograft rejection(K) 0.0036 37 25 2.74E-10 9.60E-09 HLA-DRB4, HLA-DRB3, HLA-DRB1, GZMB, HLA-DQA2, HLA-
DQA1, HLA-DQB1, TNF, HLA-B, HLA-F, HLA-E, HLA-DPA1, HLA-
DMA, HLA-DMB, HLA-DPB1, HLA-DOA, HLA-DOB, HLA-DRA, 
FASLG, PRF1, CD28, CD40, CD86, CD80, FAS 
PI3K-Akt signalling 
pathway(K) 
0.0338 345 96 3.77E-10 1.28E-08 PDGFB, PDGFC, FN1, JAK2, JAK3, JAK1, EGFR, COL3A1, 
ITGB4, ITGB8, ITGB6, ITGA2, ITGA1, ITGA8, ITGA5, IL2RG, 
IL2RA, IL2RB, KDR, LPAR1, LPAR4, PCK2, IGF1, SYK, RELA, 
VEGFC, VEGFA, KITLG, IL7R, FGF11, PDPK1, CSF1, TNC, 
FGF1, IFNAR2, COL27A1, PGF, MCL1, TLR4, TLR2, COMP, 
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EFNA5, EFNA3, FGFR3, FGFR2, FGFR1, COL6A2, COL6A1, 
COL6A3, COL6A6, THBS2, THBS1, NOS3, PPP2R3B, PPP2R2C, 
NGFR, COL1A1, COL1A2, COL11A1, BCL2L11, FLT4, PIK3CD, 
FASLG, PIK3CG, EPHA2, PIK3R5, CD19, OSMR, CCND2, 
PDGFRB, PDGFRA, IL6, COL5A1, COL5A3, COL5A2, LAMC2, 
LAMA2, LAMA3, LAMB3, CREB3L1, PHLPP2, CSF3R, CSF1R, 
VWF, IL3RA, SOS1, SOS2, GNG10, GNG11, RPTOR, TNXB, 
COL4A2, COL4A1, COL4A4, COL4A3, BAD 
Toxoplasmosis(K) 0.0116 118 47 4.70E-10 1.51E-08 HLA-DRB4, HLA-DRB3, HLA-DRB1, JAK2, JAK1, CIITA, RELA, 
GNAI2, IRAK1, PDPK1, HLA-DQA2, HLA-DQA1, HLA-DQB1, 
ALOX5, LDLR, IL10RB, IL10RA, TNF, MAP2K3, TLR4, TLR2, 
CASP8, MAPK8, HLA-DPA1, HLA-DMA, HLA-DMB, STAT1, HLA-
DPB1, HLA-DOA, HLA-DOB, SOCS1, HLA-DRA, MYD88, 
PIK3CD, PIK3CG, BIRC3, PIK3R5, CD40, LAMC2, LAMA2, 
LAMA3, LAMB3, MAPK13, MAPK11, TGFB1, NFKBIA, BAD 
TCR signalling in 
na&#xef;ve CD8+ T 
cells(N) 
0.0053 54 30 4.72E-10 1.51E-08 MAP3K8, SHC1, LCP2, CD247, CARD11, PDPK1, PRKCQ, 
BCL10, MAP3K14, LAT, LCK, VAV1, TRPV6, ZAP70, PTPRC, 
PTPN6, PRF1, RASSF5, CD28, CD3G, CD3E, CD3D, CD86, 
CD80, CD8B, CD8A, RASGRP1, GRAP2, STIM1, SOS1 
T cell receptor 
signalling pathway(K) 
0.0102 104 43 8.63E-10 2.67E-08 MAP3K8, LCP2, CDC42, CD247, PPP3CC, RELA, CARD11, 
PDPK1, CD4, PRKCQ, BCL10, ICOS, NFATC2, CSF2, TNF, 
MAP3K14, LAT, LCK, CBLC, VAV1, ZAP70, CTLA4, PTPRC, 
PIK3CD, PIK3CG, PTPN6, PIK3R5, CD28, CD3G, CD3E, CD3D, 
PAK1, PAK6, CD8B, CD8A, RASGRP1, MAPK13, MAPK11, ITK, 
GRAP2, SOS1, SOS2, NFKBIA 
T cell activation(P) 0.0079 81 37 9.71E-10 2.91E-08 LCP2, CDC42, CD247, PPP3CC, RAC2, PRKCQ, HLA-DQA2, 
HLA-DQA1, NFATC2, NFATC4, LAT, LCK, VAV1, ZAP70, MAPK8, 
HLA-DPA1, HLA-DMA, HLA-DMB, HLA-DOA, NFKB2, PTPRC, 
HLA-DRA, PIK3CD, PIK3CG, CD28, CD3G, CD3E, CD3D, PAK1, 
CD74, CD86, GRAP2, ITPR1, SOS1, SOS2, WAS, NFKBIA 
Proteoglycans in 
cancer(K) 
0.0199 203 65 1.69E-09 4.89E-08 FRS2, FN1, EGFR, WNT7B, WNT7A, ITGA2, ITGA5, ROCK1, 
CDC42, KDR, IGF1, ARHGEF1, VEGFA, PLAU, PDPK1, TNF, 
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CBLC, TIAM1, TLR4, TLR2, WNT5B, WNT5A, WNT3A, FGFR1, 
WNT2B, PLAUR, DCN, THBS1, LUM, HSPG2, FLNB, FLNC, 
PIK3CD, FASLG, PIK3CG, PPP1R12C, PTPN6, ANK3, ANK1, 
PIK3R5, PAK1, GPC1, PPP1CA, WNT4, MMP2, MMP9, MAPK13, 
MAPK11, HIF1A, PLCG2, FZD1, WNT10B, WNT10A, FZD7, 
MRAS, HCLS1, HBEGF, ITPR1, ITPR2, SOS1, SOS2, EZR, FAS, 
TGFB1, CAMK2D 
Viral myocarditis(K) 0.0057 58 30 2.38E-09 6.66E-08 CXADR, HLA-DRB4, HLA-DRB3, HLA-DRB1, ITGB2, ITGAL, 
RAC2, HLA-DQA2, HLA-DQA1, HLA-DQB1, HLA-B, HLA-F, HLA-
E, CASP8, MYH6, HLA-DPA1, HLA-DMA, HLA-DMB, HLA-DPB1, 
HLA-DOA, HLA-DOB, HLA-DRA, PRF1, CD28, CD40, CD86, 
CD80, LAMA2, ABL2, EIF4G1 
Chagas disease 
(American 
trypanosomiasis)(K) 
0.0102 104 42 2.63E-09 7.11E-08 CD247, IL1B, RELA, GNAI2, IRAK1, TNF, TLR9, TLR4, TLR2, 
C1QB, C1QA, C1QC, CASP8, GNA15, MAPK8, PPP2R2C, C3, 
TICAM1, MYD88, PIK3CD, FASLG, PIK3CG, CCL5, CCL3, CCL2, 
PIK3R5, CD3G, CD3E, CD3D, CCL3L1, IL6, MAPK13, MAPK11, 
SERPINE1, ACE, PLCB3, CFLAR, FAS, TGFB1, NFKBIA, 
BDKRB2, TGFBR2 
Herpes simplex 
infection(K) 
0.018 184 60 3.73E-09 9.70E-08 HLA-DRB4, HLA-DRB3, HLA-DRB1, JAK2, JAK1, TNFSF14, IL15, 
IL1B, RELA, CFP, HLA-DQA2, HLA-DQA1, HLA-DQB1, TNF, 
IFNAR2, PML, IFIT1, HLA-B, HLA-F, HLA-E, TLR9, TLR3, TLR2, 
CASP8, OAS1, OAS2, OAS3, LTA, MAPK8, C3, HLA-DPA1, HLA-
DMA, HLA-DMB, STAT1, HLA-DPB1, HLA-DOA, HLA-DOB, 
TICAM1, SOCS3, HLA-DRA, MYD88, FASLG, CCL5, CCL2, 
PVRL2, PVRL1, CD74, PPP1CA, IL6, IRF7, TAF13, MED8, TAP2, 
TAP1, TRAF2, TRAF1, TRAF3, ARNTL, FAS, NFKBIA 
GPVI-mediated 
activation cascade(R) 
0.0048 49 27 4.05E-09 1.05E-07 JAK2, JAK3, JAK1, SHC1, LCP2, IL2RG, IL2RA, IL2RB, RAC2, 
FCER1G, SYK, PDPK1, CSF2, LAT, LCK, VAV1, PDPN, LYN, 
PIK3CD, PIK3CG, PTPN6, PIK3R6, PIK3R5, PLCG2, IL3RA, 
CSF2RB, CSF2RA 
Influenza A(K) 0.0171 175 57 9.49E-09 2.37E-07 HLA-DRB4, HLA-DRB3, HLA-DRB1, JAK2, JAK1, CIITA, 
TNFSF10, IL18, IL1A, IL1B, RELA, IL33, PRSS3, NUP98, HLA-
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DQA2, HLA-DQA1, HLA-DQB1, TNF, IFNAR2, MAP2K3, PML, 
TLR4, TLR3, CASP1, OAS1, OAS2, OAS3, MAPK8, HLA-DPA1, 
HLA-DMA, HLA-DMB, STAT1, HLA-DPB1, HLA-DOA, HLA-DOB, 
TICAM1, SOCS3, TNFRSF10B, TNFRSF10D, CXCL10, HLA-
DRA, MYD88, PIK3CD, FASLG, PIK3CG, FURIN, CCL5, CCL2, 
RSAD2, PIK3R5, IL6, IRF7, MAPK13, MAPK11, PYCARD, FAS, 
NFKBIA 
Phagosome(K) 0.015 153 52 1.11E-08 2.66E-07 HLA-DRB4, HLA-DRB3, HLA-DRB1, PLA2R1, CORO1A, ITGB2, 
ITGA2, ITGA5, C1R, ATP6V1C2, MSR1, CD209, HLA-DQA2, 
HLA-DQA1, HLA-DQB1, TCIRG1, HLA-B, HLA-F, HLA-E, RAB7B, 
TLR4, TLR2, COMP, NOS1, THBS2, THBS1, C3, TUBA1A, HLA-
DPA1, HLA-DMA, HLA-DMB, HLA-DPB1, NCF1, NCF2, NCF4, 
HLA-DOA, HLA-DOB, TUBA4A, HLA-DRA, FCGR3A, FCGR1A, 
FCGR2B, FCGR2C, CTSS, CD36, STX18, CYBA, MRC2, TAP2, 
TAP1, CLEC7A, MARCO 
Signalling by 
Interleukins(R) 
0.0274 280 78 1.65E-08 3.81E-07 FRS2, PDGFB, NEFL, JAK2, JAK3, JAK1, DUSP5, DUSP7, 
EGFR, MAP3K8, SHC1, NRG1, IL2RG, IL2RA, IL2RB, IL27RA, 
LGALS9, STAT5B, IL11, SYK, IL18, IL1A, IL1B, RELA, GRIN1, 
KITLG, FBXW11, IRAK1, IRAK2, IL7R, PTK2B, CNTF, TOLLIP, 
CLCF1, CSF2, FGF1, LAT, NOD1, NOD2, IL1RN, IL1R1, LIF, 
VAV1, FGFR3, FGFR2, FGFR1, BLNK, CASP1, RASA2, PSME2, 
PELI3, STAT1, SOCS3, NFKB2, MYD88, RASGRF2, PIK3CD, 
KSR1, PTPN6, OSMR, PDGFRB, PDGFRA, RASGRP1, 
RASGRP4, RASGRP3, IL6, HAVCR2, HBEGF, RASAL1, RASAL3, 
IL3RA, SOS1, EBI3, INPP5D, CSF2RB, CSF2RA, MARK3, 
CAMK2D 
MAPK signalling 
pathway(K) 
0.025 255 73 1.66E-08 3.81E-07 CACNA2D1, CACNA2D3, CACNA2D4, DDIT3, PDGFB, DUSP5, 
DUSP1, DUSP7, EGFR, TAOK2, MAP3K8, MAP3K6, MAP3K5, 
CDC42, NTRK2, PPP3CC, RAC2, IL1A, IL1B, RELA, RELB, 
MAP3K2, CACNA1C, CACNA1I, FGF11, MKNK1, FGF1, TNF, 
MAP2K3, MAP3K14, RPS6KA2, RPS6KA1, IL1R1, FGFR3, 
FGFR2, FGFR1, RASA2, MAPK8, GNA12, ECSIT, FLNB, FLNC, 
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MAPKAPK2, MAX, NFKB2, RASGRF2, FASLG, ARRB2, PPM1A, 
PTPN7, PTPRR, PAK1, PDGFRB, PDGFRA, RASGRP1, 
RASGRP4, RASGRP3, PLA2G4F, PLA2G4E, MAPK13, MAPK11, 
MRAS, CACNB1, DUSP10, TRAF2, SOS1, SOS2, GADD45B, 
GADD45A, MAP4K1, FAS, TGFB1, TGFBR2 
Primary 
immunodeficiency(K) 
0.0035 36 22 1.83E-08 4.21E-07 JAK3, CIITA, IL2RG, BTK, IL7R, CD4, ICOS, LCK, CD79A, BLNK, 
ZAP70, AIRE, PTPRC, CD19, CD40, TNFRSF13B, CD3E, CD3D, 
CD8B, CD8A, TAP2, TAP1 
ECM-receptor 
interaction(K) 
0.0085 87 36 1.94E-08 4.26E-07 FN1, COL3A1, ITGB4, ITGB8, ITGB6, ITGA2, ITGA1, ITGA8, 
ITGA5, TNC, COL27A1, COMP, COL6A2, COL6A1, COL6A3, 
COL6A6, THBS2, THBS1, HSPG2, COL1A1, COL1A2, COL11A1, 
CD36, COL5A1, COL5A3, COL5A2, LAMC2, LAMA2, LAMA3, 
LAMB3, VWF, TNXB, COL4A2, COL4A1, COL4A4, COL4A3 
Amoebiasis(K) 0.0106 108 41 2.17E-08 4.78E-07 FN1, COL3A1, ITGB2, ACTN1, IL1B, RELA, CSF2, TNF, 
COL27A1, IL1R1, RAB7B, TLR4, TLR2, GNA15, COL1A1, 
COL1A2, SERPINB13, COL11A1, PIK3CD, PIK3CG, CD1D, 
PIK3R5, CTSG, IL6, COL5A1, COL5A3, COL5A2, LAMC2, 
LAMA2, LAMA3, LAMB3, SERPINB3, SERPINB4, SERPINB2, 
PLCB3, COL4A2, COL4A1, COL4A4, COL4A3, TGFB1, CXCL1 
CXCR4-mediated 
signalling events(N) 
0.0078 80 34 2.55E-08 5.35E-07 HLA-DRB1, JAK2, BLK, CDC42, CD247, STAT5B, GNAI2, GRK6, 
PDPK1, PTK2B, CD4, LCK, VAV1, HCK, LIMK1, LYN, STAT1, 
PTPRC, CXCL12, HLA-DRA, ARRB2, PTPN6, CD3G, CD3E, 
CD3D, PAK1, RGS1, SSH1, MMP9, PLCB3, INPP5D, CXCR4, 
FGR, BAD 
NOD-like receptor 
signalling pathway(K) 
0.0056 57 27 8.40E-08 1.76E-06 PYDC1, NAIP, IL18, IL1B, RELA, CARD18, TNFAIP3, TNF, 
NOD1, NLRC4, NOD2, NLRP1, CASP8, CASP1, MAPK8, BIRC3, 
CCL5, CCL2, IL6, MAPK13, MAPK11, MEFV, CARD9, PYCARD, 
NFKBIA, CXCL1, CXCL2 
Platelet activation(K) 0.0127 130 44 1.62E-07 3.25E-06 COL3A1, ITGA2, LCP2, ROCK1, BTK, FCER1G, SYK, ARHGEF1, 
GNAI2, ADCY4, ADCY7, COL27A1, P2RY1, F2RL3, GUCY1B3, 
GUCY1A3, GUCY1A2, NOS3, MYLK, LYN, COL1A1, COL1A2, 
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FERMT3, COL11A1, PTGS1, PIK3CD, PIK3CG, PIK3R5, 
PPP1CA, RASGRP1, COL5A1, COL5A3, COL5A2, PLA2G4F, 
PLA2G4E, MAPK13, MAPK11, PLCG2, PLCB3, STIM1, ITPR1, 
ITPR2, VWF, PTGIR 
B cell activation(P) 0.0058 59 27 1.64E-07 3.28E-06 BTK, GRAP, RAC2, SYK, MAP3K2, NFATC2, NFATC4, CD79B, 
CD79A, VAV1, BLNK, MAPK8, LYN, NFKB2, PTPRC, PIK3CD, 
PIK3CG, CD19, CD22, MAPK13, MAPK11, PLCG2, ITPR1, 
ITPR2, SOS1, SOS2, NFKBIA 
Autoimmune thyroid 
disease(K) 
0.0051 52 25 1.90E-07 3.61E-06 HLA-DRB4, HLA-DRB3, HLA-DRB1, GZMB, HLA-DQA2, HLA-
DQA1, HLA-DQB1, HLA-B, HLA-F, HLA-E, CTLA4, HLA-DPA1, 
HLA-DMA, HLA-DMB, HLA-DPB1, HLA-DOA, HLA-DOB, HLA-
DRA, FASLG, PRF1, CD28, CD40, CD86, CD80, FAS 
Signalling by NGF(R) 0.0382 390 95 2.32E-07 4.41E-06 FRS2, PDGFB, MOV10, NEFL, JAK2, JAK3, JAK1, DUSP5, 
DUSP7, EGFR, SHC1, NRG1, ADORA2A, IL2RG, NTRK2, IL2RA, 
IL2RB, NET1, ARHGEF3, ARHGEF4, ARHGEF1, ARHGEF7, 
RELA, GRIN1, KITLG, IRAK1, PDPK1, ADCY4, ADCY7, FGD3, 
CSF2, FGF1, LAT, PLEKHG5, LCK, HDAC2, TNRC6A, RPS6KA2, 
RPS6KA1, TIAM1, MAGED1, PSENEN, VAV1, FGFR3, FGFR2, 
FGFR1, RASA2, MAPK8, MEF2A, PRKAR1B, PSME2, NGEF, 
PRKAR2B, NGFR, MAPKAPK2, BCL2L11, MYD88, RASGRF2, 
PIK3CD, KSR1, FURIN, CD19, CD28, AP2A1, PCSK6, AATF, 
CD86, CD80, PDGFRB, PDGFRA, RASGRP1, RASGRP4, 
RASGRP3, ARHGEF17, MAPK13, MAPK11, HBEGF, PHLPP2, 
ITPR1, ITPR2, RASAL1, RASAL3, IL3RA, SOS1, SOS2, PDE1B, 
PDE1A, CAMK4, CSF2RB, CSF2RA, MARK3, NFKBIA, CAMK2D, 
BAD, TRAT1 
Malaria(K) 0.0048 49 24 2.39E-07 4.54E-06 ITGB2, ITGAL, IL18, IL1B, VCAM1, TNF, CR1, PECAM1, TLR9, 
TLR4, TLR2, COMP, SELE, SELP, THBS2, THBS1, MYD88, 
LRP1, CCL2, CD40, CD36, IL6, KLRB1, TGFB1 
Toll-like receptor 
signalling pathway(K) 
0.0104 106 38 2.84E-07 5.11E-06 MAP3K8, IL1B, RELA, IRAK1, TOLLIP, TNF, IFNAR2, MAP2K3, 
TLR9, TLR8, TLR4, TLR3, TLR2, CCL4L1, CASP8, MAPK8, 
STAT1, TICAM1, CXCL10, CXCL11, MYD88, PIK3CD, PIK3CG, 
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CCL5, CCL3, PIK3R5, CD40, CD86, CD80, CCL3L1, IL6, IRF7, 
IRF5, MAPK13, MAPK11, TRAF3, NFKBIA, CXCL9 
Inflammation mediated 
by chemokine and 
cytokine signalling 
pathway(P) 
0.0071 73 30 3.28E-07 5.91E-06 JAK2, CISH, ITGAL, ROCK1, GRAP, RAC2, MAP3K2, GRK6, 
PDPK1, PTK2B, VAV1, ALOX12, COL6A1, GNA15, MYLK, 
SOCS3, NFKB2, PIK3CD, PIK3CG, CCR4, PLCG2, PLCB3, 
PLCD3, PLCD1, VWF, SOS1, PLCL2, NFKBIA, RGS13, ALOX5AP 
Ras signalling 
pathway(K) 
0.0222 227 63 4.45E-07 7.69E-06 PDGFB, PDGFC, EGFR, SHC1, CDC42, KDR, IGF1, RAC2, 
RELA, VEGFC, GRIN1, VEGFA, KITLG, ETS2, PLD2, FGF11, 
CSF1, FGF1, PGF, LAT, CALML5, CALML3, TIAM1, EFNA5, 
EFNA3, FGFR3, FGFR2, FGFR1, ZAP70, RASA2, MAPK8, 
NGFR, FLT4, RASGRF2, PIK3CD, FASLG, PIK3CG, KSR1, 
RASSF5, EPHA2, PIK3R5, PAK1, PAK6, PDGFRB, PDGFRA, 
RASGRP1, RASGRP4, RASGRP3, PLA2G4F, PLA2G4E, 
PLA2G2A, PLCG2, REL, MRAS, CSF1R, RASAL1, RASAL3, 
ABL2, SOS1, SOS2, GNG10, GNG11, BAD 
Asthma(K) 0.0029 30 18 4.52E-07 7.69E-06 HLA-DRB4, HLA-DRB3, HLA-DRB1, FCER1A, FCER1G, MS4A2, 
HLA-DQA2, HLA-DQA1, HLA-DQB1, TNF, HLA-DPA1, HLA-DMA, 
HLA-DMB, HLA-DPB1, HLA-DOA, HLA-DOB, HLA-DRA, CD40 
Signalling by VEGF(R) 0.0268 274 72 5.02E-07 8.54E-06 FRS2, PDGFB, SHB, NEFL, JAK2, JAK3, JAK1, DUSP5, DUSP7, 
EGFR, SHC1, NRG1, ROCK1, IL2RG, CDC42, IL2RA, IL2RB, 
KDR, NRP1, NRP2, VEGFC, GRIN1, VEGFA, KITLG, PDPK1, 
PTK2B, NCKAP1L, CSF2, FGF1, PGF, LAT, SH2D2A, VAV1, 
FGFR3, FGFR2, FGFR1, RASA2, NOS3, PSME2, NCF1, NCF2, 
NCF4, MAPKAPK2, FLT4, RASGRF2, KSR1, BAIAP2, PAK1, 
PDGFRB, PDGFRA, CYBA, RASGRP1, RASGRP4, RASGRP3, 
MAPK13, MAPK11, CYFIP2, HBEGF, CDH5, ITPR1, ITPR2, 
RASAL1, RASAL3, IL3RA, SOS1, WASF2, ELMO1, ELMO2, 
CSF2RB, CSF2RA, MARK3, CAMK2D 
Validated 
transcriptional targets 
of AP1 family members 
Fra1 and Fra2(N) 
0.0036 37 20 5.33E-07 9.06E-06 ITGB4, PLAU, GJA1, HMOX1, NFATC2, FOSL2, FOSL1, THBD, 
LIF, PLAUR, DCN, NOS3, COL1A2, CCL2, IL6, MMP1, MMP2, 
MMP9, LAMA3, JUNB 
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Pertussis(K) 0.0073 75 30 5.68E-07 9.08E-06 ITGB2, ITGA5, C1S, C1R, IL1A, IL1B, RELA, GNAI2, IRAK1, TNF, 
NOD1, CALML5, CALML3, TLR4, C1QB, C1QA, C1QC, CASP7, 
CASP1, MAPK8, C2, C3, TICAM1, MYD88, IL6, IRF8, MAPK13, 
MAPK11, SERPING1, PYCARD 
Fc gamma R-mediated 
phagocytosis(K) 
0.009 92 34 6.06E-07 9.70E-06 ARPC3, CDC42, RAC2, SYK, PLD2, ASAP3, ARPC1B, GSN, LAT, 
PPAP2B, VAV1, HCK, AMPH, DNM2, LIMK2, LIMK1, LYN, NCF1, 
PTPRC, PIK3CD, PIK3CG, FCGR3A, FCGR1A, FCGR2B, 
PIK3R5, PAK1, PLA2G4F, PLA2G4E, BIN1, PLCG2, WASF2, 
INPP5D, WAS, DOCK2 
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Table T3-7: Full list of pathways enriched for genes positively correlated (at 
FDR<0.00001) with tumour VDR expression in the TCGA metastatic 
melanomas 
The source database for each of the enriched pathways are indicated by a letter 
in parentheses after each pathway gene set name. The source database 
annotations are: C - CellMap, R – Reactome, K – KEGG, N – NCI PID, P - 
Panther, and B – BioCarta.  
The description of column headers are:  Ratio of protein in gene set: ratios of 
numbers of genes contained in pathways to total genes in the Reactome FI 
network; Number of protein in gene set: numbers of genes in pathways; Protein 
from network: numbers of hit genes from the query gene list; Nodes: nodal genes 
from my input query gene list, which ‘matches’ with the genes in a particular 
pathway; P-value was estimated by Reactome FIViz using hypergeometric test 
and the corresponding FDR was estimated by Benjamini Hochberg multiple 
correction 
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Chemokine signalling 
pathway(K) 
0.0183 187 74 1.11E-16 1.57E-14 LYN, JAK3, STAT1, NCF1, CXCL13, CXCL14, CXCL16, CXCL10, 
CXCL11, CXCL12, PIK3CD, ARRB2, PIK3CG, CCL8, CCL7, 
CCL5, CCL4, CCL3, CCL2, PIK3R5, CCR1, GNGT2, RAC2, 
CCR8, CCR7, CCR6, CCR5, CCR4, CCR3, CCR2, CCL3L1, 
RASGRP2, PTK2B, PRKCB, ITK, CCL14, CCL13, CCL11, 
ADCY4, ADCY2, ADCY1, ADCY7, CCL19, CCL18, CCL17, 
CCL23, CCL22, CCL21, CCL20, CCL26, XCL2, XCL1, CX3CR1, 
TIAM1, XCR1, VAV1, HCK, CXCR5, WAS, CXCR4, CXCR6, 
CXCR1, CXCR3, CXCR2, ELMO1, NFKBIA, CXCL6, CXCL9, 
CXCL1, CXCL3, CXCL2, CXCL5, FGR, DOCK2 
Extracellular matrix 
organization(R) 
0.0243 248 96 1.11E-16 1.57E-14 F11R, COL13A1, PDGFB, ADAMTS14, FN1, COL1A1, COL1A2, 
TPSAB1, BGN, MMP10, MMP12, MMP11, MMP13, COL11A1, 
JAM2, COL3A1, EFEMP1, IBSP, COL17A1, ITGAM, ITGB4, 
ITGB3, ITGB2, ITGAL, ITGAX, ITGB8, ITGB7, ITGA4, ITGA3, 
ITGAD, ITGA7, ITGA5, COL15A1, ICAM2, ICAM3, ICAM4, ICAM1, 
ACTN1, SDC1, CTSS, CTSK, CTSG, CTSD, CTSB, LOXL1, 
PCOLCE, VCAM1, COL5A1, COL5A3, COL5A2, LAMC2, MMP7, 
MMP1, MMP2, MMP3, MMP8, MMP9, VCAN, PLEC, LAMA2, 
LAMA3, LAMB3, COL7A1, SERPINE1, COL12A1, ELN, COL10A1, 
TIMP1, FMOD, TNC, COL27A1, ADAM8, VTN, ITGA11, 
COL14A1, ADAMTS2, PECAM1, MFAP5, MFAP4, TLL1, COL8A2, 
COL8A1, KLK7, COMP, COL4A4, COL4A3, LTBP1, FBLN2, 
FBLN5, TGFB1, DCN, COL6A2, COL6A1, COL6A3, THBS1, LUM 
GPCR ligand 
binding(R) 
0.0381 389 107 1.11E-16 1.57E-14 HTR7, C3AR1, FPR1, FPR3, FPR2, C3, GPR18, PTAFR, 
P2RY13, P2RY10, GPR68, GPR65, CXCL13, CXCL16, ADORA1, 
UTS2, HTR1F, CXCL10, CXCL11, CXCL12, ADORA2A, CCL7, 
CCL5, CCL4, CCL3, CCL2, LPAR1, CCR1, MC1R, LPAR5, CCR8, 
CCR7, CCR6, CCR5, CCR4, CCR3, CCR2, RAMP3, RAMP1, 
CCRL2, CCL3L1, WNT1, WNT2, GRM2, SSTR2, SSTR3, GRPR, 
ADM, GPR132, ANXA1, TACR1, CCL11, CCL19, CCL17, CCL23, 
CCL22, CCL21, CCL20, AGT, ADM2, CYSLTR1, CYSLTR2, 
ADRA2A, XCL2, XCL1, CX3CR1, P2RY6, P2RY2, PTGFR, 
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NTSR1, XCR1, FFAR2, EDN1, OPRD1, PTGER2, PTGER3, 
CXCR5, CXCR4, CXCR6, CXCR1, CXCR3, CXCR2, SAA1, 
F2RL1, GHRL, F2RL3, PMCH, WNT5A, APLNR, SUCNR1, 
C5AR1, ADRB2, HRH1, HRH2, NMUR1, CXCL6, CXCL9, CXCL1, 
CXCL3, CXCL2, CXCL5, BDKRB2, BDKRB1, PTGIR, S1PR1, 
S1PR4, POMC 
Cytokine-cytokine 
receptor interaction(K) 
0.0259 265 133 1.11E-16 1.57E-14 PDGFB, IL20RA, IL20RB, IL22RA2, NGFR, IL22RA1, CTF1, 
EGFR, IL12RB1, IL12RB2, CXCL13, CXCL14, CXCL16, 
TNFRSF8, TNFRSF4, TNFRSF11B, TNFRSF11A, TNFRSF17, 
TNFRSF9, TNFRSF10C, TNFRSF10A, TNFRSF10D, CXCL10, 
CXCL11, CXCL12, FLT3, FASLG, TNFSF13B, TNFRSF1B, 
IL2RG, CCL8, CCL7, CCL5, CCL4, CCL3, CCL2, IL2RA, IL2RB, 
TNFRSF6B, TNFSF10, TNFSF11, IL12B, IL12A, CCR1, TNFSF14, 
TNFSF13, CD27, CD40, TNFRSF13B, IL24, CCR8, CCR7, CCR6, 
CCR5, CCR4, CCR3, CCR2, IL10, IL11, TNFRSF12A, IL15, IL18, 
IL1A, IL1B, CD70, OSM, VEGFC, KITLG, IL18R1, PDGFRA, IL4R, 
CCL3L1, INHBA, IL6, IL7, IL7R, IL9R, TNFSF4, TNFSF8, CCL14, 
CCL13, CCL11, CCL19, CCL18, CCL17, CCL23, CCL22, CCL21, 
CCL20, IL10RA, CLCF1, CCL26, CSF3, CSF3R, CSF2, CSF1, 
TNF, EDAR, CSF1R, IL3RA, XCL2, XCL1, CX3CR1, IL21R, 
IL15RA, IL1R1, IL1R2, FLT3LG, IL23A, XCR1, LIF, CXCR5, 
CXCR4, CXCR6, CXCR1, CXCR3, CXCR2, CD40LG, IL18RAP, 
HGF, CSF2RB, CSF2RA, TGFB1, BMPR1B, CXCL6, CXCL9, 
CXCL1, CXCL3, CXCL2, CXCL5, IFNG, LTA, LTB 
Osteoclast 
differentiation(K) 
0.0128 131 61 1.11E-16 1.57E-14 SPI1, STAT1, NCF1, NCF2, NCF4, TNFRSF11B, TNFRSF11A, 
SOCS3, SOCS1, NFKB2, ITGB3, FHL2, PIK3CD, PIK3CG, 
FCGR3A, FCGR3B, LCP2, FCGR1A, FCGR2A, FCGR2B, 
TNFSF11, BTK, PIK3R5, CTSK, SYK, IL1A, IL1B, RELB, CYBB, 
CYBA, OSCAR, TYROBP, IRF9, MAPK13, TEC, JUNB, PLCG2, 
FOSL2, FOSL1, CYLD, CSF1, TNF, CSF1R, TREM2, LCK, IL1R1, 
LILRA6, LILRA1, LILRA3, LILRA4, LILRA5, LILRB1, LILRB2, 
LILRB4, LILRB5, CAMK4, SIRPG, TGFB1, NFKBIA, BLNK, IFNG 
 
 
223 
GeneSet Ratio Of Protein In GeneSet 
No. Of Protein 
In GeneSet 
Protein From 
Network P-value FDR Nodes 
Hematopoietic cell 
lineage(K) 
0.0085 87 57 1.11E-16 1.57E-14 ITGAM, FLT3, ITGB3, ITGA4, ITGA3, ITGA5, FCGR1A, IL2RA, 
ANPEP, CD1E, CD1C, CD1B, CD1A, CD19, CD14, CD24, CD22, 
CD3G, CD3E, CD3D, CD38, CD37, CD33, IL11, MME, IL1A, IL1B, 
KITLG, IL4R, CD8B, CD8A, IL6, IL7, IL7R, MS4A1, IL9R, CD2, 
CD4, CD5, CD7, CD9, GP5, FCER2, CSF3, CSF3R, CSF2, CSF1, 
TNF, CSF1R, CR2, CR1, IL3RA, IL1R1, IL1R2, FLT3LG, GP1BA, 
CSF2RA 
NF-kappa B signalling 
pathway(K) 
0.0089 91 45 3.33E-16 3.53E-14 LYN, PTGS2, TICAM2, LY96, TNFRSF11A, NFKB2, CXCL12, 
TNFSF13B, BIRC3, CCL4, ICAM1, TNFSF11, BTK, CD14, 
TNFSF14, CD40, SYK, IL1B, RELB, PLAU, CARD11, VCAM1, 
TNFAIP3, BCL2A1, PRKCB, PRKCQ, PLCG2, CCL13, CCL19, 
CCL21, TNF, LAT, LBP, TRAF1, LCK, IL1R1, GADD45B, TLR4, 
CD40LG, NFKBIA, CXCL2, BLNK, ZAP70, LTA, LTB 
IL12-mediated 
signalling events(N) 
0.006 61 37 3.33E-16 3.53E-14 STAT4, IL12RB1, IL12RB2, STAT1, SOCS1, NFKB2, FASLG, 
IL2RG, CCL4, CCL3, GZMA, GZMB, IL2RA, IL2RB, CD247, 
IL12B, IL12A, CD3G, CD3E, CD3D, CCR5, IL18, IL1B, RELB, 
IL18R1, EOMES, CD8B, CD8A, TBX21, CD4, LCK, B2M, IL1R1, 
GADD45B, GADD45G, IL18RAP, IFNG 
Rheumatoid 
arthritis(K) 
0.0087 89 42 1.49E-14 1.40E-12 CTLA4, TNFRSF11A, CXCL12, ITGB2, ITGAL, TNFSF13B, CCL5, 
CCL3, CCL2, ICAM1, TNFSF11, TNFSF13, CD28, CTSK, IL11, 
IL15, IL18, IL1A, IL1B, CD86, CD80, CCL3L1, IL6, MMP1, MMP3, 
TEK, CCL20, CSF2, CSF1, TNF, TCIRG1, IL23A, ATP6V0D2, 
ATP6V0A4, TLR4, TLR2, TGFB1, CXCL6, CXCL1, CXCL5, IFNG, 
LTB 
Natural killer cell 
mediated 
cytotoxicity(K) 
0.0131 134 52 2.39E-14 2.01E-12 KLRK1, HCST, KIR3DL1, KIR3DL2, TNFRSF10C, TNFRSF10A, 
TNFRSF10D, ITGB2, PIK3CD, FASLG, ITGAL, PIK3CG, 
FCGR3A, FCGR3B, LCP2, GZMB, PTPN6, CD247, CD244, PRF1, 
ICAM2, ICAM1, TNFSF10, PIK3R5, RAC2, FCER1G, SYK, NCR3, 
CD48, MICB, TYROBP, KIR2DL3, KIR2DL4, PTK2B, PRKCB, 
PLCG2, KIR2DS4, CSF2, TNF, LAT, LCK, SH2D1A, SH2D1B, 
RAET1E, RAET1G, VAV1, KLRC1, KLRC2, KLRD1, ULBP2, 
ZAP70, IFNG 
 
 
224 
GeneSet Ratio Of Protein In GeneSet 
No. Of Protein 
In GeneSet 
Protein From 
Network P-value FDR Nodes 
Amoebiasis(K) 0.0106 108 46 3.10E-14 2.39E-12 FN1, COL1A1, COL1A2, SERPINB13, COL11A1, COL3A1, 
ITGAM, ITGB2, PIK3CD, PIK3CG, IL12B, IL12A, ACTN1, PIK3R5, 
CD14, C8G, CTSG, IL10, IL1B, IL6, COL5A1, COL5A3, COL5A2, 
LAMC2, LAMA2, LAMA3, LAMB3, LAMB4, PRKCB, SERPINB3, 
SERPINB4, SERPINB2, ADCY1, CSF2, TNF, COL27A1, IL1R1, 
IL1R2, TLR4, TLR2, COL4A4, COL4A3, TGFB1, CXCL1, IFNG, 
GNA15 
Malaria(K) 0.0048 49 30 1.53E-13 1.07E-11 KLRK1, ITGB2, ITGAL, CCL2, ICAM1, IL12A, SDC1, CD40, IL10, 
IL18, IL1B, VCAM1, IL6, CSF3, TNF, CR1, PECAM1, TLR9, TLR4, 
TLR2, CD40LG, COMP, HGF, KLRB1, TGFB1, SELE, SELP, 
IFNG, THBS2, THBS1 
TNF signalling 
pathway(K) 
0.0108 110 45 2.30E-13 1.49E-11 CASP10, RIPK3, PTGS2, MAP3K8, MAP3K5, SOCS3, CXCL10, 
PIK3CD, PIK3CG, TNFRSF1B, BIRC3, CCL5, CCL2, ICAM1, 
PIK3R5, IL15, IL1B, VEGFC, IL18R1, VCAM1, IL6, TNFAIP3, 
MMP3, MMP9, MAPK13, CREB3L1, JUNB, CCL20, CSF2, CSF1, 
TNF, BCL3, TRAF1, CEBPB, NOD2, LIF, EDN1, MLKL, SELE, 
NFKBIA, CXCL1, CXCL3, CXCL2, CXCL5, LTA 
Beta1 integrin cell 
surface interactions(N) 
0.0065 66 34 4.47E-13 2.68E-11 FN1, COL1A1, COL1A2, COL11A1, JAM2, COL3A1, ITGA4, 
ITGA3, ITGA7, ITGA5, CD14, PLAU, TGM2, NPNT, VCAM1, 
COL5A1, COL5A2, LAMC2, LAMA2, LAMA3, LAMB3, COL7A1, 
TNC, VTN, ITGA11, COL4A4, COL4A3, TGFBI, PLAUR, COL6A2, 
COL6A1, COL6A3, THBS2, THBS1 
Staphylococcus 
aureus infection(K) 
0.0054 55 31 5.00E-13 2.80E-11 C3AR1, FPR1, FPR3, FPR2, C2, C3, PTAFR, ITGAM, ITGB2, 
ITGAL, FCGR3A, FCGR3B, MBL2, DSG1, C1S, C1R, FCGR1A, 
FCGR2A, FCGR2B, ICAM1, IL10, SELPLG, MASP1, CFB, CFD, 
CFH, C1QB, C1QA, C1QC, C5AR1, SELP 
Tuberculosis(K) 0.0173 177 58 7.81E-13 4.14E-11 C3, CASP10, SPHK1, STAT1, PLA2R1, CORO1A, CIITA, ITGAM, 
ITGB2, FCGR3A, FCGR3B, ITGAX, FCGR1A, FCGR2A, 
FCGR2B, IL12B, IL12A, CD14, CD209, CTSS, CTSD, IL10, 
FCER1G, SYK, IL18, IL1A, IL1B, CD74, IRAK2, IL6, MAPK13, 
PLK3, MRC2, MRC1, IL10RA, CARD9, TNF, CLEC4E, CLEC7A, 
LSP1, TCIRG1, LBP, CR1, CEBPB, NOD2, CALML5, CALML3, 
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IL23A, ATP6V0D2, ATP6V0A4, TLR1, TLR9, TLR6, TLR4, TLR2, 
TGFB1, IFNG, CAMK2A 
ECM-receptor 
interaction(K) 
0.0085 87 38 2.55E-12 1.25E-10 FN1, COL1A1, COL1A2, COL11A1, COL3A1, IBSP, ITGB4, 
ITGB3, ITGB8, ITGB7, ITGA4, ITGA3, ITGA7, ITGA5, SDC1, 
COL5A1, COL5A3, COL5A2, LAMC2, LAMA2, LAMA3, LAMB3, 
LAMB4, GP5, TNC, COL27A1, VTN, ITGA11, GP1BA, TNXB, 
COMP, COL4A4, COL4A3, COL6A2, COL6A1, COL6A3, THBS2, 
THBS1 
Beta2 integrin cell 
surface interactions(N) 
0.0028 29 22 4.70E-12 2.21E-10 F11R, THY1, C3, ITGAM, ITGB2, ITGAL, ITGAX, ITGAD, 
FCGR2A, SPON2, ICAM2, ICAM3, ICAM4, ICAM1, PLAU, 
VCAM1, PROC, CYR61, GP1BA, CD40LG, TGFBI, PLAUR 
Signalling by 
Interleukins(R) 
0.0274 280 75 5.86E-12 2.58E-10 PSME2, PDGFB, GRIN2A, GRIN2D, JAK3, DUSP5, CTF1, EGFR, 
IL12RB2, STAT1, PSMB8, PSMB9, MAP3K8, SOCS3, NFKB2, 
RASGRF2, RASGRF1, PIK3CD, NRG1, IL2RG, IL2RA, IL2RB, 
PTPN6, IL27RA, IL12A, LGALS9, EREG, IL27, IL11, SYK, IL18, 
IL1A, IL1B, OSM, GRIN1, KITLG, PDGFRA, RASGRP1, 
RASGRP4, RASGRP3, IRAK2, IL6, IL7, IL7R, RASGEF1A, IRAK3, 
PSMB10, PTK2B, TEC, TEK, HAVCR2, CLCF1, CSF2, FGF1, 
FGF7, RASAL1, RASAL3, LAT, IL3RA, NOD2, IL1RN, IL1R1, 
IL1R2, EBI3, INPP5D, LIF, VAV1, HGF, CSF2RB, CSF2RA, 
FGFR2, BLNK, CASP1, RASA4, CAMK2A 
Cell adhesion 
molecules (CAMs)(K) 
0.0139 142 49 8.22E-12 3.45E-10 F11R, CLDN5, CLDN4, CLDN3, L1CAM, CTLA4, JAM2, SIGLEC1, 
CD274, PTPRC, CNTNAP2, ITGAM, ITGB2, ITGAL, SPN, ITGB8, 
ITGB7, ITGA4, PDCD1, ICAM2, ICAM3, ICAM1, CD226, CD28, 
SDC1, CD22, CD40, SELPLG, CD86, CD80, CD8B, CD8A, 
VCAM1, VCAN, CD2, CD4, CD6, ICOS, PECAM1, NFASC, 
ICOSLG, CLDN23, PDCD1LG2, CLDN14, CD40LG, SELE, SELP, 
SELL, CDH15 
Cell surface 
interactions at the 
vascular wall(R) 
0.0098 100 40 9.56E-12 3.83E-10 F11R, CXADR, LYN, FN1, L1CAM, JAM2, ITGAM, ITGB3, ITGB2, 
ITGAL, SPN, ITGAX, ITGA4, ITGA3, ITGA5, PTPN6, CD244, 
GRB7, FCER1G, CD48, SELPLG, CD74, PROCR, DOK2, PROC, 
 
 
226 
GeneSet Ratio Of Protein In GeneSet 
No. Of Protein 
In GeneSet 
Protein From 
Network P-value FDR Nodes 
MMP1, CD2, TEK, GAS6, CD177, TREM1, THBD, LCK, PECAM1, 
INPP5D, SIRPG, SELE, SELP, SELL, AMICA1 
Measles(K) 0.0131 134 46 4.22E-11 1.60E-09 JAK3, IKBKE, STAT1, TNFRSF10C, TNFRSF10A, TNFRSF10D, 
PIK3CD, FASLG, PIK3CG, IL2RG, IL2RA, IL2RB, FCGR2B, 
TNFSF10, IL12B, IL12A, PIK3R5, SLAMF1, CD209, CD28, TP73, 
CD3G, CD3E, CD3D, IL1A, IL1B, CCND2, IL6, TNFAIP3, IRF7, 
IRF9, MX1, PRKCQ, IFIH1, TACR1, SH2D1A, TLR9, TLR7, TLR4, 
TLR2, HSPA6, NFKBIA, OAS1, IFNG, OAS2, OAS3 
Primary 
immunodeficiency(K) 
0.0035 36 23 4.48E-11 1.61E-09 JAK3, AICDA, PTPRC, CIITA, IL2RG, BTK, CD19, CD40, 
TNFRSF13B, CD3E, CD3D, CD8B, CD8A, IL7R, CD4, ICOS, 
TAP2, TAP1, LCK, CD79A, CD40LG, BLNK, ZAP70 
Pertussis(K) 0.0073 75 33 5.74E-11 2.01E-09 C2, C3, TICAM2, LY96, ITGAM, ITGB2, ITGA5, C1S, C1R, IL12B, 
IL12A, CD14, IL10, IL1A, IL1B, IL6, IRF1, IRF8, MAPK13, 
SERPING1, TNF, PYCARD, CALML5, CALML3, IL23A, TLR4, 
C1QB, C1QA, C1QC, NLRP3, CXCL6, CXCL5, CASP1 
TCR signalling in 
na&#xef;ve CD8+ T 
cells(N) 
0.0053 54 27 2.11E-10 6.96E-09 MAP3K8, PTPRC, LCP2, PTPN6, CD247, PRF1, RASSF5, CD28, 
CD3G, CD3E, CD3D, CD86, CD80, CD8B, CD8A, CARD11, 
RASGRP2, RASGRP1, PRKCB, PRKCQ, GRAP2, LAT, LCK, 
B2M, VAV1, TRPV6, ZAP70 
IL23-mediated 
signalling events(N) 
0.0035 36 22 2.66E-10 8.44E-09 STAT4, IL12RB1, STAT1, SOCS3, ITGA3, CCL2, IL12B, IL24, 
CD3E, IL18, IL1B, IL18R1, IL6, CD4, TNF, IL23A, ALOX12B, 
IL18RAP, NFKBIA, CXCL9, CXCL1, IFNG 
TCR signalling in 
naïve CD4+ T cells(N) 
0.0066 67 30 2.83E-10 8.44E-09 SLA2, MAP3K8, PTPRC, LCP2, FYB, PTPN6, CD247, RASSF5, 
CD28, CD3G, CD3E, CD3D, CD86, CD80, CARD11, RASGRP2, 
RASGRP1, CD4, PRKCB, PRKCQ, ITK, GRAP2, LAT, LCK, 
INPP5D, MAP4K1, VAV1, WAS, TRPV6, ZAP70 
Integrin signalling 
pathway(P) 
0.0155 158 49 2.91E-10 8.44E-09 COL13A1, FN1, COL1A1, COL1A2, COL11A1, COL3A1, MAP3K5, 
COL17A1, ITGAM, ITGB4, ITGB3, ITGB2, PIK3CD, ITGAL, 
PIK3CG, ITGAX, ITGB8, ITGB7, ITGA4, ITGA3, ITGAD, ITGA7, 
ITGA5, COL15A1, ACTN1, RRAS, ITGBL1, GRAP, RAC2, 
COL5A1, COL5A3, COL5A2, RND1, PTK2B, MAPK13, COL7A1, 
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COL12A1, COL10A1, ITGA11, COL14A1, PIK3C2B, COL8A2, 
COL8A1, COL4A4, COL4A3, ELMO1, COL6A2, COL6A1, COL6A3 
Jak-STAT signalling 
pathway(K) 
0.0155 158 49 2.91E-10 8.44E-09 IL20RA, IL20RB, IL22RA2, IL22RA1, JAK3, CTF1, STAT4, 
IL12RB1, IL12RB2, STAT1, PIM1, CISH, SOCS3, SOCS1, 
PIK3CD, PIK3CG, IL2RG, IL2RA, IL2RB, PTPN6, IL27RA, IL12B, 
IL12A, PIK3R5, IL24, IL10, IL11, IL15, OSM, CCND2, IL4R, IL6, 
IL7, IL7R, IL9R, IRF9, IL10RA, CSF3, CSF3R, CSF2, IL3RA, 
IL21R, IL15RA, IL23A, LIF, CSF2RB, CSF2RA, AOX1, IFNG 
Toll-like receptor 
signalling pathway(K) 
0.0104 106 38 6.44E-10 1.80E-08 IKBKE, STAT1, MAP3K8, TICAM2, LY96, CXCL10, CXCL11, 
PIK3CD, PIK3CG, CCL5, CCL4, CCL3, IL12B, IL12A, PIK3R5, 
CD14, CD40, CTSK, IL1B, CD86, CD80, CCL3L1, IL6, IRF7, IRF5, 
MAPK13, TNF, LBP, TLR1, TLR9, TLR8, TLR7, TLR6, TLR5, 
TLR4, TLR2, NFKBIA, CXCL9 
Gastrin-CREB 
signalling pathway via 
PKC and MAPK(R) 
0.0354 362 82 1.66E-09 4.48E-08 PSME2, PDGFB, FPR2, GRIN2A, GRIN2D, JAK3, DUSP5, 
PTAFR, EGFR, P2RY10, PSMB8, PSMB9, GPR68, GPR65, 
UTS2, RASGRF2, RASGRF1, NRG1, IL2RG, IL2RA, IL2RB, 
EREG, LPAR1, LPAR5, GRIN1, KITLG, RGS2, PDGFRA, 
RASGRP2, RASGRP1, RASGRP4, RASGRP3, RASGEF1A, 
MMP3, PSMB10, TEK, GRPR, PRKCH, PRKCQ, GPR132, 
ANXA1, TACR1, CCL23, AGT, DGKG, CSF2, DGKA, FGF1, 
CYSLTR1, FGF7, CYSLTR2, RASAL1, RASAL3, LAT, IL3RA, 
XCL2, XCL1, P2RY6, P2RY2, RPS6KA2, RPS6KA1, PTGFR, 
NTSR1, XCR1, FFAR2, EDN1, SAA1, F2RL1, GHRL, F2RL3, 
PMCH, CSF2RB, CSF2RA, HRH1, NMUR1, FGFR2, BDKRB2, 
BDKRB1, RASA4, RGS18, CAMK2A, GNA15 
PI3K-Akt signalling 
pathway(K) 
0.0338 345 79 2.09E-09 5.44E-08 PDGFB, NGFR, FN1, COL1A1, COL1A2, JAK3, COL11A1, EGFR, 
COL3A1, IBSP, ITGB4, ITGB3, PIK3CD, FASLG, PIK3CG, ITGB8, 
ITGB7, ITGA4, ITGA3, ITGA7, ITGA5, IL2RG, IL2RA, IL2RB, 
PIK3AP1, LPAR1, PIK3R5, CD19, IGF1, LPAR5, GNGT2, SYK, 
OSM, VEGFC, KITLG, CCND2, PDGFRA, IL4R, IL6, FGF14, 
COL5A1, IL7, COL5A3, COL5A2, IL7R, FGF11, LAMC2, LAMA2, 
LAMA3, LAMB3, LAMB4, TEK, CREB3L1, MYB, CSF3, CSF3R, 
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CSF1, TNC, FGF1, FGF7, COL27A1, CSF1R, VTN, ITGA11, 
IL3RA, TLR4, TLR2, TNXB, COMP, HGF, COL4A4, COL4A3, 
FGFR2, COL6A2, COL6A1, COL6A3, THBS2, THBS1, PPP2R2C 
Pathways in cancer(K) 0.0389 397 87 2.41E-09 6.03E-08 SPI1, FZD10, PDGFB, FN1, WNT9A, PTGS2, EGFR, EGLN3, 
STAT1, WNT7B, WNT7A, NFKB2, CXCL12, FLT3, PIK3CD, 
FASLG, PIK3CG, ITGA3, BIRC3, NTRK1, RASSF5, LPAR1, 
TGFA, PIK3R5, IGF1, LPAR5, GNGT2, RAC2, VEGFC, KITLG, 
PDGFRA, TCF7, PLD1, RASGRP2, RASGRP1, RASGRP4, 
RASGRP3, WNT1, WNT2, IL6, FGF14, FGF11, LAMC2, MMP1, 
MMP2, MMP9, LAMA2, LAMA3, LAMB3, LAMB4, PRKCB, 
DAPK2, PLCG2, WNT10B, WNT10A, RET, PAX8, ADCY4, 
ADCY2, ADCY1, ADCY7, CSF3R, FGF1, FGF7, CSF1R, 
PLEKHG5, TRAF1, CEBPA, CBLC, FLT3LG, RUNX1, PTGER2, 
PTGER3, CXCR4, F2RL3, WNT5B, HGF, WNT5A, COL4A4, 
COL4A3, CSF2RA, TGFB1, NFKBIA, FGFR2, BDKRB2, BDKRB1, 
WNT16 
Inflammatory bowel 
disease (IBD)(K) 
0.0064 65 28 2.51E-09 6.03E-08 GATA3, STAT4, IL12RB1, IL12RB2, STAT1, RORC, FOXP3, 
IL2RG, IL12B, IL12A, IL10, IL18, IL1A, IL1B, IL18R1, IL4R, IL6, 
TBX21, TNF, NOD2, IL21R, IL23A, TLR5, TLR4, TLR2, IL18RAP, 
TGFB1, IFNG 
GPVI-mediated 
activation cascade(R) 
0.0048 49 24 3.09E-09 7.42E-08 LYN, JAK3, PIK3CD, PIK3CG, LCP2, IL2RG, IL2RA, IL2RB, 
PTPN6, PIK3R6, PIK3R5, RAC2, FCER1G, SYK, PLCG2, CSF2, 
LAT, LCK, IL3RA, RHOG, VAV1, PDPN, CSF2RB, CSF2RA 
Leukocyte 
transendothelial 
migration(K) 
0.0116 118 39 3.51E-09 8.08E-08 F11R, CLDN5, CLDN4, CLDN3, MYL9, THY1, JAM2, NCF1, 
NCF2, NCF4, CXCL12, ITGAM, ITGB2, PIK3CD, ITGAL, PIK3CG, 
ITGA4, ICAM1, RASSF5, ACTN1, PIK3R5, RAC2, CYBB, CYBA, 
VCAM1, MMP2, MMP9, PTK2B, MAPK13, PRKCB, PLCG2, ITK, 
PECAM1, EZR, CLDN23, RHOH, VAV1, CLDN14, CXCR4 
Urokinase-type 
plasminogen activator 
(uPA) and uPAR-
mediated signalling(N) 
0.0041 42 22 4.26E-09 9.21E-08 FPR1, FPR3, FPR2, FN1, MMP12, MMP13, EGFR, ITGAM, 
ITGB3, ITGB2, ITGA3, ITGA5, CTSG, PLAU, MMP3, MMP9, 
SERPINE1, VTN, KLK4, HGF, TGFB1, PLAUR 
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Chagas disease 
(American 
trypanosomiasis)(K) 
0.0102 104 36 4.39E-09 9.21E-08 C3, PIK3CD, FASLG, PIK3CG, CCL5, CCL3, CCL2, CD247, 
IL12B, IL12A, PIK3R5, CD3G, CD3E, CD3D, IL10, IL1B, CCL3L1, 
IL6, MAPK13, SERPINE1, ACE, ADCY1, TNF, TLR9, TLR6, TLR4, 
TLR2, C1QB, C1QA, C1QC, TGFB1, NFKBIA, BDKRB2, IFNG, 
GNA15, PPP2R2C 
T cell receptor 
signalling pathway(K) 
0.0102 104 36 4.39E-09 9.21E-08 CTLA4, MAP3K8, PTPRC, PIK3CD, PIK3CG, LCP2, PTPN6, 
PDCD1, CD247, PIK3R5, CD28, CD3G, CD3E, CD3D, IL10, 
CD8B, CD8A, CARD11, RASGRP1, MAPK13, CD4, TEC, PRKCQ, 
ICOS, ITK, CSF2, TNF, GRAP2, LAT, LCK, CBLC, VAV1, 
CD40LG, NFKBIA, ZAP70, IFNG 
Leishmaniasis(K) 0.007 72 29 5.68E-09 1.19E-07 C3, PTGS2, STAT1, NCF1, NCF2, NCF4, ITGAM, ITGB2, 
FCGR3A, FCGR3B, ITGA4, FCGR1A, FCGR2A, PTPN6, IL12B, 
IL12A, IL10, IL1A, IL1B, CYBA, MAPK13, PRKCB, TNF, CR1, 
TLR4, TLR2, TGFB1, NFKBIA, IFNG 
IL4-mediated 
signalling events(N) 
0.0063 64 27 7.37E-09 1.47E-07 SPI1, THY1, COL1A1, COL1A2, PIGR, JAK3, SOCS3, SOCS1, 
AICDA, ITGB3, IL2RG, PTPN6, EGR2, IL10, IL4R, DOK2, MYB, 
FCER2, CCL11, CCL17, CCL26, CEBPB, INPP5D, PARP14, 
CD40LG, SELP, LTA 
Complement and 
coagulation 
cascades(K) 
0.0068 69 28 8.84E-09 1.77E-07 C3AR1, C2, C3, MBL2, C1S, C1R, C8G, PLAU, MASP1, PROC, 
SERPINE1, SERPINF2, SERPING1, CFB, CFD, CFH, SERPINA1, 
SERPIND1, THBD, CR2, CR1, C1QB, C1QA, C1QC, C5AR1, 
BDKRB2, BDKRB1, PLAUR 
IL27-mediated 
signalling events(N) 
0.0025 26 17 1.05E-08 2.00E-07 GATA3, STAT4, IL12RB1, IL12RB2, STAT1, IL27RA, IL12B, 
IL12A, IL27, IL18, IL1B, IL6, TBX21, TNF, EBI3, TGFB1, IFNG 
DAP12 interactions(R) 0.0292 298 69 1.47E-08 2.80E-07 PSME2, PDGFB, GRIN2A, KLRK1, PRKAR2B, GRIN2D, JAK3, 
DUSP5, EGFR, PSMB8, PSMB9, RASGRF2, RASGRF1, PIK3CD, 
NRG1, LCP2, IL2RG, IL2RA, IL2RB, EREG, BTK, CD19, CD28, 
SYK, GRIN1, KITLG, CD86, CD80, PDGFRA, TYROBP, 
RASGRP1, RASGRP4, RASGRP3, RASGEF1A, PSMB10, TEK, 
PLCG2, KIR2DS4, ADCY4, ADCY2, ADCY1, ADCY7, CSF2, 
FGF1, FGF7, GRAP2, CLEC5A, RASAL1, RASAL3, CD300LB, 
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LAT, TREM2, TREM1, LCK, IL3RA, B2M, SIGLEC15, SIGLEC14, 
VAV1, CAMK4, CD300E, CSF2RB, CSF2RA, KLRC2, KLRD1, 
FGFR2, RASA4, CAMK2A, TRAT1 
IL12 signalling 
mediated by 
STAT4(N) 
0.003 31 18 2.34E-08 4.21E-07 STAT4, IL2RA, CD247, PRF1, CD28, CD3G, CD3E, CD3D, IL18, 
IL18R1, CD86, CD80, IRF1, TBX21, CD4, IL18RAP, TGFB1, IFNG 
Intestinal immune 
network for IgA 
production(K) 
0.0046 47 22 3.03E-08 5.45E-07 PIGR, TNFRSF17, AICDA, CXCL12, TNFSF13B, ITGB7, ITGA4, 
TNFSF13, CD28, CD40, TNFRSF13B, IL10, IL15, CD86, CD80, 
IL6, ICOS, ICOSLG, IL15RA, CXCR4, CD40LG, TGFB1 
Beta3 integrin cell 
surface interactions(N) 
0.0042 43 21 3.07E-08 5.53E-07 F11R, PDGFB, THY1, FN1, L1CAM, COL1A1, COL1A2, SPHK1, 
IBSP, ITGB3, SDC1, PLAU, TNC, VTN, CYR61, PECAM1, 
COL4A4, COL4A3, TGFBI, PLAUR, THBS1 
Focal adhesion(K) 0.0203 207 53 3.30E-08 5.61E-07 MYL9, PDGFB, FN1, COL1A1, COL1A2, COL11A1, EGFR, 
COL3A1, IBSP, ITGB4, ITGB3, RASGRF1, PIK3CD, PIK3CG, 
ITGB8, ITGB7, ITGA4, ITGA3, ITGA7, ITGA5, BIRC3, ACTN1, 
PIK3R5, IGF1, RAC2, VEGFC, CCND2, PDGFRA, COL5A1, 
COL5A3, COL5A2, LAMC2, LAMA2, LAMA3, LAMB3, LAMB4, 
PRKCB, TNC, COL27A1, VTN, ITGA11, PARVG, VAV1, TNXB, 
COMP, HGF, COL4A4, COL4A3, COL6A2, COL6A1, COL6A3, 
THBS2, THBS1 
Validated 
transcriptional targets 
of AP1 family 
members Fra1 and 
Fra2(N) 
0.0036 37 19 6.41E-08 1.09E-06 COL1A2, ITGB4, CCL2, PLAU, IL6, MMP1, MMP2, MMP9, 
LAMA3, GJA1, JUNB, HMOX1, FOSL2, FOSL1, IVL, THBD, LIF, 
PLAUR, DCN 
Legionellosis(K) 0.0054 55 23 1.08E-07 1.73E-06 C3, NFKB2, ITGAM, ITGB2, IL12B, IL12A, CD14, IL18, IL1B, IL6, 
TNF, PYCARD, CR1, NLRC4, TLR5, TLR4, TLR2, HSPA6, 
NFKBIA, CXCL1, CXCL3, CXCL2, CASP1 
Platelet activation(K) 0.0127 130 38 1.24E-07 1.99E-06 LYN, COL1A1, COL1A2, FERMT3, COL11A1, PTGS1, COL3A1, 
ITGB3, PIK3CD, PIK3CG, LCP2, FCGR2A, BTK, PIK3R5, 
FCER1G, SYK, RASGRP2, RASGRP1, COL5A1, COL5A3, 
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COL5A2, PLA2G4F, PLA2G4D, PLA2G4E, MAPK13, PLCG2, 
GP5, APBB1IP, ADCY4, ADCY2, ADCY1, ADCY7, COL27A1, 
GP1BA, F2RL3, GUCY1B3, GUCY1A3, PTGIR 
Interferon gamma 
signalling(R) 
0.0072 74 27 1.32E-07 2.11E-06 PTAFR, STAT1, SOCS3, SOCS1, CIITA, FCGR1A, PTPN6, IFI30, 
ICAM1, MT2A, TRIM21, TRIM22, VCAM1, IRF1, IRF7, IRF8, IRF5, 
IRF9, B2M, OASL, OAS1, IFNG, OAS2, OAS3, CAMK2A, GBP2, 
GBP1 
Toll-Like Receptors 
Cascades(R) 
0.0129 132 38 1.80E-07 2.74E-06 LGMN, IKBKE, RIPK3, TLR10, MAP3K8, TICAM2, LY96, SOCS1, 
LY86, NFKB2, ITGAM, ITGB2, BIRC3, BTK, CD14, CTSS, CTSK, 
CTSB, IRAK2, IRAK3, IRF7, PLCG2, S100A12, CD180, LBP, 
NOD2, RPS6KA2, RPS6KA1, TLR1, TLR9, TLR8, TLR7, TLR6, 
TLR5, TLR4, TLR2, SAA1, NFKBIA 
Protein digestion and 
absorption(K) 
0.0088 90 30 1.83E-07 2.74E-06 COL13A1, COL1A1, COL1A2, FXYD2, COL11A1, COL3A1, CPA3, 
COL17A1, COL15A1, KCNQ1, MME, COL5A1, COL5A3, COL5A2, 
COL7A1, COL12A1, PRSS3, ELN, COL10A1, SLC8A1, COL27A1, 
COL14A1, MEP1A, COL4A4, COL4A3, DPP4, COL6A2, COL6A1, 
COL6A3, ATP1A3 
Interferon alpha/beta 
signalling(R) 
0.0065 66 25 1.93E-07 2.90E-06 STAT1, PSMB8, SOCS3, SOCS1, PTPN6, RSAD2, IFI27, BST2, 
ISG15, ISG20, IRF1, IRF7, IRF8, IRF5, IRF9, SAMHD1, MX1, 
IFITM1, IFI6, OASL, OAS1, OAS2, OAS3, USP18, GBP2 
NOD-like receptor 
signalling pathway(K) 
0.0056 57 23 2.01E-07 3.01E-06 BIRC3, CCL5, CCL2, IL18, IL1B, CARD18, IL6, TNFAIP3, 
MAPK13, MEFV, CARD9, TNF, PYCARD, PSTPIP1, NLRC4, 
NOD2, NLRP3, NLRP1, NFKBIA, CXCL1, CXCL2, CASP5, CASP1 
Proteoglycans in 
cancer(K) 
0.0199 203 50 2.50E-07 3.51E-06 FZD10, FN1, WNT9A, EGFR, WNT7B, WNT7A, HPSE, ITGB3, 
PIK3CD, FASLG, PIK3CG, ITGA5, PTPN6, IL12B, ANK3, ANK1, 
PIK3R5, RRAS, IGF1, SDC1, PLAU, WNT1, WNT2, MMP2, 
MMP9, MAPK13, PRKCB, PLCG2, WNT10B, WNT10A, HCLS1, 
TNF, VTN, CBLC, TIAM1, EZR, TWIST2, TLR4, TLR2, WNT5B, 
HGF, WNT5A, TGFB1, ESR1, PLAUR, WNT16, DCN, CAMK2A, 
THBS1, LUM 
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B cell receptor 
signalling pathway(K) 
0.007 72 26 2.72E-07 3.80E-06 LYN, PIK3CD, PIK3CG, PTPN6, FCGR2B, PIK3AP1, BTK, 
PIK3R5, CD19, CD22, RAC2, SYK, CD72, CARD11, DAPP1, 
RASGRP3, PRKCB, PLCG2, CR2, IFITM1, CD79B, CD79A, 
INPP5D, VAV1, NFKBIA, BLNK 
Fc gamma R-mediated 
phagocytosis(K) 
0.009 92 30 2.87E-07 4.02E-06 LYN, SPHK1, NCF1, PTPRC, PIK3CD, PIK3CG, FCGR3A, 
FCGR1A, FCGR2A, FCGR2B, PIK3R5, RAC2, SYK, PLD1, 
PLA2G4F, PLA2G4D, PLA2G4E, ASAP3, PRKCB, PLCG2, LAT, 
INPP5D, VAV1, HCK, WAS, AMPH, SCIN, DOCK2, LIMK2, LIMK1 
Rap1 signalling 
pathway(K) 
0.0207 211 51 3.30E-07 4.63E-06 SKAP1, FPR1, PDGFB, GRIN2A, NGFR, EGFR, ITGAM, ITGB3, 
ITGB2, PIK3CD, ITGAL, PIK3CG, ADORA2A, LCP2, FYB, 
RASSF5, LPAR1, PIK3R5, RRAS, IGF1, LPAR5, ID1, RAC2, 
VEGFC, GRIN1, KITLG, PDGFRA, RASGRP2, RASGRP3, 
FGF14, FGF11, MAPK13, TEK, PRKCB, APBB1IP, ADCY4, 
ADCY2, ADCY1, ADCY7, CSF1, FGF1, FGF7, CSF1R, LAT, 
CALML5, CALML3, TIAM1, F2RL3, HGF, FGFR2, THBS1 
Downstream signalling 
in na&#xef;ve CD8+ T 
cells(N) 
0.0063 64 24 4.01E-07 5.21E-06 STAT4, TNFRSF4, TNFRSF9, FASLG, IL2RG, GZMB, IL2RA, 
IL2RB, PTPN7, CD247, PRF1, CD3G, CD3E, CD3D, EOMES, 
CD8B, CD8A, JUNB, PRKCB, PRKCQ, FOSL1, TNF, B2M, IFNG 
African 
trypanosomiasis(K) 
0.0033 34 17 4.46E-07 5.80E-06 IDO2, IDO1, FASLG, ICAM1, IL12B, IL12A, IL10, IL18, IL1B, 
VCAM1, IL6, PRKCB, TNF, TLR9, F2RL1, SELE, IFNG 
Phagosome(K) 0.015 153 40 9.48E-07 1.23E-05 C3, NCF1, NCF2, NCF4, TUBA4A, PLA2R1, CORO1A, ITGAM, 
ITGB3, ITGB2, FCGR3A, FCGR3B, MBL2, ITGA5, C1R, FCGR1A, 
FCGR2A, FCGR2B, CD14, MSR1, CD209, CTSS, CYBB, CYBA, 
MRC2, MRC1, TUBB3, TAP2, TAP1, CLEC7A, TCIRG1, 
ATP6V0D2, ATP6V0A4, MARCO, TLR6, TLR4, TLR2, COMP, 
THBS2, THBS1 
Inflammatory mediator 
regulation of TRP 
channels(K) 
0.0096 98 30 1.03E-06 1.34E-05 PIK3CD, PIK3CG, NTRK1, PIK3R5, IGF1, IL1B, PLA2G4F, 
PLA2G4D, PLA2G4E, MAPK13, PRKCH, PRKCB, PRKCQ, 
PLCG2, ADCY4, ADCY2, ADCY1, ADCY7, P2RY2, CALML5, 
CALML3, IL1R1, PTGER2, F2RL1, HRH1, TRPV2, TRPV4, 
BDKRB2, BDKRB1, CAMK2A 
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Calcineurin-regulated 
NFAT-dependent 
transcription in 
lymphocytes(N) 
0.0045 46 19 1.60E-06 2.08E-05 GATA3, CTLA4, PTGS2, FOXP3, FASLG, IL2RA, IKZF1, EGR2, 
EGR3, TBX21, JUNB, PRKCQ, FOSL1, BATF3, CSF2, DGKA, 
TNF, CD40LG, IFNG 
Influenza A(K) 0.0171 175 43 1.81E-06 2.17E-05 IKBKE, STAT1, SOCS3, TNFRSF10C, TNFRSF10A, 
TNFRSF10D, CXCL10, CIITA, PIK3CD, FASLG, PIK3CG, CCL5, 
CCL2, ICAM1, TNFSF10, IL12B, IL12A, RSAD2, PIK3R5, IL18, 
IL1A, IL1B, IL33, IL6, IRF7, IRF9, MX1, MAPK13, PRSS3, 
PRKCB, IFIH1, TNF, PYCARD, TLR7, TLR4, NLRP3, HSPA6, 
NFKBIA, CASP1, OAS1, IFNG, OAS2, OAS3 
TNFR2 non-canonical 
NF-kB pathway(R) 
0.0094 96 29 1.99E-06 2.39E-05 PSME2, PSMB8, PSMB9, TNFRSF4, TNFRSF11B, TNFRSF11A, 
TNFRSF17, NFKB2, FASLG, TNFSF13B, TNFRSF1B, BIRC3, 
TNFRSF6B, TNFSF11, TNFSF14, TNFSF13, CD27, CD40, 
TNFRSF13B, TNFRSF12A, RELB, CD70, PSMB10, TNFSF4, 
TNF, EDAR, CD40LG, LTA, LTB 
Signalling by SCF-
KIT(R) 
0.0259 265 57 2.51E-06 3.01E-05 PSME2, PDGFB, GRIN2A, LYN, GRIN2D, JAK3, DUSP5, EGFR, 
STAT1, PSMB8, PSMB9, SOCS1, RASGRF2, RASGRF1, 
PIK3CD, NRG1, IL2RG, SH2B3, SH2B2, IL2RA, IL2RB, PTPN6, 
EREG, GRB7, CD19, CD28, GRAP, PTPRU, GRIN1, KITLG, 
CD86, CD80, PDGFRA, RASGRP1, RASGRP4, RASGRP3, 
RASGEF1A, MMP9, PSMB10, TEC, TEK, CSF2, FGF1, FGF7, 
GRAP2, RASAL1, RASAL3, LAT, LCK, IL3RA, VAV1, CSF2RB, 
CSF2RA, FGFR2, RASA4, CAMK2A, TRAT1 
Immunoregulatory 
interactions between a 
Lymphoid and a non-
Lymphoid cell(R) 
0.0242 247 54 2.91E-06 3.39E-05 CXADR, C3, KLRK1, HCST, KIR3DL1, KIR3DL2, ITGB2, ITGAL, 
FCGR3A, ITGB7, ITGA4, FCGR1A, CD247, FCGR2B, ICAM2, 
ICAM3, ICAM4, ICAM1, CD226, CD19, SLAMF6, CD40, CD3G, 
CD3E, CD3D, CD33, NCR3, MICB, OSCAR, TYROBP, CD8B, 
CD8A, KIR2DL3, KIR2DL4, VCAM1, CD200R1, CD300LB, 
TREM2, TREM1, IFITM1, B2M, SH2D1A, SH2D1B, RAET1E, 
LILRA1, LILRB1, LILRB2, CD40LG, CD300E, KLRB1, KLRC1, 
SELL, KLRD1, AMICA1 
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Antigen processing 
and presentation(K) 
0.0075 77 25 2.94E-06 3.39E-05 PSME2, LGMN, KIR3DL1, KIR3DL2, CIITA, IFI30, CTSS, CTSB, 
CD74, CD8B, CD8A, KIR2DL3, KIR2DL4, TAPBP, CD4, KIR2DS4, 
TNF, TAP2, TAP1, B2M, KLRC1, KLRC2, HSPA6, KLRD1, IFNG 
amb2 Integrin 
signalling(N) 
0.003 31 15 3.08E-06 3.39E-05 THY1, JAM2, CTGF, ITGAM, ITGB2, ICAM1, MST1R, SELPLG, 
PLAU, IL6, MMP2, MMP9, TNF, HCK, SELP 
Interleukin signalling 
pathway(P) 
0.0054 55 20 5.62E-06 6.18E-05 SPI1, SLA2, SPIB, IL20RA, JAK3, IL12RB1, IL12RB2, IL2RA, 
IL2RB, IL15, IL18, IL16, IL1A, IL4R, IL7, IL10RA, IL3RA, 
RPS6KA1, IL23A, CXCR1 
Transcriptional 
misregulation in 
cancer(K) 
0.0175 179 42 7.15E-06 7.86E-05 SPI1, SPINT1, NGFR, PBX3, FLI1, GRIA3, ITGAM, FLT3, ITGB7, 
PTCRA, BIRC3, FCGR1A, NTRK1, GZMB, IL2RB, CD14, IGF1, 
CD40, CCR7, CD86, CCND2, PLAU, IL6, LYL1, MMP3, MMP9, 
BCL2A1, PAX5, PAX8, CSF2, CSF1R, TRAF1, CEBPA, CEBPB, 
CEBPE, IL1R2, RUNX2, RUNX1, LMO2, MYCN, NR4A3, WNT16 
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Table T3-8: Full list of pathways enriched for genes negatively correlated (at 
FDR<0.05) with tumour VDR expression in the TCGA metastatic melanomas 
The source database for each of the enriched pathways are indicated by a letter 
in parentheses after each pathway gene set name. The source database 
annotations are: C - CellMap, R – Reactome, K – KEGG, N – NCI PID, P - 
Panther, and B – BioCarta.  
The description of column headers are:  Ratio of protein in gene set: ratios of 
numbers of genes contained in pathways to total genes in the Reactome FI 
network; Number of protein in gene set: numbers of genes in pathways; Protein 
from network: numbers of hit genes from the query gene list; Nodes: nodal genes 
from my input query gene list, which ‘matches’ with the genes in a particular 
pathway; P-value was estimated by Reactome FIViz using hypergeometric test 
and the corresponding FDR was estimated by Benjamini Hochberg multiple 
correction 
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GeneSet Ratio Of Protein In GeneSet 
No. Of Protein 
In GeneSet 
Protein From 
Network P-value FDR Nodes 
Wnt signalling 
pathway(P) 
0.0262 268 12 3.43E-06 1.11E-03 CDH8, TLE4, PRKCA, PCDHA11, PCDHB5, PCDHB3, CDH10, 
GNG7, CTNNA2, TCF7L1, PCDH9, PCDH7 
Metabolism of 
carbohydrates(R) 
0.0234 239 9 2.27E-04 0.0192 HS6ST2, BCAN, CSPG5, SLC2A4, CHST9, GPC3, GPC2, GPC4, 
HS3ST5 
Cadherin signalling 
pathway(P) 
0.0098 100 6 2.41E-04 0.0192 PCDHA11, PCDHB5, PCDHB3, CTNNA2, PCDH9, PCDH7 
Ephrin A  reverse 
signalling(N) 
0.0003 3 2 3.25E-04 0.0192 EPHA5, EFNA5 
cAMP signalling 
pathway(K) 
0.0195 199 8 3.34E-04 0.0192 CHRM1, ATP1B2, GRIA1, GRIA2, GRIA4, FXYD1, ATP1A2, 
ATP2B3 
Heterotrimeric G-protein 
signalling pathway-Gq 
alpha and Go alpha 
mediated pathway(P) 
0.0106 108 6 3.61E-04 0.0192 CHRM1, PRKCA, GPSM1, GRM7, GARNL3, GNG7 
Glutamatergic 
synapse(K) 
0.0112 114 6 4.80E-04 0.0221 PRKCA, GRIA1, GRIA2, GRIA4, GRM7, GNG7 
Signalling by 
NODAL(R) 0.0019 19 3 6.28E-04 0.0229 GDF1, LEFTY1, ACVR2B 
TGF-beta signalling 
pathway(P) 
0.0078 80 5 6.74E-04 0.0229 GDF1, MSTN, LEFTY1, GDF11, ACVR2B 
PI3K-Akt signalling 
pathway(K) 
0.0338 345 10 7.89E-04 0.0229 CHRM1, IGF1R, PRKCA, EFNA5, PDGFD, FGF17, SGK3, FIGF, 
COL11A2, GNG7 
Ras signalling 
pathway(K) 
0.0222 227 8 7.89E-04 0.0229 IGF1R, PRKCA, SHC2, EFNA5, PDGFD, FGF17, FIGF, GNG7 
Dopaminergic 
synapse(K) 
0.0126 129 6 9.09E-04 0.0236 SCN1A, PRKCA, GRIA1, GRIA2, GRIA4, GNG7 
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GeneSet Ratio Of Protein In GeneSet 
No. Of Protein 
In GeneSet 
Protein From 
Network P-value FDR Nodes 
Proximal tubule 
bicarbonate 
reclamation(K) 
0.0023 23 3 1.09E-03 0.0261 ATP1B2, SLC9A3, ATP1A2 
Circadian 
entrainment(K) 
0.0093 95 5 1.44E-03 0.0331 PRKCA, GRIA1, GRIA2, GRIA4, GNG7 
Long-term 
depression(K) 
0.0059 60 4 1.88E-03 0.0376 IGF1R, PRKCA, GRIA1, GRIA2 
Retrograde 
endocannabinoid 
signalling(K) 
0.0099 101 5 1.88E-03 0.0376 PRKCA, GRIA1, GRIA2, GRIA4, GNG7 
EPHA forward 
signalling(N) 
0.003 31 3 2.53E-03 0.0456 EPHA5, EPHA6, EFNA5 
Amphetamine 
addiction(K) 
0.0066 67 4 2.79E-03 0.0474 PRKCA, GRIA1, GRIA2, GRIA4 
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Table T3-9: Scoring of LMC primary melanoma sections stained with anti-VDR 
antibody. 
Slide 
number 
Number of cytoplasmic 
VDR +ve tumour cells 
Number of nuclear VDR 
+ve tumour cells 
Number of VDR +ve 
TILs 
1 2 3 none 
2 0 36 none 
3 2 12 none 
4 1 0 none 
5 1 0 none 
6 2 0 none 
7 1 0 none 
8 2 8 none 
9 3 12 none 
10 3 12 none 
11 0 0 none 
12 3 16 some 
13 2 1 none 
14 3 36 some 
15 0 1 some 
16 2 8 none 
17 3 25 lots 
18 2 9 none 
19 3 20 some 
20 2 0 none 
21 1 1 none 
22 1 0 none 
23 1 169 lots 
24 1 9 none 
25 1 0 none 
26 1 10 none 
27 2 0 none 
28 2 2 none 
29 2 40 some 
30 0 0 none 
 
239 
 
A.2 Primer sequences used for Sanger Sequencing of VDR 
plasmid 
Table T4-1: Table of primers used to check sequence of the cloned VDR plasmid, 
using Sanger Sequencing. 
Three rounds of sequencing checks were done to span various regions of the 
plasmid. Tm- the melting temperature o primer sequence, Nts- number of 
nucleotides 
Primer# Tm Nts Primer Sequence 
Round 1    
Primer 1 52 29 AATTGTAAGCGTTAATATTTTGTTAAAAT 
Primer 2 50 18 GACAGCAGGCTGAATAAT            
Primer 3 52 22 AAAATGATGTCATGGCTTTAGA        
Primer 4 61 16 GCGTTGCCTTCGCCCC              
Primer 5 53 19 TCCTTTGTCCCAAATCTGG           
Primer 6 52 17 TGTCTGAGGAGCAACAG             
Primer 7 60 14 GCTGCCGCCACCCG                
Primer 8 62 20 CCACGGGGACGTGGTTTTCC          
Primer 9 60 22 AGTTGCCAGCCATCTGTTGTTT        
Primer 10 51 29 AACTACCCATTTTATTATATATTAGTCAC 
Primer 11 62 21 TAATGAATCGGCCAACGCGCG         
Primer 12 52 20 AAAAGAGTTGGTAGCTCTTG          
Primer 13 52 18 GTCAGAAGTAAGTTGGCC            
Round 2    
Primer 14 51 25 TCGACATTGATTATTGACTAGTTAT  
Primer 15 58 24 GAAAGTTTCCTTTTATGGCGAGGC 
Primer 16 58 21 CGCAGCCATTGCCTTTTATGG     
Primer 17 61 20 CAAGGCCCTGTTCACCTGCC 
Primer 18 58 23 TACAGCATCCAAAAGGTCATCGG 
Primer 19 58 21 CCCTTGTGCTAGAGGTGTTCG 
Round 3    
Primer 20  61 20 GCGGAGCCGAAATCTGGGAG 
Primer 21 60 27  CTTCTTCTTTTTCCTACAGCTCCTGGG 
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A.3 Tables of output from enrichment analyses performed in 
Chapter 5 
In the case of tables containing output from enrichment analyses, pathways are 
presented based on variable FDR thresholds. The reason for this being, repetitive 
pathways appear at lower thresholds and hence the necessity to drop the display of 
these pathways.  
 
 
Table T5-1: Full list of pathways (at FDR<0.00001) enriched for genes that are 
expressed significantly higher in ulcerated tumours compared to non-
ulcerated tumours). Output from Reactome FIViz 
The source database for each of the enriched pathways are indicated by a letter 
in parentheses after each pathway gene set name. The source database 
annotations are: C - CellMap, R – Reactome, K – KEGG, N – NCI PID, P - 
Panther, and B – BioCarta.  
The description of column headers are:  Ratio of protein in gene set: ratios of 
numbers of genes contained in pathways to total genes in the Reactome FI 
network; Number of protein in gene set: numbers of genes in pathways; Protein 
from network: numbers of hit genes from the query gene list; Nodes: nodal genes 
from my input query gene list, which ‘matches’ with the genes in a particular 
pathway; P-value was estimated by Reactome FIViz using hypergeometric test 
and the corresponding FDR was estimated by Benjamini Hochberg multiple 
correction 
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GeneSet Ratio Of Protein In GeneSet 
No. Of Protein 
In GeneSet 
Protein From 
Network P-value FDR Nodes 
Mitotic 
Prometaphase(R) 
0.0097 99 43 1.11E-16 4.89E-14 CDCA5, NCAPG, CDCA8, CENPA, CENPE, CENPF, APITD1, 
CENPI, CENPK, CENPL, CENPM, CENPO, CENPQ, CASC5, 
NDC80, BIRC5, CDC20, DSN1, KIF2C, SPC24, MAD2L1, 
ERCC6L, BUB1B, CCNB2, CCNB1, SGOL2, SGOL1, AURKB, 
SMC4, NUP98, SKA1, SKA2, PLK1, NUF2, MAD1L1, HDAC8, 
ZWINT, AHCTF1, ZWILCH, KNTC1, KIF18A, ITGB3BP, BUB1 
Mitotic Metaphase and 
Anaphase(R) 
0.016 163 56 1.11E-16 4.89E-14 PSMD4, PSMD3, CDCA5, CDCA8, PSMA5, CENPA, PSMB7, 
PSMB4, PSMB5, PSMB2, CENPE, CENPF, PSMC6, APITD1, 
CENPI, CENPK, CENPL, CENPM, CENPO, CENPQ, CASC5, 
NDC80, BIRC5, CDC20, FBXO5, DSN1, KIF2C, SPC24, 
MAD2L1, ERCC6L, BUB1B, PSMD12, PSMD11, PSMD14, 
PSMD13, UBE2C, SGOL2, SGOL1, AURKB, NUP98, SKA1, 
SKA2, PLK1, NUF2, VRK1, MAD1L1, ESPL1, HDAC8, ZWINT, 
AHCTF1, ZWILCH, PTTG1, KNTC1, KIF18A, ITGB3BP, BUB1 
Signalling by Rho 
GTPases(R) 
0.0316 323 81 2.22E-16 6.51E-14 CDCA8, IQGAP3, CENPA, FLNA, CENPE, CENPF, APITD1, 
CENPI, CENPK, CENPL, CENPM, CENPO, CENPQ, FAM13B, 
CASC5, CDC25C, NDC80, ARHGAP11A, ARHGAP11B, BIRC5, 
PIK3C3, CDC42, PRC1, CDC20, HIST2H3A, ROPN1, DSN1, 
RACGAP1, A2M, PTK2, GRB2, KIF14, TAX1BP3, KIF2C, 
ARHGEF2, ARHGEF7, PAK2, SPC24, MAD2L1, ERCC6L, 
BUB1B, RHPN2, ECT2, SGOL2, SGOL1, YWHAG, ARHGEF11, 
ARHGEF17, AURKB, TRIO, WIPF2, WIPF3, DEPDC1B, NUP98, 
SKA1, SKA2, STARD13, PLK1, ARPC1B, NUF2, CIT, FGD1, 
FGD4, MAD1L1, RHOBTB1, SRGAP2, NF2, HIST1H3A, ZWINT, 
HIST1H4A, AHCTF1, CTNNB1, ZWILCH, KNTC1, ARHGAP26, 
KIF18A, DIAPH3, ARAP3, ITGB3BP, BUB1, LIMK1 
Mitotic G1-G1/S 
phases(R) 
0.0123 126 43 1.97E-13 4.13E-11 PSMD4, PSMD3, DHFR, LIN52, PSMA5, PSMB7, PSMB4, 
PSMB5, PSMB2, PSMC6, CDC25A, PKMYT1, MNAT1, MCM10, 
DBF4, E2F1, E2F3, E2F5, FBXO5, POLA1, PCNA, RPA3, 
CCNE2, CCNE1, PSMD12, PSMD11, PSMD14, PSMD13, 
CCNB1, RRM2, POLE2, CDC7, CDC6, CDK2, TFDP2, MCM3, 
MCM4, SKP2, CDT1, TOP2A, PRIM1, TYMS, LIN9 
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GeneSet Ratio Of Protein In GeneSet 
No. Of Protein 
In GeneSet 
Protein From 
Network P-value FDR Nodes 
Cell Cycle 
Checkpoints(R) 
0.0146 149 47 2.35E-13 4.13E-11 MDC1, PSMD4, PSMD3, PSMA5, PSMB7, PSMB4, PSMB5, 
PSMB2, PSMC6, PIAS4, CDC25C, CDC25A, PKMYT1, MCM10, 
SUMO1, DBF4, CDC20, BRCA1, RPA3, RAD1, MAD2L1, 
BUB1B, UBE2V2, PSMD12, PSMD11, PSMD14, PSMD13, 
CCNB2, CCNB1, UBE2C, YWHAG, RNF8, CDC7, CDC6, NBN, 
MAD1L1, CDK2, RFC3, RFC4, MCM3, MCM4, CHEK2, CHEK1, 
HIST1H4A, ATR, CLSPN, H2AFX 
Synthesis of DNA(R) 0.0094 96 34 2.51E-11 3.67E-09 PSMD4, PSMD3, PSMA5, PSMB7, PSMB4, PSMB5, PSMB2, 
PSMC6, POLA1, PCNA, RPA3, PSMD12, PSMD11, PSMD14, 
PSMD13, POLD3, POLD4, POLD1, POLE2, CDC6, CDK2, 
RFC3, RFC4, RFC1, MCM3, MCM4, DNA2, CDT1, FEN1, 
PRIM1, GINS1, GINS3, GINS4, LIG1 
S Phase(R) 0.0117 120 38 4.18E-11 5.22E-09 PSMD4, PSMD3, CDCA5, PSMA5, PSMB7, PSMB4, PSMB5, 
PSMB2, PSMC6, CDC25A, MNAT1, POLA1, PCNA, RPA3, 
PSMD12, PSMD11, PSMD14, PSMD13, POLD3, POLD4, 
POLD1, POLE2, CDC6, CDK2, RFC3, RFC4, RFC1, MCM3, 
MCM4, SKP2, DNA2, CDT1, FEN1, PRIM1, GINS1, GINS3, 
GINS4, LIG1 
Mitochondrial 
translation(R) 
0.0087 89 31 2.80E-10 3.08E-08 MRPL19, MRPL16, MRPL12, MRPL13, MRPL27, MRPL28, 
MRPL24, MRPL21, MRPL39, MRPL35, MRPL32, MRPL33, 
MRPL42, MRPL53, MRPL50, MRPL51, MRPL3, MRPS17, 
MRPS28, MRPS23, MRPS7, MRPS5, MRPS33, MRPS34, 
MRPS30, MRPS18A, GFM2, MRRF, CHCHD1, TUFM, DAP3 
Cell cycle(K) 0.0121 124 37 3.76E-10 3.52E-08 CDC25C, CDC25A, CDC25B, PKMYT1, ZBTB17, DBF4, E2F1, 
E2F3, E2F5, CDC20, PCNA, MAD2L2, MAD2L1, BUB1B, 
CCNE2, CCNE1, CCNB2, CCNB1, YWHAG, CCNA2, PLK1, 
CDC7, CDC6, MAD1L1, CDK2, ESPL1, TFDP2, MCM3, MCM4, 
TTK, CHEK2, CHEK1, SKP2, ATR, PTTG1, SMAD4, BUB1 
HDR through 
Homologous 
Recombination (HR) 
0.0083 85 30 4.00E-10 3.52E-08 MDC1, PPP4R2, PIAS4, BLM, SUMO1, EXO1, BRIP1, XRCC3, 
BRCA1, BRCA2, RPA3, RAD1, UBE2V2, RNF8, ERCC4, NBN, 
RAD51AP1, CDK2, RFC3, RFC4, CHEK1, DNA2, HIST1H4A, 
ATR, RAD51C, EME1, TIMELESS, CLSPN, TOPBP1, H2AFX 
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GeneSet Ratio Of Protein In GeneSet 
No. Of Protein 
In GeneSet 
Protein From 
Network P-value FDR Nodes 
or Single Strand 
Annealing (SSA)(R) 
PLK1 signalling 
events(N) 
0.0043 44 21 1.04E-09 8.30E-08 CENPE, CDC25C, CDC25B, ODF2, NDC80, PRC1, CDC20, 
FBXO5, KIF20A, SPC24, ERCC6L, BUB1B, CCNB1, ECT2, 
SGOL1, AURKA, PLK1, TPX2, TUBG1, CLSPN, BUB1 
RNA Polymerase I, 
RNA Polymerase III, 
and Mitochondrial 
Transcription(R) 
0.0087 89 30 1.14E-09 8.33E-08 EHMT2, POLRMT, MNAT1, ZNRD1, SSB, HIST2H3A, TFB2M, 
TTF1, RRN3, TAF1A, CD3EAP, GTF2H1, GTF2H3, GTF2H4, 
UBTF, POLR1A, POLR1C, POLR1E, RBBP7, POLR2K, 
POLR3A, POLR3C, POLR3D, POLR3G, POLR3K, HIST1H3A, 
HIST1H4A, TWISTNB, CBX3, SNAPC5 
DNA replication(K) 0.0035 36 19 1.29E-09 8.66E-08 RNASEH2C, RNASEH2A, POLA1, PCNA, RPA3, POLD3, 
POLD4, POLD1, POLE4, POLE2, RFC3, RFC4, RFC1, MCM3, 
MCM4, DNA2, FEN1, PRIM1, LIG1 
Nucleosome 
assembly(R) 
0.0028 29 17 2.06E-09 1.27E-07 CENPA, APITD1, CENPI, CENPK, CENPL, CENPM, CENPO, 
CENPQ, CASC5, SMARCA5, NPM1, HJURP, OIP5, RBBP7, 
HIST1H4A, RSF1, ITGB3BP 
Mitotic G2-G2/M 
phases(R) 
0.0109 111 33 3.63E-09 2.10E-07 LIN52, CENPF, CENPJ, NEK2, CDC25C, CDC25A, CDC25B, 
PKMYT1, ODF2, MNAT1, FOXM1, E2F1, E2F3, CEP192, 
CCNB2, CCNB1, YWHAG, CCNA2, DCTN1, AURKA, CEP70, 
CEP76, CEP78, PLK4, PLK1, CEP63, ALMS1, CDK2, CEP152, 
TUBB, TUBG1, SDCCAG8, LIN9 
Nucleotide Excision 
Repair(R) 
0.01 102 31 6.54E-09 3.52E-07 ACTL6A, INO80E, MNAT1, ISY1, SUMO1, ACTR8, PCNA, 
RPA3, UBE2V2, POLD3, POLD4, POLD1, ERCC4, ERCC8, 
RNF111, GTF2H1, GTF2H3, GTF2H4, COPS5, RFC3, RFC4, 
RFC1, POLR2B, POLR2C, POLR2G, POLR2K, ZNF830, 
PRPF19, PARP1, LIG1, LIG3 
Aurora B signalling(N) 0.0039 40 19 6.89E-09 3.52E-07 NCAPG, CDCA8, CENPA, NDC80, BIRC5, KIF20A, RACGAP1, 
KIF23, KIF2C, NPM1, KLHL9, SGOL1, AURKB, AURKA, SMC4, 
STMN1, NCL, PPP2R5D, BUB1 
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GeneSet Ratio Of Protein In GeneSet 
No. Of Protein 
In GeneSet 
Protein From 
Network P-value FDR Nodes 
Validated targets of C-
MYC transcriptional 
activation(N) 
0.0073 75 26 8.28E-09 3.98E-07 ACTL6A, ODC1, RUVBL2, CDC25A, BIRC5, E2F3, EIF4E, 
RCC1, NPM1, SUPT7L, CCNB1, HMGA1, CAD, TAF9, TAF12, 
PRDX3, MINA, TK1, NBN, NCL, UBTF, POLR3D, NME2, NME1, 
SMAD4, HSPA4 
M/G1 Transition(R) 0.008 82 27 1.23E-08 5.66E-07 PSMD4, PSMD3, PSMA5, PSMB7, PSMB4, PSMB5, PSMB2, 
PSMC6, GMNN, MCM10, DBF4, E2F1, E2F3, POLA1, RPA3, 
PSMD12, PSMD11, PSMD14, PSMD13, POLE2, CDC7, CDC6, 
CDK2, MCM3, MCM4, CDT1, PRIM1 
Fanconi anemia 
pathway(N) 
0.0044 45 19 4.29E-08 1.89E-06 APITD1, BLM, BRIP1, XRCC3, BRCA1, BRCA2, RAD1, UBE2T, 
NBN, FANCI, FANCC, FANCB, RFC3, RFC4, CHEK1, ATR, 
FANCD2, TOPBP1, H2AFX 
ATR signalling 
pathway(N) 
0.0036 37 17 6.74E-08 2.76E-06 CDC25C, CDC25A, BRCA2, RAD1, CCNA2, PLK1, CDC6, NBN, 
CDK2, RFC3, RFC4, CHEK1, ATR, FANCD2, TIMELESS, 
CLSPN, TOPBP1 
NoRC negatively 
regulates rRNA 
expression(R) 
0.0048 49 19 1.56E-07 6.24E-06 SAP30BP, MNAT1, ZNRD1, HIST2H3A, SMARCA5, TTF1, 
TAF1A, CD3EAP, GTF2H1, GTF2H3, GTF2H4, UBTF, POLR1A, 
POLR1C, POLR1E, POLR2K, HIST1H3A, HIST1H4A, TWISTNB 
APC/C-mediated 
degradation of cell 
cycle proteins(R) 
0.008 82 25 1.75E-07 6.66E-06 PSMD4, PSMD3, PSMA5, PSMB7, PSMB4, PSMB5, PSMB2, 
PSMC6, NEK2, CDC20, FBXO5, MAD2L1, BUB1B, PSMD12, 
PSMD11, PSMD14, PSMD13, CCNB1, UBE2C, AURKB, 
AURKA, PLK1, CDK2, SKP2, PTTG1 
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Table T5-2: Full list of pathways (at FDR<0.0001) enriched for genes that are 
expressed significantly lower in ulcerated tumours compared to non-
ulcerated tumours). Output from Reactome FIViz 
The source database for each of the enriched pathways are indicated by a letter 
in parentheses after each pathway gene set name. The source database 
annotations are: C - CellMap, R – Reactome, K – KEGG, N – NCI PID, P - 
Panther, and B – BioCarta.  
The description of column headers are:  Ratio of protein in gene set: ratios of 
numbers of genes contained in pathways to total genes in the Reactome FI 
network; Number of protein in gene set: numbers of genes in pathways; Protein 
from network: numbers of hit genes from the query gene list; Nodes: nodal genes 
from my input query gene list, which ‘matches’ with the genes in a particular 
pathway; P-value was estimated by Reactome FIViz using hypergeometric test 
and the corresponding FDR was estimated by Benjamini Hochberg multiple 
correction 
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GeneSet Ratio Of Protein In GeneSet 
No. Of Protein 
In GeneSet 
Protein From 
Network P-value FDR Nodes 
Extracellular matrix 
organization(R) 0.0243 248 49 1.45E-11 1.17E-08 
ELANE, ELN, MMP11, MMP19, JAM3, COL3A1, FMOD, 
EFEMP2, EFEMP1, CDH1, COL17A1, ITGB4, ITGB2, ITGAL, 
ITGB6, ITGA8, LRP4, MFAP4, SPARC, COL8A2, KLK7, SDC1, 
COL9A2, CTSG, LOXL1, COMP, CASK, COL4A4, COL4A6, 
COL4A5, LTBP4, FBLN2, FBLN5, VCAM1, TGFB3, BMP7, 
BMP4, BMP2, LAMC2, FGA, DCN, COL6A2, COL6A1, COL6A3, 
LAMA5, LAMA2, LAMA3, LAMB3, COL7A1 
Pathways in 
cancer(K) 0.0389 397 61 9.67E-10 3.70E-07 
SPI1, DAPK2, AR, WNT10B, WNT10A, JUP, CDKN1A, ADCY7, 
EGFR, EGLN3, CDKN2B, WNT7B, WNT7A, CDH1, ZBTB16, 
FLT3, FASLG, PIK3CG, PLEKHG5, BIRC3, CEBPA, CBLC, 
RASSF5, FLT3LG, LPAR1, TGFA, RALGDS, LPAR5, NCOA4, 
KIT, PTGER2, PTGER3, GNAI1, RXRA, FAS, PDGFRB, 
COL4A4, COL4A6, COL4A5, RASGRP1, WNT3, FGF22, WNT4, 
WNT3A, TGFB3, PTCH1, BMP4, NFKBIA, BMP2, FGFR3, 
FGF11, FGFR2, LAMC2, AXIN2, LAMA5, LAMA2, LAMA3, 
WNT11, ERBB2, LAMB3, LAMB4 
ECM-receptor 
interaction(K) 0.0085 87 25 1.38E-09 3.70E-07 
GP6, COL3A1, TNN, ITGB4, ITGB6, ITGA8, SDC1, CD36, 
TNXB, COMP, COL4A4, COL4A6, COL4A5, CHAD, LAMC2, 
COL6A2, COL6A1, COL6A3, COL6A6, LAMA5, LAMA2, LAMA3, 
THBS2, LAMB3, LAMB4 
Cytokine-cytokine 
receptor 
interaction(K) 
0.0259 265 45 9.87E-09 1.99E-06 
IL20RA, IL20RB, IL22RA1, IFNGR1, CCL13, EGFR, CCL19, 
CCL21, IL10RA, CCL27, EPO, CXCL14, CXCL16, CXCL10, 
CXCL11, FLT3, FASLG, TNFSF13B, CX3CR1, IL2RG, CCL5, 
TNFSF10, IL15RA, FLT3LG, XCR1, CX3CL1, CCR7, IL15, IL18, 
OSMR, KIT, CXCR1, CXCR3, FAS, IL18R1, IL18RAP, PDGFRB, 
LIFR, TGFB3, BMP7, BMP2, CXCL9, GHR, LTB, ACVR2A 
Interferon gamma 
signalling(R) 0.0072 74 21 3.48E-08 5.60E-06 
HLA-DQA2, HLA-DQA1, JAK2, HLA-DPA1, IFNGR1, HLA-DQB2, 
HLA-DPB1, PIAS1, HLA-DRA, PTPN6, B2M, TRIM22, HLA-B, 
HLA-E, VCAM1, OAS2, OAS3, IRF8, IRF6, IRF9, CAMK2G 
Beta1 integrin cell 
surface 
interactions(N) 
0.0065 66 19 1.25E-07 1.67E-05 
COL3A1, F13A1, ITGA8, PLAU, COL4A4, COL4A6, COL4A5, 
VCAM1, LAMC2, FGA, COL6A2, COL6A1, COL6A3, LAMA5, 
LAMA2, LAMA3, THBS2, LAMB3, COL7A1 
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GeneSet Ratio Of Protein In GeneSet 
No. Of Protein 
In GeneSet 
Protein From 
Network P-value FDR Nodes 
HTLV-I infection(K) 0.0253 258 41 2.54E-07 2.92E-05 
SPI1, MYB, HLA-DQA2, HLA-DQA1, WNT10B, WNT10A, 
NFATC2, CDKN1A, TSPO, HLA-DPA1, ADCY7, HLA-DMB, 
CDKN2B, WNT7B, WNT7A, HLA-DPB1, HLA-DOB, HLA-DRA, 
ITGB2, ITGAL, PIK3CG, LCK, IL2RG, IL15RA, HLA-B, HLA-E, 
CD3G, CD3E, CD3D, PPP3CB, IL15, ETS2, CCND2, PDGFRB, 
WNT3, WNT4, VCAM1, WNT3A, TGFB3, NFKBIA, WNT11 
Cell adhesion 
molecules 
(CAMs)(K) 
0.0139 142 28 3.73E-07 3.69E-05 
CLDN1, HLA-DQA2, HLA-DQA1, HLA-DPA1, HLA-DMB, JAM3, 
HLA-DPB1, SIGLEC1, CDH1, HLA-DOB, PTPRC, HLA-DRA, 
ITGB2, ITGAL, SPN, NEO1, ITGA8, PVRL1, HLA-B, HLA-E, 
OCLN, SDC1, PTPRF, CLDN23, CLDN16, CD8A, VCAM1, 
CNTN1 
PI3K-Akt signalling 
pathway(K) 0.0338 345 49 4.57E-07 3.69E-05 
MYB, CDKN1A, JAK2, EGFR, COL3A1, EPO, TNN, RPS6, 
FOXO3, ITGB4, FASLG, PIK3CG, ITGB6, ITGA8, IL2RG, 
EPHA2, LPAR1, LPAR5, OSMR, KIT, SGK2, TNXB, RXRA, 
COMP, CCND2, PDGFRB, COL4A4, COL4A6, COL4A5, EFNA5, 
CHAD, FGF22, EFNA3, FGFR3, FGF11, FGFR2, LAMC2, GHR, 
COL6A2, COL6A1, COL6A3, COL6A6, LAMA5, LAMA2, LAMA3, 
THBS2, LAMB3, LAMB4, PPP2R2C 
Inflammatory bowel 
disease (IBD)(K) 0.0064 65 18 4.61E-07 3.69E-05 
GATA3, HLA-DQA2, HLA-DQA1, HLA-DPA1, IFNGR1, HLA-
DMB, HLA-DPB1, RORC, RORA, HLA-DOB, MAF, HLA-DRA, 
NOD2, IL2RG, IL18, IL18R1, IL18RAP, TGFB3 
Axon guidance(K) 0.0124 127 25 1.60E-06 1.17E-04 
DPYSL2, UNC5B, NGEF, NFATC2, PLXNC1, PLXNA3, 
PLXNB1, SEMA3D, SEMA4A, SEMA4D, SEMA4B, EPHB6, 
EPHB1, EPHA4, EPHA1, EPHA2, ROBO2, PPP3CB, RHOD, 
GNAI1, PAK6, EFNA5, EFNB1, EFNA3, SLIT3 
Chemical 
carcinogenesis(K) 0.0079 81 19 2.50E-06 1.67E-04 
CYP2E1, ADH7, GSTO2, CYP2C19, CYP2C18, UGT1A1, 
CYP3A5, UGT1A5, UGT1A3, UGT1A9, UGT1A7, UGT1A6, 
MGST1, MGST2, AKR1C2, GSTA4, GSTA3, ALDH3A1, 
ALDH3B2 
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In GeneSet 
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Network P-value FDR Nodes 
Metabolism of 
xenobiotics by 
cytochrome P450(K) 
0.0072 74 18 2.79E-06 1.73E-04 
CYP2E1, ADH7, GSTO2, UGT1A1, CYP3A5, UGT1A5, UGT1A3, 
UGT1A9, UGT1A7, UGT1A6, MGST1, MGST2, AKR1C1, 
AKR1C2, GSTA4, GSTA3, ALDH3A1, ALDH3B2 
Drug metabolism - 
cytochrome P450(K) 0.0067 68 17 3.67E-06 2.06E-04 
CYP2E1, ADH7, GSTO2, CYP2C19, UGT1A1, CYP3A5, 
UGT1A5, UGT1A3, UGT1A9, UGT1A7, UGT1A6, MGST1, 
MGST2, GSTA4, GSTA3, ALDH3A1, ALDH3B2 
IL12-mediated 
signalling events(N) 0.006 61 16 3.90E-06 2.06E-04 
JAK2, HLA-DRA, FASLG, LCK, IL2RG, CD247, B2M, GADD45B, 
GADD45G, CD3G, CD3E, CD3D, IL18, IL18R1, IL18RAP, CD8A 
T cell activation(P) 0.0079 81 18 9.37E-06 4.69E-04 
HLA-DQA2, HLA-DQA1, NFATC2, HLA-DPA1, HLA-DMB, 
PTPRC, HLA-DRA, PIK3CG, LCK, CD247, B2M, CD3G, CD3E, 
CD3D, PPP3CB, VAV3, CD74, NFKBIA 
Amoebiasis(K) 0.0106 108 21 1.28E-05 6.04E-04 
SERPINB3, SERPINB4, SERPINB2, SERPINB13, COL3A1, 
ITGB2, PIK3CG, CTSG, RAB7B, COL4A4, COL4A6, COL4A5, 
TGFB3, HSPB1, LAMC2, LAMA5, LAMA2, LAMA3, GNA15, 
LAMB3, LAMB4 
Toxoplasmosis(K) 0.0116 118 22 1.52E-05 6.69E-04 
HLA-DQA2, HLA-DQA1, JAK2, HLA-DPA1, IFNGR1, HLA-DMB, 
IL10RA, HLA-DPB1, HLA-DOB, HLA-DRA, PIK3CG, BIRC3, 
GNAI1, TGFB3, NFKBIA, LAMC2, LAMA5, LAMA2, LAMA3, 
LAMB3, LAMB4, MAPK13 
TCR signalling in 
na&#xef;ve CD8+ T 
cells(N) 
0.0053 54 14 1.75E-05 7.35E-04 MAP3K8, PTPRC, LCK, MALT1, PTPN6, CD247, RASSF5, B2M, CD3G, CD3E, CD3D, CD8A, RASGRP1, TRPV6 
Staphylococcus 
aureus infection(K) 0.0054 55 14 2.13E-05 8.54E-04 
CFD, CFH, C3, HLA-DQA2, HLA-DQA1, HLA-DPA1, HLA-DMB, 
HLA-DPB1, HLA-DOB, HLA-DRA, ITGB2, ITGAL, DSG1, C1S 
Focal adhesion(K) 0.0203 207 31 2.27E-05 8.62E-04 
EGFR, FLNB, COL3A1, TNN, ITGB4, PIK3CG, ITGB6, ITGA8, 
BIRC3, VAV3, TNXB, PAK6, COMP, CCND2, PDGFRB, 
COL4A4, COL4A6, COL4A5, CHAD, LAMC2, COL6A2, COL6A1, 
COL6A3, COL6A6, LAMA5, LAMA2, LAMA3, THBS2, ERBB2, 
LAMB3, LAMB4 
249 
 
References 
 
1. Breslow A. Thickness, cross-sectional areas and depth of invasion in the 
prognosis of cutaneous melanoma. Ann Surg. 1970;172(5):902-8. 
2. Edge SB, and Compton CC. The American Joint Committee on Cancer: the 7th 
edition of the AJCC cancer staging manual and the future of TNM. Ann Surg 
Oncol. 2010;17(6):1471-4. 
3. Kashani-Sabet M, Sagebiel RW, Ferreira CM, Nosrati M, and Miller JR, 3rd. 
Vascular involvement in the prognosis of primary cutaneous melanoma. Arch 
Dermatol. 2001;137(9):1169-73. 
4. Shain AH, and Bastian BC. From melanocytes to melanomas. Nature reviews 
Cancer. 2016;16(6):345-58. 
5. Bastian BC. The molecular pathology of melanoma: an integrated taxonomy of 
melanocytic neoplasia. Annual review of pathology. 2014;9(239-71. 
6. UK CR. Cancer Research UK Melanoma skin cancer incidence statistics. 
https://www.cancerresearchuk.org/health-professional/cancer-
statistics/statistics-by-cancer-type/melanoma-skin-cancer/incidence#heading-
Zero.  Accessed January, 2019. 
7. Linos E, Swetter SM, Cockburn MG, Colditz GA, and Clarke CA. Increasing 
burden of melanoma in the United States. J Invest Dermatol. 2009;129(7):1666-
74. 
8. 2012 G. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 
http://globocan.iarc.fr. 
9. Kosary CL, Altekruse SF, Ruhl J, Lee R, and Dickie L. Clinical and prognostic 
factors for melanoma of the skin using SEER registries: collaborative stage data 
collection system, version 1 and version 2. Cancer. 2014;120 Suppl 23(3807-
14. 
10. Karimkhani C, Green AC, Nijsten T, Weinstock MA, Dellavalle RP, Naghavi M, 
and Fitzmaurice C. The global burden of melanoma: results from the Global 
Burden of Disease Study 2015. Br J Dermatol. 2017;177(1):134-40. 
11. Crombie IK. Variation of melanoma incidence with latitude in North America and 
Europe. Br J Cancer. 1979;40(5):774-81. 
12. Baade P, Meng X, Youlden D, Aitken J, and Youl P. Time trends and latitudinal 
differences in melanoma thickness distribution in Australia, 1990-2006. Int J 
Cancer. 2012;130(1):170-8. 
250 
 
13. Natalie H. Matthews W-QL, Abrar A. Qureshi, Martin A. Weinstock, and 
Eunyoung Cho. In: Ward WH FJ ed. Cutaneous Melanoma: Etiology and 
Therapy. Brisbane: Codon Publications; 2017. 
14. WHO. 2002. 
15. Eide MJ, and Weinstock MA. Association of UV index, latitude, and melanoma 
incidence in nonwhite populations--US Surveillance, Epidemiology, and End 
Results (SEER) Program, 1992 to 2001. Arch Dermatol. 2005;141(4):477-81. 
16. Levine H, Afek A, Shamiss A, Derazne E, Tzur D, Astman N, Keinan-Boker L, 
Mimouni D, and Kark JD. Country of origin, age at migration and risk of 
cutaneous melanoma: a migrant cohort study of 1,100,000 Israeli men. Int J 
Cancer. 2013;133(2):486-94. 
17. Garbe C, and Leiter U. Melanoma epidemiology and trends. Clin Dermatol. 
2009;27(1):3-9. 
18. Weir HK, Marrett LD, Cokkinides V, Barnholtz-Sloan J, Patel P, Tai E, Jemal A, 
Li J, Kim J, and Ekwueme DU. Melanoma in adolescents and young adults 
(ages 15-39 years): United States, 1999-2006. J Am Acad Dermatol. 2011;65(5 
Suppl 1):S38-49. 
19. Watson M, Geller AC, Tucker MA, Guy GP, Jr., and Weinstock MA. Melanoma 
burden and recent trends among non-Hispanic whites aged 15-49years, United 
States. Prev Med. 2016;91(294-8. 
20. Bulliard JL, and Cox B. Cutaneous malignant melanoma in New Zealand: trends 
by anatomical site, 1969-1993. Int J Epidemiol. 2000;29(3):416-23. 
21. Surveillance E, and End Results (SEER). 2015. 
22. Li WQ, Qureshi AA, Ma J, Goldstein AM, Giovannucci EL, Stampfer MJ, and 
Han J. Personal history of prostate cancer and increased risk of incident 
melanoma in the United States. J Clin Oncol. 2013;31(35):4394-9. 
23. Li WQ, Cho E, Weinstock MA, Mashfiq H, and Qureshi AA. Epidemiological 
Assessments of Skin Outcomes in the Nurses' Health Studies. Am J Public 
Health. 2016;106(9):1677-83. 
24. Downing A, Newton-Bishop JA, and Forman D. Recent trends in cutaneous 
malignant melanoma in the Yorkshire region of England; incidence, mortality 
and survival in relation to stage of disease, 1993-2003. Br J Cancer. 
2006;95(1):91-5. 
25. Whiteman DC, Green AC, and Olsen CM. The Growing Burden of Invasive 
Melanoma: Projections of Incidence Rates and Numbers of New Cases in Six 
Susceptible Populations through 2031. J Invest Dermatol. 2016;136(6):1161-
71. 
251 
 
26. Chen L, and Jin S. Trends in mortality rates of cutaneous melanoma in East 
Asian populations. PeerJ. 2016;4(e2809. 
27. Jemal A, Saraiya M, Patel P, Cherala SS, Barnholtz-Sloan J, Kim J, Wiggins 
CL, and Wingo PA. Recent trends in cutaneous melanoma incidence and death 
rates in the United States, 1992-2006. J Am Acad Dermatol. 2011;65(5 Suppl 
1):S17-25 e1-3. 
28. Ward-Peterson M, Acuna JM, Alkhalifah MK, Nasiri AM, Al-Akeel ES, Alkhaldi 
TM, Dawari SA, and Aldaham SA. Association Between Race/Ethnicity and 
Survival of Melanoma Patients in the United States Over 3 Decades: A 
Secondary Analysis of SEER Data. Medicine (Baltimore). 2016;95(17):e3315. 
29. Wu XC, Eide MJ, King J, Saraiya M, Huang Y, Wiggins C, Barnholtz-Sloan JS, 
Martin N, Cokkinides V, Miller J, et al. Racial and ethnic variations in incidence 
and survival of cutaneous melanoma in the United States, 1999-2006. J Am 
Acad Dermatol. 2011;65(5 Suppl 1):S26-37. 
30. Bradford PT, Goldstein AM, McMaster ML, and Tucker MA. Acral lentiginous 
melanoma: incidence and survival patterns in the United States, 1986-2005. 
Arch Dermatol. 2009;145(4):427-34. 
31. Shen W, Sakamoto N, and Yang L. Melanoma-specific mortality and competing 
mortality in patients with non-metastatic malignant melanoma: a population-
based analysis. BMC Cancer. 2016;16(413. 
32. Joosse A, de Vries E, Eckel R, Nijsten T, Eggermont AM, Holzel D, Coebergh 
JW, Engel J, and Munich Melanoma G. Gender differences in melanoma 
survival: female patients have a decreased risk of metastasis. J Invest Dermatol. 
2011;131(3):719-26. 
33. Van Der Esch EP, Cascinelli N, Preda F, Morabito A, and Bufalino R. Stage I 
melanoma of the skin: evaluation of prognosis according to histologic 
characteristics. Cancer. 1981;48(7):1668-73. 
34. Thompson JF, Shaw HM, Hersey P, and Scolyer RA. The history and future of 
melanoma staging. J Surg Oncol. 2004;86(4):224-35. 
35. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, 
Gershenwald JE, Houghton A, Jr., Kirkwood JM, et al. Final version of the 
American Joint Committee on Cancer staging system for cutaneous melanoma. 
J Clin Oncol. 2001;19(16):3635-48. 
36. Balch CM, Wilkerson JA, Murad TM, Soong SJ, Ingalls AL, and Maddox WA. 
The prognostic significance of ulceration of cutaneous melanoma. Cancer. 
1980;45(12):3012-7. 
252 
 
37. Zendee Elaba MJM, Philip Kerr, Jane M. Grant-Kels. In: Murphy MJ ed. 
Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma. 
2012. 
38. Debniak T. Familial malignant melanoma - overview. Hered Cancer Clin Pract. 
2004;2(3):123-9. 
39. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan 
MD, Clark WH, Jr., Tucker MA, and Dracopoli NC. Germline p16 mutations in 
familial melanoma. Nat Genet. 1994;8(1):15-21. 
40. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran 
T, Miki Y, Weaver-Feldhaus J, et al. Analysis of the p16 gene (CDKN2) as a 
candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet. 
1994;8(1):23-6. 
41. Bruce JL, Hurford RK, Jr., Classon M, Koh J, and Dyson N. Requirements for 
cell cycle arrest by p16INK4a. Mol Cell. 2000;6(3):737-42. 
42. Weber HO, Samuel T, Rauch P, and Funk JO. Human p14(ARF)-mediated cell 
cycle arrest strictly depends on intact p53 signalling pathways. Oncogene. 
2002;21(20):3207-12. 
43. Goldstein AM, Chan M, Harland M, Gillanders EM, Hayward NK, Avril MF, Azizi 
E, Bianchi-Scarra G, Bishop DT, Bressac-de Paillerets B, et al. High-risk 
melanoma susceptibility genes and pancreatic cancer, neural system tumours, 
and uveal melanoma across GenoMEL. Cancer Res. 2006;66(20):9818-28. 
44. Harland M, Taylor CF, Chambers PA, Kukalizch K, Randerson-Moor JA, Gruis 
NA, de Snoo FA, ter Huurne JA, Goldstein AM, Tucker MA, et al. A mutation 
hotspot at the p14ARF splice site. Oncogene. 2005;24(28):4604-8. 
45. Mistry SH, Taylor C, Randerson-Moor JA, Harland M, Turner F, Barrett JH, 
Whitaker L, Jenkins RB, Knowles MA, Bishop JA, et al. Prevalence of 9p21 
deletions in UK melanoma families. Genes Chromosomes Cancer. 
2005;44(3):292-300. 
46. Randerson-Moor JA, Harland M, Williams S, Cuthbert-Heavens D, Sheridan E, 
Aveyard J, Sibley K, Whitaker L, Knowles M, Bishop JN, et al. A germline 
deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour 
syndrome family. Hum Mol Genet. 2001;10(1):55-62. 
47. Aoude LG, Wadt KA, Pritchard AL, and Hayward NK. Genetics of familial 
melanoma: 20 years after CDKN2A. Pigment Cell Melanoma Res. 
2015;28(2):148-60. 
48. Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, Hayward N, 
and Dracopoli NC. Germline mutations in the p16INK4a binding domain of 
CDK4 in familial melanoma. Nat Genet. 1996;12(1):97-9. 
253 
 
49. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, 
Nagore E, Hemminki K, et al. TERT promoter mutations in familial and sporadic 
melanoma. Science. 2013;339(6122):959-61. 
50. Robles-Espinoza CD, Harland M, Ramsay AJ, Aoude LG, Quesada V, Ding Z, 
Pooley KA, Pritchard AL, Tiffen JC, Petljak M, et al. POT1 loss-of-function 
variants predispose to familial melanoma. Nat Genet. 2014;46(5):478-81. 
51. Shi J, Yang XR, Ballew B, Rotunno M, Calista D, Fargnoli MC, Ghiorzo P, 
Bressac-de Paillerets B, Nagore E, Avril MF, et al. Rare missense variants in 
POT1 predispose to familial cutaneous malignant melanoma. Nat Genet. 
2014;46(5):482-6. 
52. Aoude LG, Pritchard AL, Robles-Espinoza CD, Wadt K, Harland M, Choi J, 
Gartside M, Quesada V, Johansson P, Palmer JM, et al. Nonsense mutations 
in the shelterin complex genes ACD and TERF2IP in familial melanoma. J Natl 
Cancer Inst. 2015;107(2). 
53. Bertolotto C, Lesueur F, Giuliano S, Strub T, de Lichy M, Bille K, Dessen P, 
d'Hayer B, Mohamdi H, Remenieras A, et al. A SUMOylation-defective MITF 
germline mutation predisposes to melanoma and renal carcinoma. Nature. 
2011;480(7375):94-8. 
54. Yokoyama S, Woods SL, Boyle GM, Aoude LG, MacGregor S, Zismann V, 
Gartside M, Cust AE, Haq R, Harland M, et al. A novel recurrent mutation in 
MITF predisposes to familial and sporadic melanoma. Nature. 
2011;480(7375):99-103. 
55. Fernandez LP, Milne RL, Pita G, Floristan U, Sendagorta E, Feito M, Aviles JA, 
Martin-Gonzalez M, Lazaro P, Benitez J, et al. Pigmentation-related genes and 
their implication in malignant melanoma susceptibility. Exp Dermatol. 
2009;18(7):634-42. 
56. Planelles D, Nagore E, Moret A, Botella-Estrada R, Vila E, Guillen C, and 
Montoro JA. HLA class II polymorphisms in Spanish melanoma patients: 
homozygosity for HLA-DQA1 locus can be a potential melanoma risk factor. Br 
J Dermatol. 2006;154(2):261-6. 
57. Pena-Chilet M, Blanquer-Maceiras M, Ibarrola-Villava M, Martinez-Cadenas C, 
Martin-Gonzalez M, Gomez-Fernandez C, Mayor M, Aviles JA, Lluch A, and 
Ribas G. Genetic variants in PARP1 (rs3219090) and IRF4 (rs12203592) genes 
associated with melanoma susceptibility in a Spanish population. BMC Cancer. 
2013;13(160. 
58. Ibarrola-Villava M, Martin-Gonzalez M, Lazaro P, Pizarro A, Lluch A, and Ribas 
G. Role of glutathione S-transferases in melanoma susceptibility: association 
with GSTP1 rs1695 polymorphism. Br J Dermatol. 2012;166(6):1176-83. 
254 
 
59. Denzer N, Vogt T, and Reichrath J. Vitamin D receptor (VDR) polymorphisms 
and skin cancer: A systematic review. Dermatoendocrinol. 2011;3(3):205-10. 
60. Narayanan DL, Saladi RN, and Fox JL. Ultraviolet radiation and skin cancer. Int 
J Dermatol. 2010;49(9):978-86. 
61. Elwood JM, Lee JA, Walter SD, Mo T, and Green AE. Relationship of melanoma 
and other skin cancer mortality to latitude and ultraviolet radiation in the United 
States and Canada. Int J Epidemiol. 1974;3(4):325-32. 
62. Moan J, Dahlback A, and Setlow RB. Epidemiological support for an hypothesis 
for melanoma induction indicating a role for UVA radiation. Photochem 
Photobiol. 1999;70(2):243-7. 
63. Holman CD, and Armstrong BK. Cutaneous malignant melanoma and indicators 
of total accumulated exposure to the sun: an analysis separating histogenetic 
types. J Natl Cancer Inst. 1984;73(1):75-82. 
64. Whiteman DC, Whiteman CA, and Green AC. Childhood sun exposure as a risk 
factor for melanoma: a systematic review of epidemiologic studies. Cancer 
Causes Control. 2001;12(1):69-82. 
65. Elwood JM, and Jopson J. Melanoma and sun exposure: an overview of 
published studies. Int J Cancer. 1997;73(2):198-203. 
66. Pfahlberg A, Kolmel KF, Gefeller O, and Febim Study G. Timing of excessive 
ultraviolet radiation and melanoma: epidemiology does not support the 
existence of a critical period of high susceptibility to solar ultraviolet radiation- 
induced melanoma. Br J Dermatol. 2001;144(3):471-5. 
67. Chang YM, Barrett JH, Bishop DT, Armstrong BK, Bataille V, Bergman W, 
Berwick M, Bracci PM, Elwood JM, Ernstoff MS, et al. Sun exposure and 
melanoma risk at different latitudes: a pooled analysis of 5700 cases and 7216 
controls. Int J Epidemiol. 2009;38(3):814-30. 
68. Runger TM. Mechanisms of Melanoma Promotion by Ultraviolet Radiation. J 
Invest Dermatol. 2016;136(9):1751-2. 
69. Beissert S, and Loser K. Molecular and cellular mechanisms of 
photocarcinogenesis. Photochem Photobiol. 2008;84(1):29-34. 
70. Kamenisch Y, Baban TS, Schuller W, von Thaler AK, Sinnberg T, Metzler G, 
Bauer J, Schittek B, Garbe C, Rocken M, et al. UVA-Irradiation Induces 
Melanoma Invasion via the Enhanced Warburg Effect. J Invest Dermatol. 
2016;136(9):1866-75. 
71. Waster P, Rosdahl I, Gilmore BF, and Seifert O. Ultraviolet exposure of 
melanoma cells induces fibroblast activation protein-alpha in fibroblasts: 
Implications for melanoma invasion. Int J Oncol. 2011;39(1):193-202. 
255 
 
72. Leonard MK, Pamidimukkala N, Puts GS, Snyder DE, Slominski AT, and 
Kaetzel DM. The HGF/SF Mouse Model of UV-Induced Melanoma as an In Vivo 
Sensor for Metastasis-Regulating Gene. Int J Mol Sci. 2017;18(8). 
73. Bald T, Quast T, Landsberg J, Rogava M, Glodde N, Lopez-Ramos D, 
Kohlmeyer J, Riesenberg S, van den Boorn-Konijnenberg D, Homig-Holzel C, 
et al. Ultraviolet-radiation-induced inflammation promotes angiotropism and 
metastasis in melanoma. Nature. 2014;507(7490):109-13. 
74. Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, Cheng 
E, Davis MJ, Goh G, Choi M, et al. Exome sequencing identifies recurrent 
somatic RAC1 mutations in melanoma. Nat Genet. 2012;44(9):1006-14. 
75. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, 
Bignell GR, Bolli N, Borg A, Borresen-Dale AL, et al. Signatures of mutational 
processes in human cancer. Nature. 2013;500(7463):415-21. 
76. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, 
Carter SL, Stewart C, Mermel CH, Roberts SA, et al. Mutational heterogeneity 
in cancer and the search for new cancer-associated genes. Nature. 
2013;499(7457):214-8. 
77. Cancer Genome Atlas Network. Electronic address imo, and Cancer Genome 
Atlas N. Genomic Classification of Cutaneous Melanoma. Cell. 
2015;161(7):1681-96. 
78. Clark WH, Jr., Reimer RR, Greene M, Ainsworth AM, and Mastrangelo MJ. 
Origin of familial malignant melanomas from heritable melanocytic lesions. 'The 
B-K mole syndrome'. Arch Dermatol. 1978;114(5):732-8. 
79. Elder DE, Goldman LI, Goldman SC, Greene MH, and Clark WH, Jr. Dysplastic 
nevus syndrome: a phenotypic association of sporadic cutaneous melanoma. 
Cancer. 1980;46(8):1787-94. 
80. Duffy K, and Grossman D. The dysplastic nevus: from historical perspective to 
management in the modern era: part II. Molecular aspects and clinical 
management. J Am Acad Dermatol. 2012;67(1):19 e1-2; quiz 31-2. 
81. MacKie RM. Nevi as risk factors for melanoma. Pediatr Dermatol. 
1992;9(4):340-1. 
82. Bergman W, and Fusaro RM. Precursor lesions to melanoma. Clin Dermatol. 
1992;10(1):21-9. 
83. Newton Bishop JA, Bataille V, Pinney E, and Bishop DT. Family studies in 
melanoma: identification of the atypical mole syndrome (AMS) phenotype. 
Melanoma Res. 1994;4(4):199-206. 
84. Ang CG, Kelly JW, Fritschi L, and Dowling JP. Characteristics of familial and 
non-familial melanoma in Australia. Melanoma Res. 1998;8(5):459-64. 
256 
 
85. Hashemi J, Linder S, Platz A, and Hansson J. Melanoma development in 
relation to non-functional p16/INK4A protein and dysplastic naevus syndrome in 
Swedish melanoma kindreds. Melanoma Res. 1999;9(1):21-30. 
86. Landi MT, Calista D, Landi G, Bernucci I, Bertazzi PA, Clark WH, Jr., Goldstein 
AM, and Tucker MA. Clinical characteristics of 20 Italian melanoma-prone 
families. Arch Dermatol. 1999;135(12):1554-5. 
87. Ruiz A, Puig S, Malvehy J, Lazaro C, Lynch M, Gimenez-Arnau AM, Puig L, 
Sanchez-Conejo J, Estivill X, and Castel T. CDKN2A mutations in Spanish 
cutaneous malignant melanoma families and patients with multiple melanomas 
and other neoplasia. J Med Genet. 1999;36(6):490-3. 
88. Avril MF, Chompret A, Verne-Fourment L, Terrier-Lacombe MJ, Spatz A, Fizazi 
K, Bressac-de Paillerets B, Demenais F, and Theodore C. Association between 
germ cell tumours, large numbers of naevi, atypical naevi and melanoma. 
Melanoma Res. 2001;11(2):117-22. 
89. Slade J, Marghoob AA, Salopek TG, Rigel DS, Kopf AW, and Bart RS. Atypical 
mole syndrome: risk factor for cutaneous malignant melanoma and implications 
for management. J Am Acad Dermatol. 1995;32(3):479-94. 
90. Crijns MB, Vink J, Van Hees CL, Bergman W, and Vermeer BJ. Dysplastic nevi. 
Occurrence in first- and second-degree relatives of patients with 'sporadic' 
dysplastic nevus syndrome. Arch Dermatol. 1991;127(9):1346-51. 
91. Tucker MA, and Goldstein AM. Melanoma etiology: where are we? Oncogene. 
2003;22(20):3042-52. 
92. Chang YM, Newton-Bishop JA, Bishop DT, Armstrong BK, Bataille V, Bergman 
W, Berwick M, Bracci PM, Elwood JM, Ernstoff MS, et al. A pooled analysis of 
melanocytic nevus phenotype and the risk of cutaneous melanoma at different 
latitudes. Int J Cancer. 2009;124(2):420-8. 
93. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Abeni D, Boyle P, and Melchi 
CF. Meta-analysis of risk factors for cutaneous melanoma: I. Common and 
atypical naevi. Eur J Cancer. 2005;41(1):28-44. 
94. Bataille V, Grulich A, Sasieni P, Swerdlow A, Newton Bishop J, McCarthy W, 
Hersey P, and Cuzick J. The association between naevi and melanoma in 
populations with different levels of sun exposure: a joint case-control study of 
melanoma in the UK and Australia. Br J Cancer. 1998;77(3):505-10. 
95. Harrison SL, MacLennan R, Speare R, and Wronski I. Sun exposure and 
melanocytic naevi in young Australian children. Lancet. 1994;344(8936):1529-
32. 
96. Stierner U. Melanocytes, moles and melanoma--a study on UV effects. Acta 
Derm Venereol Suppl (Stockh). 1991;168(1-31. 
257 
 
97. Falchi M, Bataille V, Hayward NK, Duffy DL, Bishop JA, Pastinen T, Cervino A, 
Zhao ZZ, Deloukas P, Soranzo N, et al. Genome-wide association study 
identifies variants at 9p21 and 22q13 associated with development of cutaneous 
nevi. Nat Genet. 2009;41(8):915-9. 
98. Bishop JA, Wachsmuth RC, Harland M, Bataille V, Pinney E, Mac KP, Baglietto 
L, Cuzick J, and Bishop DT. Genotype/phenotype and penetrance studies in 
melanoma families with germline CDKN2A mutations. J Invest Dermatol. 
2000;114(1):28-33. 
99. Zhu G, Montgomery GW, James MR, Trent JM, Hayward NK, Martin NG, and 
Duffy DL. A genome-wide scan for naevus count: linkage to CDKN2A and to 
other chromosome regions. Eur J Hum Genet. 2007;15(1):94-102. 
100. de Snoo FA, Hottenga JJ, Gillanders EM, Sandkuijl LA, Jones MP, Bergman W, 
van der Drift C, van Leeuwen I, van Mourik L, Huurne JA, et al. Genome-wide 
linkage scan for atypical nevi in p16-Leiden melanoma families. Eur J Hum 
Genet. 2008;16(9):1135-41. 
101. Halpern AC, Guerry Dt, Elder DE, Trock B, Synnestvedt M, and Humphreys T. 
Natural history of dysplastic nevi. J Am Acad Dermatol. 1993;29(1):51-7. 
102. Tsao H, Bevona C, Goggins W, and Quinn T. The transformation rate of moles 
(melanocytic nevi) into cutaneous melanoma: a population-based estimate. 
Arch Dermatol. 2003;139(3):282-8. 
103. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, 
Hostetter G, Wagner U, Kakareka J, et al. High frequency of BRAF mutations in 
nevi. Nat Genet. 2003;33(1):19-20. 
104. Loewe R, Kittler H, Fischer G, Fae I, Wolff K, and Petzelbauer P. BRAF kinase 
gene V599E mutation in growing melanocytic lesions. J Invest Dermatol. 
2004;123(4):733-6. 
105. Papp T, Schipper H, Kumar K, Schiffmann D, and Zimmermann R. Mutational 
analysis of the BRAF gene in human congenital and dysplastic melanocytic 
naevi. Melanoma Res. 2005;15(5):401-7. 
106. Zalaudek I, Guelly C, Pellacani G, Hofmann-Wellenhof R, Trajanoski S, Kittler 
H, Scope A, Marghoob AA, Longo C, Leinweber B, et al. The dermoscopical 
and histopathological patterns of nevi correlate with the frequency of BRAF 
mutations. J Invest Dermatol. 2011;131(2):542-5. 
107. Damsky WE, and Bosenberg M. Melanocytic nevi and melanoma: unraveling a 
complex relationship. Oncogene. 2017;36(42):5771-92. 
108. Laud K, Marian C, Avril MF, Barrois M, Chompret A, Goldstein AM, Tucker MA, 
Clark PA, Peters G, Chaudru V, et al. Comprehensive analysis of CDKN2A 
(p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases 
258 
 
considered to be at heightened risk of melanoma. J Med Genet. 2006;43(1):39-
47. 
109. Michaloglou C, Vredeveld LC, Mooi WJ, and Peeper DS. BRAF(E600) in benign 
and malignant human tumours. Oncogene. 2008;27(7):877-95. 
110. Roh MR, Eliades P, Gupta S, and Tsao H. Genetics of melanocytic nevi. 
Pigment Cell Melanoma Res. 2015;28(6):661-72. 
111. Scherer D, and Kumar R. Genetics of pigmentation in skin cancer--a review. 
Mutat Res. 2010;705(2):141-53. 
112. Bliss JM, Ford D, Swerdlow AJ, Armstrong BK, Cristofolini M, Elwood JM, Green 
A, Holly EA, Mack T, MacKie RM, et al. Risk of cutaneous melanoma associated 
with pigmentation characteristics and freckling: systematic overview of 10 case-
control studies. The International Melanoma Analysis Group (IMAGE). Int J 
Cancer. 1995;62(4):367-76. 
113. Jablonski NG, and Chaplin G. The evolution of human skin coloration. J Hum 
Evol. 2000;39(1):57-106. 
114. Morgan AM, Lo J, and Fisher DE. How does pheomelanin synthesis contribute 
to melanomagenesis?: Two distinct mechanisms could explain the 
carcinogenicity of pheomelanin synthesis. Bioessays. 2013;35(8):672-6. 
115. Ancans J, Tobin DJ, Hoogduijn MJ, Smit NP, Wakamatsu K, and Thody AJ. 
Melanosomal pH controls rate of melanogenesis, eumelanin/phaeomelanin 
ratio and melanosome maturation in melanocytes and melanoma cells. Exp Cell 
Res. 2001;268(1):26-35. 
116. Rees JL, and Healy E. Melanocortin receptors, red hair, and skin cancer. J 
Investig Dermatol Symp Proc. 1997;2(1):94-8. 
117. Rees JL, and Harding RM. Understanding the evolution of human pigmentation: 
recent contributions from population genetics. J Invest Dermatol. 2012;132(3 Pt 
2):846-53. 
118. Garcia-Borron JC, Abdel-Malek Z, and Jimenez-Cervantes C. MC1R, the cAMP 
pathway, and the response to solar UV: extending the horizon beyond 
pigmentation. Pigment Cell Melanoma Res. 2014;27(5):699-720. 
119. Beaumont KA, Shekar SN, Newton RA, James MR, Stow JL, Duffy DL, and 
Sturm RA. Receptor function, dominant negative activity and phenotype 
correlations for MC1R variant alleles. Hum Mol Genet. 2007;16(18):2249-60. 
120. Doyle JR, Fortin JP, Beinborn M, and Kopin AS. Selected melanocortin 1 
receptor single-nucleotide polymorphisms differentially alter multiple signalling 
pathways. J Pharmacol Exp Ther. 2012;342(2):318-26. 
121. Schioth HB, Phillips SR, Rudzish R, Birch-Machin MA, Wikberg JE, and Rees 
JL. Loss of function mutations of the human melanocortin 1 receptor are 
259 
 
common and are associated with red hair. Biochem Biophys Res Commun. 
1999;260(2):488-91. 
122. Valverde P, Healy E, Jackson I, Rees JL, and Thody AJ. Variants of the 
melanocyte-stimulating hormone receptor gene are associated with red hair and 
fair skin in humans. Nat Genet. 1995;11(3):328-30. 
123. Beaumont KA, Shekar SN, Cook AL, Duffy DL, and Sturm RA. Red hair is the 
null phenotype of MC1R. Hum Mutat. 2008;29(8):E88-94. 
124. Raimondi S, Sera F, Gandini S, Iodice S, Caini S, Maisonneuve P, and Fargnoli 
MC. MC1R variants, melanoma and red hair color phenotype: a meta-analysis. 
Int J Cancer. 2008;122(12):2753-60. 
125. Bishop DT, Demenais F, Iles MM, Harland M, Taylor JC, Corda E, Randerson-
Moor J, Aitken JF, Avril MF, Azizi E, et al. Genome-wide association study 
identifies three loci associated with melanoma risk. Nat Genet. 2009;41(8):920-
5. 
126. Pasquali E, Garcia-Borron JC, Fargnoli MC, Gandini S, Maisonneuve P, 
Bagnardi V, Specchia C, Liu F, Kayser M, Nijsten T, et al. MC1R variants 
increased the risk of sporadic cutaneous melanoma in darker-pigmented 
Caucasians: a pooled-analysis from the M-SKIP project. Int J Cancer. 
2015;136(3):618-31. 
127. Robles-Espinoza CD, Roberts ND, Chen S, Leacy FP, Alexandrov LB, 
Pornputtapong N, Halaban R, Krauthammer M, Cui R, Timothy Bishop D, et al. 
Germline MC1R status influences somatic mutation burden in melanoma. Nat 
Commun. 2016;7(12064. 
128. Luger TA, Scholzen T, Brzoska T, Becher E, Slominski A, and Paus R. 
Cutaneous immunomodulation and coordination of skin stress responses by 
alpha-melanocyte-stimulating hormone. Ann N Y Acad Sci. 1998;840(381-94. 
129. Catania A, Gatti S, Colombo G, and Lipton JM. Targeting melanocortin 
receptors as a novel strategy to control inflammation. Pharmacol Rev. 
2004;56(1):1-29. 
130. Jarrett SG, Carter KM, Shelton BJ, and D'Orazio JA. The melanocortin signalling 
cAMP axis accelerates repair and reduces mutagenesis of platinum-induced 
DNA damage. Sci Rep. 2017;7(1):11708. 
131. Jarrett SG, Wolf Horrell EM, Christian PA, Vanover JC, Boulanger MC, Zou Y, 
and D'Orazio JA. PKA-mediated phosphorylation of ATR promotes recruitment 
of XPA to UV-induced DNA damage. Mol Cell. 2014;54(6):999-1011. 
132. John A. D’Orazio AM, James Lagrew and W. Brooke Veith. In: Armstrong AW 
ed. Advances in Malignant Melanoma. IntechOpen; 2011. 
260 
 
133. Cambridge EL, McIntyre Z, Clare S, Arends MJ, Goulding D, Isherwood C, 
Caetano SS, Reviriego CB, Swiatkowska A, Kane L, et al. The AMP-activated 
protein kinase beta 1 subunit modulates erythrocyte integrity. Exp Hematol. 
2017;45(64-8 e5. 
134. Gudbjartsson DF, Sulem P, Stacey SN, Goldstein AM, Rafnar T, Sigurgeirsson 
B, Benediktsdottir KR, Thorisdottir K, Ragnarsson R, Sveinsdottir SG, et al. 
ASIP and TYR pigmentation variants associate with cutaneous melanoma and 
basal cell carcinoma. Nat Genet. 2008;40(7):886-91. 
135. Sulem P, Gudbjartsson DF, Stacey SN, Helgason A, Rafnar T, Magnusson KP, 
Manolescu A, Karason A, Palsson A, Thorleifsson G, et al. Genetic 
determinants of hair, eye and skin pigmentation in Europeans. Nat Genet. 
2007;39(12):1443-52. 
136. Amos CI, Wang LE, Lee JE, Gershenwald JE, Chen WV, Fang S, Kosoy R, 
Zhang M, Qureshi AA, Vattathil S, et al. Genome-wide association study 
identifies novel loci predisposing to cutaneous melanoma. Hum Mol Genet. 
2011;20(24):5012-23. 
137. Hartman ML, and Czyz M. Pro-survival role of MITF in melanoma. J Invest 
Dermatol. 2015;135(2):352-8. 
138. Hsiao JJ, and Fisher DE. The roles of microphthalmia-associated transcription 
factor and pigmentation in melanoma. Arch Biochem Biophys. 2014;563(28-34. 
139. Hilger RA, Scheulen ME, and Strumberg D. The Ras-Raf-MEK-ERK pathway in 
the treatment of cancer. Onkologie. 2002;25(6):511-8. 
140. Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK 
pathway by protein interactions. Biochem J. 2000;351 Pt 2(289-305. 
141. Houben R, Becker JC, Kappel A, Terheyden P, Brocker EB, Goetz R, and Rapp 
UR. Constitutive activation of the Ras-Raf signalling pathway in metastatic 
melanoma is associated with poor prognosis. J Carcinog. 2004;3(6. 
142. Edlundh-Rose E, Egyhazi S, Omholt K, Mansson-Brahme E, Platz A, Hansson 
J, and Lundeberg J. NRAS and BRAF mutations in melanoma tumours in 
relation to clinical characteristics: a study based on mutation screening by 
pyrosequencing. Melanoma Res. 2006;16(6):471-8. 
143. Platz A, Egyhazi S, Ringborg U, and Hansson J. Human cutaneous melanoma; 
a review of NRAS and BRAF mutation frequencies in relation to histogenetic 
subclass and body site. Mol Oncol. 2008;1(4):395-405. 
144. Burd CE, Liu W, Huynh MV, Waqas MA, Gillahan JE, Clark KS, Fu K, Martin 
BL, Jeck WR, Souroullas GP, et al. Mutation-specific RAS oncogenicity explains 
NRAS codon 61 selection in melanoma. Cancer Discov. 2014;4(12):1418-29. 
261 
 
145. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, 
Woffendin H, Garnett MJ, Bottomley W, et al. Mutations of the BRAF gene in 
human cancer. Nature. 2002;417(6892):949-54. 
146. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE, Jr., 
You MJ, DePinho RA, McMahon M, and Bosenberg M. Braf(V600E) cooperates 
with Pten loss to induce metastatic melanoma. Nat Genet. 2009;41(5):544-52. 
147. Patton EE, Widlund HR, Kutok JL, Kopani KR, Amatruda JF, Murphey RD, 
Berghmans S, Mayhall EA, Traver D, Fletcher CD, et al. BRAF mutations are 
sufficient to promote nevi formation and cooperate with p53 in the genesis of 
melanoma. Curr Biol. 2005;15(3):249-54. 
148. Yu H, McDaid R, Lee J, Possik P, Li L, Kumar SM, Elder DE, Van Belle P, 
Gimotty P, Guerra M, et al. The role of BRAF mutation and p53 inactivation 
during transformation of a subpopulation of primary human melanocytes. Am J 
Pathol. 2009;174(6):2367-77. 
149. Yu JS, and Cui W. Proliferation, survival and metabolism: the role of 
PI3K/AKT/mTOR signalling in pluripotency and cell fate determination. 
Development. 2016;143(17):3050-60. 
150. Blume-Jensen P, and Hunter T. Oncogenic kinase signalling. Nature. 
2001;411(6835):355-65. 
151. Hemmings BA, and Restuccia DF. The PI3K-PKB/Akt pathway. Cold Spring 
Harb Perspect Biol. 2015;7(4). 
152. Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, Bosenberg MW, 
Kester M, Sandirasegarane L, and Robertson GP. Deregulated Akt3 activity 
promotes development of malignant melanoma. Cancer Res. 
2004;64(19):7002-10. 
153. Robertson GP. Functional and therapeutic significance of Akt deregulation in 
malignant melanoma. Cancer Metastasis Rev. 2005;24(2):273-85. 
154. Dhawan P, Singh AB, Ellis DL, and Richmond A. Constitutive activation of 
Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-
kappaB and tumour progression. Cancer Res. 2002;62(24):7335-42. 
155. Bastian BC, LeBoit PE, Hamm H, Brocker EB, and Pinkel D. Chromosomal 
gains and losses in primary cutaneous melanomas detected by comparative 
genomic hybridization. Cancer Res. 1998;58(10):2170-5. 
156. Robertson GP, Furnari FB, Miele ME, Glendening MJ, Welch DR, Fountain JW, 
Lugo TG, Huang HJ, and Cavenee WK. In vitro loss of heterozygosity targets 
the PTEN/MMAC1 gene in melanoma. Proc Natl Acad Sci U S A. 
1998;95(16):9418-23. 
262 
 
157. Stahl JM, Cheung M, Sharma A, Trivedi NR, Shanmugam S, and Robertson 
GP. Loss of PTEN promotes tumour development in malignant melanoma. 
Cancer Res. 2003;63(11):2881-90. 
158. Conde-Perez A, Gros G, Longvert C, Pedersen M, Petit V, Aktary Z, Viros A, 
Gesbert F, Delmas V, Rambow F, et al. A caveolin-dependent and PI3K/AKT-
independent role of PTEN in beta-catenin transcriptional activity. Nat Commun. 
2015;6(8093. 
159. Davies MA, Stemke-Hale K, Tellez C, Calderone TL, Deng W, Prieto VG, Lazar 
AJ, Gershenwald JE, and Mills GB. A novel AKT3 mutation in melanoma 
tumours and cell lines. Br J Cancer. 2008;99(8):1265-8. 
160. Hartman ML, and Czyz M. MITF in melanoma: mechanisms behind its 
expression and activity. Cell Mol Life Sci. 2015;72(7):1249-60. 
161. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, 
Beroukhim R, Milner DA, Granter SR, Du J, et al. Integrative genomic analyses 
identify MITF as a lineage survival oncogene amplified in malignant melanoma. 
Nature. 2005;436(7047):117-22. 
162. Rivera RS, Nagatsuka H, Gunduz M, Cengiz B, Gunduz E, Siar CH, Tsujigiwa 
H, Tamamura R, Han KN, and Nagai N. C-kit protein expression correlated with 
activating mutations in KIT gene in oral mucosal melanoma. Virchows Arch. 
2008;452(1):27-32. 
163. Ashida A, Takata M, Murata H, Kido K, and Saida T. Pathological activation of 
KIT in metastatic tumours of acral and mucosal melanomas. Int J Cancer. 
2009;124(4):862-8. 
164. Sherr CJ. Principles of tumour suppression. Cell. 2004;116(2):235-46. 
165. Akslen LA, Monstad SE, Larsen B, Straume O, and Ogreid D. Frequent 
mutations of the p53 gene in cutaneous melanoma of the nodular type. Int J 
Cancer. 1998;79(1):91-5. 
166. Papp T, Jafari M, and Schiffmann D. Lack of p53 mutations and loss of 
heterozygosity in non-cultured human melanocytic lesions. J Cancer Res Clin 
Oncol. 1996;122(9):541-8. 
167. Krauthammer M, Kong Y, Bacchiocchi A, Evans P, Pornputtapong N, Wu C, 
McCusker JP, Ma S, Cheng E, Straub R, et al. Exome sequencing identifies 
recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. 
Nat Genet. 2015;47(9):996-1002. 
168. Paget S. The distribution of secondary growths in cancer of the breast. 1889. 
Cancer Metastasis Rev. 1989;8(2):98-101. 
169. Gambichler T, Kempka J, Kampilafkos P, Bechara FG, Altmeyer P, and Stucker 
M. Clinicopathological characteristics of 270 patients with lentigo maligna and 
263 
 
lentigo maligna melanoma: data from a German skin cancer centre. Br J 
Dermatol. 2014;171(6):1605-7. 
170. Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu Y, Gong Z, Zhang S, Zhou J, Cao 
K, et al. Role of tumour microenvironment in tumourigenesis. J Cancer. 
2017;8(5):761-73. 
171. McGovern VJ. Spontaneous regression of melanoma. Pathology. 1975;7(2):91-
9. 
172. Park CK, and Kim SK. Clinicopathological significance of intratumoural and 
peritumoural lymphocytes and lymphocyte score based on the histologic 
subtypes of cutaneous melanoma. Oncotarget. 2017;8(9):14759-69. 
173. Saldanha G, Flatman K, Teo KW, and Bamford M. A Novel Numerical Scoring 
System for Melanoma Tumour-infiltrating Lymphocytes Has Better Prognostic 
Value Than Standard Scoring. Am J Surg Pathol. 2017;41(7):906-14. 
174. Donizy P, Kaczorowski M, Halon A, Leskiewicz M, Kozyra C, and Matkowski R. 
Paucity of tumour-infiltrating lymphocytes is an unfavorable prognosticator and 
predicts lymph node metastases in cutaneous melanoma patients. Anticancer 
Res. 2015;35(1):351-8. 
175. Fortes C, Mastroeni S, Mannooranparampil TJ, Passarelli F, Zappala A, 
Annessi G, Marino C, Caggiati A, Russo N, and Michelozzi P. Tumour-infiltrating 
lymphocytes predict cutaneous melanoma survival. Melanoma Res. 
2015;25(4):306-11. 
176. Weiss SA, Han SW, Lui K, Tchack J, Shapiro R, Berman R, Zhong J, 
Krogsgaard M, Osman I, and Darvishian F. Immunologic heterogeneity of 
tumour-infiltrating lymphocyte composition in primary melanoma. Hum Pathol. 
2016;57(116-25. 
177. Lee SJ, Lim HJ, Choi YH, Chang YH, Lee WJ, Kim DW, and Yoon GS. The 
clinical significance of tumour-infiltrating lymphocytes and microscopic satellites 
in acral melanoma in a korean population. Ann Dermatol. 2013;25(1):61-6. 
178. Barnes TA, and Amir E. HYPE or HOPE: the prognostic value of infiltrating 
immune cells in cancer. Br J Cancer. 2018;118(2):e5. 
179. Eriksson H, Frohm-Nilsson M, Jaras J, Kanter-Lewensohn L, Kjellman P, 
Mansson-Brahme E, Vassilaki I, and Hansson J. Prognostic factors in localized 
invasive primary cutaneous malignant melanoma: results of a large population-
based study. Br J Dermatol. 2015;172(1):175-86. 
180. Kakavand H, Vilain RE, Wilmott JS, Burke H, Yearley JH, Thompson JF, Hersey 
P, Long GV, and Scolyer RA. Tumour PD-L1 expression, immune cell correlates 
and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. Mod 
Pathol. 2015;28(12):1535-44. 
264 
 
181. Erdag G, Schaefer JT, Smolkin ME, Deacon DH, Shea SM, Dengel LT, 
Patterson JW, and Slingluff CL, Jr. Immunotype and immunohistologic 
characteristics of tumour-infiltrating immune cells are associated with clinical 
outcome in metastatic melanoma. Cancer Res. 2012;72(5):1070-80. 
182. Garg K, Maurer M, Griss J, Bruggen MC, Wolf IH, Wagner C, Willi N, Mertz KD, 
and Wagner SN. Tumour-associated B cells in cutaneous primary melanoma 
and improved clinical outcome. Hum Pathol. 2016;54(157-64. 
183. Ladanyi A, Kiss J, Mohos A, Somlai B, Liszkay G, Gilde K, Fejos Z, Gaudi I, 
Dobos J, and Timar J. Prognostic impact of B-cell density in cutaneous 
melanoma. Cancer Immunol Immunother. 2011;60(12):1729-38. 
184. Messaoudene M, Perier A, Fregni G, Neves E, Zitvogel L, Cremer I, Chanal J, 
Sastre-Garau X, Deschamps L, Marinho E, et al. Characterization of the 
Microenvironment in Positive and Negative Sentinel Lymph Nodes from 
Melanoma Patients. PLoS One. 2015;10(7):e0133363. 
185. Knol AC, Nguyen JM, Quereux G, Brocard A, Khammari A, and Dreno B. 
Prognostic value of tumour-infiltrating Foxp3+ T-cell subpopulations in 
metastatic melanoma. Exp Dermatol. 2011;20(5):430-4. 
186. Harlin H, Kuna TV, Peterson AC, Meng Y, and Gajewski TF. Tumour 
progression despite massive influx of activated CD8(+) T cells in a patient with 
malignant melanoma ascites. Cancer Immunol Immunother. 2006;55(10):1185-
97. 
187. Cabrera CM. The double role of the endoplasmic reticulum chaperone tapasin 
in peptide optimization of HLA class I molecules. Scand J Immunol. 
2007;65(6):487-93. 
188. Bernsen MR, Hakansson L, Gustafsson B, Krysander L, Rettrup B, Ruiter D, 
and Hakansson A. On the biological relevance of MHC class II and B7 
expression by tumour cells in melanoma metastases. Br J Cancer. 
2003;88(3):424-31. 
189. Seliger B, Ritz U, Abele R, Bock M, Tampe R, Sutter G, Drexler I, Huber C, and 
Ferrone S. Immune escape of melanoma: first evidence of structural alterations 
in two distinct components of the MHC class I antigen processing pathway. 
Cancer Res. 2001;61(24):8647-50. 
190. Hussein MR. Dendritic cells and melanoma tumourigenesis: an insight. Cancer 
Biol Ther. 2005;4(5):501-5. 
191. Janeway CA Jr TP, Walport M, et al. Immunobiology: The Immune System in 
Health and Disease. New York: Garland Science; 2001. 
265 
 
192. Passarelli A, Mannavola F, Stucci LS, Tucci M, and Silvestris F. Immune system 
and melanoma biology: a balance between immunosurveillance and immune 
escape. Oncotarget. 2017;8(62):106132-42. 
193. Cooper MA, Colonna M, and Yokoyama WM. Hidden talents of natural killers: 
NK cells in innate and adaptive immunity. EMBO Rep. 2009;10(10):1103-10. 
194. Mirjacic Martinovic KM, Babovic N, Dzodic RR, Jurisic VB, Tanic NT, and 
Konjevic GM. Decreased expression of NKG2D, NKp46, DNAM-1 receptors, 
and intracellular perforin and STAT-1 effector molecules in NK cells and their 
dim and bright subsets in metastatic melanoma patients. Melanoma Res. 
2014;24(4):295-304. 
195. Tarazona R, Duran E, and Solana R. Natural Killer Cell Recognition of 
Melanoma: New Clues for a More Effective Immunotherapy. Front Immunol. 
2015;6(649. 
196. Beissert S, Schwarz A, and Schwarz T. Regulatory T cells. J Invest Dermatol. 
2006;126(1):15-24. 
197. Talmadge JE, and Gabrilovich DI. History of myeloid-derived suppressor cells. 
Nature reviews Cancer. 2013;13(10):739-52. 
198. Munn DH. Indoleamine 2,3-dioxygenase, tumour-induced tolerance and 
counter-regulation. Curr Opin Immunol. 2006;18(2):220-5. 
199. Lakshmikanth T, Burke S, Ali TH, Kimpfler S, Ursini F, Ruggeri L, Capanni M, 
Umansky V, Paschen A, Sucker A, et al. NCRs and DNAM-1 mediate NK cell 
recognition and lysis of human and mouse melanoma cell lines in vitro and in 
vivo. J Clin Invest. 2009;119(5):1251-63. 
200. Jordan KR, Amaria RN, Ramirez O, Callihan EB, Gao D, Borakove M, Manthey 
E, Borges VF, and McCarter MD. Myeloid-derived suppressor cells are 
associated with disease progression and decreased overall survival in 
advanced-stage melanoma patients. Cancer Immunol Immunother. 
2013;62(11):1711-22. 
201. Madar S, Goldstein I, and Rotter V. 'Cancer associated fibroblasts'--more than 
meets the eye. Trends Mol Med. 2013;19(8):447-53. 
202. Kalluri R. The biology and function of fibroblasts in cancer. Nature reviews 
Cancer. 2016;16(9):582-98. 
203. Cortez E, Roswall P, and Pietras K. Functional subsets of mesenchymal cell 
types in the tumour microenvironment. Semin Cancer Biol. 2014;25(3-9. 
204. Ishii G, Ochiai A, and Neri S. Phenotypic and functional heterogeneity of cancer-
associated fibroblast within the tumour microenvironment. Adv Drug Deliv Rev. 
2016;99(Pt B):186-96. 
266 
 
205. Lakins MA, Ghorani E, Munir H, Martins CP, and Shields JD. Cancer-associated 
fibroblasts induce antigen-specific deletion of CD8 (+) T Cells to protect tumour 
cells. Nat Commun. 2018;9(1):948. 
206. Ziani L, Safta-Saadoun TB, Gourbeix J, Cavalcanti A, Robert C, Favre G, 
Chouaib S, and Thiery J. Melanoma-associated fibroblasts decrease tumour cell 
susceptibility to NK cell-mediated killing through matrix-metalloproteinases 
secretion. Oncotarget. 2017;8(12):19780-94. 
207. Hirata E, Girotti MR, Viros A, Hooper S, Spencer-Dene B, Matsuda M, Larkin J, 
Marais R, and Sahai E. Intravital imaging reveals how BRAF inhibition 
generates drug-tolerant microenvironments with high integrin beta1/FAK 
signalling. Cancer Cell. 2015;27(4):574-88. 
208. Dunn GP, Old LJ, and Schreiber RD. The three Es of cancer immunoediting. 
Annu Rev Immunol. 2004;22(329-60. 
209. Farkona S, Diamandis EP, and Blasutig IM. Cancer immunotherapy: the 
beginning of the end of cancer? BMC Med. 2016;14(73. 
210. Peggs KS, Quezada SA, and Allison JP. Cell intrinsic mechanisms of T-cell 
inhibition and application to cancer therapy. Immunol Rev. 2008;224(141-65. 
211. Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, Hipkiss EL, Ravi 
S, Kowalski J, Levitsky HI, et al. Role of LAG-3 in regulatory T cells. Immunity. 
2004;21(4):503-13. 
212. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, 
Rutkowski P, McNeil C, Kalinka-Warzocha E, et al. Nivolumab in previously 
untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320-
30. 
213. Taube JM, Young GD, McMiller TL, Chen S, Salas JT, Pritchard TS, Xu H, 
Meeker AK, Fan J, Cheadle C, et al. Differential Expression of Immune-
Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for 
PD-1 Pathway Blockade. Clin Cancer Res. 2015;21(17):3969-76. 
214. Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalenik SR, 
Vilgelm AE, Feld E, Johnson AS, Greenplate AR, et al. Melanoma-specific 
MHC-II expression represents a tumour-autonomous phenotype and predicts 
response to anti-PD-1/PD-L1 therapy. Nat Commun. 2016;7(10582. 
215. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh 
LA, Postow MA, Wong P, Ho TS, et al. Genetic basis for clinical response to 
CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99. 
216. Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, 
Hillen U, Foppen MHG, Goldinger SM, et al. Genomic correlates of response to 
CTLA-4 blockade in metastatic melanoma. Science. 2015;350(6257):207-11. 
267 
 
217. Riaz N, Havel JJ, Kendall SM, Makarov V, Walsh LA, Desrichard A, Weinhold 
N, and Chan TA. Recurrent SERPINB3 and SERPINB4 mutations in patients 
who respond to anti-CTLA4 immunotherapy. Nat Genet. 2016;48(11):1327-9. 
218. Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-
Maoz B, Pang J, Chmielowski B, Cherry G, et al. Genomic and Transcriptomic 
Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell. 
2017;168(3):542. 
219. Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan 
V, Wang F, Cooper ZA, Reddy SM, et al. Integrated molecular analysis of 
tumour biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of 
response and resistance. Sci Transl Med. 2017;9(379). 
220. Inoue H, Park JH, Kiyotani K, Zewde M, Miyashita A, Jinnin M, Kiniwa Y, 
Okuyama R, Tanaka R, Fujisawa Y, et al. Intratumoural expression levels of 
PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with 
response to nivolumab in metastatic melanoma. Oncoimmunology. 
2016;5(9):e1204507. 
221. Johnson DB, Frampton GM, Rioth MJ, Yusko E, Xu Y, Guo X, Ennis RC, 
Fabrizio D, Chalmers ZR, Greenbowe J, et al. Targeted Next Generation 
Sequencing Identifies Markers of Response to PD-1 Blockade. Cancer Immunol 
Res. 2016;4(11):959-67. 
222. Hogan SA, Courtier A, Cheng PF, Jaberg-Bentele NF, Goldinger SM, Manuel 
M, Perez S, Plantier N, Mouret JF, Nguyen-Kim TDL, et al. Peripheral Blood 
TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy 
against Melanoma. Cancer Immunol Res. 2019;7(1):77-85. 
223. Bouillon R, and Suda T. Vitamin D: calcium and bone homeostasis during 
evolution. Bonekey Rep. 2014;3(480. 
224. Holick MF, MacLaughlin JA, Clark MB, Holick SA, Potts JT, Jr., Anderson RR, 
Blank IH, Parrish JA, and Elias P. Photosynthesis of previtamin D3 in human 
skin and the physiologic consequences. Science. 1980;210(4466):203-5. 
225. Webb AR, DeCosta BR, and Holick MF. Sunlight regulates the cutaneous 
production of vitamin D3 by causing its photodegradation. J Clin Endocrinol 
Metab. 1989;68(5):882-7. 
226. Klingberg E, Olerod G, Konar J, Petzold M, and Hammarsten O. Seasonal 
variations in serum 25-hydroxy vitamin D levels in a Swedish cohort. Endocrine. 
2015;49(3):800-8. 
227. Field S, Davies J, Bishop DT, and Newton-Bishop JA. Vitamin D and melanoma. 
Dermatoendocrinol. 2013;5(1):121-9. 
268 
 
228. Bikle DD. Vitamin D metabolism, mechanism of action, and clinical applications. 
Chem Biol. 2014;21(3):319-29. 
229. Deeb KK, Trump DL, and Johnson CS. Vitamin D signalling pathways in cancer: 
potential for anticancer therapeutics. Nature reviews Cancer. 2007;7(9):684-
700. 
230. Haussler MR, Jurutka PW, Mizwicki M, and Norman AW. Vitamin D receptor 
(VDR)-mediated actions of 1alpha,25(OH)(2)vitamin D(3): genomic and non-
genomic mechanisms. Best practice & research Clinical endocrinology & 
metabolism. 2011;25(4):543-59. 
231. Altucci L, Leibowitz MD, Ogilvie KM, de Lera AR, and Gronemeyer H. RAR and 
RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov. 
2007;6(10):793-810. 
232. Haussler MR, Haussler CA, Jurutka PW, Thompson PD, Hsieh JC, Remus LS, 
Selznick SH, and Whitfield GK. The vitamin D hormone and its nuclear receptor: 
molecular actions and disease states. J Endocrinol. 1997;154 Suppl(S57-73. 
233. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, 
Blumberg B, Kastner P, Mark M, Chambon P, et al. The nuclear receptor 
superfamily: the second decade. Cell. 1995;83(6):835-9. 
234. Baker AR, McDonnell DP, Hughes M, Crisp TM, Mangelsdorf DJ, Haussler MR, 
Pike JW, Shine J, and O'Malley BW. Cloning and expression of full-length cDNA 
encoding human vitamin D receptor. Proc Natl Acad Sci U S A. 
1988;85(10):3294-8. 
235. Wan LY, Zhang YQ, Chen MD, Liu CB, and Wu JF. Relationship of structure 
and function of DNA-binding domain in vitamin D receptor. Molecules. 
2015;20(7):12389-99. 
236. Kraichely DM, and MacDonald PN. Transcriptional activation through the 
vitamin D receptor in osteoblasts. Frontiers in bioscience : a journal and virtual 
library. 1998;3(d821-33. 
237. Umesono K, Murakami KK, Thompson CC, and Evans RM. Direct repeats as 
selective response elements for the thyroid hormone, retinoic acid, and vitamin 
D3 receptors. Cell. 1991;65(7):1255-66. 
238. Kim MS, Fujiki R, Murayama A, Kitagawa H, Yamaoka K, Yamamoto Y, Mihara 
M, Takeyama K, and Kato S. 1Alpha,25(OH)2D3-induced transrepression by 
vitamin D receptor through E-box-type elements in the human parathyroid 
hormone gene promoter. Molecular endocrinology. 2007;21(2):334-42. 
239. Ozono K, Liao J, Kerner SA, Scott RA, and Pike JW. The vitamin D-responsive 
element in the human osteocalcin gene. Association with a nuclear proto-
269 
 
oncogene enhancer. The Journal of biological chemistry. 1990;265(35):21881-
8. 
240. Kerner SA, Scott RA, and Pike JW. Sequence elements in the human 
osteocalcin gene confer basal activation and inducible response to hormonal 
vitamin D3. Proc Natl Acad Sci U S A. 1989;86(12):4455-9. 
241. Spencer TE, Jenster G, Burcin MM, Allis CD, Zhou J, Mizzen CA, McKenna NJ, 
Onate SA, Tsai SY, Tsai MJ, et al. Steroid receptor coactivator-1 is a histone 
acetyltransferase. Nature. 1997;389(6647):194-8. 
242. Kraichely DM, Collins JJ, 3rd, DeLisle RK, and MacDonald PN. The autonomous 
transactivation domain in helix H3 of the vitamin D receptor is required for 
transactivation and coactivator interaction. The Journal of biological chemistry. 
1999;274(20):14352-8. 
243. Kraichely DM, Nakai YD, and MacDonald PN. Identification of an autonomous 
transactivation domain in helix H3 of the vitamin D receptor. Journal of cellular 
biochemistry. 1999;75(1):82-92. 
244. Rachez C, Suldan Z, Ward J, Chang CP, Burakov D, Erdjument-Bromage H, 
Tempst P, and Freedman LP. A novel protein complex that interacts with the 
vitamin D3 receptor in a ligand-dependent manner and enhances VDR 
transactivation in a cell-free system. Genes & development. 1998;12(12):1787-
800. 
245. Peleg S, and Nguyen CV. The importance of nuclear import in protection of the 
vitamin D receptor from polyubiquitination and proteasome-mediated 
degradation. Journal of cellular biochemistry. 2010;110(4):926-34. 
246. Van Cromphaut SJ, Dewerchin M, Hoenderop JG, Stockmans I, Van Herck E, 
Kato S, Bindels RJ, Collen D, Carmeliet P, Bouillon R, et al. Duodenal calcium 
absorption in vitamin D receptor-knockout mice: functional and molecular 
aspects. Proc Natl Acad Sci U S A. 2001;98(23):13324-9. 
247. Portale AA, Halloran BP, and Morris RC, Jr. Physiologic regulation of the serum 
concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men. J Clin 
Invest. 1989;83(5):1494-9. 
248. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: 
consequences for bone loss and fractures and therapeutic implications. Endocr 
Rev. 2001;22(4):477-501. 
249. Wang Y, Zhu J, and DeLuca HF. Where is the vitamin D receptor? Arch Biochem 
Biophys. 2012;523(1):123-33. 
250. Holick MF. Vitamin D: A millenium perspective. Journal of cellular biochemistry. 
2003;88(2):296-307. 
270 
 
251. Norman AW. Minireview: vitamin D receptor: new assignments for an already 
busy receptor. Endocrinology. 2006;147(12):5542-8. 
252. Carlberg C. Genome-wide (over)view on the actions of vitamin D. Front Physiol. 
2014;5(167. 
253. C W. On the use and administration of cod-liver oil in pulmonary consumption. 
London Journal of Medicine. 1849;1:1–18( 
254. Ginde AA, Mansbach JM, and Camargo CA, Jr. Association between serum 25-
hydroxyvitamin D level and upper respiratory tract infection in the Third National 
Health and Nutrition Examination Survey. Arch Intern Med. 2009;169(4):384-90. 
255. Laaksi I, Ruohola JP, Tuohimaa P, Auvinen A, Haataja R, Pihlajamaki H, and 
Ylikomi T. An association of serum vitamin D concentrations < 40 nmol/L with 
acute respiratory tract infection in young Finnish men. Am J Clin Nutr. 
2007;86(3):714-7. 
256. Cannell JJ, Vieth R, Umhau JC, Holick MF, Grant WB, Madronich S, Garland 
CF, and Giovannucci E. Epidemic influenza and vitamin D. Epidemiol Infect. 
2006;134(6):1129-40. 
257. Rodriguez M, Daniels B, Gunawardene S, and Robbins GK. High frequency of 
vitamin D deficiency in ambulatory HIV-Positive patients. AIDS Res Hum 
Retroviruses. 2009;25(1):9-14. 
258. Munger KL, Levin LI, Hollis BW, Howard NS, and Ascherio A. Serum 25-
hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 
2006;296(23):2832-8. 
259. Littorin B, Blom P, Scholin A, Arnqvist HJ, Blohme G, Bolinder J, Ekbom-Schnell 
A, Eriksson JW, Gudbjornsdottir S, Nystrom L, et al. Lower levels of plasma 25-
hydroxyvitamin D among young adults at diagnosis of autoimmune type 1 
diabetes compared with control subjects: results from the nationwide Diabetes 
Incidence Study in Sweden (DISS). Diabetologia. 2006;49(12):2847-52. 
260. Merlino LA, Curtis J, Mikuls TR, Cerhan JR, Criswell LA, Saag KG, and Iowa 
Women's Health S. Vitamin D intake is inversely associated with rheumatoid 
arthritis: results from the Iowa Women's Health Study. Arthritis Rheum. 
2004;50(1):72-7. 
261. Kamen D, and Aranow C. Vitamin D in systemic lupus erythematosus. Curr Opin 
Rheumatol. 2008;20(5):532-7. 
262. Bhalla AK, Amento EP, Clemens TL, Holick MF, and Krane SM. Specific high-
affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood 
mononuclear cells: presence in monocytes and induction in T lymphocytes 
following activation. J Clin Endocrinol Metab. 1983;57(6):1308-10. 
271 
 
263. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber 
J, Wu K, Meinken C, et al. Toll-like receptor triggering of a vitamin D-mediated 
human antimicrobial response. Science. 2006;311(5768):1770-3. 
264. Camp RL, Dolled-Filhart M, and Rimm DL. X-tile: a new bio-informatics tool for 
biomarker assessment and outcome-based cut-point optimization. Clin Cancer 
Res. 2004;10(21):7252-9. 
265. Wang TT, Tavera-Mendoza LE, Laperriere D, Libby E, MacLeod NB, Nagai Y, 
Bourdeau V, Konstorum A, Lallemant B, Zhang R, et al. Large-scale in silico 
and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target 
genes. Molecular endocrinology. 2005;19(11):2685-95. 
266. Bhalla AK, Amento EP, Serog B, and Glimcher LH. 1,25-Dihydroxyvitamin D3 
inhibits antigen-induced T cell activation. Journal of immunology. 
1984;133(4):1748-54. 
267. Nunn JD, Katz DR, Barker S, Fraher LJ, Hewison M, Hendy GN, and O'Riordan 
JL. Regulation of human tonsillar T-cell proliferation by the active metabolite of 
vitamin D3. Immunology. 1986;59(4):479-84. 
268. Barrat FJ, Cua DJ, Boonstra A, Richards DF, Crain C, Savelkoul HF, de Waal-
Malefyt R, Coffman RL, Hawrylowicz CM, and O'Garra A. In vitro generation of 
interleukin 10-producing regulatory CD4(+) T cells is induced by 
immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-
inducing cytokines. The Journal of experimental medicine. 2002;195(5):603-16. 
269. Heine G, Niesner U, Chang HD, Steinmeyer A, Zugel U, Zuberbier T, Radbruch 
A, and Worm M. 1,25-dihydroxyvitamin D(3) promotes IL-10 production in 
human B cells. European journal of immunology. 2008;38(8):2210-8. 
270. Shirakawa AK, Nagakubo D, Hieshima K, Nakayama T, Jin Z, and Yoshie O. 
1,25-dihydroxyvitamin D3 induces CCR10 expression in terminally 
differentiating human B cells. Journal of immunology. 2008;180(5):2786-95. 
271. Autier P, Boniol M, Pizot C, and Mullie P. Vitamin D status and ill health--author's 
reply. Lancet Diabetes Endocrinol. 2014;2(4):275-6. 
272. To SH. Statistics How To. 
https://www.statisticshowto.datasciencecentral.com/reverse-causality/. 
273. Amer M, and Qayyum R. Relation between serum 25-hydroxyvitamin D and C-
reactive protein in asymptomatic adults (from the continuous National Health 
and Nutrition Examination Survey 2001 to 2006). Am J Cardiol. 
2012;109(2):226-30. 
274. Mondul AM, Weinstein SJ, Layne TM, and Albanes D. Vitamin D and Cancer 
Risk and Mortality: State of the Science, Gaps, and Challenges. Epidemiol Rev. 
2017;39(1):28-48. 
272 
 
275. Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, Mullie P, and Autier 
P. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels 
and colorectal, breast and prostate cancer and colorectal adenoma. Int J 
Cancer. 2011;128(6):1414-24. 
276. Lee JE, Li H, Chan AT, Hollis BW, Lee IM, Stampfer MJ, Wu K, Giovannucci E, 
and Ma J. Circulating levels of vitamin D and colon and rectal cancer: the 
Physicians' Health Study and a meta-analysis of prospective studies. Cancer 
Prev Res (Phila). 2011;4(5):735-43. 
277. Ma Y, Zhang P, Wang F, Yang J, Liu Z, and Qin H. Association between vitamin 
D and risk of colorectal cancer: a systematic review of prospective studies. J 
Clin Oncol. 2011;29(28):3775-82. 
278. Weinstein SJ, Yu K, Horst RL, Ashby J, Virtamo J, and Albanes D. Serum 25-
hydroxyvitamin D and risks of colon and rectal cancer in Finnish men. Am J 
Epidemiol. 2011;173(5):499-508. 
279. Chandler PD, Buring JE, Manson JE, Giovannucci EL, Moorthy MV, Zhang S, 
Lee IM, and Lin JH. Circulating Vitamin D Levels and Risk of Colorectal Cancer 
in Women. Cancer Prev Res (Phila). 2015;8(8):675-82. 
280. Shao T, Klein P, and Grossbard ML. Vitamin D and breast cancer. Oncologist. 
2012;17(1):36-45. 
281. Yin L, Grandi N, Raum E, Haug U, Arndt V, and Brenner H. Meta-analysis: 
serum vitamin D and breast cancer risk. Eur J Cancer. 2010;46(12):2196-205. 
282. Trump DL, and Aragon-Ching JB. Vitamin D in prostate cancer. Asian J Androl. 
2018;20(3):244-52. 
283. Zhang H, Zhang H, Wen X, Zhang Y, Wei X, and Liu T. Vitamin D Deficiency 
and Increased Risk of Bladder Carcinoma: A Meta-Analysis. Cell Physiol 
Biochem. 2015;37(5):1686-92. 
284. Zhao Y, Chen C, Pan W, Gao M, He W, Mao R, Lin T, and Huang J. 
Comparative efficacy of vitamin D status in reducing the risk of bladder cancer: 
A systematic review and network meta-analysis. Nutrition. 2016;32(5):515-23. 
285. Chen GC, Zhang ZL, Wan Z, Wang L, Weber P, Eggersdorfer M, Qin LQ, and 
Zhang W. Circulating 25-hydroxyvitamin D and risk of lung cancer: a dose-
response meta-analysis. Cancer Causes Control. 2015;26(12):1719-28. 
286. Zhang L, Wang S, Che X, and Li X. Vitamin D and lung cancer risk: a 
comprehensive review and meta-analysis. Cell Physiol Biochem. 
2015;36(1):299-305. 
287. Tang JY, Parimi N, Wu A, Boscardin WJ, Shikany JM, Chren MM, Cummings 
SR, Epstein EH, Jr., Bauer DC, and Osteoporotic Fractures in Men Study G. 
273 
 
Inverse association between serum 25(OH) vitamin D levels and non-melanoma 
skin cancer in elderly men. Cancer Causes Control. 2010;21(3):387-91. 
288. Newton-Bishop JA, Beswick S, Randerson-Moor J, Chang YM, Affleck P, Elliott 
F, Chan M, Leake S, Karpavicius B, Haynes S, et al. Serum 25-hydroxyvitamin 
D3 levels are associated with breslow thickness at presentation and survival 
from melanoma. J Clin Oncol. 2009;27(32):5439-44. 
289. Timerman D, McEnery-Stonelake M, Joyce CJ, Nambudiri VE, Hodi FS, Claus 
EB, Ibrahim N, and Lin JY. Vitamin D deficiency is associated with a worse 
prognosis in metastatic melanoma. Oncotarget. 2017;8(4):6873-82. 
290. Gambichler T, Bindsteiner M, Hoxtermann S, and Kreuter A. Serum 25-
hydroxyvitamin D serum levels in a large German cohort of patients with 
melanoma. Br J Dermatol. 2013;168(3):625-8. 
291. Fang S, Sui D, Wang Y, Liu H, Chiang YJ, Ross MI, Gershenwald JE, Cormier 
JN, Royal RE, Lucci A, et al. Association of Vitamin D Levels With Outcome in 
Patients With Melanoma After Adjustment For C-Reactive Protein. J Clin Oncol. 
2016;34(15):1741-7. 
292. Wyatt C, Lucas RM, Hurst C, and Kimlin MG. Vitamin D deficiency at melanoma 
diagnosis is associated with higher Breslow thickness. PLoS One. 
2015;10(5):e0126394. 
293. Colston K, Colston MJ, and Feldman D. 1,25-dihydroxyvitamin D3 and 
malignant melanoma: the presence of receptors and inhibition of cell growth in 
culture. Endocrinology. 1981;108(3):1083-6. 
294. Hager G, Formanek M, Gedlicka C, Thurnher D, Knerer B, and Kornfehl J. 
1,25(OH)2 vitamin D3 induces elevated expression of the cell cycle-regulating 
genes P21 and P27 in squamous carcinoma cell lines of the head and neck. 
Acta Otolaryngol. 2001;121(1):103-9. 
295. Koike M, Elstner E, Campbell MJ, Asou H, Uskokovic M, Tsuruoka N, and 
Koeffler HP. 19-nor-hexafluoride analogue of vitamin D3: a novel class of potent 
inhibitors of proliferation of human breast cell lines. Cancer Res. 
1997;57(20):4545-50. 
296. Kumagai T, O'Kelly J, Said JW, and Koeffler HP. Vitamin D2 analog 19-nor-
1,25-dihydroxyvitamin D2: antitumour activity against leukemia, myeloma, and 
colon cancer cells. J Natl Cancer Inst. 2003;95(12):896-905. 
297. Liu M, Lee MH, Cohen M, Bommakanti M, and Freedman LP. Transcriptional 
activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced 
differentiation of the myelomonocytic cell line U937. Genes & development. 
1996;10(2):142-53. 
274 
 
298. Saramaki A, Banwell CM, Campbell MJ, and Carlberg C. Regulation of the 
human p21(waf1/cip1) gene promoter via multiple binding sites for p53 and the 
vitamin D3 receptor. Nucleic Acids Res. 2006;34(2):543-54. 
299. Yang X, Young LH, and Voigt JM. Expression of a vitamin D-regulated gene 
(VDUP-1) in untreated- and MNU-treated rat mammary tissue. Breast Cancer 
Res Treat. 1998;48(1):33-44. 
300. Junn E, Han SH, Im JY, Yang Y, Cho EW, Um HD, Kim DK, Lee KW, Han PL, 
Rhee SG, et al. Vitamin D3 up-regulated protein 1 mediates oxidative stress via 
suppressing the thioredoxin function. Journal of immunology. 
2000;164(12):6287-95. 
301. Byrne BM, and Welsh J. Altered thioredoxin subcellular localization and redox 
status in MCF-7 cells following 1,25-dihydroxyvitamin D3 treatment. J Steroid 
Biochem Mol Biol. 2005;97(1-2):57-64. 
302. Ricca C, Aillon A, Bergandi L, Alotto D, Castagnoli C, and Silvagno F. Vitamin 
D Receptor Is Necessary for Mitochondrial Function and Cell Health. Int J Mol 
Sci. 2018;19(6). 
303. Pendas-Franco N, Garcia JM, Pena C, Valle N, Palmer HG, Heinaniemi M, 
Carlberg C, Jimenez B, Bonilla F, Munoz A, et al. DICKKOPF-4 is induced by 
TCF/beta-catenin and upregulated in human colon cancer, promotes tumour cell 
invasion and angiogenesis and is repressed by 1alpha,25-dihydroxyvitamin D3. 
Oncogene. 2008;27(32):4467-77. 
304. Larriba MJ, Valle N, Palmer HG, Ordonez-Moran P, Alvarez-Diaz S, Becker KF, 
Gamallo C, de Herreros AG, Gonzalez-Sancho JM, and Munoz A. The inhibition 
of Wnt/beta-catenin signalling by 1alpha,25-dihydroxyvitamin D3 is abrogated 
by Snail1 in human colon cancer cells. Endocr Relat Cancer. 2007;14(1):141-
51. 
305. Palmer HG, Larriba MJ, Garcia JM, Ordonez-Moran P, Pena C, Peiro S, Puig I, 
Rodriguez R, de la Fuente R, Bernad A, et al. The transcription factor SNAIL 
represses vitamin D receptor expression and responsiveness in human colon 
cancer. Nat Med. 2004;10(9):917-9. 
306. Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Maor-Aloni R, Siegfried Z, 
Shiff I, Kogan I, Shay M, Kalo E, et al. Modulation of the vitamin D3 response 
by cancer-associated mutant p53. Cancer Cell. 2010;17(3):273-85. 
307. Jones PA, and Baylin SB. The epigenomics of cancer. Cell. 2007;128(4):683-
92. 
308. Lopes N, Carvalho J, Duraes C, Sousa B, Gomes M, Costa JL, Oliveira C, 
Paredes J, and Schmitt F. 1Alpha,25-dihydroxyvitamin D3 induces de novo E-
275 
 
cadherin expression in triple-negative breast cancer cells by CDH1-promoter 
demethylation. Anticancer Res. 2012;32(1):249-57. 
309. Reichrath J, Rech M, Moeini M, Meese E, Tilgen W, and Seifert M. In vitro 
comparison of the vitamin D endocrine system in 1,25(OH)2D3-responsive and 
-resistant melanoma cells. Cancer Biol Ther. 2007;6(1):48-55. 
310. Slominski AT, Janjetovic Z, Kim TK, Wright AC, Grese LN, Riney SJ, Nguyen 
MN, and Tuckey RC. Novel vitamin D hydroxyderivatives inhibit melanoma 
growth and show differential effects on normal melanocytes. Anticancer Res. 
2012;32(9):3733-42. 
311. Randerson-Moor JA, Taylor JC, Elliott F, Chang YM, Beswick S, Kukalizch K, 
Affleck P, Leake S, Haynes S, Karpavicius B, et al. Vitamin D receptor gene 
polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-
control comparisons and a meta-analysis of published VDR data. Eur J Cancer. 
2009;45(18):3271-81. 
312. Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar 
AJ, Faries MB, Kirkwood JM, McArthur GA, et al. Melanoma staging: Evidence-
based changes in the American Joint Committee on Cancer eighth edition 
cancer staging manual. CA Cancer J Clin. 2017;67(6):472-92. 
313. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, 
Buzaid AC, Cochran AJ, Coit DG, Ding S, et al. Final version of 2009 AJCC 
melanoma staging and classification. J Clin Oncol. 2009;27(36):6199-206. 
314. Du P, Kibbe WA, and Lin SM. lumi: a pipeline for processing Illumina microarray. 
Bioinformatics. 2008;24(13):1547-8. 
315. Lauss M, Visne I, Kriegner A, Ringner M, Jonsson G, and Hoglund M. Monitoring 
of technical variation in quantitative high-throughput datasets. Cancer Inform. 
2013;12(193-201. 
316. Nsengimana J, Laye J, Filia A, O'Shea S, Muralidhar S, Pozniak J, Droop A, 
Chan M, Walker C, Parkinson L, et al. beta-Catenin-mediated immune evasion 
pathway frequently operates in primary cutaneous melanomas. J Clin Invest. 
2018;128(5):2048-63. 
317. Scheinin I, Sie D, Bengtsson H, van de Wiel MA, Olshen AB, van Thuijl HF, van 
Essen HF, Eijk PP, Rustenburg F, Meijer GA, et al. DNA copy number analysis 
of fresh and formalin-fixed specimens by shallow whole-genome sequencing 
with identification and exclusion of problematic regions in the genome assembly. 
Genome Res. 2014;24(12):2022-32. 
318. Venkatraman ES, and Olshen AB. A faster circular binary segmentation 
algorithm for the analysis of array CGH data. Bioinformatics. 2007;23(6):657-
63. 
276 
 
319. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, and Getz G. 
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal 
somatic copy-number alteration in human cancers. Genome Biol. 
2011;12(4):R41. 
320. StataCorp. College Station, TX: StataCorp LP.; 2015. 
321. Wu G, and Stein L. A network module-based method for identifying cancer 
prognostic signatures. Genome Biol. 2012;13(12):R112. 
322. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, 
Schwikowski B, and Ideker T. Cytoscape: a software environment for integrated 
models of biomolecular interaction networks. Genome Res. 2003;13(11):2498-
504. 
323. Wu G, Feng X, and Stein L. A human functional protein interaction network and 
its application to cancer data analysis. Genome Biol. 2010;11(5):R53. 
324. Jones G, Strugnell SA, and DeLuca HF. Current understanding of the molecular 
actions of vitamin D. Physiological reviews. 1998;78(4):1193-231. 
325. Carlberg C, Bendik I, Wyss A, Meier E, Sturzenbecker LJ, Grippo JF, and 
Hunziker W. Two nuclear signalling pathways for vitamin D. Nature. 
1993;361(6413):657-60. 
326. Murayama A, Kim MS, Yanagisawa J, Takeyama K, and Kato S. 
Transrepression by a liganded nuclear receptor via a bHLH activator through 
co-regulator switching. EMBO J. 2004;23(7):1598-608. 
327. Fujiki R, Kim MS, Sasaki Y, Yoshimura K, Kitagawa H, and Kato S. Ligand-
induced transrepression by VDR through association of WSTF with acetylated 
histones. EMBO J. 2005;24(22):3881-94. 
328. Chen KS, and DeLuca HF. Cloning of the human 1 alpha,25-dihydroxyvitamin 
D-3 24-hydroxylase gene promoter and identification of two vitamin D-
responsive elements. Biochim Biophys Acta. 1995;1263(1):1-9. 
329. Wali RK, Baum CL, Sitrin MD, and Brasitus TA. 1,25(OH)2 vitamin D3 stimulates 
membrane phosphoinositide turnover, activates protein kinase C, and increases 
cytosolic calcium in rat colonic epithelium. J Clin Invest. 1990;85(4):1296-303. 
330. Morelli S, Buitrago C, Boland R, and de Boland AR. The stimulation of MAP 
kinase by 1,25(OH)(2)-vitamin D(3) in skeletal muscle cells is mediated by 
protein kinase C and calcium. Mol Cell Endocrinol. 2001;173(1-2):41-52. 
331. Hsieh JC, Jurutka PW, Galligan MA, Terpening CM, Haussler CA, Samuels DS, 
Shimizu Y, Shimizu N, and Haussler MR. Human vitamin D receptor is 
selectively phosphorylated by protein kinase C on serine 51, a residue crucial 
to its trans-activation function. Proc Natl Acad Sci U S A. 1991;88(20):9315-9. 
277 
 
332. Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, Selznick 
SH, Dominguez CE, and Jurutka PW. The nuclear vitamin D receptor: biological 
and molecular regulatory properties revealed. J Bone Miner Res. 
1998;13(3):325-49. 
333. Wikvall K. Cytochrome P450 enzymes in the bioactivation of vitamin D to its 
hormonal form (review). Int J Mol Med. 2001;7(2):201-9. 
334. Carmeliet G, Dermauw V, and Bouillon R. Vitamin D signalling in calcium and 
bone homeostasis: a delicate balance. Best practice & research Clinical 
endocrinology & metabolism. 2015;29(4):621-31. 
335. Peleg S, Ismail A, Uskokovic MR, and Avnur Z. Evidence for tissue- and cell-
type selective activation of the vitamin D receptor by Ro-26-9228, a noncalcemic 
analog of vitamin D3. Journal of cellular biochemistry. 2003;88(2):267-73. 
336. Bikle DD. Vitamin D regulated keratinocyte differentiation. Journal of cellular 
biochemistry. 2004;92(3):436-44. 
337. Gombart AF, Borregaard N, and Koeffler HP. Human cathelicidin antimicrobial 
peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly 
up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB journal : 
official publication of the Federation of American Societies for Experimental 
Biology. 2005;19(9):1067-77. 
338. Schauber J, Dorschner RA, Coda AB, Buchau AS, Liu PT, Kiken D, Helfrich YR, 
Kang S, Elalieh HZ, Steinmeyer A, et al. Injury enhances TLR2 function and 
antimicrobial peptide expression through a vitamin D-dependent mechanism. J 
Clin Invest. 2007;117(3):803-11. 
339. Matsumoto K, Hashimoto K, Nishida Y, Hashiro M, and Yoshikawa K. Growth-
inhibitory effects of 1,25-dihydroxyvitamin D3 on normal human keratinocytes 
cultured in serum-free medium. Biochem Biophys Res Commun. 
1990;166(2):916-23. 
340. Garland CF, Garland FC, Gorham ED, Lipkin M, Newmark H, Mohr SB, and 
Holick MF. The role of vitamin D in cancer prevention. Am J Public Health. 
2006;96(2):252-61. 
341. Palacios C, and Gonzalez L. Is vitamin D deficiency a major global public health 
problem? J Steroid Biochem Mol Biol. 2014;144 Pt A(138-45. 
342. Baggerly CA, Cuomo RE, French CB, Garland CF, Gorham ED, Grant WB, 
Heaney RP, Holick MF, Hollis BW, McDonnell SL, et al. Sunlight and Vitamin D: 
Necessary for Public Health. J Am Coll Nutr. 2015;34(4):359-65. 
343. Huang SJ, Wang XH, Liu ZD, Cao WL, Han Y, Ma AG, and Xu SF. Vitamin D 
deficiency and the risk of tuberculosis: a meta-analysis. Drug Des Devel Ther. 
2017;11(91-102. 
278 
 
344. Kamen DL, Cooper GS, Bouali H, Shaftman SR, Hollis BW, and Gilkeson GS. 
Vitamin D deficiency in systemic lupus erythematosus. Autoimmun Rev. 
2006;5(2):114-7. 
345. Hypponen E, Laara E, Reunanen A, Jarvelin MR, and Virtanen SM. Intake of 
vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet. 
2001;358(9292):1500-3. 
346. Laverny G, and Metzger D. Vitamin D (Fourth Edition). 2018. 
347. Hsieh JC, Sisk JM, Jurutka PW, Haussler CA, Slater SA, Haussler MR, and 
Thompson CC. Physical and functional interaction between the vitamin D 
receptor and hairless corepressor, two proteins required for hair cycling. The 
Journal of biological chemistry. 2003;278(40):38665-74. 
348. Skorija K, Cox M, Sisk JM, Dowd DR, MacDonald PN, Thompson CC, and 
Demay MB. Ligand-independent actions of the vitamin D receptor maintain hair 
follicle homeostasis. Molecular endocrinology. 2005;19(4):855-62. 
349. Trivedi T, Zheng Y, Fournier PGJ, Murthy S, John S, Schillo S, Dunstan CR, 
Mohammad KS, Zhou H, Seibel MJ, et al. The vitamin D receptor is involved in 
the regulation of human breast cancer cell growth via a ligand-independent 
function in cytoplasm. Oncotarget. 2017;8(16):26687-701. 
350. Guzey M, Luo J, and Getzenberg RH. Vitamin D3 modulated gene expression 
patterns in human primary normal and cancer prostate cells. Journal of cellular 
biochemistry. 2004;93(2):271-85. 
351. Swami S, Raghavachari N, Muller UR, Bao YP, and Feldman D. Vitamin D 
growth inhibition of breast cancer cells: gene expression patterns assessed by 
cDNA microarray. Breast Cancer Res Treat. 2003;80(1):49-62. 
352. Suzuki T, Tazoe H, Taguchi K, Koyama Y, Ichikawa H, Hayakawa S, Munakata 
H, and Isemura M. DNA microarray analysis of changes in gene expression 
induced by 1,25-dihydroxyvitamin D3 in human promyelocytic leukemia HL-60 
cells. Biomed Res. 2006;27(3):99-109. 
353. Wood RJ, Tchack L, Angelo G, Pratt RE, and Sonna LA. DNA microarray 
analysis of vitamin D-induced gene expression in a human colon carcinoma cell 
line. Physiol Genomics. 2004;17(2):122-9. 
354. Jensen SS, Madsen MW, Lukas J, Binderup L, and Bartek J. Inhibitory effects 
of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. 
Molecular endocrinology. 2001;15(8):1370-80. 
355. Yanagisawa J, Yanagi Y, Masuhiro Y, Suzawa M, Watanabe M, Kashiwagi K, 
Toriyabe T, Kawabata M, Miyazono K, and Kato S. Convergence of 
transforming growth factor-beta and vitamin D signalling pathways on SMAD 
transcriptional coactivators. Science. 1999;283(5406):1317-21. 
279 
 
356. Aguilera O, Pena C, Garcia JM, Larriba MJ, Ordonez-Moran P, Navarro D, 
Barbachano A, Lopez de Silanes I, Ballestar E, Fraga MF, et al. The Wnt 
antagonist DICKKOPF-1 gene is induced by 1alpha,25-dihydroxyvitamin D3 
associated to the differentiation of human colon cancer cells. Carcinogenesis. 
2007;28(9):1877-84. 
357. Tong WM, Kallay E, Hofer H, Hulla W, Manhardt T, Peterlik M, and Cross HS. 
Growth regulation of human colon cancer cells by epidermal growth factor and 
1,25-dihydroxyvitamin D3 is mediated by mutual modulation of receptor 
expression. Eur J Cancer. 1998;34(13):2119-25. 
358. Vink-van Wijngaarden T, Pols HA, Buurman CJ, Birkenhager JC, and van 
Leeuwen JP. Inhibition of insulin- and insulin-like growth factor-I-stimulated 
growth of human breast cancer cells by 1,25-dihydroxyvitamin D3 and the 
vitamin D3 analogue EB1089. Eur J Cancer. 1996;32A(5):842-8. 
359. Kallay E, Pietschmann P, Toyokuni S, Bajna E, Hahn P, Mazzucco K, 
Bieglmayer C, Kato S, and Cross HS. Characterization of a vitamin D receptor 
knockout mouse as a model of colorectal hyperproliferation and DNA damage. 
Carcinogenesis. 2001;22(9):1429-35. 
360. Majewski S, Skopinska M, Marczak M, Szmurlo A, Bollag W, and Jablonska S. 
Vitamin D3 is a potent inhibitor of tumour cell-induced angiogenesis. J Investig 
Dermatol Symp Proc. 1996;1(1):97-101. 
361. Flynn G, Chung I, Yu WD, Romano M, Modzelewski RA, Johnson CS, and 
Trump DL. Calcitriol (1,25-dihydroxycholecalciferol) selectively inhibits 
proliferation of freshly isolated tumour-derived endothelial cells and induces 
apoptosis. Oncology. 2006;70(6):447-57. 
362. Nakagawa K, Kawaura A, Kato S, Takeda E, and Okano T. Metastatic growth 
of lung cancer cells is extremely reduced in Vitamin D receptor knockout mice. 
J Steroid Biochem Mol Biol. 2004;89-90(1-5):545-7. 
363. Gonzalez-Sancho JM, Alvarez-Dolado M, and Munoz A. 1,25-Dihydroxyvitamin 
D3 inhibits tenascin-C expression in mammary epithelial cells. FEBS letters. 
1998;426(2):225-8. 
364. Spina CS, Tangpricha V, Uskokovic M, Adorinic L, Maehr H, and Holick MF. 
Vitamin D and cancer. Anticancer Res. 2006;26(4A):2515-24. 
365. Slominski AT, Kim TK, Janjetovic Z, Tuckey RC, Bieniek R, Yue J, Li W, Chen 
J, Nguyen MN, Tang EK, et al. 20-Hydroxyvitamin D2 is a noncalcemic analog 
of vitamin D with potent antiproliferative and prodifferentiation activities in 
normal and malignant cells. American journal of physiology Cell physiology. 
2011;300(3):C526-41. 
280 
 
366. Janjetovic Z, Brozyna AA, Tuckey RC, Kim TK, Nguyen MN, Jozwicki W, Pfeffer 
SR, Pfeffer LM, and Slominski AT. High basal NF-kappaB activity in 
nonpigmented melanoma cells is associated with an enhanced sensitivity to 
vitamin D3 derivatives. Br J Cancer. 2011;105(12):1874-84. 
367. Skobowiat C, Oak AS, Kim TK, Yang CH, Pfeffer LM, Tuckey RC, and Slominski 
AT. Noncalcemic 20-hydroxyvitamin D3 inhibits human melanoma growth in in 
vitro and in vivo models. Oncotarget. 2017;8(6):9823-34. 
368. Brozyna AA, Jozwicki W, and Slominski AT. Decreased VDR expression in 
cutaneous melanomas as marker of tumour progression: new data and 
analyses. Anticancer Res. 2014;34(6):2735-43. 
369. Lewis JG, and Elder PA. Serum 25-OH vitamin D2 and D3 are stable under 
exaggerated conditions. Clin Chem. 2008;54(11):1931-2. 
370. Lideikaite A, Mozuraitiene J, and Letautiene S. Analysis of prognostic factors for 
melanoma patients. Acta Med Litu. 2017;24(1):25-34. 
371. Bikle DD. Vitamin D and the skin: Physiology and pathophysiology. Rev Endocr 
Metab Disord. 2012;13(1):3-19. 
372. Nsengimana J, Laye J, Filia A, Walker C, Jewell R, Van den Oord JJ, Wolter P, 
Patel P, Sucker A, Schadendorf D, et al. Independent replication of a melanoma 
subtype gene signature and evaluation of its prognostic value and biological 
correlates in a population cohort. Oncotarget. 2015;6(13):11683-93. 
373. Angelova M, Charoentong P, Hackl H, Fischer ML, Snajder R, Krogsdam AM, 
Waldner MJ, Bindea G, Mlecnik B, Galon J, et al. Characterization of the 
immunophenotypes and antigenomes of colorectal cancers reveals distinct 
tumour escape mechanisms and novel targets for immunotherapy. Genome 
Biol. 2015;16(64. 
374. Tuoresmaki P, Vaisanen S, Neme A, Heikkinen S, and Carlberg C. Patterns of 
genome-wide VDR locations. PLoS One. 2014;9(4):e96105. 
375. McLean CY, Bristor D, Hiller M, Clarke SL, Schaar BT, Lowe CB, Wenger AM, 
and Bejerano G. GREAT improves functional interpretation of cis-regulatory 
regions. Nat Biotechnol. 2010;28(5):495-501. 
376. Najita JS, Swetter SM, Geller AC, Gershenwald JE, Zelen M, and Lee SJ. Sex 
Differences in Age at Primary Melanoma Diagnosis in a Population-Based 
Analysis (US Surveillance, Epidemiology, and End Results, 2005-2011). J 
Invest Dermatol. 2016;136(9):1894-7. 
377. Garbe C, Buttner P, Bertz J, Burg G, d'Hoedt B, Drepper H, Guggenmoos-
Holzmann I, Lechner W, Lippold A, Orfanos CE, et al. Primary cutaneous 
melanoma. Identification of prognostic groups and estimation of individual 
prognosis for 5093 patients. Cancer. 1995;75(10):2484-91. 
281 
 
378. SACN TSACoN. SACN recommendations on vitamin D. 2016. 
379. Mocellin S, and Nitti D. Vitamin D receptor polymorphisms and the risk of 
cutaneous melanoma: a systematic review and meta-analysis. Cancer. 
2008;113(9):2398-407. 
380. Sandilands A, Sutherland C, Irvine AD, and McLean WH. Filaggrin in the 
frontline: role in skin barrier function and disease. J Cell Sci. 2009;122(Pt 
9):1285-94. 
381. Lauss M, Nsengimana J, Staaf J, Newton-Bishop J, and Jonsson G. Consensus 
of Melanoma Gene Expression Subtypes Converges on Biological Entities. J 
Invest Dermatol. 2016;136(12):2502-5. 
382. Heikkinen S, Vaisanen S, Pehkonen P, Seuter S, Benes V, and Carlberg C. 
Nuclear hormone 1alpha,25-dihydroxyvitamin D3 elicits a genome-wide shift in 
the locations of VDR chromatin occupancy. Nucleic Acids Res. 
2011;39(21):9181-93. 
383. Ramagopalan SV, Heger A, Berlanga AJ, Maugeri NJ, Lincoln MR, Burrell A, 
Handunnetthi L, Handel AE, Disanto G, Orton SM, et al. A ChIP-seq defined 
genome-wide map of vitamin D receptor binding: associations with disease and 
evolution. Genome Res. 2010;20(10):1352-60. 
384. Ding N, Yu RT, Subramaniam N, Sherman MH, Wilson C, Rao R, Leblanc M, 
Coulter S, He M, Scott C, et al. A vitamin D receptor/SMAD genomic circuit 
gates hepatic fibrotic response. Cell. 2013;153(3):601-13. 
385. Meyer MB, Goetsch PD, and Pike JW. VDR/RXR and TCF4/beta-catenin 
cistromes in colonic cells of colorectal tumour origin: impact on c-FOS and c-
MYC gene expression. Molecular endocrinology. 2012;26(1):37-51. 
386. Daily K, Patel VR, Rigor P, Xie X, and Baldi P. MotifMap: integrative genome-
wide maps of regulatory motif sites for model species. BMC Bioinformatics. 
2011;12(495. 
387. Xie X, Rigor P, and Baldi P. MotifMap: a human genome-wide map of candidate 
regulatory motif sites. Bioinformatics. 2009;25(2):167-74. 
388. Cancer Genome Atlas N. Genomic Classification of Cutaneous Melanoma. Cell. 
2015;161(7):1681-96. 
389. Jonsson G, Busch C, Knappskog S, Geisler J, Miletic H, Ringner M, Lillehaug 
JR, Borg A, and Lonning PE. Gene expression profiling-based identification of 
molecular subtypes in stage IV melanomas with different clinical outcome. Clin 
Cancer Res. 2010;16(13):3356-67. 
390. Bennesch MA, and Picard D. Minireview: Tipping the balance: ligand-
independent activation of steroid receptors. Molecular endocrinology. 
2015;29(3):349-63. 
282 
 
391. Lagishetty V, Liu NQ, and Hewison M. Vitamin D metabolism and innate 
immunity. Mol Cell Endocrinol. 2011;347(1-2):97-105. 
392. Kearns MD, and Tangpricha V. The role of vitamin D in tuberculosis. J Clin 
Transl Endocrinol. 2014;1(4):167-9. 
393. Chen L, Eapen MS, and Zosky GR. Vitamin D both facilitates and attenuates 
the cellular response to lipopolysaccharide. Sci Rep. 2017;7(45172. 
394. Akbas EM, Gungor A, Ozcicek A, Akbas N, Askin S, and Polat M. Vitamin D and 
inflammation: evaluation with neutrophil-to-lymphocyte ratio and platelet-to-
lymphocyte ratio. Arch Med Sci. 2016;12(4):721-7. 
395. Souto Filho JTD, de Andrade AS, Ribeiro FM, Alves PAS, and Simonini VRF. 
Impact of vitamin D deficiency on increased blood eosinophil counts. Hematol 
Oncol Stem Cell Ther. 2018;11(1):25-9. 
396. Long MD, and Campbell MJ. Pan-cancer analyses of the nuclear receptor 
superfamily. Nucl Receptor Res. 2015;2( 
397. Mallbris L, Edstrom DW, Sundblad L, Granath F, and Stahle M. UVB 
upregulates the antimicrobial protein hCAP18 mRNA in human skin. J Invest 
Dermatol. 2005;125(5):1072-4. 
398. Newton-Bishop JA, Chang YM, Elliott F, Chan M, Leake S, Karpavicius B, 
Haynes S, Fitzgibbon E, Kukalizch K, Randerson-Moor J, et al. Relationship 
between sun exposure and melanoma risk for tumours in different body sites in 
a large case-control study in a temperate climate. Eur J Cancer. 
2011;47(5):732-41. 
399. Saccone D, Asani F, and Bornman L. Regulation of the vitamin D receptor gene 
by environment, genetics and epigenetics. Gene. 2015;561(2):171-80. 
400. Essa S, Reichrath S, Mahlknecht U, Montenarh M, Vogt T, and Reichrath J. 
Signature of VDR miRNAs and epigenetic modulation of vitamin D signalling in 
melanoma cell lines. Anticancer Res. 2012;32(1):383-9. 
401. SnapGene. 
402. Li Z, Michael IP, Zhou D, Nagy A, and Rini JM. Simple piggyBac transposon-
based mammalian cell expression system for inducible protein production. Proc 
Natl Acad Sci U S A. 2013;110(13):5004-9. 
403. van der Weyden L, Arends MJ, Campbell AD, Bald T, Wardle-Jones H, Griggs 
N, Velasco-Herrera MD, Tuting T, Sansom OJ, Karp NA, et al. Genome-wide in 
vivo screen identifies novel host regulators of metastatic colonization. Nature. 
2017;541(7636):233-6. 
404. Speak AO, Swiatkowska A, Karp NA, Arends MJ, Adams DJ, and van der 
Weyden L. A high-throughput in vivo screening method in the mouse for 
283 
 
identifying regulators of metastatic colonization. Nat Protoc. 2017;12(12):2465-
77. 
405. Zhong Z, Ethen NJ, and Williams BO. WNT signalling in bone development and 
homeostasis. Wiley Interdiscip Rev Dev Biol. 2014;3(6):489-500. 
406. Cianferotti L, and Demay MB. VDR-mediated inhibition of DKK1 and SFRP2 
suppresses adipogenic differentiation of murine bone marrow stromal cells. 
Journal of cellular biochemistry. 2007;101(1):80-8. 
407. Katoh M. WNT/PCP signalling pathway and human cancer (review). Oncol Rep. 
2005;14(6):1583-8. 
408. Weeraratna AT, Becker D, Carr KM, Duray PH, Rosenblatt KP, Yang S, Chen 
Y, Bittner M, Strausberg RL, Riggins GJ, et al. Generation and analysis of 
melanoma SAGE libraries: SAGE advice on the melanoma transcriptome. 
Oncogene. 2004;23(12):2264-74. 
409. Aviles-Izquierdo JA, and Lazaro-Ochaita P. Histological ulceration as a 
prognostic factor in cutaneous melanoma: a study of 423 cases in Spain. Clin 
Transl Oncol. 2012;14(3):237-40. 
410. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, 
Meyer L, Gress DM, Byrd DR, and Winchester DP. The Eighth Edition AJCC 
Cancer Staging Manual: Continuing to build a bridge from a population-based 
to a more "personalized" approach to cancer staging. CA Cancer J Clin. 
2017;67(2):93-9. 
411. Spatz A, Cook MG, Elder DE, Piepkorn M, Ruiter DJ, and Barnhill RL. 
Interobserver reproducibility of ulceration assessment in primary cutaneous 
melanomas. Eur J Cancer. 2003;39(13):1861-5. 
412. Hantschke M, Bastian BC, and LeBoit PE. Consumption of the epidermis: a 
diagnostic criterion for the differential diagnosis of melanoma and Spitz nevus. 
Am J Surg Pathol. 2004;28(12):1621-5. 
413. Braun-Falco M, Friedrichson E, and Ring J. Subepidermal cleft formation as a 
diagnostic marker for cutaneous malignant melanoma. Hum Pathol. 
2005;36(4):412-5. 
414. Bonnelykke-Behrndtz ML, Schmidt H, Christensen IJ, Damsgaard TE, Moller 
HJ, Bastholt L, Norgaard PH, and Steiniche T. Prognostic stratification of 
ulcerated melanoma: not only the extent matters. American journal of clinical 
pathology. 2014;142(6):845-56. 
415. In 't Hout FE, Haydu LE, Murali R, Bonenkamp JJ, Thompson JF, and Scolyer 
RA. Prognostic importance of the extent of ulceration in patients with clinically 
localized cutaneous melanoma. Ann Surg. 2012;255(6):1165-70. 
284 
 
416. Storr SJ, Safuan S, Mitra A, Elliott F, Walker C, Vasko MJ, Ho B, Cook M, 
Mohammed RA, Patel PM, et al. Objective assessment of blood and lymphatic 
vessel invasion and association with macrophage infiltration in cutaneous 
melanoma. Mod Pathol. 2012;25(4):493-504. 
417. Jewell R, Elliott F, Laye J, Nsengimana J, Davies J, Walker C, Conway C, Mitra 
A, Harland M, Cook MG, et al. The clinicopathological and gene expression 
patterns associated with ulceration of primary melanoma. Pigment Cell 
Melanoma Res. 2015;28(1):94-104. 
418. von Schuckmann LA, Smith D, Hughes MCB, Malt M, van der Pols JC, 
Khosrotehrani K, Smithers BM, and Green AC. Associations of Statins and 
Diabetes with Diagnosis of Ulcerated Cutaneous Melanoma. J Invest Dermatol. 
2017;137(12):2599-605. 
419. Eggermont AM, Suciu S, Testori A, Kruit WH, Marsden J, Punt CJ, Santinami 
M, Sales F, Schadendorf D, Patel P, et al. Ulceration and stage are predictive 
of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 
18952 and EORTC 18991. Eur J Cancer. 2012;48(2):218-25. 
420. Koelblinger P, Emberger M, Drach M, Cheng PF, Lang R, Levesque MP, Bauer 
JW, and Dummer R. Increased tumour cell PD-L1 expression, macrophage and 
dendritic cell infiltration characterise the tumour microenvironment of ulcerated 
primary melanomas. J Eur Acad Dermatol Venereol. 2018. 
421. Rakosy Z, Ecsedi S, Toth R, Vizkeleti L, Hernandez-Vargas H, Lazar V, Emri G, 
Szatmari I, Herceg Z, Adany R, et al. Integrative genomics identifies gene 
signature associated with melanoma ulceration. PLoS One. 2013;8(1):e54958. 
422. Olmeda D, Cerezo-Wallis D, Riveiro-Falkenbach E, Pennacchi PC, Contreras-
Alcalde M, Ibarz N, Cifdaloz M, Catena X, Calvo TG, Canon E, et al. Whole-
body imaging of lymphovascular niches identifies pre-metastatic roles of 
midkine. Nature. 2017;546(7660):676-80. 
423. Bhardwaj V. Science behind Non-Specific Science; For Molecular Biologist & 
Bio-technologist. Notion press; 2014. 
424. Schena M, Shalon D, Davis RW, and Brown PO. Quantitative monitoring of gene 
expression patterns with a complementary DNA microarray. Science. 
1995;270(5235):467-70. 
425. Chibon F. Cancer gene expression signatures - the rise and fall? Eur J Cancer. 
2013;49(8):2000-9. 
426. Simon R, Radmacher MD, Dobbin K, and McShane LM. Pitfalls in the use of 
DNA microarray data for diagnostic and prognostic classification. J Natl Cancer 
Inst. 2003;95(1):14-8. 
285 
 
427. Kim IJ, Kang HC, and Park JG. Microarray applications in cancer research. 
Cancer Res Treat. 2004;36(4):207-13. 
428. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller 
H, Loh ML, Downing JR, Caligiuri MA, et al. Molecular classification of cancer: 
class discovery and class prediction by gene expression monitoring. Science. 
1999;286(5439):531-7. 
429. Evers DL, Fowler CB, Cunningham BR, Mason JT, and O'Leary TJ. The effect 
of formaldehyde fixation on RNA: optimization of formaldehyde adduct removal. 
J Mol Diagn. 2011;13(3):282-8. 
430. Fan JB, Yeakley JM, Bibikova M, Chudin E, Wickham E, Chen J, Doucet D, 
Rigault P, Zhang B, Shen R, et al. A versatile assay for high-throughput gene 
expression profiling on universal array matrices. Genome Res. 2004;14(5):878-
85. 
431. Weinstein SJ, Mondul AM, Yu K, Layne TM, Abnet CC, Freedman ND, 
Stolzenberg-Solomon RZ, Lim U, Gail MH, and Albanes D. Circulating 25-
hydroxyvitamin D up to 3 decades prior to diagnosis in relation to overall and 
organ-specific cancer survival. Eur J Epidemiol. 2018;33(11):1087-99. 
 
